Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Placebo

Aliases
0.5N saline, 0.9% normal saline, 0.9% Normal saline, 0.9% Normal Saline, 0.9% saline (333 other aliases)
Name
Placebo
FDA Approved
Yes

5897 clinical trials

1 organization

1 drug

5 abstracts

2878 indications

1 document

Indication
Allergic bronchopulmonary aspergillosis (ABPA)
Indication
Multiple Myeloma
Indication
Healthy
Indication
Glioblastoma
Indication
Osteosarcoma
Indication
Nonalcoholic Steatohepatitis
Indication
Diabetes Mellitus
Indication
Type 2 Diabetes
Indication
Advanced Cancer
Indication
Type 2
Indication
Psoriasis Vulgaris
Indication
Psoriasis
Indication
Chronic Lymphocytic Leukemia
Indication
Congestive Heart Failure
Indication
Lung Cancer
Indication
Becker Muscular Dystrophy
Indication
Metastatic Castration-resistant Prostate Cancer
Indication
Overactive Bladder
Indication
Inflammatory Bowel Disease
Indication
Urinary incontinence
Indication
Hemophilia A
Indication
Hepatocellular Carcinoma
Indication
Diabetic Nephropathy
Indication
Hemophilia B
Indication
Acute Myeloid Leukemia
Indication
NSCLC
Indication
Cough
Indication
Invasive Pulmonary Aspergillosis
Indication
Atopic Dermatitis
Indication
Malignant Glioma
Indication
Dermatitis
Indication
Major Depressive Disorder
Indication
Renal Cell Carcinoma
Indication
Atopic
Indication
HIV Infection
Indication
Hidradenitis Suppurativa
Indication
Cancer
Indication
Cervical Cancer
Indication
Primary Sclerosing Cholangitis
Indication
cancer
Indication
Non-Hodgkin lymphoma
Indication
Primary MDS (Very Low
Indication
Age-Related Macular Degeneration
Indication
Head and Neck Squamous Cell Carcinoma
Indication
Healthy Subjects
Indication
Actinic Keratosis
Indication
Mesothelioma
Indication
Diabetic Macular Edema
Indication
Essential Tremor
Indication
Non-Small Cell Lung
Indication
Pain
Indication
Healthy Volunteer Study
Indication
Cold Urticaria
Indication
Epithelioid Sarcoma
Indication
Low or Intermediate IPSS-R With <5% Blasts
Indication
Phenylketonuria
Indication
Myoclonic Epilepsies
Indication
Allergic Rhinitis
Indication
Acute Lymphoblastic Leukemia
Indication
Idiopathic Pulmonary Fibrosis
Indication
Small Lymphocytic Lymphoma
Indication
Healthy Control Participants
Indication
Squamous Cell Carcinoma of the Head and Neck
Indication
Influenza
Indication
Breast Cancer
Indication
Celiac Disease
Indication
Progressive
Indication
Esophageal squamous cell carcinoma
Indication
Type 2 Diabetes Mellitus
Indication
Acute Respiratory Infection
Indication
Obesity
Indication
Colorectal Cancer
Indication
Esophageal Squamous Cell Carcinoma
Indication
Refractory Chronic Cough
Indication
Type 1 Diabetes
Indication
Gliosarcoma
Indication
Gastroenteritis
Indication
Amyloidosis
Indication
HIV Infections
Indication
Depression
Indication
Helicobacter pylori infection
Indication
Bladder Cancer
Indication
Amyotrophic lateral sclerosis
Indication
Endometrial Neoplasms
Indication
Major
Indication
Congenital Adrenal Hyperplasia
Indication
Ovarian Cancer
Indication
Amyotrophic Lateral Sclerosis (ALS)
Indication
Dry Eye Syndrome
Indication
Pregnancy Related
Indication
lymphoma
Indication
Gastroparesis
Indication
Solid Tumors
Indication
Bleeding
Indication
Melanoma
Indication
Paroxysmal Nocturnal Hemoglobinuria
Indication
Migraine Disorders
Indication
lung cancer
Indication
Pulmonary Hypertension
Indication
Anemia
Indication
Solid Tumor
Indication
Medullary Thyroid Carcinoma
Indication
Childhood
Indication
Migraine
Indication
Pulmonary Arterial Hypertension
Indication
Allergic Conjunctivitis
Indication
GIST
Indication
Breast Neoplasms
Indication
Hypogonadism
Indication
Retinitis Pigmentosa
Indication
male
Indication
Soft Tissue Sarcoma
Indication
Urinary Tract Infections
Indication
Systemic Lupus Erythematosus
Indication
Allergic Bronchopulmonary Aspergillosis
Indication
Stomach Cancer
Indication
Pyelonephritis
Indication
Tetanus
Indication
Eye Disorders
Indication
Non-Hodgkin
Indication
Asthma
Indication
Psoriatic Arthritis
Indication
Friedreich Ataxia
Indication
pharmacokinetics
Indication
Diarrhea induced by drug or toxin
Indication
Chronic Obstructive Pulmonary Disease
Indication
Safety Issues
Indication
Bipolar Disorder
Indication
Healthy Participants
Indication
Respiratory Tract Infections
Indication
C3 glomerulopathy
Indication
Human Metapneumovirus Infection
Indication
Esophageal Cancer
Indication
Schizophrenia
Indication
Parainfluenza infection
Indication
Limited-Stage Small Cell Lung Cancer
Indication
Respiratory Syncytial Viral Infection
Indication
Membranoproliferative Glomerulonephritis
Indication
Juvenile Idiopathic Arthritis
Indication
Adult
Indication
Chronic Rhinosinusitis With Nasal Polyps
Indication
Cholangiocarcinoma
Indication
Parkinson's disease
Indication
Human
Indication
Hypertension
Indication
COVID-19
Indication
Geographic Atrophy
Indication
C3 Glomerulopathy
Indication
Hypercholesterolemia
Indication
DM1
Indication
Myotonic Dystrophy 1
Indication
Agitation, Psychomotor
Indication
Tumor
Indication
Metastatic Castrate Resistant Prostate Cancer
Indication
Myotonic Dystrophy
Indication
C3 Glomerulonephritis
Indication
Fallopian tube cancer
Indication
Photodamaged Skin
Indication
Down syndrome
Indication
Myotonic Dystrophy Type 1 (DM1)
Indication
Anal High Grade Squamous Intraepithelial Lesion
Indication
pneumococcal disease
Indication
Alport Syndrome
Indication
Duchenne muscular dystrophy
Indication
ulcerative colitis
Indication
Myotonic Disorders
Indication
Fabry Disease
Indication
Steinert Disease
Indication
Schizoaffective disorder
Indication
Anal Precancerous Condition
Indication
Myotonic Muscular Dystrophy
Indication
Chronic
Indication
Extensive-stage Small-cell Lung Cancer
Indication
focal segmental glomerulosclerosis
Indication
Dengue
Indication
Pneumococcal Infections
Indication
Anal intraepithelial neoplasia 2/3
Indication
Stroke
Indication
Schizophreniform Disorder
Indication
Bacterial Infections
Indication
ARDS
Indication
Human Papillomavirus Infection
Indication
Prostate Cancer
Indication
Follicular Lymphoma
Indication
Lupus Erythematosus
Indication
Systemic
Indication
Bipolar I Disorder
Indication
Crohn's Disease
Indication
Dementia with Lewy Bodies
Indication
Nonalcoholic
Indication
Gaucher's Disease
Indication
viral infection
Indication
chronic kidney disease
Indication
HIV/AIDS
Indication
Spinal Muscular Atrophy
Indication
Graft-versus-host disease
Indication
Glioblastoma Multiforme
Indication
Eosinophilic Gastroenteritis
Indication
Transthyretin Amyloid Cardiomyopathy
Indication
Meningitis
Indication
Glioma
Indication
Metastasis
Indication
Unspecified
Indication
Brain Tumor
Indication
respiratory disease
Indication
Methylmalonic acidemia
Indication
degenerative disc disease
Indication
Meningococcal
Indication
Neurofibromatosis 1
Indication
Anaemia
Indication
Systemic Lupus Erythematosus (SLE)
Indication
Propionic Acidemia
Indication
Myopia
Indication
Ankylosing Spondylitis
Indication
Metastatic Cancer
Indication
Iron-deficiency
Indication
Analgesic
Indication
Opioid Use Disorder
Indication
Non-alcoholic Steatohepatitis (NASH)
Indication
Osteoarthritis of the Knee
Indication
Dense Deposit Disease
Indication
Arthritis
Indication
Postoperative
Indication
Alzheimer's Disease
Indication
Cataract
Indication
Leukemia
Indication
Ischemia/Reperfusion Injury
Indication
Acute Respiratory Distress Syndrome
Indication
Gingivitis
Indication
Anthrax
Indication
Pancreatic Cancer
Indication
Lupus Nephritis
Indication
Healthy Volunteer
Indication
Hodgkin lymphoma
Indication
Kidney Diseases
Indication
Immune Thrombocytopenia
Indication
Intractable
Indication
Dysmenorrhea
Indication
Neuroendocrine Carcinoma
Indication
Glaucoma
Indication
Prurigo Nodularis
Indication
Pulmonary
Indication
Acute Graft Versus Host Disease
Indication
Polycythemia Vera
Indication
MDS
Indication
Open-Angle
Indication
Pruritus
Indication
End-Stage Renal Disease
Indication
Fibromyalgia
Indication
Autism Spectrum Disorder
Indication
ocular hypertension
Indication
End-Stage Kidney Disease
Indication
Pneumococcal Infection
Indication
Myelodysplastic Syndrome
Indication
Lymphoma
Indication
Epithelial Ovarian Cancer
Indication
ADHD
Indication
Community-acquired Pneumonia
Indication
Familial Chylomicronemia Syndrome
Indication
HIV-1 infection
Indication
HIV
Indication
Hemorrhage
Indication
Acute Pancreatitis
Indication
Kidney Failure
Indication
Diabetic Retinopathy
Indication
Influenza with Pneumonia
Indication
Fallopian Tube Neoplasms
Indication
Vascular Dementia
Indication
Pneumonia
Indication
Attention-Deficit/Hyperactivity Disorder - Combined Type
Indication
Aging
Indication
Infections
Indication
Cytomegalovirus Infection
Indication
Anal Cancer
Indication
Otomycosis
Indication
Kidney Transplant
Indication
Safety and Tolerability
Indication
Attention Deficit Hyperactivity
Indication
Narcolepsy
Indication
Stargardt Macular Dystrophy
Indication
Bile Duct Cancer
Indication
Myelofibrosis
Indication
Multiple Sclerosis
Indication
malignant
Indication
Cirrhosis
Indication
Frozen Shoulder
Indication
Myelodysplastic Syndromes
Indication
Breast Neoplasm
Indication
Botulism
Indication
Anal Dysplasia
Indication
Attention Deficit Hyperactivity Disorder
Indication
Head and Neck Cancer
Indication
Type 1 Hypersensitivity
Indication
Hepatocellular
Indication
ADHD Combined
Indication
Human Papillomavirus Disease
Indication
Low Back Pain
Indication
Endometriosis
Indication
headache
Indication
Attention-deficit Hyperactivity
Indication
Biliary
Indication
Nasopharyngeal Carcinoma
Indication
T cell
Indication
Herpes Zoster
Indication
Chronic Plaque Psoriasis
Indication
Fragile X Syndrome
Indication
Chronic Rhinosinusitis
Indication
Non-transfusion-dependent Thalassemia
Indication
IgA Nephropathy
Indication
Respiratory Syncytial Virus Infections
Indication
myeloid
Indication
Acute
Indication
Age-related macular degeneration
Indication
Vasomotor Symptoms Associated With Menopause
Indication
Myelomonocytic
Indication
Hot Flashes
Indication
Stomach Neoplasms
Indication
Myasthenia Gravis
Indication
Endometrial Cancer
Indication
Metastatic Melanoma
Indication
Pharyngitis
Indication
Relapsing-Remitting
Indication
Parkinson's Disease
Indication
tobacco dependence
Indication
Aplastic Anemia
Indication
Dengue Fever
Indication
Castration-Resistant Prostate Cancer
Indication
Constipation
Indication
Osteoarthritis, Knee
Indication
Ewing Sarcoma
Indication
PD-L1 Gene Mutation
Indication
mantle cell lymphoma
Indication
Attention-Deficit/Hyperactivity Disorder
Indication
Drug Effect
Indication
Juvenile Psoriatic Arthritis
Indication
Primary Open Angle Glaucoma
Indication
Chronic Spontaneous Urticaria
Indication
Sickle Cell Disease
Indication
Hereditary Angioedema
Indication
Pancreatic Ductal Adenocarcinoma
Indication
Pediatric
Indication
pharmacodynamics
Indication
BRCA2
Indication
Chronic Kidney Disease
Indication
Chronic Systolic Heart Failure
Indication
HIV-1
Indication
Ovarian Serous Adenocarcinoma
Indication
Seasonal Influenza
Indication
Bipolar disorder
Indication
Central Nervous System
Indication
Suicidal Ideation
Indication
Respiratory Syncytial Virus
Indication
Small Cell Lung Cancer
Indication
Atherosclerotic Cardiovascular Disease
Indication
Familial Hypercholesterolemia
Indication
triple-negative breast cancer
Indication
Tardive Dyskinesia
Indication
Heart Attack
Indication
Atrial Fibrillation
Indication
Osteoarthritis
Indication
ANCA-Associated Vasculitis
Indication
Amyotrophic Lateral Sclerosis
Indication
Japanese Encephalitis
Indication
Liver Impairment
Indication
Rheumatoid
Indication
Opioid-Induced Constipation
Indication
Cognitive Disorders
Indication
Primary Biliary Cholangitis
Indication
Knee
Indication
Neurogenic Bladder
Indication
Mumps
Indication
Respiratory Distress Syndrome
Indication
Mirabegron Pharmacokinetics
Indication
Primary Peritoneal Cancer
Indication
painful diabetic neuropathy
Indication
stroke
Indication
Unresectable
Indication
Fibrosis of the Liver
Indication
Bacteria
Indication
Primary Dysmenorrhea
Indication
Stomach Adenocarcinoma
Indication
pre-eclampsia
Indication
Head and Neck
Indication
Crohn's disease
Indication
Overdose
Indication
Recurrent
Indication
systemic sclerosis
Indication
Squamous Cell Carcinoma of Head and Neck
Indication
Colorectal cancer
Indication
Systemic lupus erythematosus
Indication
Acromegaly
Indication
Respiratory Tract Diseases
Indication
Cytokine Storm
Indication
Head Trauma
Indication
Bipolar Disorder II
Indication
Low Myelodysplastic Syndrome
Indication
Major Depressive Episode
Indication
Chronic Hepatitis B
Indication
Venous Thromboembolism
Indication
borderline personality disorder
Indication
Triple-Negative Breast Cancer
Indication
Metastatic Castration Resistant Prostate Cancer
Indication
Cardiovascular Diseases
Indication
Cystic Fibrosis
Indication
Infection
Indication
Osteoporosis
Indication
Breast
Indication
IgA nephropathy
Indication
Diffuse Large B-cell Lymphoma
Indication
Healthy Adult
Indication
Malaria
Indication
Chronic Kidney Failure
Indication
Dyskinesia
Indication
Gout
Indication
Medication-Induced
Indication
CIN 2/3
Indication
Beta Thalassemia Major
Indication
Rheumatoid Arthritis
Indication
Human Papillomavirus Infections
Indication
Immune Thrombocytopenic Purpura
Indication
Age-related Macular Degeneration
Indication
Uterine Fibroids
Indication
NAFLD
Indication
Dyslipidemia
Indication
Periprosthetic Joint Infection
Indication
Metabolic Syndrome
Indication
Angelman Syndrome
Indication
Lung Diseases
Indication
Osteogenesis Imperfecta
Indication
Mantle Cell
Indication
Interstitial
Indication
Hyperuricemia
Indication
Anal High-grade Squamous Intraepithelial Lesion
Indication
Chikungunya Virus
Indication
Myocarditis
Indication
Anal HSIL
Indication
Anal Human Papillomavirus Infection
Indication
Nasal Polyps
Indication
Chorea
Indication
Beta Thalassemia
Indication
Soft Tissue
Indication
Alzheimer's disease
Indication
Anxiety
Indication
Memory Impairment
Indication
Zika virus
Indication
Post-bariatric Hypoglycemia
Indication
Beta-thalassemia
Indication
Heart Failure with Preserved Ejection Fraction
Indication
Cerebral Adrenoleukodystrophy
Indication
Adrenoleukodystrophy
Indication
Plaque Psoriasis
Indication
Gastroesophageal Cancer
Indication
Dysplasia
Indication
Acute Exacerbation of COPD
Indication
Cervical Intraepithelial Neoplasia
Indication
Peanut Allergy
Indication
Human Papillomavirus Related Disease
Indication
lipid metabolism disorder
Indication
Inflammation
Indication
Coronary Artery Disease
Indication
Corneal Edema
Indication
Blepharitis
Indication
Ehlers-Danlos Syndrome, Vascular
Indication
Alcohol Use Disorder
Indication
Pregnancy Complications
Indication
Bunion
Indication
Adenovirus Infection
Indication
Colon Cancer
Indication
Post-Traumatic Stress Disorder
Indication
Muscle atrophy
Indication
polymyositis
Indication
Dermatomyositis
Indication
Colitis
Indication
Colorectal Cancer Metastatic
Indication
Generalized Anxiety Disorder
Indication
Ulcerative
Indication
Critical Limb Ischemia
Indication
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Indication
Chickenpox
Indication
Triple-negative Breast Cancer
Indication
Norovirus infection
Indication
Coronary Heart Disease
Indication
Adult Health
Indication
postmenopausal symptoms
Indication
Alopecia Areata
Indication
Systemic Sclerosis
Indication
Peripheral Neuropathy
Indication
Tear Trough Eyelid Deformity
Indication
Infectious Diseases
Indication
Neurogenic Orthostatic Hypotension
Indication
Tolerability
Indication
Postsurgical Pain
Indication
Frontotemporal Dementia
Indication
Microcystic Lymphatic Malformation
Indication
Warm Autoimmune Hemolytic Anemia
Indication
Autism
Indication
Non-Cystic Fibrosis Bronchiectasis
Indication
Vasomotor Symptoms
Indication
Adult Healthy Volunteers
Indication
Dental Caries
Indication
Alpha-1 Antitrypsin Deficiency
Indication
Warts
Indication
Seizure
Indication
Non-squamous non-small cell lung cancer
Indication
Diabetes
Indication
Type 1
Indication
Spinal and Bulbar Muscular Atrophy
Indication
Kennedy's Disease
Indication
Immune thrombocytopenic purpura
Indication
Chronic Pain
Indication
Polycystic Kidney Disease
Indication
Nail Fungus
Indication
Autosomal Dominant
Indication
Postherpetic Neuralgia
Indication
Diabetic Neuropathy
Indication
Complex Regional Pain Syndrome
Indication
Carpal Tunnel Syndrome
Indication
Hepatitis B
Indication
HIV neuropathy
Indication
Sensory Neuropathy
Indication
Neuropathy
Indication
Deep Vein Thrombosis
Indication
Post-Thrombotic Syndrome
Indication
Cholestasis
Indication
Scleroderma
Indication
Gonorrhea
Indication
Intrahepatic
Indication
Eosinophilic Esophagitis
Indication
Clostridium difficile infection
Indication
Type 1 Diabetes Mellitus
Indication
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Indication
Hypophosphatasia
Indication
Cachexia
Indication
Mantle Cell Lymphoma
Indication
Chronic Inducible Urticaria
Indication
Angioedema
Indication
Pre-Exposure Prophylaxis of HIV Infection
Indication
Ebola
Indication
Pulmonary Fibrosis
Indication
Heavy menstrual bleeding
Indication
Eosinophilic Gastritis
Indication
Genetic Diseases
Indication
Low blood pressure
Indication
Inborn
Indication
Sickle Cell Anemia
Indication
Skin Cancer
Indication
Acne
Indication
Gastric Cancer
Indication
Small Cell Lung Carcinoma
Indication
Menopause
Indication
Hypertriglyceridemia
Indication
Efficacy and Safety
Indication
Urticaria
Indication
Epilepsy
Indication
Peripheral neuropathy
Indication
Postpartum Depression
Indication
Cataplexy
Indication
Alcoholic Hepatitis
Indication
Respiratory Syncytial Virus Infection
Indication
Excessive Daytime Sleepiness
Indication
Human Metapneumovirus
Indication
Sleep Disorder
Indication
Anemia of Chronic Kidney Disease
Indication
Birch pollen allergy
Indication
Squamous-cell Non-Small-cell Lung Cancer
Indication
Sleep Disturbance
Indication
NASH
Indication
Liver
Indication
Sleep-Wake Disorders
Indication
Glycogen Storage Disease Type 1A
Indication
Ocular
Indication
Chronic Kidney Disease and Systemic Inflammation
Indication
Encephalitis
Indication
Secondary Hyperparathyroidism
Indication
Pompe Disease
Indication
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Indication
Acne Vulgaris
Indication
Lyme Disease
Indication
Narcolepsy Type 1
Indication
Narcolepsy Type 2
Indication
Generalized Pustular Psoriasis
Indication
Endocrine System Diseases
Indication
Sexually Transmitted Infections
Indication
BK virus infection
Indication
B-cell
Indication
Vitiligo
Indication
Cytomegalovirus Infections
Indication
Postoperative Pain
Indication
Hypoparathyroidism
Indication
Epstein-Barr Virus Infections
Indication
Parathyroid Disorders
Indication
Human Herpesvirus 6 Infection
Indication
Chlamydia
Indication
Virus Diseases
Indication
Carcinoid Syndrome
Indication
Progressive Multifocal Leukoencephalopathy
Indication
Merkel Cell Carcinoma
Indication
menstrually associated migraine
Indication
HER2-Positive Breast Carcinoma
Indication
Cutaneous Squamous Cell Carcinoma
Indication
Hyperkalemia
Indication
Diabetic Peripheral Neuropathy
Indication
General Anesthesia
Indication
Familial
Indication
Heart Failure with Reduced Ejection Fraction
Indication
Healthy Volunteers
Indication
Vascular Diseases
Indication
Mucosal melanoma
Indication
Acute Kidney Injury
Indication
Heart Failure with Mid-Range Ejection Fraction
Indication
Hyperlipidaemia
Indication
HTLV-1-Associated Myelopathy (HAM)
Indication
Urinary Tract Infection
Indication
Lynch syndrome
Indication
Pertussis
Indication
Dilated Cardiomyopathy
Indication
Vaso-occlusive Pain Episode
Indication
Non-Alcoholic Steatohepatitis
Indication
Vaso-occlusive Crisis
Indication
Brain Cancer
Indication
Malnutrition
Indication
Hypertrophic Cardiomyopathy
Indication
Non-alcoholic Steatohepatitis
Indication
Neurofibromatosis type 1
Indication
HIV infection
Indication
Non-Small Cell Lung Cancer Stage IV
Indication
Primary Hyperoxaluria Type 1
Indication
Stargardt Disease
Indication
Diffuse
Indication
Acute Intermittent Porphyria
Indication
Sclerosis
Indication
Stargardt disease
Indication
Oral Mucositis
Indication
Quality of Life
Indication
Mucositis
Indication
Bacteremia
Indication
Fecal Incontinence
Indication
Staphylococcus aureus
Indication
Staphylococcus aureus bacteremia
Indication
Dry Eye
Indication
Triple Negative Breast Cancer
Indication
Chemotherapy Toxicity
Indication
Nonalcoholic Fatty Liver Disease
Indication
Primary Sjögren's Syndrome
Indication
Genetic Risk Factor
Indication
Idiopathic Hypersomnia
Indication
Psychotic Disorders
Indication
Irritable Bowel Syndrome
Indication
Mood Disorders
Indication
Hypertrophic Obstructive Cardiomyopathy
Indication
Primary Immune Thrombocytopenia
Indication
Mental Disorders
Indication
Chronic Heart Failure
Indication
Ulcerative Colitis
Indication
Hyperlipemia
Indication
Niemann-Pick Disease
Indication
Alopecia
Indication
Squamous Cell Carcinoma
Indication
Androgenetic
Indication
Adenomatous Polyposis Coli
Indication
Type C
Indication
Pharmacodynamics
Indication
Heart Failure With Reduced Ejection Fraction (HFrEF)
Indication
Respiratory Tract Disease
Indication
Chronic Diabetic Foot Ulcers
Indication
Post-COVID-19 Syndrome
Indication
Neuropathic Pain
Indication
Gastrointestinal Diseases
Indication
Developmental and Epileptic Encephalopathy
Indication
Dravet syndrome
Indication
Hyperphosphatemia
Indication
Nonproliferative Diabetic Retinopathy
Indication
Hyperlipidemia
Indication
Lennox-Gastaut syndrome
Indication
Thrombocytopenia
Indication
Raynaud's Phenomenon
Indication
Leiomyosarcoma
Indication
Pulmonary Disease
Indication
Facet Joint Pain
Indication
Pediatric Disorder
Indication
Chronic Obstructive
Indication
Severe Hypertriglyceridemia
Indication
Angina pectoris
Indication
Antineoplastic Agents
Indication
Generalized
Indication
Short Bowel Syndrome
Indication
Chondrosarcoma
Indication
Pain Syndrome
Indication
Large B-Cell
Indication
Ischemia-reperfusion injury
Indication
Schistosomiasis
Indication
Tuberculosis
Indication
Bullous Pemphigoid
Indication
Urogenital Neoplasms
Indication
Chronic Pain Syndrome
Indication
Mycobacterium avium complex lung disease
Indication
Back Pain
Indication
Mycobacterium Avium Complex Lung Disease
Indication
low back pain
Indication
Cervical Intraepithelial Neoplasia 1 (CIN1)
Indication
Chronic Myeloid Leukemia
Indication
Chronic Lower Back Pain
Indication
Cushing's syndrome
Indication
Sjögren's syndrome
Indication
Diabetic Foot Ulcer
Indication
Head and Neck Neoplasms
Indication
Peritoneal Cancer
Indication
Hepatic Encephalopathy
Indication
Tuberous Sclerosis Complex
Indication
Hearing impairment
Indication
Achondroplasia
Indication
Hematologic Neoplasms
Indication
Hearing Loss due to Cochlear Trauma
Indication
Transthyretin Amyloidosis
Indication
Obstructive Hypertrophic Cardiomyopathy
Indication
Graft Versus Host Disease (GVHD)
Indication
Thrombosis
Indication
Myoclonic
Indication
Non-cystic Fibrosis Bronchiectasis
Indication
Primary Hyperoxaluria Type 2
Indication
Urologic Diseases
Indication
Genetic Disease
Indication
Lipoprotein Disorder
Indication
Primary Hyperoxaluria Type 3
Indication
Netherton Syndrome
Indication
Biliary Atresia
Indication
Cardiovascular Disease
Indication
Tooth Decay
Indication
Squamous Cell
Indication
Idiopathic
Indication
Severe Depression
Indication
Chinese Healthy Volunteer
Indication
HIV-1 Infection
Indication
Refractory Status Epilepticus
Indication
Mixed Guttate/Plaque Psoriasis
Indication
Pleural or Peritoneal Malignant Mesothelioma
Indication
Familial Adenomatous Polyposis
Indication
Burns
Indication
Healthy Subject
Indication
Stereotactic Body Radiation Therapy
Indication
Anterior Circulation Infarct
Indication
Tenosynovial Giant Cell Tumor
Indication
Pigmented Villonodular Synovitis
Indication
Lacunar Anterior Circulation Infarct
Indication
Giant Cell Tumor of Tendon Sheath
Indication
Localised
Indication
urinary incontinence
Indication
Membranous Nephropathy
Indication
SSIs
Indication
Primary Progressive Multiple Sclerosis
Indication
PTSD
Indication
Progressive supranuclear palsy
Indication
Lennox-Gastaut Syndrome
Indication
Peripheral Arterial Disease
Indication
Painful Diabetic Neuropathy
Indication
melanoma
Indication
Guillain-Barre Syndrome
Indication
Healthy Adult Males
Indication
Treatment-Resistant
Indication
NPM1-mutated Acute Myeloid Leukemia
Indication
Stage IV
Indication
PIK3CA-related Overgrowth Spectrum (PROS)
Indication
HIV-1/HBV Co-Infection
Indication
Advanced Cancers
Indication
Metastatic Castration-sensitive Prostate Cancer
Indication
GM2 Gangliosidosis
Indication
Fallopian Tube Adenocarcinoma
Indication
HER2-positive breast cancer
Indication
Autoimmune Hemolytic Anemia
Indication
Neurodegenerative Diseases
Indication
Salmonella infection
Indication
Peritoneal Neoplasms
Indication
Glomerulonephritis
Indication
Primary Mitochondrial Myopathy
Indication
Osteochondrodysplasia
Indication
Congenital Hyperinsulinism
Indication
complicated intra-abdominal infections
Indication
Islet Transplantation in Diabetes Mellitus Type 1
Indication
Anxiety Disorders
Indication
Hemolysis
Indication
Submental fat
Indication
Stress
Indication
Mental health
Indication
Cardiomyopathy
Indication
Liver Metastases
Indication
COVID-19 vaccine
Indication
Duchenne Muscular Dystrophy
Indication
Hypertrophic
Indication
Ankylosing spondylitis
Indication
Frown Lines
Indication
Hypoxic-Ischemic Encephalopathy
Indication
Migraine with Aura
Indication
Hypertrophic Obstructive
Indication
Graves' Disease
Indication
Cervical cancer
Indication
Muscular Atrophy
Indication
Allergy
Indication
spinal
Indication
Palmoplantar Pustulosis
Indication
Breast Cancer, Stage IV
Indication
Stage III NSCLC
Indication
Hypoxia
Indication
Hepatitis
Indication
central neuropathic pain
Indication
Axial Spondyloarthritis
Indication
Streptococcal Infections, Group B
Indication
Pulmonary Embolism
Indication
Paraplegia
Indication
Dementia
Indication
Non-alcoholic Fatty Liver Disease
Indication
Phantom Limb Syndrome With Pain
Indication
Frontotemporal
Indication
Substance Use Disorders
Indication
Phantom Pain
Indication
Traumatic Brain Injury
Indication
Myeloproliferative Neoplasm
Indication
Glabellar Frown Lines
Indication
Lipodystrophy
Indication
Dental Caries in Children
Indication
XIAP deficiency
Indication
Metastatic Breast Cancer
Indication
Lymphocytopenia
Indication
Thyroid Cancer
Indication
Tolerance
Indication
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Indication
Diarrhea
Indication
Type 2 diabetes
Indication
Muscular Dystrophy
Indication
Biliary Tract Neoplasms
Indication
Mitochondrial Myopathy
Indication
Miscarriage
Indication
Duchenne
Indication
Skin Diseases
Indication
Mitochondrial Pathology
Indication
Muscular Disorders
Indication
Mitochondrial DNA Mutation
Indication
Hormone receptor positive
Indication
Opioid-use Disorder
Indication
Atrophic
Indication
Myelosuppression
Indication
infertility
Indication
Muscular Diseases
Indication
Mitochondrial Diseases
Indication
Neutropenia
Indication
Neuromuscular Disorders
Indication
Woman
Indication
Mitochondrial DNA Deletion
Indication
X-Linked
Indication
Fertility Disorders
Indication
Nervous System Diseases
Indication
Behcet Syndrome
Indication
Mitochondrial DNA Depletion
Indication
Mitochondrial Metabolism Defect
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Indication
Mitochondrial Complex I Deficiency
Indication
Neurofibromatosis Type 2
Indication
Subarachnoid Hemorrhage (Aneurysmal)
Indication
Human Papillomavirus
Indication
Non-erosive Reflux Disease
Indication
Opioid Use
Indication
Mycosis Fungoides
Indication
Connective Tissue Diseases
Indication
Metastatic Non-Small Cell Lung Cancer
Indication
COVID-19 Pneumonia
Indication
Geographic
Indication
Cerebrovascular Stroke
Indication
Primary Progressive
Indication
Autoimmune Diseases
Indication
Cerebrovascular Atherosclerosis
Indication
Intracranial Arteriosclerosis
Indication
Progressive Familial Intrahepatic Cholestasis
Indication
Glucocerebrosidase Deficiency
Indication
Diabetic Foot Infection
Indication
Metastatic Castration-Resistant Prostate Cancer
Indication
Uveitis
Indication
Interstitial Cystitis
Indication
Gallbladder Cancer
Indication
Aortic Valve Disease
Indication
Aortic Valve Stenosis
Indication
Secondary
Indication
Heart Failure
Indication
Canker Sores
Indication
Disruptive Behavior
Indication
Spasticity
Indication
Hypothalamic Obesity
Indication
Non-Erosive GERD
Indication
Heartburn
Indication
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease
Indication
Primary Biliary Cirrhosis
Indication
Clostridioides difficile infection
Indication
Chronic Graft Versus Host Disease
Indication
Cytokine Release Syndrome
Indication
Impotence
Indication
Vertigo
Indication
Androgenetic Alopecia
Indication
Dysautonomia
Indication
Spinocerebellar Ataxia
Indication
Fungi Infections
Indication
Phase I
Indication
Interstitial Lung Disease
Indication
Allergic Fungal Rhinosinusitis
Indication
Safety
Indication
Pertussis/Whooping Cough
Indication
Melioidosis
Indication
Spinocerebellar Ataxia Type 7
Indication
Spinocerebellar Ataxia Type 8
Indication
Oncology
Indication
Microvascular Obstruction
Indication
Childhood-Onset Fluency Disorder
Indication
Bordetella pertussis
Indication
Hospital-Acquired Pneumonia
Indication
Wheezing Lower Respiratory Illness
Indication
Ventilator-associated pneumonia
Indication
Toothache
Indication
Eczema
Indication
Intra-abdominal infection
Indication
Mitochondrial Myopathies
Indication
Diabetic Neuropathies
Indication
Sepsis
Indication
Rectal Neoplasms
Indication
Diabetic Polyneuropathy
Indication
Peripheral Neuropathy With Type 2 Diabetes
Indication
Sexual Dysfunction
Indication
Borderline Resectable Pancreatic Cancer
Indication
CDD - CDKL5 Deficiency Disorder
Indication
Sarcopenia
Indication
Elevated LDL-C
Indication
Extranodal NK/T-cell Lymphoma
Indication
Tympanic Membrane Perforation
Indication
thrombolysis
Indication
Spinal Cord Injuries
Indication
Immunotherapy
Indication
Upper Respiratory Tract Infections
Indication
Rett Syndrome
Indication
Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Indication
Spinal Cord Injury, Chronic
Indication
Vulvovaginal Atrophy
Indication
MELAS
Indication
Metabolism and Nutrition Disorders
Indication
Systemic Juvenile Idiopathic Arthritis
Indication
Thromboembolic Events
Indication
Ascites
Indication
Respiratory viral infection
Indication
Staphylococcus aureus bloodstream infection
Indication
Hepatorenal syndrome
Indication
Allergic rhinitis
Indication
Peripheric Vascular Enfermedad
Indication
Spinal Cord Injury
Indication
Insomnia
Indication
End Stage Renal Disease
Indication
Atopic Hand and Foot Dermatitis
Indication
Graft-Versus-Host Disease
Indication
Hematopoietic Stem Cell Transplantation
Indication
Asymptomatic Condition
Indication
Malaria caused by Plasmodium falciparum
Indication
Upper Limb Spasticity
Indication
Leishmaniasis
Indication
Refractory Invasive Pulmonary Aspergillosis
Indication
Primary Myelofibrosis
Indication
Cardiovascular Risk
Indication
Ovarian Neoplasm Epithelial
Indication
Traveler's Diarrhea
Indication
Locally Advanced or Metastatic Breast Cancer
Indication
Ovarian Cancer Recurrent
Indication
Acute Myocardial Infarction
Indication
Dyspnea
Indication
pleural effusion
Indication
Huntington's disease
Indication
Arrhythmogenic Right Ventricular Cardiomyopathy
Indication
Irritable Bowel Syndrome With Constipation (IBS-C)
Indication
First in Man Study to Evaluate Initial Safety
Indication
Metastatic Non Small Cell Lung Cancer
Indication
Post-essential Thrombocythemia Myelofibrosis
Indication
Meningococcal Infection
Indication
Sickle Cell
Indication
EPP (Erythropoietic Protoporphyria)
Indication
Chronic Inflammatory Demyelinating Polyneuropathy
Indication
Non-Small Cell
Indication
Melanoma stage III
Indication
Open-heart surgery
Indication
Early Alzheimer's Disease
Indication
Renal Replacement Therapy
Indication
Mild Cognitive Impairment Due to Alzheimer's Disease
Indication
Antithrombin Deficiency
Indication
Postpartum
Indication
Osteoarthritis of Knee
Indication
Postnatal Depression
Indication
Non-small Cell Lung Cancer Stage IV
Indication
Angiosarcoma
Indication
Healthy Adults
Indication
Undifferentiated Pleomorphic Sarcoma
Indication
Nonalcoholic steatohepatitis
Indication
Food Allergy
Indication
Agitation
Indication
SMA
Indication
Chronic Cough
Indication
Social Anxiety Disorder
Indication
Primary Generalized Tonic-Clonic Seizures
Indication
Renal Anemia
Indication
Hemochromatosis
Indication
Idiopathic Interstitial Pneumonia
Indication
Sarcoidosis
Indication
Electrocardiogram
Indication
Respiratory Bronchiolitis Associated Interstitial Lung Disease
Indication
Desquamative Interstitial Pneumonia
Indication
Painful intercourse
Indication
Cryptogenic Organizing Pneumonia
Indication
Gastroesophageal reflux disease
Indication
Crow's feet
Indication
Acute Interstitial Pneumonitis
Indication
Idiopathic Lymphoid Interstitial Pneumonia
Indication
Idiopathic Pleuroparenchymal Fibroelastosis
Indication
Chronic Heart Failure With Reduced Ejection Fraction
Indication
CPVT1
Indication
Congenital Heart Defect
Indication
Congenital
Indication
Type C1
Indication
Heart Diseases
Indication
Monkeypox
Indication
Ventricular Tachycardia
Indication
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Indication
Lumbosacral Radiculopathy
Indication
Cognitive Impairment
Indication
Childhood Epilepsy
Indication
alopecia areata
Indication
Sciatica
Indication
Disease
Indication
Resistant Hypertension
Indication
Brain Diseases
Indication
Inflammatory Diseases
Indication
Staphylococcus aureus infection
Indication
Central Nervous System Diseases
Indication
Pseudomonas Infection
Indication
Surgical Site Infection
Indication
Metastatic Urothelial Carcinoma
Indication
RNA Virus Infections
Indication
SARS
Indication
Cocaine use disorder
Indication
Juvenile Neuronal Ceroid Lipofuscinosis
Indication
SARS-CoV-2
Indication
Respiratory Infection
Indication
Cardiac Edema (CHF)
Indication
Ocular Surgery
Indication
Breast Carcinoma
Indication
Immunocompromised
Indication
Metastatic Colorectal Cancer
Indication
Cold
Indication
Facioscapulohumeral muscular dystrophy (FSHD)
Indication
FSHD1
Indication
Functional Dyspepsia
Indication
FSHD2
Indication
Foot-and-Mouth Disease
Indication
Knee Osteoarthritis
Indication
Familial Mediterranean fever
Indication
Facioscapulohumeral Muscular Dystrophy
Indication
Facioscapulohumeral Muscular Dystrophy Type 1
Indication
Fascioscapulohumeral Muscular Dystrophy Type 2
Indication
Newly Diagnosed
Indication
Anorexia
Indication
Trauma
Indication
Acute Liver Failure
Indication
FIGO Stage III-IV
Indication
Dystrophy
Indication
Trauma Injury
Indication
Acute Liver Injury
Indication
Facioscapulohumeral Muscular
Indication
Complete Response
Indication
Mild Cognitive Impairment
Indication
Partial Response
Indication
Mastocytosis
Indication
Enteric Hyperoxaluria
Indication
Facioscapulohumeral Muscular Dystrophy 2
Indication
Idiopathic Male Infertility
Indication
Dry Eye Disease
Indication
Cardiac Repolarization
Indication
Insulin Resistance
Indication
Presbyopia
Indication
Monocarboxylate Transporter 8 Deficiency
Indication
Allan-Herndon-Dudley Syndrome
Indication
Postoperative Ileus
Indication
Recurrent or Metastatic
Indication
Sleep Disorders
Indication
Preterm Birth
Indication
Circadian Rhythm
Indication
Inadequate Milk Production
Indication
Muscle Atrophy
Indication
Chronobiology Disorders
Indication
Stomach
Indication
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Indication
Gastroesophageal Reflux
Indication
Multiple System Atrophy
Indication
Lymphoproliferative Disorders
Indication
Peripheral
Indication
Cutaneous
Indication
Fructose Intolerance
Indication
Chronic obstructive pulmonary disease (COPD)
Indication
Desmoid Tumor
Indication
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Indication
Parkinson disease psychosis
Indication
Vascular Access Complication
Indication
Pustulosis Palmoplantaris
Indication
Post-surgical Neuropathic Pain
Indication
Adolescence
Indication
Cervical Dystonia
Indication
Keratoconus
Indication
Heterozygous Familial Hypercholesterolemia
Indication
Knee Replacement
Indication
Homozygous Familial Hypercholesterolemia
Indication
Prevention
Indication
Healthy Adult Participants
Indication
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Indication
Pancreatic Adenocarcinoma
Indication
Rhinitis
Indication
Notalgia Paresthetica
Indication
ST Elevation Myocardial Infarction
Indication
Alexander Disease
Indication
Persistent Pulmonary Hypertension of the Newborn
Indication
Prader-Willi Syndrome
Indication
Attention-Deficit Hyperactivity Disorder
Indication
Claudication
Indication
Abuse Potential
Indication
Psoriatic
Indication
Nocturnal
Indication
Post COVID-19 Condition
Indication
Long COVID
Indication
Malignant Solid Neoplasm
Indication
Anal Fistula
Indication
Acute Coronary Syndrome
Indication
Startle Response
Indication
IBS - Irritable Bowel Syndrome
Indication
Sinusitis
Indication
Polyp
Indication
Facioscapulohumeral muscular dystrophy
Indication
Proteinuria
Indication
Facioscapulohumeral
Indication
Atrophies
Indication
Fatigue
Indication
Ischemia
Indication
Landouzy-Dejerine
Indication
Angina
Indication
Sensorineural Deafness
Indication
Hyperammonemia
Indication
Landouzy Dejerine
Indication
Sudden Sensorineural Hearing Loss
Indication
Follicle-stimulating hormone
Indication
Upper Tract Urothelial Carcinoma
Indication
Social Anxiety Disorder in Autistic Adults
Indication
Focal Onset Seizures
Indication
Long Haul COVID
Indication
Chronic Graft-versus-host Disease
Indication
Long-Haul COVID-19
Indication
Conjunctivitis
Indication
Neuromyelitis Optica Spectrum Disorder
Indication
Fatty Liver
Indication
Anaphylaxis
Indication
Schizoaffective Disorder
Indication
Ventilator-associated Pneumonia
Indication
Spinal Muscular Atrophy Type 2
Indication
Motion Sickness
Indication
Chronic Thromboembolic Pulmonary Hypertension
Indication
HPV
Indication
Radiotherapy
Indication
Metabolism
Indication
Diabetic Peripheral Neuropathic Pain
Indication
Gastroesophageal Junction Adenocarcinoma
Indication
Hearing Loss, Sensorineural
Indication
Small for Gestational Age
Indication
Chronic Knee Pain
Indication
Transient Ischemic Attack
Indication
Chronic Rhinosinusitis Without Nasal Polyps
Indication
sinusitis
Indication
Respiratory Disorder
Indication
Bronchopulmonary Dysplasia
Indication
Mycobacterial Infections
Indication
Nontuberculous
Indication
Organic Acidemia
Indication
COPD Exacerbation
Indication
Chronic Obstructive Pulmonary Disease with Acute Lower Respiratory Infection
Indication
generalized lipodystrophy
Indication
Rhinovirus
Indication
Viral Infection
Indication
RNA
Indication
Enterovirus
Indication
Enterovirus Infections
Indication
Human Rhinovirus Infection
Indication
Liver Transplant
Indication
Respiratory Complication
Indication
Upper Respiratory Tract Infection
Indication
Upper Respiratory Infection
Indication
Upper Respiratory Disorder
Indication
Viral Upper Respiratory Infection
Indication
Respiratory
Indication
Chronic obstructive pulmonary disease
Indication
Lower Respiratory Disease
Indication
Lower Respiratory Disorder
Indication
Lower Respiratory Tract Infections
Indication
Chronic Respiratory Disease
Indication
Pelvic Organ Prolapse
Indication
Chronic Lung Disease
Indication
Chronic Lower Respiratory Diseases
Indication
Tinnitus
Indication
Retinopathy of Prematurity
Indication
Coagulation Disorder
Indication
Paclitaxel
Indication
Hypogammaglobulinemia
Indication
Ornithine Transcarbamylase Deficiency
Indication
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Indication
Long QT syndrome
Indication
Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)
Indication
Small Intestinal Bacterial Overgrowth
Indication
hip
Indication
NLRC4 gain-of-function
Indication
Autoinflammation With Infantile Enterocolitis
Indication
Chikungunya
Indication
CDC42 Mutations
Indication
Falciparum
Indication
Age-Related
Indication
RSV
Indication
Vulvovaginal Candidiasis
Indication
Postoperative Complications
Indication
Anesthesia
Indication
Epstein-Barr Virus Infection
Indication
Allergic Rhinoconjunctivitis
Indication
Drug-Induced Liver Injury
Indication
House Dust Mite Allergy
Indication
Pollen Allergy
Indication
Myocardial Infarction
Indication
Bronchiectasis
Indication
Obstructive Sleep Apnea
Indication
Homocystinuria
Indication
Pharmacokinetics of AEF0217
Indication
Pharmacology
Indication
Palmoplantar Psoriasis
Indication
Alzheimer's Disease Psychosis
Indication
acute decompensated heart failure
Indication
systolic
Indication
Heart Failure With Reduced Ejection Fraction
Indication
Binge Eating Disorder
Indication
Mycobacterium abscessus infection
Indication
Premenstrual Syndrome
Indication
Neurotrophic Keratopathy
Indication
Nontuberculous Mycobacterial Lung Disease
Indication
Nontuberculous Mycobacterial Pulmonary Infection
Indication
Atherosclerosis
Indication
Lipoprotein(a)
Indication
Neuromyelitis Optica Spectrum Disorders
Indication
Vasculitis
Indication
Clostridium difficile
Indication
Pancreatic Neuroendocrine Tumor
Indication
Clostridium difficile infection recurrence
Indication
Stress Reaction
Indication
Clostridioides difficile infection recurrence
Indication
Homeostasis
Indication
Bone
Indication
Clostridium difficile Infection
Indication
Post-Polycythemia Vera Myelofibrosis
Indication
Post-Essential Thrombocythemia Myelofibrosis
Indication
Essential Thrombocythemia
Indication
Hypoplastic Left Heart Syndrome
Indication
Hypothalamic Injury-induced Obesity (HIO)
Indication
MASH
Indication
Mild
Indication
Hypotrichosis
Indication
Hair Disorders
Indication
Nonalcoholic steatohepatitis (NASH)
Indication
Pathological Conditions
Indication
Anatomical
Indication
Peripheral Artery Disease
Indication
Health Volunteer
Indication
Transthyretin-Mediated Amyloid Cardiomyopathy
Indication
Sprained Ankle
Indication
Ocular Surface Disease
Indication
Polycystic Liver Disease
Indication
Pmm2-CDG
Indication
Cholera
Indication
Chronic Pancreatitis
Indication
Hepatitis C
Indication
Post-acute Respiratory Complications of COVID-19
Indication
Rapidly Progressive Glomerulonephritis
Indication
Focal-Onset Seizures
Indication
Epidermolysis Bullosa Dystrophica
Indication
Bronchiolitis Obliterans
Indication
Ischemic Stroke
Indication
Hemorrhagic Cystitis
Indication
Primary
Indication
Epidermolysis Bullosa
Indication
Junctional
Indication
Tobacco Use Disorder
Indication
Gout Flare
Indication
Acute Ischemic Stroke
Indication
RSV Immunization
Indication
Still's Disease
Indication
Adult-Onset
Indication
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Indication
advanced liver fibrosis
Indication
Infectious Disease
Indication
Respiratory Tract Infection
Indication
Vulvar Cancer
Indication
Rotator Cuff Tear
Indication
Lower Eyelid Steatoblepharon
Indication
Glabellar Lines
Indication
Lateral Epicondylitis
Indication
Postmenopausal
Indication
Cytomegalovirus Disease
Indication
Apathy in Dementia
Indication
Schnitzler syndrome
Indication
Chemotherapy-induced Thrombocytopenia
Indication
Cardiac
Indication
ANCA-associated Vasculitis
Indication
Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury
Indication
Cerebral Palsy
Indication
Systemic Inflammation
Indication
Septic shock
Indication
Meningioma
Indication
Myositis
Indication
Plantar Fasciitis
Indication
Chronic Hand Eczema
Indication
Insomnia Disorder
Indication
Night-time urination
Indication
Autonomous Cortisol Secretion
Indication
Primary Pulmonary Hypertension
Indication
ACTH-independent Cushing syndrome
Indication
Adrenal Cushing Syndrome
Indication
Somatic
Indication
Rotator Cuff Tendinopathy
Indication
Lower Urinary Tract Symptoms
Indication
Symptomatic Neurogenic Orthostatic Hypotension
Indication
Post-polycythemia Vera Myelofibrosis
Indication
Chronic Infection
Indication
Early-stage Parkinson's Disease
Indication
Diarrhea related to cancer therapy
Indication
Chemotherapy-Induced Diarrhea
Indication
Major Depressive Disorder With Suicidal Ideation With Intent
Indication
Polymyalgia Rheumatica
Indication
Overactive Bladder Syndrome
Indication
Dyspepsia
Indication
Ewing sarcoma
Indication
Coronavirus Infection
Indication
SOD1 gene mutation
Indication
Churg-Strauss Syndrome
Indication
Ischemic
Indication
Immunoproliferative Disorders
Indication
Immune System Diseases
Indication
Chronic Cystitis
Indication
Abdominal Aortic Aneurysm
Indication
Bacterial Cystitis
Indication
Chronic Bacterial Cystitis
Indication
Enzyme Inhibitors
Indication
Dengue virus
Indication
Genital Diseases
Indication
Musculoskeletal Disorders
Indication
Rheumatic Diseases
Indication
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Indication
Locally Advanced
Indication
Agitation in Patients With Dementia of the Alzheimer's Type
Indication
Hypereosinophilic Syndrome
Indication
Early Onset
Indication
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With
Indication
Uremic Pruritus
Indication
Hormone-receptor Positive Breast Cancer
Indication
Malignant Edema
Indication
Critical Illness
Indication
Dravet Syndrome
Indication
Metastatic hormone-sensitive prostate cancer
Indication
Pulmonary Hypertension Due to Left Heart Disease
Indication
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Indication
Tauopathy
Indication
Neurocognitive Disorders
Indication
Malignant Melanoma
Indication
Recurrent Pericarditis
Indication
Nonalcoholic Steatohepatitis With Liver Fibrosis
Indication
Chemotherapy-induced Neuropathic Pain
Indication
Thyroid Eye Disease
Indication
Hormonal
Indication
Androgen
Indication
Hormones
Indication
Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
Indication
Hormone Substitutes
Indication
Hormone Antagonists
Indication
Abiraterone
Indication
Corticosteroid Synthesis Inhibitors
Indication
Cytochrome P-450
Indication
prednisolone
Indication
Prednisolone
Indication
Cyclin-Dependent Kinase 4
Indication
CDK6
Indication
Intestinal Diseases
Indication
Colonic Diseases
Indication
autoimmune disease
Indication
Abdominal Pain
Indication
Alagille syndrome
Indication
Chemotherapy-Induced Anemia
Indication
Norovirus Gastroenteritis
Indication
Hereditary Angioedema Type II
Indication
Hereditary Angioedema with C1 Esterase Inhibitor Deficiency
Indication
Hereditary Angioedema Type 1
Indication
Hereditary Angioedema - Type 2
Indication
C1 Esterase Inhibitor Deficiency
Indication
C1 Inhibitor Deficiency
Indication
Discoid
Indication
Subacute Cutaneous
Indication
Hypertrophic Scar
Indication
Sexual Arousal Disorder
Indication
Chronic Liver Disease
Indication
Vulvar Diseases
Indication
Vulvar HSIL
Indication
vulvar intraepithelial neoplasia
Indication
Usual Type
Indication
Vulvar Intraepithelial Neoplasia 2 (Usual Type)
Indication
Vulvar intraepithelial neoplasia 3
Indication
Von Willebrand disease
Indication
Vincristine III
Indication
VIN Grade 2
Indication
VIN 3
Indication
High-grade intraepithelial neoplasia
Indication
Transthyretin-Mediated Amyloidosis
Indication
Metastatic Hormone Sensitive Prostate Cancer
Indication
Fibrodysplasia Ossificans Progressiva
Indication
Acute Hepatic Porphyria
Indication
Porphyria
Indication
Acute Intermittent
Indication
Acute Porphyria
Indication
Hereditary Coproporphyria
Indication
Variegate Porphyria
Indication
ALA Dehydratase Deficient Porphyria
Indication
Cardiac Surgery Postoperative Complications
Indication
HPV-related malignancy
Indication
Fragile X syndrome
Indication
Alcohol-Associated Hepatitis
Indication
Extrahepatic Cholangiocarcinoma
Indication
Gallbladder carcinoma
Indication
Relapsing-remitting multiple sclerosis
Indication
Peripheral Nerve Injury
Indication
Post-Traumatic Neuralgia
Indication
Viral Respiratory Illnesses
Indication
Brachial plexopathy
Indication
Lipid metabolism
Indication
Recurrent Vulvovaginal Candidiasis
Indication
Achilles tendinopathy
Indication
Subacute Cutaneous Lupus Erythematosus
Indication
Cutaneous Lupus Erythematosus
Indication
Drug-Resistant Epilepsy
Indication
Surgery
Indication
Leigh syndrome
Indication
Tourette syndrome
Indication
Behçet's Disease
Indication
Post-traumatic Stress Disorder
Indication
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Indication
Lipid Metabolism Disorder
Indication
Metabolic disorder
Indication
Inborn Errors
Indication
Drug Interaction
Indication
Hyperlipoproteinemias
Indication
Prodromal Alzheimer's Disease
Indication
Amyloid Plaque
Indication
Beta Amyloid
Indication
Alzheimer's Disease in Down Syndrome
Indication
Fibrosis
Indication
Cervical Spondylotic Myelopathy
Indication
Healthy Adult Volunteers
Indication
Cholinergic Urticaria
Indication
Ulcerative colitis
Indication
Impaired Vaccine Response
Indication
Urinary tract infection
Indication
Nonmetastatic Castration-Resistant Prostate Cancer
Indication
Proteinuric Kidney Disease
Indication
ADPKD
Indication
erythropoietic protoporphyria
Indication
X-Linked Lymphoproliferative Syndrome
Indication
Complement Deficiencies
Indication
Injuries
Indication
Kidney Disease
Indication
Necrotizing enterocolitis
Indication
Chronic Venous Stasis Ulcer
Indication
Heart disease
Indication
Arrhythmia
Indication
diastolic
Indication
Primary Generalized Epilepsy
Indication
Chronic Kidney Disease stage 4
Indication
Dentin Sensitivity
Indication
Breast Cancer Related Lymphoedema
Indication
Pancreatic Cancer Metastatic
Indication
Lymphedema
Indication
Distal RTA
Indication
Allergic Diseases
Indication
Fuchs Endothelial Corneal Dystrophy
Indication
Dentin Hypersensitivity
Indication
Endothelial dysfunction
Indication
Spasticity due to Stroke or Traumatic Brain Injury
Indication
Methamphetamine dependence
Indication
Lesch-Nyhan Syndrome
Indication
Self-harm
Indication
Gastrointestinal Disorder
Indication
Unintentional Weight Loss
Indication
Glucose Metabolism Disorders
Indication
Osteoarthritis of the Thumb
Indication
herpes simplex
Indication
Systemic Sclerosis With Lung Involvement
Indication
Cerebral Amyloid Angiopathy
Indication
Wound Healing
Indication
Wound Healing Disturbance
Indication
Wound Healing Disorder
Indication
Delayed Wound Healing
Indication
Non-Alcoholic SteatoHepatitis (NASH)
Indication
End-stage Kidney Disease (ESKD)
Indication
Acute on Chronic Liver Failure
Indication
Influenza A
Indication
Platysmal Band
Indication
Healthy Elderly
Indication
Insulin-Dependent
Indication
Hidradenitis
Indication
COPD exacerbation
Indication
Intermediate
Indication
Non-segmental Vitiligo
Indication
Polyneuropathy
Indication
Obsessive-Compulsive Disorder
Indication
Inflammatory Demyelinating
Indication
Chronic Fatigue Syndrome
Indication
Resectable Non-small Cell Lung Cancer
Indication
portal
Indication
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Indication
frailty
Indication
Cannabis Use Disorder
Indication
Hemolytic
Indication
Trigeminal Neuralgia
Indication
Focal Onset Seizure
Indication
Focal Onset Epilepsy
Indication
STGD1
Indication
Partial Lipodystrophy
Indication
Idiopathic Inflammatory Myositis
Indication
Basal Cell
Indication
Calcific Aortic Valve Disease
Indication
Acute Respiratory Viral Infection
Indication
Parkinson Disease 6
Indication
Early-Onset
Indication
Hypoglycemia
Indication
Sleep Apnea
Indication
ANCA Associated Vasculitis
Indication
Testicular germ cell tumor
Indication
Chemotherapy-induced Nausea and Vomiting
Indication
Conventional Chondrosarcoma with IDH1 Mutation
Indication
Systemic Treatment Regimen
Indication
Musculoskeletal Injury
Indication
Acute Non-cardioembolic Ischemic Stroke
Indication
Chronic Idiopathic Urticaria
Indication
Lower Respiratory Tract Illness
Indication
Common Warts
Indication
Atherosclerotic Cardiovascular Disease (ASCVD)
Indication
Elevated Lp(a)
Indication
Non-metastatic
Indication
Mesopic Vision
Indication
Night Vision Loss
Indication
Breast Density
Indication
Hyposmia
Indication
Anhedonia
Indication
Masseter Muscle Prominence
Indication
Lower Respiratory Tract Infection
Indication
obstructive sleep apnea
Indication
Orphan Cholestatic Liver Diseases
Indication
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Indication
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Indication
Chronic Prostatitis
Indication
Chronic Pelvic Pain Syndrome
Indication
Streptococcal toxic shock syndrome
Indication
Healthy Participants Study
Indication
Indolent
Indication
Cushing's Syndrome
Indication
Cushing's disease
Indication
Cortisol
Indication
Ectopic ACTH Secretion
Indication
Soil-Transmitted Helminthiasis
Indication
Vaccines
Indication
Dementia (Moderate)
Indication
ST Segment Elevation Myocardial Infarction
Indication
Cerebral Contusion
Indication
Adolescent
Indication
CIN2
Indication
CIN III
Indication
Genital Warts
Indication
AIS
Indication
Irritable Bowel Syndrome with Diarrhea
Indication
Chronic medication overuse headache
Indication
Irritable Bowel Syndrome with Constipation
Indication
Chronic Constipation
Indication
Chronic Bronchitis
Indication
Steroid-Dependent Crohn's Disease
Indication
meningococcal immunization
Indication
Macrophage Activation Syndrome
Indication
Adult-onset Still's disease
Indication
Arrhythmogenic Cardiomyopathy
Indication
Graft-Vs-Host Disease
Indication
Gastrointestinal Tract
Indication
Mental Illness
Indication
Chronic Kidney Disease stage3
Indication
Vitamin D deficiency
Indication
Penile Cancer
Indication
PIN-1
Indication
PIN-2
Indication
PIN-3
Indication
AIN1
Indication
AIN2
Indication
AIN3
Indication
Erythropoietic Protoporphyria (EPP)
Indication
X-Linked Protoporphyria
Indication
Joint Pain
Indication
Wrinkles
Indication
Ventilator-Associated Infection
Indication
Wound
Indication
Cancer Pain
Indication
Arteritis, Giant Cell
Indication
progressive relapsing multiple sclerosis
Indication
Sensorineural
Indication
Lung Transplant Rejection
Indication
Severe COVID-19
Indication
Perennial Allergic Rhinitis
Indication
Parkinson Disease Dementia
Indication
Spinocerebellar Ataxia Genotype Type 1
Indication
Spinocerebellar Ataxia Genotype Type 2
Indication
Spinocerebellar Ataxia Genotype Type 3
Indication
Spinocerebellar Ataxia Genotype 6
Indication
Spinocerebellar Ataxia Genotype Type 10
Indication
Scar
Indication
lymphatic malformation
Indication
Nausea
Indication
Arrhythmogenic Right Ventricular Dysplasia
Indication
Psychomotor
Indication
Atopic hand eczema
Indication
Idiopathic Inflammatory Myopathies
Indication
Lower Respiratory Tract Disease
Indication
Cardiometabolic Diseases
Indication
Hemorrhoids Without Complication
Indication
Preclinical Alzheimer's Disease
Indication
Thyroid Diseases
Indication
Chronic Hepatitis B Infection
Indication
Cardiac Disease
Indication
Cardiopulmonary Bypass
Indication
Huntington's chorea
Indication
Spinal Muscular Atrophy Type 3
Indication
Neuromuscular Manifestations
Indication
Postoperative Dental Pain
Indication
Fungal Pneumonia
Indication
Chronic Migraine in Children
Indication
Respiratory Syncytial Virus Immunization
Indication
Cutaneous Melanoma
Indication
Cardiac surgery
Indication
Vaping
Indication
E-Cigarette Use
Indication
Barth Syndrome
Indication
Bladder Pain Syndrome
Indication
Primary Axillary Hyperhidrosis
Indication
Avian Influenza
Indication
Charcot-Marie-Tooth Disease
Indication
Viral Lung Infection and Acute Respiratory Failure
Indication
Focal Segmental Glomerulosclerosis
Indication
Nontuberculous Mycobacterial Pulmonary Disease
Indication
Fibrostenotic Crohn's Disease
Indication
Herpes Labialis
Indication
Ampullary Cancer
Indication
Acne Rosacea
Indication
Stress Disorders
Indication
Post-Traumatic
Indication
Burn
Indication
Herniated Disc
Indication
Horizontal Forehead Lines
Indication
Lateral Canthal Lines
Indication
Systemic Lupus
Indication
Graves Ophthalmopathy
Indication
Systemic Mastocytosis
Indication
Orbital Diseases
Indication
Proptosis
Indication
Opioid Withdrawal
Indication
Erythromelalgia
Indication
Ventricular Dysfunction
Indication
Left
Indication
Haemophilia A
Indication
Status Epilepticus
Indication
Mitochondrial Encephalopathy
Indication
MELAS Syndrome
Indication
Seborrheic Dermatitis
Indication
Dedifferentiated Liposarcoma
Indication
Chromosome 15q Duplication Syndrome
Indication
STEMI
Indication
Parenteral Nutrition Associated Liver Disease
Indication
Tinea Versicolor
Indication
Wheezing
Indication
Cystinuria
Indication
Healthy Volunteers Only
Indication
SORD Deficiency
Indication
Vitamin D Deficiency
Indication
Muscle Spasticity
Indication
Drug Safety
Indication
Angioplasty
Indication
Immune System Disorder
Indication
Migraine With Aura
Indication
Cognitive Impairment Associated With Schizophrenia
Indication
Migraine Without Aura
Indication
Osteoarthritis of the Hand
Indication
Neurocognitive Impairment
Indication
Type 1 diabetes
Indication
neuropathic pain
Indication
Limb-Girdle Muscular Dystrophies
Indication
Gastrointestinal Symptoms
Indication
Acute Migraine
Indication
Sativex
Indication
Hashimoto Thyroiditis
Indication
Familial Mediterranean Fever
Indication
Exercise Performance
Indication
Noise-Induced Hearing Loss
Indication
Rotavirus Gastroenteritis
Indication
Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Indication
Lassa fever
Indication
Metabolic Acidosis
Indication
Nervous System Disorders
Indication
Parapsoriasis
Indication
Rosacea
Indication
Retinal Detachment
Indication
autoimmune encephalitis
Indication
Elderly
Indication
Molluscum Contagiosum
Indication
Stem Cell Transplant Complications
Indication
tummy tuck
Indication
Chagas Disease
Indication
Nicotine Dependence
Indication
Foot Ulcer
Indication
Soft Tissue Injury
Indication
Malignant Neoplasm
Indication
Postoperative Cognitive Dysfunction
Indication
Partial Seizures
Indication
Nalbuphine
Indication
Angiofibroma of Face
Indication
Proliferative Vitreoretinopathy
Indication
Tuberous Sclerosis
Indication
IGF1R
Indication
Substance Use Disorder
Indication
Human Metapneumovirus and Human Parainfluenza Infection
Indication
Exophthalmos
Indication
Meniere's Disease
Indication
Hashimoto
Indication
Chronic Abnormal Immune Activation in HIV/AIDS
Indication
Diabetic Nephropathies
Indication
Adult AML
Indication
Relapsed or Refractory
Indication
Focal Segmental
Indication
Dexmedetomidine
Indication
Nephrosis
Indication
Chiauranib
Indication
Chronic Coronary Syndrome
Indication
Lipoid
Indication
Escherichia coli Infections
Indication
Squamous non-small cell lung cancer
Indication
Bloodstream Infection
Indication
Diabetes Complications
Indication
Vomiting
Indication
End-stage Renal Disease
Indication
Nephritis
Indication
Meniere's disease
Indication
hypogonadotropic hypogonadism
Indication
Neuropathy Peripheral
Indication
Trichomoniasis
Indication
Neurobehavioral Disinhibition
Indication
Immune suppression
Indication
Abdominoplasty
Indication
Endoscopic Sinus Surgery
Indication
Ototoxicity
Indication
Pre-Diabetes
Indication
Atopic dermatitis
Indication
Guillain-Barré syndrome
Indication
hATTR Amyloidosis
Indication
Sphingomyelin lipidosis
Indication
Primary Osteoarthritis of Hip
Indication
Persistent
Indication
MRSA
Indication
Hypersomnia
Indication
Epileptic Encephalopathy
Indication
Lupus Nephritis (LN)
Indication
Safety in Healthy Volunteers
Indication
Epileptic Encephalopathy with Continuous Spike and Wave During Sleep
Indication
Ocular Graft-versus-host Disease
Indication
Fracture Healing
Indication
KLH and Imiquimod Induced Skin Inflammation
Indication
Atopic Healthy Subjects
Indication
Symptoms and Signs
Indication
Detrusor Muscle Hyperactivity
Indication
Mild Allergic Diseases
Indication
Bardet-Biedl Syndrome
Indication
Lewy Body Disease
Indication
pemphigoid
Indication
Myotonic Dystrophy Type 1
Indication
Bullous
Indication
Mechanically-induced disease
Indication
IgA
Indication
Multiple System Atrophy with Orthostatic Hypotension
Indication
Autonomic Failure
Indication
Orthostatic hypotension
Indication
Adult-Onset Still's Disease
Indication
Orthostatic Hypotension
Indication
Amyloid Cardiomyopathy
Indication
KEAP1 Gene Mutation
Indication
VAIN-I
Indication
Pure Autonomic Failure With Orthostatic Hypotension
Indication
Malabsorption
Indication
VAIN III
Indication
NRF2 gene mutation
Indication
Parkinson Disease With Orthostatic Hypotension
Indication
Vitamin I
Indication
NFE2L2 Gene Mutation
Indication
VAIN - Vaginal Intraepithelial Neoplasia 2
Indication
Post-operative dental pain
Indication
Nausea and Vomiting in Pregnancy
Indication
Chronic Lung Allograft Dysfunction
Indication
Chronic Inflammatory Disease
Indication
Amyloid Transthyretin Cardiomyopathy
Indication
Polycystic Ovary Syndrome
Indication
Local
Indication
Impaired Cognitive Function
Indication
Age-related Wet Macular Degeneration
Indication
Miosis
Indication
Subjective
Indication
Vocal Cord Scar
Indication
Food Effect
Indication
Postoperative Analgesia
Indication
Adhesive Capsulitis
Indication
Inguinal Hernia
Indication
Sialorrhea
Indication
Severe Acute Respiratory Syndrome (SARS)
Indication
Therapy
Indication
Oral Dysbiosis
Indication
Immune-Mediated Inflammatory Diseases
Indication
Herpes labialis
Indication
Space
Indication
Healthy Volunteers with Type 2 Diabetes
Indication
PCDH19-Related Epilepsy
Indication
Adult Stem Cells
Indication
Liver Dysfunction
Indication
Progressive Fibrosing Interstitial Lung Disease
Indication
Immune
Indication
Chemotherapy-Induced Thrombocytopenia
Indication
Heparin-Induced Thrombocytopenia
Indication
Newborn
Indication
Norovirus
Indication
Chronic Pruritus
Indication
Mast Cell Activation Syndrome
Indication
Mast Cell Activation Disorder Idiopathic
Indication
Agitation in Alzheimer's Disease
Indication
Bardet-Biedl syndrome
Indication
Pancreatitis
Indication
Healthy Subjects (Indication: Asthma)
Indication
Type III
Indication
Alström Syndrome
Indication
Discogenic Pain
Indication
COVID-19 ARDS
Indication
Nervous System
Indication
Donor Site Complication
Indication
QT prolongation
Indication
Mild Traumatic Brain Injury
Indication
Hospital-acquired Bacterial Pneumonia
Indication
Lumbosacral Radicular Pain
Indication
ER-positive Breast Cancer
Indication
Medication
Indication
Chinese
Indication
Vaccine
Indication
Dyslexia
Indication
Night Waking
Indication
Post-traumatic stress disorder
Indication
Nonsense Mutation
Indication
Trauma- and Stressor-Related Disorders
Indication
Neuroinflammatory Response
Indication
Contact Lens Discomfort
Indication
BK Virus-associated Nephropathy
Indication
Thrombotic thrombocytopenic purpura
Indication
Diabetic Cardiomyopathy
Indication
Heart Failure With Preserved Ejection Fraction
Indication
Acute Respiratory Tract Infections
Indication
Radiation Exposure
Indication
Clostridioides difficile
Indication
Alcohol use disorder
Indication
Acute Hypoxemic Respiratory Failure
Indication
HOCM
Indication
Lymphatic Diseases
Indication
Low Anterior Resection Syndrome
Indication
Stomatitis
Indication
Anxiety Disorders in Children
Indication
Bipolar 1 Depression
Indication
Palliative Care
Indication
Cervical High Grade Squamous Intraepithelial Lesion
Indication
Severe Acute Respiratory Syndrome Pneumonia
Indication
Intracerebral hemorrhage
Indication
HSIL
Indication
Viral
Indication
Metastatic Cervical Cancer
Indication
Pure Autonomic Failure
Indication
Alcohol Intoxication
Indication
Hemodiafiltration
Indication
Castration-Resistant Prostate Carcinoma
Indication
Senile Osteoporosis
Indication
Lumbar Disc Herniation
Indication
Kidney Removal
Indication
Hemorrhagic Stroke
Indication
Campylobacter Infections
Indication
Genetic
Indication
Drug-resistant Partial Onset Seizure
Indication
Chronic Intestinal Pseudo-obstruction
Indication
Bacterial Vaginosis
Indication
Non-Alcoholic Steatohepatitis (NASH)
Indication
Proopiomelanocortin Deficiency
Indication
Hepatitis C Virus Infection
Indication
Pelvic organ prolapse
Indication
Snakebite
Indication
Influenza-like Illness
Indication
Chronic Allograft Injury
Indication
narcolepsy with cataplexy
Indication
Envenoming
Indication
Hyperoxaluria
Indication
Snake
Indication
Chronic Hepatitis
Indication
Adjustment Disorder with Anxious Mood
Indication
Kidney Stone
Indication
Fuchs' Endothelial Corneal Dystrophy
Indication
Rotator Cuff Injuries
Indication
periodontitis
Indication
Coeliac Disease
Indication
Stress Ulcer Bleeding
Indication
Thrombotic Disease
Indication
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Indication
Intermittent Explosive Disorder
Indication
Cardiovascular Disease and Lipoprotein(a)
Indication
Cancer Cachexia
Indication
Scar Prevention
Indication
Chronic Hand Dermatitis
Indication
Cardiovascular Risk Factor
Indication
Exocrine Pancreatic Insufficiency
Indication
Masseteric Hypertrophy
Indication
Bipolar I Depression
Indication
Weight Management
Indication
Urticarial Vasculitis With Monoclonal Immunoglobulin M Component
Indication
Schnitzler
Indication
Major Depressive Disorder With Anxious Distress
Indication
Cardiogenic Shock
Indication
Influenza viral infections
Indication
Membranous nephropathy
Indication
Primary Peritoneal
Indication
Heredodegenerative Disorders
Indication
Acute Lower Back Pain
Indication
Parkinson
Indication
Sézary Syndrome
Indication
Fatty Liver Disease
Indication
Subjects With Hyperlipidemia
Indication
Breast Neoplasm Female
Indication
restless legs syndrome
Indication
Opioid Dependence
Indication
Hemophilic Arthropathy
Indication
Pancreatic Acinar Cell Carcinoma
Indication
Jet Lag Insomnia
Indication
Treatment-Resistant Depression
Indication
Recurrent Calcium Oxalate Kidney Stone Disease
Indication
Neuromyelitis Optica (NMO)
Indication
Atrial Fibrillation With Rapid Ventricular Response
Indication
Prophylaxis
Indication
Chronic Chest Pain
Indication
Autoimmune
Indication
Allergic Rhinitis due to Weed Pollen
Indication
Toxicity
Indication
Thromboembolism
Indication
Optic Neuropathy
Indication
Hematopoietic and Lymphoid System Neoplasm
Indication
Mixed Connective Tissue Disease
Indication
Optic Neuritis
Indication
Demyelination
Indication
Human Prevention
Indication
Sezary Syndrome
Indication
Obstructive
Indication
Eosinophilic Esophagitis (EoE)
Indication
Enhanced Recovery After Surgery
Indication
Chronic Stable Heart Failure
Indication
Esophageal Varices
Indication
Levodopa-induced Dyskinesia
Indication
posterior
Indication
Osteopenia
Indication
Mood Disorder
Indication
Preneoplastic Conditions
Indication
Prostatic Intraepithelial Neoplasia
Indication
Fuchs' Endothelial Dystrophy
Indication
Fuchs
Indication
Hallucinogen-persisting perception disorder
Indication
health
Indication
Ureteral Injury During Surgery
Indication
Impaired Glucose Tolerance
Indication
Acute Mountain Sickness
Indication
Back
Indication
Substance Abuse
Indication
Herpes simplex virus type 2
Indication
Female Sexual Arousal Disorder
Indication
Female Sexual Dysfunction
Indication
Urinary Tract Infections in Children
Indication
Acute Gastroenteritis
Indication
Dexamethasone
Indication
Nephrosclerosis
Indication
Autoimmune Pulmonary Alveolar Proteinosis
Indication
Partial Seizure
Indication
Polyradiculoneuropathy
Indication
Schizophrenia-related Psychotic Disorder
Indication
Chronic Inflammatory Demyelinating
Indication
EGFR Inhibitor-Induced Acneiform Lesions
Indication
Endometriosis-related Pain
Indication
COVID-19 Vaccination
Indication
Post-acute COVID-19 syndrome
Indication
Viral Disease
Indication
Contact Lens-induced Corneal Disorder
Indication
Postmenopausal Vasomotor Symptoms
Indication
Acute Red Eye
Indication
Acneiform Eruptions
Indication
Corneal Fluorescein Staining
Indication
Orthomyxoviridae Infections
Indication
Bunionectomy
Indication
Submental Fullness
Indication
Prolonged QTc Interval
Indication
Vitamin D
Indication
Post-surgical Ocular Inflammation
Indication
SARS coronavirus
Indication
Shigellosis
Indication
Iron Deficiency Anemia
Indication
Knee Pain
Indication
Post-surgical Ocular Pain
Indication
Cluster Headache
Indication
Healthy Non-dependent
Indication
Recreational Sedative Users
Indication
Endometrial Related Pain
Indication
Spinal Fusion
Indication
Bipolar II Disorder
Indication
Langerhans Cell Histiocytosis
Indication
Post-Traumatic Headache
Indication
Post-Concussion Syndrome
Indication
Nonalcoholic Fatty Liver
Indication
pericarditis
Indication
Tobacco use disorder
Indication
Leptin Receptor Deficiency Obesity
Indication
Not Determined
Indication
Specific Developmental Disorders of Scholastic Skills
Indication
Chronic Ocular Graft-versus-host Disease
Indication
Lewy Body Dementia
Indication
End-Stage Renal Disease Requiring Hemodialysis
Indication
Common cold
Indication
Chronic lower back pain
Indication
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
Indication
Herpes Simplex Infections
Indication
Brain
Indication
Behavioral Symptoms
Indication
Contrast-Induced Acute Kidney Injury
Indication
Endocrine Tumors
Indication
PPD
Indication
Postpartum Disorder
Indication
Hereditary Hemorrhagic Telangiectasia (HHT)
Indication
Brain Swelling
Indication
Large Hemispheric Infarction
Indication
Venous Thrombosis
Indication
Rotavirus Infections
Indication
Chronic Idiopathic Constipation
Indication
Sickle Beta 0 Thalassemia
Indication
Acute Heart Failure With Reduced Ejection Fraction
Indication
APOL1-mediated Kidney Disease
Indication
Sore Throat
Indication
Tonsillitis
Indication
Germline BRCA1/2 Mutations
Indication
Blood sugar
Indication
Spasticity in Multiple Sclerosis
Indication
Myostatin-related muscle hypertrophy
Indication
Human parainfluenza virus
Indication
COVID-19 with ARDS
Indication
High-Risk Non-Muscle-Invasive Bladder Cancer
Indication
Chronic Migraine
Indication
Delirium
Indication
Moderate Upper Facial Lines
Indication
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Indication
Severe Upper Facial Lines
Indication
Aspirin
Indication
Chronic Pseudomonas Aeruginosa Infection
Indication
Familial Amyloid Cardiomyopathy
Indication
Airway Inflammation
Indication
facial droop
Indication
Preeclampsia
Indication
Non Proliferative Diabetic Retinopathy
Indication
ATTR-CM
Indication
Proliferative Diabetic Retinopathy
Indication
Alzheimer's Disease With Vascular Pathology
Indication
Low
Indication
Clostridium Infections
Indication
Panic Disorder
Indication
Ileus
Indication
Postoperative Adhesions
Indication
Non-Erosive Esophageal Reflux Disease
Indication
End Stage Renal Disease on Dialysis
Indication
Hypoxemia
Indication
RSV Infection
Indication
Autoimmune Necrotizing Myopathy
Indication
Overlap Myositis
Indication
Juvenile Myositis
Indication
Klebsiella pneumoniae infection
Indication
Pemphigus
Indication
Allogeneic
Indication
Opioid Abuse
Indication
Food Affect
Indication
Irritable Mood
Indication
Overactive Bladder With Urge Urinary Incontinence
Indication
Single Ascending Dose
Indication
Maximum Applicable Dose
Indication
Suicide
Indication
Respiratory Disorders
Indication
Gut Microbiome
Indication
Irritability associated with autism spectrum disorder (ASD)
Indication
Catheter Occlusion
Indication
Endocarditis
Indication
Electrocardiography
Indication
Dengue Hemorrhagic Fever
Indication
Intrahepatic Cholestasis of Pregnancy
Indication
Pancreatectomy for Chronic Pancreatitis
Indication
Connective Tissue Disease
Indication
Cerebral Cavernous Malformation
Indication
Strain
Indication
Autologous Stem Cell Transplant
Indication
Infantile Spasm
Indication
Hip Fracture
Indication
Healthy Non-elderly and Elderly Adults
Indication
Epilepsy with Myoclonic Absences Syndrome
Indication
Aspirin-induced
Indication
HIV-I
Indication
Pulmonary Mycobacterium Avium Complex Infection
Indication
Anemia in Chronic Kidney Disease
Indication
Nail Psoriasis
Indication
Tachycardia
Indication
CTX
Indication
Pneumonitis
Indication
Supraventricular tachycardia
Indication
Chronic hepatitis C virus infection
Indication
Paroxysmal Supraventricular Tachycardia
Indication
Neurasthenia
Indication
Adjustment Disorders
Indication
Pro-opiomelanocortin (POMC) Deficiency Obesity
Indication
Corneal Inflammation
Indication
Beta-blocker
Indication
Cardiac Troponin
Indication
Focal Seizure
Indication
portal hypertension
Indication
Cannabis Intoxication
Indication
Arginase I Deficiency
Indication
Argininemia
Indication
Transplant Complication
Indication
Acute respiratory distress syndrome
Indication
Cytomegalovirus (CMV)-Positive Recipients
Indication
Hematopoietic Cell Transplant
Indication
Coronary Microvascular Dysfunction
Indication
Coronary Microvascular Disease
Indication
Focal Seizures
Indication
Liver Diseases
Indication
puerperal disorders
Indication
Cocaine Use
Indication
Cocaine Intoxication
Indication
Cocaine Toxicity
Indication
Cocaine Abuse
Indication
Endophthalmitis
Indication
Cocaine Adverse Reaction
Indication
Postoperative Delirium
Indication
Cystic Fibrosis Pulmonary Exacerbation
Indication
System sclerosis
Indication
Healthy Males
Indication
Pelvic Floor Disorders
Indication
Intervertebral Disc Degeneration
Indication
Shock
Indication
Septicemia
Indication
Pulmonary Hypertension Due to Lung Diseases
Indication
Acute Infectious Conjunctivitis
Indication
Manic Episode
Indication
Staphylococcal Infections
Indication
Agitation in Adolescents and Young Adults With Autism Spectrum Disorder
Indication
Schizophreniform
Indication
Advanced Gastric Cancer
Indication
Flank Mass
Indication
Temporomandibular Disorders (TMD)
Indication
Autoimmunity
Indication
Onchocerciasis
Indication
Cerebral Edema
Indication
Acute Pain
Indication
Rhizomelic Chondrodysplasia Punctata
Indication
Mitral Valve Insufficiency
Indication
Postpartum Hemorrhage
Indication
Diabetic Kidney Disease
Indication
Cannabis withdrawal
Indication
Lipohypertrophy
Indication
Hepatic Steatosis
Indication
Cancer-related Fatigue
Indication
Survival
Indication
SARS-CoV-2 Infection
Indication
Safety and Pharmacokinetic
Indication
Metabolic diseases
Indication
Immune Complex-mediated Autoimmune Diseases
Indication
Peripheral Sensory Neuropathy
Indication
Analgesia Disorder
Indication
HIV-associated polyneuropathy
Indication
Post-polio Syndrome
Indication
Primary Sjogren's Syndrome
Indication
Hypomagnesemia
Drug
placebo
Indication
Tetrahydrocannabinol
Indication
Marijuana
Indication
cannabis
Indication
Stage II Breast Cancer
Indication
Stage IIB Breast Cancer
Indication
Cannabis Use
Indication
Hematopoietic and Lymphoid Cell Neoplasm
Indication
Breast Cancer, Anatomic Stage IIIA AJCC v8
Indication
Alcohol consumption
Indication
Breast Cancer, Anatomic Stage IIIB AJCC v8
Indication
Second Trimester Abortion
Indication
Kidney Stones
Indication
Breast Cancer AJCC Stage IA
Indication
Autoimmune Inner Ear Disease
Indication
Surgical Treatment for Cancer
Indication
Long-Term Survivors
Indication
Syncope
Indication
Stage IIA Breast Cancer
Indication
Subarachnoid Hemorrhage
Indication
Prognostic Stage IIB Breast Cancer AJCC v8
Indication
Arthritis of Hip
Indication
Hematologic and Lymphocytic Disorder
Indication
Wrist Fracture
Indication
Breast Cancer, Prognostic Stage III AJCC v8
Indication
Vitamin C
Indication
Stage IIIA Breast Cancer
Indication
Stage IIIB Breast Cancer
Indication
Syringomyelia
Indication
Pain Management
Indication
Spontaneous Bacterial Peritonitis
Indication
Upper respiratory congestion
Indication
Bell's Palsy
Indication
Concussion
Indication
Cerebral
Indication
Hyperandrogenism
Indication
Recurrent Pregnancy Loss
Indication
Food IgE-mediated Allergy
Indication
Beta-blockers
Indication
Tendonitis
Indication
Myocardial Strain
Indication
Preeclampsia Severe
Indication
Central Nervous System Sensitization
Indication
Leiomyoma
Indication
Omalizumab
Indication
Hyperalgesia
Indication
Uterine
Indication
Allergy to House Dust Mites
Indication
Acute Chest Syndrome
Indication
Colorectal Disorders
Indication
Intellectual disability
Indication
Affective Symptoms
Indication
Severe Obesity
Indication
Scoliosis
Indication
lumbar spinal stenosis
Indication
Idiopathic Normal Pressure Hydrocephalus
Indication
Stage IV Cutaneous Melanoma
Indication
Fontan Procedure
Indication
Tobacco Use
Indication
Hyperglycemia
Indication
Tranexamic Acid
Indication
Inflammatory Response
Indication
Chronic Inflammation
Indication
Vasodilation
Indication
premature birth
Indication
BCR-ABL1-positive
Indication
Periodontal Diseases
Indication
Psychosis
Indication
Amputation
Indication
Spinal Cord Diseases
Indication
Oxidative Stress
Indication
Gonadal Disorders
Indication
DNA damage
Indication
Radiation Induced
Indication
Stage IIIC Cutaneous Melanoma AJCC v8
Indication
Antibiotic Prophylaxis
Indication
Burning Mouth Syndrome
Indication
Biomarkers
Indication
Pediatrics
Indication
Congenital heart defects
Indication
Tetrahydrobiopterin Deficiency
Indication
Abortion
Indication
Postoperative Urinary Retention
Indication
Allogeneic Disease
Indication
Transgender
Indication
Graft Versus Host Reaction
Indication
Clonal Cytopenia of Undetermined Significance
Indication
Acute Heart Failure
Indication
Rib Fractures
Indication
Schistosoma mansoni
Indication
Oxytocin
Indication
Difficulty swallowing
Indication
Cerebral Small Vessel Diseases
Indication
Diabetic Nephropathy Type 2
Indication
Behcet's Disease
Indication
Endodontic Disease
Indication
Healthy Control
Indication
probiotics
Indication
Barrett's Esophagus
Indication
Postoperative Atrial Fibrillation
Indication
Chronic Low Back Pain
Indication
Naltrexone
Indication
ADHD in Adults
Indication
Placebo
Indication
ADHD with Mood Disorder
Indication
Physical Activity
Indication
Pancreatic Insufficiency
Indication
Histamine
Indication
Peripartum Cardiomyopathy
Indication
Cerebral Arteriovenous Malformation
Indication
Post-stroke Cognitive Impairment
Indication
Aneurysm
Indication
Postoperative Nausea and Vomiting
Indication
Smoking
Indication
Renal Transplant Complication Non-Function
Indication
Appendicitis
Indication
Antibiotic Resistant Infection
Indication
Thyroid Nodule
Indication
agalactia
Indication
Aortic
Indication
Tuberculous Meningitis
Indication
Spinal Cord Injury Cervical
Indication
HPS
Indication
Intellectual Disability
Indication
Hypoxic-ischemic encephalopathy
Indication
Healthy Controls
Indication
Kidney stones
Indication
Fentanyl
Indication
Cannabidiol
Indication
Secondary Progressive
Indication
Hallux Valgus
Indication
Snake envenomation
Indication
Bone Sarcoma
Indication
Post-Operative Pain Control
Indication
Postpartum Pregnancy-Induced Hypertension
Indication
Metformin
Indication
Prediabetes
Indication
Pediatric Respiratory Diseases
Indication
Antibiotic Use
Indication
Trained Innate Immunity
Indication
Antimicrobial Resistance
Indication
Family Members
Indication
NSTEMI
Indication
Cardiac Arrest
Indication
SAPHO syndrome
Indication
Eating Disorder
Indication
Chondroma
Indication
Reperfusion Injury
Indication
Walking Capacity
Indication
Small Fiber Neuropathy
Indication
Myocardial
Indication
CIC-rearranged sarcoma
Indication
Ligament Tear Knee
Indication
Diabetes Mellitus Type 1
Indication
Methamphetamine Use Disorder
Indication
Weight
Indication
Body
Indication
Gestational Hypertension
Indication
Gallbladder Removal
Indication
Apnea of Prematurity
Indication
Caffeine
Indication
Drug-induced Cardiomyopathy
Indication
Primary Prevention
Indication
Olfactory Disorder
Indication
Premature Birth
Indication
Opioid
Indication
Upper
Indication
Anembryonic Pregnancy
Indication
Subfertility
Indication
Breast Cancer Surgery
Indication
Peanut Hypersensitivity
Indication
Nasal Vestibulitis
Indication
Cholecalciferol
Indication
Orofacial
Indication
Uric Acid Kidney Stone Disease
Indication
Attempted
Indication
Radiotherapy Side Effect
Indication
Hypoestrogenemia
Indication
Group B Streptococcal Infection
Indication
Dengue fever
Indication
Anakinra
Indication
Immuno-modulation
Indication
Anti-inflammatory Agents
Indication
pituitary
Indication
Altitude Edema
Indication
hyperinflammatory syndrome
Indication
Hip Arthropathy
Indication
Glucocorticoid
Indication
Pregnancy-Induced
Indication
Venous thromboembolism
Indication
Smoking-Related Carcinoma
Indication
tobacco-related carcinoma
Indication
Polycystic Ovarian Syndrome
Indication
Phototherapy
Indication
Urge
Indication
Anosmia
Indication
Myalgia
Indication
Parosmia
Indication
Uterine fibroids
Indication
Orofacial Pain
Indication
Urolithiasis
Indication
Benzodiazepine
Indication
Lymphangioleiomyomatosis
Indication
Vulvodynia
Indication
CDG1A
Indication
Temporomandibular Disorder
Indication
FMT
Indication
Tension Headache
Indication
Memory Deficits
Indication
Schizophrenia, Treatment Resistant
Indication
Hyperinsulinemia
Indication
Cocaine Use Disorder
Indication
Cocaine-Related Disorders
Indication
Normal Puberty
Indication
Lazy Eye
Indication
Hemoptysis
Indication
Breast Carcinoma Stage I
Indication
Lumpectomy
Indication
Heroin Use Disorder
Indication
Mastectomy
Indication
Left Ventricular Dysfunction
Indication
Postsurgical Chronic Pain
Indication
Substance-Related Disorders
Indication
Opioid-Related Disorders
Indication
Dysuria
Indication
Voiding Dysfunction
Indication
Urinary Retention
Indication
Hereditary Hemorrhagic Telangiectasia
Indication
Xiao Chai Hu Tang
Indication
Irinotecan-induced Diarrhea
Indication
Child Development
Indication
Rhabdomyolysis
Indication
Respiratory Insufficiency
Indication
Tobacco Dependence
Indication
Inherited Retinal Dystrophy
Indication
Placebo Effect on Mood Improvement
Indication
Postural Tachycardia Syndrome
Indication
Symptom
Indication
Childhood Obesity
Indication
Cognitive
Indication
Vasovagal
Indication
Interstitial Lung Disease Due to Systemic Disease
Indication
Post-mastectomy Pain Syndrome
Indication
Helminthiasis
Indication
Misophonia
Indication
Chemotherapy-induced Polyneuropathy
Indication
Prostate Cancer, Stage III AJCC v8
Indication
Hypoxemic Respiratory Failure
Indication
Human-Animal Interaction
Indication
Cancer-related Problem/Condition
Indication
Motivation
Indication
Hereditary Sensory Neuropathy Type I
Indication
Focal Motor
Indication
Recurrent Aphthous Stomatitis
Indication
methadone
Indication
Schwannomatosis
Indication
Headache Disorders
Indication
Hematopoietic and Lymphatic System Neoplasm
Indication
Subdural Hematoma
Indication
Abuse
Indication
Noise-Induced
Indication
Hepatic Injury
Indication
Non-ST Segment Elevation Myocardial Infarction
Indication
Colchicine
Indication
Intrahepatic Non Cirrhotic Portal Hypertension
Indication
Atrophic Vaginitis
Indication
Cannabis use disorder
Indication
Chinese Herbal Medicine
Indication
Posttraumatic Headache
Indication
Diverticulitis
Indication
Pelvic Pain
Indication
Randomized Controlled Trial
Indication
Hypoglycemia unawareness
Indication
Adenovirus
Indication
Empagliflozin
Indication
Cerebrovascular Disorders
Indication
SGLT2 inhibitors
Indication
BRCA2 mutation carrier
Indication
Painful periods
Indication
Pelvic Floor Injury
Indication
Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome (MDS)
Indication
Antimicrobial Prophylaxis in Prostate Surgery
Indication
Locally Advanced Neuroendocrine Neoplasm
Indication
Metastatic Neuroendocrine Neoplasm
Indication
Oxaliplatin induced peripheral neuropathy
Indication
Epistaxis
Indication
Implantable Cardioverter-Defibrillators
Indication
Insulin Sensitivity
Indication
Cardiac Resynchronization Therapy
Indication
Arteriosclerosis
Indication
Spinal Deformity
Indication
Abdominal
Indication
White Matter Lesions
Indication
Intracranial Aneurysm
Indication
Central Serous Chorioretinopathy
Indication
Small Bowel Disease
Indication
Necrotizing Fasciitis
Indication
Stimulant Use
Indication
postoperative nausea
Indication
Cytomegalovirus Anterior Uveitis
Indication
Cardiovascular Physiology
Indication
Eosinophilia
Indication
Microbial Colonization
Indication
Chronic periodontitis
Indication
Tonsillectomy
Indication
Dysphonia
Indication
Trinucleotide Repeat Expansion
Indication
High-risk Patients
Indication
Neurobehavioral Manifestations
Indication
Sex Chromosome Disorders
Indication
Allergic Reaction
Indication
Mast Cell Disorder
Indication
Death
Indication
Neurocognitive Dysfunction
Indication
Leukoplakia
Indication
Physical Performance
Indication
Intracerebral Hemorrhage Intraparenchymal
Indication
Estrogen Receptor-Positive Breast Carcinoma
Indication
Carpometacarpal Joint Arthritis of Left Thumb
Indication
Arthritis of Carpometacarpal Joint of Right Thumb
Indication
Antibody-mediated Rejection
Indication
Co-infection
Indication
Rumination Syndrome
Indication
Muscle Stiffness
Indication
Heart Transplant Failure
Indication
Estrogen Deficiency
Indication
Endurance Exercise
Indication
Infant
Indication
PTEN Gene Mutation
Indication
Cowden syndrome
Indication
Cowden Syndrome
Indication
Familial Chylomicronemia
Indication
Carotid Artery Disease
Indication
Postoperative Inflammation
Indication
Colorectal Cancer Liver Metastases
Indication
Frail Elderly Syndrome
Indication
Emotions
Indication
Renal Dysfunction
Indication
Oral Hormonal Contraceptive Use
Indication
Vasoplegia
Indication
Trivalent Salmonella Conjugate Vaccine (TSCV)
Indication
Neural Activity
Indication
Mood
Indication
Hedonic Function
Indication
Aphasia
Indication
Very Low Birth Weight
Indication
Long COVID-19 Syndrome
Indication
Trichuriasis
Indication
Ascariasis
Indication
Hookworm Infections
Indication
Memory
Indication
dcSSc
Indication
Adverse Childhood Experiences
Indication
Gestational diabetes
Indication
Cigarette
Indication
ADT
Indication
Altitude Sickness
Indication
cannabidiol
Indication
PASC Post Acute Sequelae of COVID-19
Indication
suvorexant
Indication
Urinary
Indication
Diabetic Ketoacidosis
Indication
Pollution Related Respiratory Disorder
Indication
Pollution
Indication
Hypothalamic Amenorrhea
Indication
Hyponatremia
Indication
Hand Injuries
Indication
Wrist Injuries
Indication
Herpes simplex virus type 1
Indication
Neck Pain
Indication
Labour Complication
Indication
Herpes Simplex Virus 2
Indication
Amnestic Mild Cognitive Impairment
Indication
Late Effect of Radiation
Indication
Group B Streptococcal Infections
Indication
Chemotherapy-Induced Peripheral Neuropathy
Indication
Dysbiosis
Indication
Neonatal and Perinatal Conditions
Indication
Protozoan Infections
Indication
Nicotine Use Disorder
Indication
Arterial Thrombosis
Indication
Opioid Craving
Indication
Red Blood Cell Disorder
Indication
Iron Metabolism Disorders
Indication
Type 1 Hyperlipoproteinemia
Indication
Congenital Diaphragmatic Hernia
Indication
Post-acute Sequelae of SARS-CoV-2 Infection
Indication
Hepatic Steato-Fibrosis
Indication
bipolar depression
Indication
Wrist Disease
Indication
Hand Injuries and Disorders
Indication
Ventricular Remodeling
Indication
BRCA1 mutation carrier
Indication
Neurocognition
Indication
Electrical Remodeling
Indication
Brain Disease
Indication
Hereditary Breast/Ovarian Cancer (BRCA1
Indication
Sensitivity
Indication
Estrogen Receptor Gene Mutation
Indication
Central Venous Catheter Thrombosis
Indication
Working Memory
Indication
Dialysis
Indication
Change in Sustained Attention
Indication
Colitis related to Immune System
Indication
Renal Transplant Failure
Indication
Gulf War Illness
Indication
Social Behavior
Indication
Hypercalciuria
Indication
Craving
Indication
Potential Therapeutic Role
Indication
Gingival Recession
Indication
Pancreatic Fibrosis
Indication
Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine
Indication
BCG
Indication
Duchenne Disease
Indication
Muscular Dystrophy in Children
Indication
orthopedic surgery
Indication
Menstruation
Indication
Antipsychotic agents
Indication
Acne Keloidalis Nuchae
Indication
Chronic Fatigue
Indication
Acanthokeratoconjunctivitis
Indication
Scarring Alopecia
Indication
Cholelithiasis
Indication
Infant Development
Indication
Ovarian Cysts
Indication
Stem Cell
Indication
Food Protein-Induced Allergic Proctocolitis
Indication
Geriatric
Indication
Muscle Mass
Indication
Muscle Strength
Indication
Acute Infection
Indication
Post-Surgical Complication
Indication
Organ Failure
Indication
Fracture, femoral
Indication
Misuse
Indication
End Stage Renal Failure on Dialysis
Indication
Myositis Associated Interstitial Lund Disease (MA-ILD)
Indication
Osteonecrosis of the Jaws
Indication
Alexithymia
Indication
Urgency Urinary Incontinence
Indication
Bone Density
Indication
Postoperative Pulmonary Complications
Indication
Thumb arthritis
Indication
Degenerative lumbar spinal stenosis
Indication
Necrosis
Indication
Allergic Transfusion Reaction
Indication
Avascular necrosis
Indication
Alcohol Abstinence
Indication
Cleft Lip and Palate
Indication
Bruxism
Indication
Scorpion Sting
Indication
Temporomandibular Joint Disorders
Indication
Agoraphobia
Indication
Ocular Rosacea
Indication
Empathy
Indication
Helicobacter pylori Infection
Indication
Social Familiarity
Indication
Smoking Cessation
Indication
Contracture
Indication
Familial Partial Lipodystrophy
Indication
Thermoregulation
Indication
Autoimmune Small Fiber Neuropathy
Indication
Takotsubo cardiomyopathy
Indication
Inflammatory Polyneuropathy
Indication
Muscle Cramp
Indication
Immune-Mediated Neuropathy
Indication
Osteoporotic fractures
Indication
SIAD - Syndrome of Inappropriate Antidiuresis
Indication
Disruptive Behavior Disorders
Indication
Vertical Transmission of Infectious Disease
Indication
PPROM
Indication
Respiratory Distress Syndrome in Premature Infants
Indication
Jet Lag
Indication
carotid artery stenosis
Indication
Temporomandibular Disorders
Indication
Pruritus Associated With Atopic Dermatitis
Indication
Catatonia
Indication
Postictal Delirium
Indication
Distributive Shock
Indication
Alcohol abuse
Indication
Alcohol Effects
Indication
Driving Under the Influence of Alcohol and Other Drugs
Indication
Refractory Acute Leukemia
Indication
MDMA
Indication
Contraception Optional Applicator for Insertion of Vaginal Ring
Indication
Dementia With Behavioral Disturbance
Indication
Recurrent Unexplained Implantation Failure
Indication
Neonatal Infection
Indication
LSD Reaction
Indication
Chronic Subjective Dizziness
Indication
Healthcare-Associated Pneumonia
Indication
X-linked
Indication
Diffuse Hemispheric Glioma
Indication
Stimulant Use Disorder
Indication
therapeutic vaccine
Indication
H3 G34 mutation
Indication
No-Reflow Phenomenon
Indication
Functional Abdominal Pain Syndrome
Indication
Upper Extremity Weakness
Indication
Behavioral Addiction
Indication
Pancreatic Adenosquamous Carcinoma
Indication
Pancreatic Squamous Cell Carcinoma
Indication
Rapid Eye Movement Sleep Behavior Disorder
Indication
Fibroid
Indication
Rapid Sequence Induction
Indication
Parkinsonian Signs in Older Persons
Indication
Radial Artery Occlusion
Indication
Cardiorenal Disease
Indication
Multiple Sites
Indication
Recurrent Depressive Disorder
Indication
Oral Ulcer
Indication
Calcium Phosphate Kidney Stones
Indication
Intracerebral Haemorrhage
Indication
Benzodiazepine Abuse
Indication
Polysubstance Use Disorder
Indication
Systemic Right Ventricle
Indication
Loiasis
Indication
Premenstrual Dysphoric Disorder
Indication
Staphylococcus aureus septicemia
Indication
Mucosal Melanoma
Indication
Staphylococcal Sepsis
Indication
Anticholinergic Toxicity
Indication
Pain in Limbs
Indication
phantosmia
Indication
Acute Bronchitis
Indication
Healthy Lifestyle
Indication
Trigeminal Autonomic Cephalalgias
Indication
Toxoplasmosis
Indication
Induced Birth
Indication
Neuroleptics
Indication
Sarcopenic Obesity
Indication
Hand Disease
Indication
Peptic Ulcer Disease
Indication
Glycogen Storage Disease Type VII
Indication
Glycogen Storage Disease Type II (Pompe Disease)
Indication
GYG1 deficiency
Indication
Lyme neuroborreliosis
Indication
Obsessive-compulsive disorder
Indication
Prescription Drug Abuse
Indication
Nephrocalcinosis
Indication
Gastrointestinal Hemorrhage
Indication
optic pathway glioma
Indication
Arthroscopic Knee Repair
Indication
Arthroscopic Hip Repair
Indication
Quality of Recovery
Indication
Muscle Soreness
Indication
Barotrauma
Indication
Perimenopause
Indication
D-limonene and THC Pharmacodynamics
Indication
Tic Disorders
Indication
Post-thrombotic syndrome
Indication
Neurodegeneration
Indication
Ultra short term
Indication
ST Elevated Myocardial Infarction
Indication
Postdural Puncture Headache
Indication
X-linked Protoporphyria
Indication
Right Ventricular Dysfunction
Indication
Focal Dystonia
Indication
Calcinosis
Indication
Stress vs. Control
Indication
Estradiol vs. Placebo
Indication
Duodenal Cancer
Indication
Skin Disorder
Indication
Hypoxic-ischemic Encephalopathy in Newborns
Indication
Keratinocyte Carcinoma
Indication
Oxidative Stress Injury
Indication
Female Sexual Interest/Arousal Disorder
Indication
Permeability
Indication
Fulminant Hepatic Failure
Indication
Immune Dysregulation
Indication
insomnia
Indication
Posttraumatic Confusional State
Indication
Anti-MAG Neuropathy
Indication
Facial Palsy
Indication
Facial Nerve Disorders
Indication
Lyme Neuroborreliosis
Indication
post-infectious cough
Indication
Aortic Stenosis and Lipoprotein(a) Levels
Indication
Healthcare-associated infection
Indication
Pathogen Transmission
Indication
Nutrition Disorders
Indication
Superimposed Pre-Eclampsia
Indication
Heart Block
Indication
acute myocardial infarction
Indication
Erythroplakia
Indication
Adhesions
Indication
Decision Making
Indication
Diaphragm Injury
Indication
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Indication
Endomyocardial Biopsy
Indication
Mucosal Melanoma of the Head and Neck
Indication
Heart Failure with Decompensation
Indication
Hemorrhagic telangiectasia
Indication
Microvascular angina
Indication
B-Cell Tumors
Indication
Diffuse Large B-Cell Lymphoma of Bone
Indication
Postpartum Smoking Relapse
Indication
Duodenal Carcinoma
Indication
Orthodontic Appliances
Indication
Fixed
Indication
Sleep Fragmentation
Indication
Immunosuppression
Indication
Motor Activity
Indication
Postprandial Hypoglycemia
Indication
Magnesium Deficiency
Indication
Postmenopausal Women
Indication
Surgical Bleeding
Indication
Tamoxifen
Indication
Estrogen Receptor Antagonist
Indication
Estrogens
Indication
Xeroderma
Indication
Pediatric NAFLD
Indication
Anthracycline Related Cardiotoxicity in Breast Cancer
Indication
Glucose Homeostasis
Indication
Esophageal Stenosis
Indication
Lentigo
Indication
Myofascial Pain
Indication
Transposition of Great Vessels
Indication
Renal Protection
Indication
Vaginal Vault Prolapse
Indication
Cystocele
Indication
Uterine prolapse
Indication
Non-Suicidal Self-Injury
Indication
Para-aminosalicylic acid
Indication
Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Indication
Hormonal Changes
Indication
Adipose Tissue Stem Cell
Indication
Functional Status
Indication
Hematopoietic System Cancer
Indication
Hallux Rigidus
Indication
Low Dose Naltrexone
Indication
Low-dose Naltrexone
Indication
Resistant to Conventional Therapy
Indication
Chronic Myocardial Ischemia
Indication
Drug-induced QT prolongation
Indication
Arthropathy of Knee Joint
Indication
Ozone Air Pollution
Indication
Post-traumatic Osteoarthritis
Indication
Myocardial injury
Indication
Microhematuria
Indication
Vitamin Deficiency Diseases
Indication
Pain Perception
Indication
Control
Indication
Schizophrenia (Prodromal Phase)
Indication
Independent Living
Indication
Disability-Free Survival
Indication
Menstrual Disorders
Indication
fetal distress
Indication
Prospective Study
Indication
Evidence-based Medicine
Indication
Focal Hand Dystonia
Indication
Pulmonary Hypoplasia
Indication
Polybrominated Biphenyl Poisoning
Indication
Ovarian Hyperstimulation
Indication
Pelvic Fracture
Indication
Ulcerative Colitis Exacerbation
Indication
Anal Melanoma
Indication
Bladder melanoma
Indication
Esophageal Melanoma
Indication
Melanoma of the Gallbladder
Indication
Melanoma of the Urinary System
Indication
Nasopharyngeal Melanoma
Indication
Oral Cavity Mucosal Melanoma
Indication
Sinonasal Mucosal Melanoma
Indication
Melanoma of the Urethra
Indication
Hallucinations
Indication
Auditory
Indication
Critical Illness Related Corticosteroids Insufficiency
Indication
Giardiasis
Indication
Cerebrovascular Diseases
Indication
Bronchial Epithelial Dysplasia
Indication
Risk-Reducing Salpingo-Oophorectomy (RRSO)
Indication
Exercise-Induced
Indication
Major Non-cardiac Surgeries
Indication
BPC
Indication
Non Optimal Response to UDCA
Indication
Cardiac Implantable Electronic Device (CIED) Related Infection
Indication
CIED-related Infections
Clinical trial
A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder
Status: Completed, Estimated PCD: 2023-09-18
Clinical trial
A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects
Status: Completed, Estimated PCD: 2023-12-30
Clinical trial
A Phase 2a Randomized, Doubled-Blind, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Crossover, Single Dose Study To Demonstrate Clinical Pharmacodynamic Bioequivalence of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed, Estimated PCD: 2023-08-11
Clinical trial
A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19
Status: Terminated, Estimated PCD: 2021-12-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment
Status: Completed, Estimated PCD: 2023-02-02
Clinical trial
A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.
Status: Completed, Estimated PCD: 2023-05-23
Clinical trial
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Different Doses of s.c. Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
Status: Completed, Estimated PCD: 2016-02-01
Clinical trial
Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke
Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Treatment and 14-week Extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
Status: Completed, Estimated PCD: 2023-06-22
Clinical trial
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3841136 in Healthy and Overweight Participants
Status: Completed, Estimated PCD: 2024-01-25
Clinical trial
A Single-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2060 in Japanese Older Participants With End-stage Renal Disease on Dialysis.
Status: Completed, Estimated PCD: 2024-02-15
Clinical trial
A Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
A Phase 2B, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding, Efficacy and Safety Study of HRO350 in Patients With Mild-to-moderate Psoriasis (the 'HeROPA' Study).
Status: Active (not recruiting), Estimated PCD: 2025-02-25
Clinical trial
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Status: Completed, Estimated PCD: 2020-10-07
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Multiple Rising Doses of BI 765250 Versus Placebo in Trial Participants With Moderate to Severe Plaque Psoriasis (Double-blind, Randomised, Placebo-controlled, Parallel-group Design)
Status: Recruiting, Estimated PCD: 2024-11-08
Clinical trial
A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2024-02-13
Clinical trial
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Ointment for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safety Laboratory Classroom Study in Children (6-12) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Double-blind Placebo-controlled Randomized Trial of Efficacy and Safety of Cycloferon, Enteric-coated Tablets, 150 mg, for Post-exposure Prophylaxis of Acute Respiratory Viral Infection and Influenza
Status: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Clinical Trial in Patients With Active Psoriatic Arthritis to Investigate Efficacy, Tolerability, Safety, Pharmacokinetics and Immunogenicity of ABY-035
Status: Completed, Estimated PCD: 2021-10-01
Clinical trial
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
Status: Active (not recruiting), Estimated PCD: 2031-01-24
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Patients
Status: Completed, Estimated PCD: 2023-10-10
Clinical trial
A Single/Multiple Ascending Dose Phase 1 Study of the Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Human Volunteers
Status: Completed, Estimated PCD: 2020-09-14
Clinical trial
A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)
Status: Completed, Estimated PCD: 2019-07-10
Clinical trial
A Phase1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Status: Completed, Estimated PCD: 2021-07-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2024-02-13
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Phase Ⅰa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002Following Intravenous Infusion in Healthy Subjects
Status: Completed, Estimated PCD: 2023-01-12
Clinical trial
Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Single-blind, Partially Randomised, Placebo-controlled Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses of BI 655130 in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2016-05-27
Clinical trial
A Phase 1, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Dengusiil in Healthy Adults
Status: Completed, Estimated PCD: 2021-06-11
Clinical trial
A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/Obesity
Status: Not yet recruiting, Estimated PCD: 2027-03-30
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 162 With a Single Ascending Dose in Subjects With Chronic Hepatitis B Virus Infection
Status: Not yet recruiting, Estimated PCD: 2024-07-15
Clinical trial
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Status: Active (not recruiting), Estimated PCD: 2026-07-30
Clinical trial
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Fluzoparib Monotherapy in Patients With gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Status: Terminated, Estimated PCD: 2022-02-18
Clinical trial
A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
Status: Active (not recruiting), Estimated PCD: 2024-08-07
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome
Status: Recruiting, Estimated PCD: 2025-03-05
Clinical trial
A Randomized, Double-Blind, Bilateral Comparison Study of the Safety and Efficacy of 10XB-101 in Adult Subjects With Bilateral Flank Adiposity
Status: Active (not recruiting), Estimated PCD: 2024-10-28
Clinical trial
A Randomized, Double-blind, Phase 3 Study of the Efficacy and Safety of Sindilizumab Combined With Chemotherapy or Placebo Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (ORIENT-99)
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BX-001N After Intravenous Administration in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Phase I Randomised, Single-blind, Placebo-controlled, and Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Status: Recruiting, Estimated PCD: 2024-08-09
Clinical trial
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A PHASE 1, RANDOMIZED, SPONSOR OPEN, TWO-PART CROSSOVER STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS AND FOOD EFFECT OF MULTIPLE DOSES IN PART 1 AND PALATABILITY OF A SINGLE DOSE OF SISUNATOVIR IN PART 2, IN HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2023-04-28
Clinical trial
Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A Inhibitor) in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesia
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase IV, Randomized, Observer-blind, Placebo-controlled, Multi-center Study to Assess the Prophylactic Efficacy Against Herpes Zoster, Immunogenicity and Safety of Shingrix When Administered Intramuscularly on a 2-dose Schedule in Chinese Adults Aged 50 Years and Older
Status: Completed, Estimated PCD: 2023-04-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study With Open-Label Extension to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of LMI070/Branaplam Administered as Weekly Oral Doses in Participants With Early Manifest Huntington's Disease
Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
A Multi-center Stage II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of HSK21542 Tablets for the Treatment of Moderate-to-severe Pruritus in Peritoneal Dialysis Subjects
Status: Not yet recruiting, Estimated PCD: 2024-03-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Exploring the Efficacy and Safety of Intra-nasal Administration of Merotocin in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production
Status: Terminated, Estimated PCD: 2022-11-11
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Status: Recruiting, Estimated PCD: 2027-04-14
Clinical trial
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled Phase I/IIa Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® in Bacterial Infection Treatment in Patients With Surgical Wounds
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2023-03-29
Clinical trial
A Randomized, Blind, Controlled Clinical Trial to Evaluate Safety and Immunogenicity of Live Attenuated Varicella Vaccine After a Two-dose Vaccination Course in Healthy Population Aged ≥13 Years Old
Status: , Estimated PCD: 2022-02-09
Clinical trial
Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
GL-0719 - A Phase 1, Double-blind, Placebo-controlled, Single Ascending Intravenous and Subcutaneous Injection Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and an Open-label Evaluation of Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Status: Completed, Estimated PCD: 2023-07-25
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 894416 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Status: Completed, Estimated PCD: 2018-09-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMB-101 in Healthy Volunteers and Patients With Active Rheumatoid Arthritis (RA)
Status: Not yet recruiting, Estimated PCD: 2025-12-11
Clinical trial
A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients
Status: Completed, Estimated PCD: 2021-08-19
Clinical trial
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism
Status: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
Status: Active (not recruiting), Estimated PCD: 2019-10-31
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants With Uncontrolled Moderate-to-severe Asthma
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Phase Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled To Assess Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2022-10-25
Clinical trial
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1 Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety and Tolerability, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Evaluation of 3,4-methylenedioxymethamphetamine (MDMA) on Startle Response
Status: Completed, Estimated PCD: 2020-08-01
Clinical trial
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Status: Recruiting, Estimated PCD: 2025-09-25
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
Status: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
Status: Active (not recruiting), Estimated PCD: 2023-11-21
Clinical trial
A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia
Status: Completed, Estimated PCD: 2022-07-15
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV
Status: Completed, Estimated PCD: 2023-07-13
Clinical trial
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Phase I, Participant- and Investigator-Blind, Single-center Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LY3871801 in Healthy Asian and Non-Asian Participants
Status: Completed, Estimated PCD: 2023-10-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses and Multiple Dose of HSK31679 in Healthy Volunteers and Subjects With Elevated LDL-C
Status: Completed, Estimated PCD: 2022-09-21
Clinical trial
A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age
Status: Completed, Estimated PCD: 2024-03-15
Clinical trial
SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION
Status: Active (not recruiting), Estimated PCD: 2022-03-25
Clinical trial
A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
Status: Completed, Estimated PCD: 2012-11-22
Clinical trial
A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
Status: Recruiting, Estimated PCD: 2024-03-22
Clinical trial
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED
Status: Completed, Estimated PCD: 2023-07-17
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis
Status: Completed, Estimated PCD: 2023-02-25
Clinical trial
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH
Status: Terminated, Estimated PCD: 2023-09-14
Clinical trial
A Single-center, Randomized, Double-blind,Placebo-controlled Study, to Evaluate Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of LW231 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
Status: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
Status: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis
Status: Recruiting, Estimated PCD: 2025-09-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19
Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-828
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission
Status: Completed, Estimated PCD: 2021-05-25
Clinical trial
A Placebo-controlled, Within-group Randomised, and Double-blind Trial Investigating Safety, Tolerability, and Pharmacokinetics of FE 999301 After Ascending Single and Multiple Doses in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-11-12
Clinical trial
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Status: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Status: Recruiting, Estimated PCD: 2025-06-05
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase II, Randomized, Double Blind, Double Dummy, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2025-08-28
Clinical trial
A First-in-human, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBP-671 in Healthy Subjects and In Patients With Propionic Acidemia or Methylmalonic Acidemia
Status: Terminated, Estimated PCD: 2023-11-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-02-08
Clinical trial
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase IIa, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of PBF-680 in Patients With Moderate to Severe COPD on Top of the Standard Medication
Status: Completed, Estimated PCD: 2024-02-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2025-04-10
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis Who Have Type 2 Diabetes (T2DM) or Pre-Diabetes
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Randomized, Partially Double-Blind, Four-Period, Four-Treatment, Crossover Study Investigating the Placebo-Corrected Effects of a Therapeutic Dose (100 mg) and a Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval in Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2021-06-18
Clinical trial
Phase II, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Safety and Efficacy of Mesenchymal Stem Cells (MSV-allo) in the Treatment of Lupus Nephritis
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2026-12-23
Clinical trial
Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Randomized, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SBT115301 in Healthy Participants
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Participants With Noncirrhotic Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B (Part B)
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 52-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2025-08-15
Clinical trial
A Parallel-group Treatment, Proof-of-concept Phase 2, Multicenter, Double-blind, Randomized Two-arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared With Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older With Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria
Status: Recruiting, Estimated PCD: 2027-02-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2053 in Subjects With Normal or Elevated Low-Density Lipoprotein Cholesterol
Status: Not yet recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3, Clinical Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Status: Active (not recruiting), Estimated PCD: 2024-12-17
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis
Status: Recruiting, Estimated PCD: 2026-03-24
Clinical trial
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2024-08-16
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evalution the Safety, Tolerability of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of BAY 3018250 in Patients With Symptomatic Proximal Deep Vein Thrombosis
Status: Recruiting, Estimated PCD: 2025-05-02
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Phase 1b/2a, 2-Part Study; Part 1: Randomized, Double-Blind, Crossover, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGK-1 Kinase Inhibition by LQT-1213 on Dofetilide-Induced QTc Prolongation in Healthy Adult Subjects. Part 2: Single-Blind, Multiple-Dose, Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LQT-1213 in Patients Diagnosed With Type 2 or 3 Long QT Syndrome
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities
Status: Completed, Estimated PCD: 2018-03-27
Clinical trial
A SINGLE CENTER, RANDOMIZED, INVESTIGATOR- AND PARTICIPANT-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ETHNOBRIDGING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE-DOSE OF UCB9741 IN HEALTHY CAUCASIAN AND JAPANESE PARTICIPANTS
Status: Not yet recruiting, Estimated PCD: 2025-07-29
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomised, Placebo Controlled, Double Blinded Study Assessing the Safety, Tolerability and Pharmacokinetics of Single and Multiple Subcutaneous Doses of NNC0638-0355 in Participants With Overweight or Obesity
Status: Not yet recruiting, Estimated PCD: 2025-09-18
Clinical trial
A Multicenter, Randomized, Dose-Ranging, Double-Masked, Placebo-Controlled Phase 2 Study Evaluating the Safety and Efficacy of RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Status: Completed, Estimated PCD: 2014-09-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ⅰb/Ⅱ Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10506 in Chinese Adult Participants With Insomnia Disorder
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2025-07-19
Clinical trial
A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS
Status: Completed, Estimated PCD: 2022-09-02
Clinical trial
Early Phase 2 Clinical Trial of E6011 in Patients With Active Crohn's Disease
Status: Active (not recruiting), Estimated PCD: 2022-03-16
Clinical trial
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)
Status: Active (not recruiting), Estimated PCD: 2024-07-09
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of PRAX-944 in the Treatment of Adults With Essential Tremor
Status: Completed, Estimated PCD: 2023-02-09
Clinical trial
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-alpha During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection
Status: Completed, Estimated PCD: 2011-11-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Status: Terminated, Estimated PCD: 2023-11-24
Clinical trial
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Self-administered Subcutaneous Selatogrel for Prevention of All-cause Death and Treatment of Acute Myocardial Infarction in Subjects With a Recent History of Acute Myocardial Infarction
Status: , Estimated PCD: 2025-08-01
Clinical trial
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1595043 (Double-blind, Randomised, Placebocontrolled, Parallel Group Design) in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-01-14
Clinical trial
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Evaluation of the Effects of Neurexan® on Short-Term Insomnia, Daytime Performance and Stress Response by Polysomnography (PSG), Electroencephalogram (EEG), Stress Biomarkers and Patient-Reported Outcomes (PROs)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
ADVANCE-2: Addressing Dementia Via Agitation-Centered Evaluation 2: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer's Disease Agitation
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2021-08-25
Clinical trial
A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough
Status: Completed, Estimated PCD: 2020-12-08
Clinical trial
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate Efficacy and Safety of Qsymia in Obese Patients
Status: Completed, Estimated PCD: 2023-10-30
Clinical trial
A Multi-center, Randomized, Placebo-controlled, Double-blinded Then Open 2 Stages Clinical Trial to Evaluate the Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Status: Completed, Estimated PCD: 2017-02-01
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2018-08-14
Clinical trial
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
Status: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of VX-407 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 1, First-In-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
Status: Completed, Estimated PCD: 2020-08-14
Clinical trial
Phase I, Randomised, Double-masked, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Male and Female Volunteers
Status: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Treatment-Naïve Adults With HIV-1 Infection
Status: Recruiting, Estimated PCD: 2024-10-21
Clinical trial
A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single And Multiple Doses Of CSL040 In Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF) Patients
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-02-17
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Status: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus
Status: Completed, Estimated PCD: 2019-11-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1, Observer-blind, Randomized, Placebo-Controlled Study to Evaluate Reactogenicity, Safety and Immune Response of an HSV-targeted Immunotherapy in HSV-2 Seronegative Japanese Participants Aged 18-40 Years
Status: Completed, Estimated PCD: 2023-11-29
Clinical trial
A Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of FE 999049 for Treatment of Men With Idiopathic Infertility
Status: Recruiting, Estimated PCD: 2026-07-15
Clinical trial
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2025-02-13
Clinical trial
A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability
Status: Active (not recruiting), Estimated PCD: 2023-11-21
Clinical trial
A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A Study to Evaluate the Effect of Oral Administration of Jaktinib Hydrochloride Tablets on QT/Corrected QT (QTc) Interval in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Status: Completed, Estimated PCD: 2020-10-06
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects
Status: Completed, Estimated PCD: 2014-05-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis.
Status: Recruiting, Estimated PCD: 2026-10-03
Clinical trial
A Phase 1, Randomized, Multicenter, Double-blind, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 69 Years Old
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Auxora for the Treatment of AKI and Modulation of Injurious "Crosstalk" With the Lung: A Randomized Control Trial (KOURAGE)
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Single and Multiple Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Topical Ointment YR001 in Adult Healthy Volunteers
Status: Completed, Estimated PCD: 2023-08-14
Clinical trial
A Phase I/IIa Trial to Evaluate the Safety, Tolerability, PK, and Preliminary Efficacy of Single and Multiple Ascending Doses of YN001 in Healthy Subjects and Multiple Ascending Doses of YN001 in Patient With Coronary Atherosclerosis
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Status: Recruiting, Estimated PCD: 2025-03-28
Clinical trial
A Phase 3 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Withdrawal Study Evaluating ADV7103 In Pediatric and Adult Subjects With Distal Renal Tubular Acidosis (dRTA)
Status: Terminated, Estimated PCD: 2023-12-20
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Status: Recruiting, Estimated PCD: 2030-01-03
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Status: Completed, Estimated PCD: 2023-11-22
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Evaluating Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 1291583 One Tablet Once Daily Over 12 Weeks Versus Placebo in Adult Patients With Cystic Fibrosis Bronchiectasis (Clairafly™)
Status: Recruiting, Estimated PCD: 2024-12-16
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Status: Completed, Estimated PCD: 2023-02-21
Clinical trial
A Ph I Randomized Double-Blind First-in-Human Single Ascending Dose & Multiple Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of SOR102 in Healthy Adult Participants and Patient Volunteers With Mild to Severe Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)
Status: Completed, Estimated PCD: 2024-01-29
Clinical trial
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Status: Recruiting, Estimated PCD: 2027-01-19
Clinical trial
A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis
Status: Recruiting, Estimated PCD: 2026-10-09
Clinical trial
Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study
Status: Completed, Estimated PCD: 2023-11-20
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Intravenous Infusion or Subcutaneous Injection Doses of BI 765250 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Active (not recruiting), Estimated PCD: 2024-09-16
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adults Using Nicotine-containing E-cigarettes
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
Status: , Estimated PCD: 2027-02-23
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-designed, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of KH001 in Patients With Dentin Hypersensitivity
Status: Not yet recruiting, Estimated PCD: 2024-08-23
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer's Dementia
Status: Active (not recruiting), Estimated PCD: 2028-03-03
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Status: Completed, Estimated PCD: 2024-02-13
Clinical trial
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
Status: Completed, Estimated PCD: 2017-04-25
Clinical trial
A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of BMS-986447 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-11-27
Clinical trial
Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone in the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age.
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Double-blinded, Placebo-controlled, Single Ascending Dose, Two-part, Randomized, Phase 2 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BB-031 in Acute Ischemic Stroke Patients
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants With Non-Dialysis Dependent Chronic Kidney Disease and Anemia
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder
Status: Completed, Estimated PCD: 2020-08-11
Clinical trial
Randomized, Placebo-controlled, Double Blind, Multi-centre Phase IIb Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Multicenter Randomized Double-blind Placebo-controlled Parallel Group Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 Cream Used in the Treatment of Mild to Moderate Plaque Psoriasis
Status: Completed, Estimated PCD: 2024-01-04
Clinical trial
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Blinded, Cross-Over Study to Evaluate the Safety and Efficacy of ARD-501 in Patients With Autism Spectrum Disorder
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Status: Terminated, Estimated PCD: 2017-03-02
Clinical trial
A Phase 1, Multi-site, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacokinetics, Safety and Preliminary Efficacy of Two Strengths of DARE-PDM1 (1% or 3%) Versus Placebo Among Women With Symptomatic Primary Dysmenorrhea
Status: Active (not recruiting), Estimated PCD: 2023-09-23
Clinical trial
A Phase IIa, Randomized, Double-blind, Dose Comparison, Placebo-controlled, Multi-centre Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS
Status: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects
Status: Active (not recruiting), Estimated PCD: 2017-11-04
Clinical trial
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Patients With Type 2 Diabetes Mellitus
Status: Active (not recruiting), Estimated PCD: 2024-04-22
Clinical trial
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus Nephritis
Status: Active (not recruiting), Estimated PCD: 2024-02-26
Clinical trial
Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo and Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain
Status: Recruiting, Estimated PCD: 2025-03-14
Clinical trial
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
Status: Recruiting, Estimated PCD: 2025-07-15
Clinical trial
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A 2-Part Study (Open-label Followed by Double-blind, Randomized, Placebo-controlled, Parallel Group) of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode
Status: Completed, Estimated PCD: 2019-05-21
Clinical trial
China Multi-regional Clinical Trial: Efficacy and Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
Status: Completed, Estimated PCD: 2021-10-27
Clinical trial
A Randomized Phase 2a, Double-blind, Placebo-Controlled Study Examining the Safety and Efficacy of BOL-DP-o-08 in Patients With Endometriosis Syndrome.
Status: Withdrawn, Estimated PCD: 2020-12-01
Clinical trial
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2020-05-06
Clinical trial
A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries
Status: Completed, Estimated PCD: 2023-02-07
Clinical trial
Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24 Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose (MAD) Study in Healthy Elderly Volunteers and Alzheimer's Disease (AD) Patients to Investigate the Safety and Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) Effects of Multiple Intravenous Infusions of NX210c
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab, in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) on a Background Therapy With Intranasal Corticosteroids
Status: Active (not recruiting), Estimated PCD: 2024-10-02
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
Status: Terminated, Estimated PCD: 2022-12-28
Clinical trial
A Randomised, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Administered in Subjects With Overweight or Obesity
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of a Single Intravenous Dose of GSK1070806 Administered to Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive
Status: Completed, Estimated PCD: 2023-07-12
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Unilateral Subjective Tinnitus
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects
Status: Completed, Estimated PCD: 2022-03-02
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
Status: Withdrawn, Estimated PCD: 2022-10-17
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Status: Recruiting, Estimated PCD: 2029-03-07
Clinical trial
A Phase II Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Chinese Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, PIK3CA Mutant Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment, Including a Subset With Pharmacokinetic Analysis
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Controlled, Randomized, First-In-Human Study of AP31969 Investigating Single and Multiple Ascending Doses and the Effect of Food in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-09-17
Clinical trial
A Phase 1b Randomized, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Status: Completed, Estimated PCD: 2023-07-12
Clinical trial
Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC)
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized Placebo-controlled Study to Assess Safety and Preliminary Efficacy of BGP345A in Patients With Constipation Due to the Use of Opioid-based Medications for the Management of Chronic Non Cancer Pain
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Tolerability of Intravenous Tonapofylline in Subjects With Acute Decompensated Heart Failure and Renal Insufficiency
Status: Completed, Estimated PCD: 2009-10-30
Clinical trial
A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
Status: Terminated, Estimated PCD: 2022-08-26
Clinical trial
A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC)
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Randomized, Double-blind, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Dose De-escalation of Orally Administered Filgotinib in Subjects With Ulcerative Colitis in Clinical Remission
Status: Terminated, Estimated PCD: 2023-10-09
Clinical trial
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study To Evaluate The Safety And Efficacy Of MK-1942 As Adjunctive Therapy In Participants With Mild To Moderate Alzheimer's Disease Dementia
Status: Terminated, Estimated PCD: 2023-09-27
Clinical trial
ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
Status: Completed, Estimated PCD: 2023-07-03
Clinical trial
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients
Status: Terminated, Estimated PCD: 2022-05-02
Clinical trial
Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study
Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
Efficacy, Safety, and Tolerability of Adjuvant GLS-1200 Topical Nasal Spray in the Prevention of Acute Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-196 Administered Intravenously to Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2021-01-29
Clinical trial
Efficacy and Safety of ES16001 in Patients With COVID-19: a Phase II/III, Multinational, Randomized, Parallel-group, Double-blind, Placebo-controlled Study
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
International, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2018-09-27
Clinical trial
A Randomised, Double-Blind, Placebo-controlled Study of Single and Multiple Ascending Doses of PN-232 in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-12-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Status: Terminated, Estimated PCD: 2023-06-09
Clinical trial
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE MECHANISM OF ACTION OF ABROCITINIB MONOTHERAPY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Status: Completed, Estimated PCD: 2021-11-16
Clinical trial
A Phase 1b，Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of JS1-1-01 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-05-31
Clinical trial
A Randomized, Single-center, Double-blind, Placebo Controlled Trial With Ascending Multiple Intravenous Doses to Determine Safety, Tolerability and Pharmacokinetics of AON-D21 in Healthy Male Subjects.
Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Select the Optimal Dose(s) of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause in Japan
Status: Completed, Estimated PCD: 2022-11-11
Clinical trial
A Two-part, Single Dose, Randomized, Single Blinded, Placebo Controlled, Phase I Study to Assess the Safety and Pharmacokinetics of Oral MT1980 in Healthy Volunteers When Dosed in the Fasted State
Status: Completed, Estimated PCD: 2022-10-04
Clinical trial
A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)
Status: Active (not recruiting), Estimated PCD: 2025-01-22
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2021-05-17
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Status: Completed, Estimated PCD: 2022-02-07
Clinical trial
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Status: Completed, Estimated PCD: 2021-06-02
Clinical trial
Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults With Major Depressive Disorder With Anxious Distress With Suboptimal Response to Standard Antidepressants
Status: Completed, Estimated PCD: 2021-09-02
Clinical trial
Multi-center, Blinded, Randomized Study With Aprocitentan in Subjects With Uncontrolled Blood Pressure and Chronic Kidney Disease Stage 3 or 4.
Status: Withdrawn, Estimated PCD: 2021-06-30
Clinical trial
A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of LOXO-292 on the QTc Interval in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2019-06-21
Clinical trial
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus
Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
Comparison of the Analgesic Effect of a New Paracetamol Formulation (Paracetamol UNIFLASH) for Buccal Use and Two Different Doses of an Oral Paracetamol Form Controlled Versus Placebo in Patients Suffering From Moderate Pain Due to a Tooth Extraction.
Status: Completed, Estimated PCD: 2022-11-08
Clinical trial
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARIS
Status: Completed, Estimated PCD: 2023-01-23
Clinical trial
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Status: Terminated, Estimated PCD: 2022-09-01
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of F-652 in Subjects With COVID-19 Pneumonia
Status: Withdrawn, Estimated PCD: 2022-04-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Status: Active (not recruiting), Estimated PCD: 2020-06-02
Clinical trial
A Prospective, Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Completed, Estimated PCD: 2009-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers
Status: Completed, Estimated PCD: 2010-06-02
Clinical trial
A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Terminated, Estimated PCD: 2021-08-03
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.
Status: Completed, Estimated PCD: 2018-01-22
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-03-05
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of STI-1558 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-10-18
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility
Status: Terminated, Estimated PCD: 2015-05-15
Clinical trial
A Two-Part (Double-Blind Placebo Controlled/Open-Label) Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Subjects With Homozygous Familial Hypercholesterolemia (Hofh) (ORION-5)
Status: Completed, Estimated PCD: 2020-03-02
Clinical trial
Efficacy and Safety of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase Ⅱ Study
Status: Not yet recruiting, Estimated PCD: 2024-05-15
Clinical trial
A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2011-09-01
Clinical trial
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Status: Completed, Estimated PCD: 2019-01-09
Clinical trial
A Double-Blind, Placebo-Controlled, Cross-over Trial, Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
Status: Withdrawn, Estimated PCD: 2023-02-01
Clinical trial
Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
Status: Completed, Estimated PCD: 2022-10-20
Clinical trial
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living With HIV-1
Status: Not yet recruiting, Estimated PCD: 2024-06-26
Clinical trial
A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Status: Completed, Estimated PCD: 2022-02-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection Administered Subcutaneously to Postmenopausal Women
Status: Recruiting, Estimated PCD: 2025-04-12
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX7728 Alone and in Combination With QPX2014 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
Safety and Efficacy of Inhaled XW001 (Interleukin 29 Analog for Nebulization) For Hospitalized COVID-19 Patients Requiring Oxygen Therapy: A Multiregional, Randomized, Double-blind, Placebo-controlled Study
Status: Withdrawn, Estimated PCD: 2022-03-10
Clinical trial
A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-198 Administered Intravenously to Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2021-02-03
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's Disease
Status: Terminated, Estimated PCD: 2021-11-17
Clinical trial
Calcium Administration to Prevent Hypotension Caused by Diltiazem Administration in the Treatment of Atrial Fibrillation With Rapid Ventricular Response
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study
Status: Completed, Estimated PCD: 2018-08-14
Clinical trial
A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
Status: Completed, Estimated PCD: 2023-05-23
Clinical trial
A Randomized, Double-blinded, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Combination Vaccine Candidates in Older Adults
Status: Completed, Estimated PCD: 2023-09-27
Clinical trial
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3819469
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates
Status: Terminated, Estimated PCD: 2021-06-17
Clinical trial
A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Randomized,Double-blind, Placebo-controlled, Multiple Ascending-Dose Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Injection in Healthy Subjects
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of Twice Daily Oral Midostaurin in Combination With Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation, and Midostaurin Single Agent Continuation Therapy in Newly Diagnosed Patients With FLT3-mutated Acute Myeloid Leukemia (AML).
Status: Completed, Estimated PCD: 2020-03-11
Clinical trial
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Status: Completed, Estimated PCD: 2021-12-21
Clinical trial
A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo
Status: , Estimated PCD: 2028-12-01
Clinical trial
A 52-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Status: Recruiting, Estimated PCD: 2025-06-13
Clinical trial
A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Status: Terminated, Estimated PCD: 2021-11-05
Clinical trial
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Status: Recruiting, Estimated PCD: 2023-07-31
Clinical trial
A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Status: Terminated, Estimated PCD: 2022-02-02
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a Single Dose of ALXN1210 Administered Subcutaneously Compared to Intravenously in Healthy Subjects
Status: Completed, Estimated PCD: 2017-07-18
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EI1071 in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-12-16
Clinical trial
A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Status: Completed, Estimated PCD: 2021-03-29
Clinical trial
A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Status: Completed, Estimated PCD: 2020-03-27
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia
Status: Completed, Estimated PCD: 2021-07-30
Clinical trial
Phase I, Randomised, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Subcutaneous Single Ascending Doses of HER-096 to Healthy Volunteer Subjects
Status: Completed, Estimated PCD: 2023-09-29
Clinical trial
A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
Status: Recruiting, Estimated PCD: 2024-05-10
Clinical trial
A Phase IIb, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive Fibrosing Interstitial Lung Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease
Status: Completed, Estimated PCD: 2020-08-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Status: Completed, Estimated PCD: 2022-02-23
Clinical trial
A Multicenter, Randomized, Double-Masked Study To Compare The Ocular Safety, Tolerability, And Efficacy Of A Topical 0.2% Ophthalmic Corticosteroid Solution (SURF-201) To Vehicle In Cataract Surgery Subjects
Status: Completed, Estimated PCD: 2020-11-03
Clinical trial
Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome): a Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Multi-center, Double-blind, Randomized, Placebo-controlled, Phase IIa Trial to Evaluate Spesolimab (BI 655130) Efficacy in Patients With Fibrostenotic Crohn's Disease
Status: Terminated, Estimated PCD: 2022-05-31
Clinical trial
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Once-Daily Application of Topical VDA-1102 Ointment for 28 Days in Subjects With Actinic Keratosis
Status: Completed, Estimated PCD: 2017-05-26
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase Ⅲ, Efficacy and Safety Study of Intravaginal Prasterone (INTRAROSA) on Postmenopausal Vulvovaginal Atrophy (VVA)
Status: Active (not recruiting), Estimated PCD: 2023-01-30
Clinical trial
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally
Status: Completed, Estimated PCD: 2021-10-06
Clinical trial
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2018-08-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
Status: Completed, Estimated PCD: 2011-07-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Completed, Estimated PCD: 2019-12-27
Clinical trial
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
Status: Completed, Estimated PCD: 2023-01-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of Daridorexant on Nighttime Respiratory Function and Sleep in Patients With Severe Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension
Status: Completed, Estimated PCD: 2015-05-22
Clinical trial
A Phase 3, Dose-Optimized, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Parallel Efficacy and Safety Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Status: Completed, Estimated PCD: 2023-06-13
Clinical trial
A Randomized, Single Blind, Placebo Controlled, Single Center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD7022 in Participants With Normal or Elevated LDL-c Cholesterol
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).
Status: Completed, Estimated PCD: 2018-07-05
Clinical trial
Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity
Status: Completed, Estimated PCD: 2021-03-27
Clinical trial
A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Status: Completed, Estimated PCD: 2015-03-09
Clinical trial
Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita
Status: Withdrawn, Estimated PCD: 2020-09-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Efficacy and Safety of SYR-472 When Orally Administered at a Dose of 25 mg Once Weekly in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
Status: Completed, Estimated PCD: 2018-04-24
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared With Oxycodone Immediate-Release Tablets and Placebo in Non-Dependent Recreational Opioid Users
Status: Completed, Estimated PCD: 2022-12-23
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Completed, Estimated PCD: 2021-07-06
Clinical trial
A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection
Status: Terminated, Estimated PCD: 2021-10-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect of ISM5411 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
Status: Recruiting, Estimated PCD: 2023-02-01
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China
Status: Not yet recruiting, Estimated PCD: 2023-04-01
Clinical trial
A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH)
Status: Completed, Estimated PCD: 2020-03-13
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Neoplasm Receiving EGFRi or MEKi Therapy
Status: Terminated, Estimated PCD: 2021-12-13
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Escalation Study to Assess the Safety and Efficacy of SL-1002 Injectable for Treatment of Knee Pain Associated With Osteoarthritis
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)
Status: Completed, Estimated PCD: 2020-09-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of Cetrelimab (JNJ 63723283), an Anti-PD-1 Monoclonal Antibody, in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Status: Completed, Estimated PCD: 2023-05-09
Clinical trial
A Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics ,Pharmacodynamics and Efficacy of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.
Status: , Estimated PCD: 2024-01-30
Clinical trial
Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
Status: Terminated, Estimated PCD: 2023-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Phase IIa Randomised, Double-blind, Placebo-controlled Study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI With TLR7 Agonist Vesatolimod (GS-9620) in Early Treated HIV-1 Infection
Status: Completed, Estimated PCD: 2022-10-03
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.
Status: Completed, Estimated PCD: 2014-10-07
Clinical trial
A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants
Status: Terminated, Estimated PCD: 2022-10-14
Clinical trial
A Phase 1a Study of IMR-687 in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2017-07-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD
Status: Terminated, Estimated PCD: 2023-07-20
Clinical trial
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Crossover, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of PF-07853578 Administered to Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
Status: Completed, Estimated PCD: 2022-03-07
Clinical trial
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Status: Completed, Estimated PCD: 2019-01-15
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With Schizophrenia
Status: Completed, Estimated PCD: 2020-05-06
Clinical trial
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
Status: Completed, Estimated PCD: 2021-01-04
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
Status: Completed, Estimated PCD: 2022-01-30
Clinical trial
Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Status: Completed, Estimated PCD: 2012-05-11
Clinical trial
A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects
Status: Completed, Estimated PCD: 2023-03-11
Clinical trial
A Phase I Dose Escalation Study of Ascending Single and Multiple Doses of the MEK Inhibitor Zapnometinib in Healthy Subjects to Evaluate the Safety & Tolerability Compared to Placebo, Additionally Evaluating Pharmacokinetics and Pharmacodynamics of Target Engagement, as Well as Investigating Possible FDI and DDI
Status: Completed, Estimated PCD: 2023-07-20
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness
Status: Completed, Estimated PCD: 2022-01-24
Clinical trial
Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection
Status: Terminated, Estimated PCD: 2023-01-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age
Status: Completed, Estimated PCD: 2018-05-02
Clinical trial
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)
Status: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study of PPI-1011 in Subjects to Assess Safety, Tolerability, and Pharmacokinetics
Status: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema
Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
A Phase Ⅱ, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus Nephritis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Placebo-Controlled, Double-Blind Controlled Study of NPC-06 in Patients With Pain Associated With Acute Herpes Zoster
Status: Completed, Estimated PCD: 2023-05-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
Status: Completed, Estimated PCD: 2020-09-16
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of BxC-I17e Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents With Lupus Nephritis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
Status: Withdrawn, Estimated PCD: 2023-07-28
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-сontrolled Comparative Study to Evaluate the Safety, Tolerability and Efficacy of XC221 Used at 100 mg Daily and at 200 mg Daily in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
Status: Completed, Estimated PCD: 2022-05-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis (PSC)
Status: Completed, Estimated PCD: 2023-06-23
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status: , Estimated PCD: 2023-12-01
Clinical trial
An Open-Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation
Status: Completed, Estimated PCD: 2020-05-25
Clinical trial
A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide
Status: Completed, Estimated PCD: 2023-06-17
Clinical trial
A Phase I, First-in-Human, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Single Ascending Dose Administrations to Healthy Male Subjects of African Ancestry
Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
Status: Terminated, Estimated PCD: 2023-06-08
Clinical trial
Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1
Status: Terminated, Estimated PCD: 2019-11-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of AER-01 (Solution for Inhalation, Delivered Via Nebulizer): As a First-In-Human Single Ascending Dose in Healthy Volunteers (Part A), and a 7-day Multiple Ascending Dose in Healthy Volunteers and Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Moderate Airflow Limitation (Part B)
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia
Status: Terminated, Estimated PCD: 2022-07-27
Clinical trial
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2022-09-05
Clinical trial
A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
Status: Completed, Estimated PCD: 2023-08-22
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Status: Completed, Estimated PCD: 2016-07-11
Clinical trial
A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients
Status: Completed, Estimated PCD: 2021-04-08
Clinical trial
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy
Status: Completed, Estimated PCD: 2018-03-30
Clinical trial
Investigation of Pharmacokinetics, Safety, and Tolerability of Multiple Subcutaneous Doses of NNC0519-0130 in Japanese and Non-Japanese Male Participants
Status: Completed, Estimated PCD: 2023-10-07
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1584862 in Japanese Healthy Male Subjects (Single- Masked, Randomised, Placebo-controlled, Parallel Group Design)
Status: Recruiting, Estimated PCD: 2024-05-28
Clinical trial
A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19
Status: Terminated, Estimated PCD: 2021-08-11
Clinical trial
A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of Two Doses of OCS 01 Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery
Status: Completed, Estimated PCD: 2020-01-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime-Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA-BN®-Filo in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2016-01-22
Clinical trial
An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
Status: Completed, Estimated PCD: 2018-06-26
Clinical trial
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE
Status: Completed, Estimated PCD: 2016-02-26
Clinical trial
A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
Prospective Randomized Study to Determine Whether Use of Rhopressa™ Accelerates Corneal Clearing After Removal of Descemet Membrane for Treatment of Fuchs Dystrophy
Status: Terminated, Estimated PCD: 2021-08-26
Clinical trial
A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of MZE001 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Status: Completed, Estimated PCD: 2022-12-21
Clinical trial
Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes
Status: Completed, Estimated PCD: 2022-07-07
Clinical trial
A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19
Status: Completed, Estimated PCD: 2021-12-28
Clinical trial
A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase: The ACTION Study
Status: Terminated, Estimated PCD: 2022-08-03
Clinical trial
A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma.
Status: Recruiting, Estimated PCD: 2025-05-09
Clinical trial
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group
Status: Active (not recruiting), Estimated PCD: 2027-03-31
Clinical trial
A Phase 1b, Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Investigate the Effects of CSL324 in the Lung After Segmental Challenge With Endotoxin
Status: Completed, Estimated PCD: 2023-07-21
Clinical trial
International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Status: Completed, Estimated PCD: 2021-11-03
Clinical trial
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Completed, Estimated PCD: 2016-08-08
Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Status: Completed, Estimated PCD: 2019-09-12
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacokinetics of SHR-1819 Injection in Adults With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2023-09-15
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Status: Completed, Estimated PCD: 2023-12-26
Clinical trial
Comparable Efficacy of Transcranial Direct Current Stimulation and Pharmacological Treatments in Children With Autism Spectrum Disorder
Status: Completed, Estimated PCD: 2022-03-15
Clinical trial
Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial
Status: , Estimated PCD: 2020-12-01
Clinical trial
A Randomized Trial of Alteplase Versus Placebo Through an Indwelling Pleural Catheter for Management of Symptomatic Septated MPE
Status: Recruiting, Estimated PCD: 2027-02-02
Clinical trial
Phase II Study to Evaluate the Efficacy and Safety of Baricitinib for Reduction of HIV in the Central Nervous System
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
Colchicine in Belgium in Patients With Coronary Artery Disease
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide in Improving Type 3 Pulmonary Hypertension.
Status: , Estimated PCD: 2023-12-31
Clinical trial
The Impact of Pre-operative Olanzapine on Quality of Recovery-40 Scores After Discharge From Ambulatory Surgery
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)
Status: Recruiting, Estimated PCD: 2026-04-23
Clinical trial
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Status: Completed, Estimated PCD: 2020-07-01
Clinical trial
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Status: Recruiting, Estimated PCD: 2030-08-31
Clinical trial
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in Type 2 Diabetes Mellitus (T2DM)
Status: , Estimated PCD: 2024-06-01
Clinical trial
A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With Spinal Cord Injury Treated With Epidural Electrical Stimulation
Status: Completed, Estimated PCD: 2023-10-04
Clinical trial
EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning: A Randamized Controlled Clinical Trial
Status: Completed, Estimated PCD: 2024-02-28
Clinical trial
52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese/Overweight Men With T2DM/Prediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters
Status: Recruiting, Estimated PCD: 2028-09-01
Clinical trial
A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
Status: Active (not recruiting), Estimated PCD: 2020-05-14
Clinical trial
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
The Efficacy and Safety of CM310 Injection in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment: A Randomized, Double-Blind, Placebo-controlled Investigator Initiated Trial (IIT) Study
Status: Completed, Estimated PCD: 2022-09-24
Clinical trial
Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia
Status: Completed, Estimated PCD: 2023-09-30
Clinical trial
Role of Cholecystokinin Receptor Blockade on the Tumor Microenvironment in Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Effects of a Novel mGluR5 Negative Allosteric Modulator on Alcohol Drinking, Neurochemistry, and Brain Reactivity to Alcohol Cues in Alcohol Use Disorder
Status: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
The Efficacy of Pentoxifylline in Reducing Post-surgical Complications in Patients Undergoing Breast Cancer Surgery
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
Lemborexant Treatment of Insomnia Linked to Epilepsy
Status: Recruiting, Estimated PCD: 2025-04-18
Clinical trial
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine (NAC) (SNAC)
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity
Status: Completed, Estimated PCD: 2021-08-10
Clinical trial
Lidocaine and Ketamine in Abdominal Surgery
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria: a Randomized Double Blind Cross-Over Trial
Status: , Estimated PCD: 2024-04-01
Clinical trial
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's Disease
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
Topiramate as an Adjuvant to Therapeutic Hypothermia for Infants With Hypoxic Ischemic Encephalopathy
Status: Terminated, Estimated PCD: 2022-01-27
Clinical trial
Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Trifluridine/Tipiracil in Third-line and Beyond for the Treatment of Metastatic Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Metformin Effect on Brain Function in Insulin Resistant Elderly People
Status: Completed, Estimated PCD: 2023-04-05
Clinical trial
A Phase I/II, Observer-blind, Randomised, Placebo-controlled, Multi-country Study to Evaluate Reactogenicity, Safety, Immune Response, and Efficacy of an HSV-targeted Immunotherapy in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
Status: Active (not recruiting), Estimated PCD: 2025-07-03
Clinical trial
Comparison of TEG-guided and Preemptive Tranexamic Acid Administration Strategies in Total Hip Replacement Surgery
Status: Not yet recruiting, Estimated PCD: 2024-11-30
Clinical trial
Understanding Opioid Use Before and After Surgery in Norway: A Prospective Multicenter Study and Randomized Double-blind Controlled Study
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Metformin for Preventing Frailty in High-risk Older Adults
Status: Completed, Estimated PCD: 2024-02-07
Clinical trial
Clinical Pharmacology and Target Validation of A Bioactive Dietary Polyphenol Preparation (BDPP) For Stress-Related Disorders
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial
Status: , Estimated PCD: 2025-12-01
Clinical trial
Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
The Efficacy and Safety of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment: A Randomized, Double-Blind, Placebo-controlled Investigator Initiated Trial.
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Efficacy and Safety of Edaravone Dexborneol Sublingual Tablet for Post-stroke Cognitive Impairment in Patients With Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Exploratory Phase II Clinical Trial.
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewybodies
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Detoxification of the Liver in Primary Sclerosing Cholangitis
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2028-10-01
Clinical trial
Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Assess the Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis Among Infants in Niger
Status: Completed, Estimated PCD: 2015-12-01
Clinical trial
Letrozole in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial
Status: Terminated, Estimated PCD: 2021-03-26
Clinical trial
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
Methylprednisolone Taper to Treat Delayed Post-Operative Recovery After Total Knee Arthroplasty: a Double-Blind Randomized Controlled Trial
Status: Terminated, Estimated PCD: 2022-07-01
Clinical trial
A RAndomized trIal Examining the Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy for Patients With Stage 4-5 CKD or Dialysis-dependent ESKD
Status: Terminated, Estimated PCD: 2023-01-31
Clinical trial
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
Status: Completed, Estimated PCD: 2022-05-27
Clinical trial
Prevention of Depression in Patients Being Treated for Head and Neck Cancer
Status: Completed, Estimated PCD: 2012-06-01
Clinical trial
Does Oral Care With Propolis Affect the Development of Oral Mucositis in Pediatric Oncology Patients: A Randomized Controlled Clinical Study
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma
Status: Completed, Estimated PCD: 2009-06-01
Clinical trial
Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age: A Non-inferiority Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU "START-or-NOT Trial". A Prospective, Randomized, Double Blinded, Multicenter Study
Status: Recruiting, Estimated PCD: 2025-06-22
Clinical trial
A Multicenter, Randomized, Double-blind Clinical Trial Evaluating the Efficacy and Safety of Etanercept Versus Placebo in the Treatment of Patients With SAPHO Syndrome
Status: Recruiting, Estimated PCD: 2028-10-18
Clinical trial
A Study to Assess the Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Osteoarthritis Patients
Status: Completed, Estimated PCD: 2014-11-26
Clinical trial
The Effects of the Histamine-3 Receptor Inverse Agonist Pitolisant on Alcohol Self-Administration in Heavy Drinkers
Status: Terminated, Estimated PCD: 2023-02-03
Clinical trial
Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).
Status: Completed, Estimated PCD: 2023-09-21
Clinical trial
A Randomized, Double-blind, Single Center, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 15 mg of Darifenacin Daily in Patients With Amyotrophic Lateral Sclerosis
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Treatment With DD01 for 48 Weeks in Overweight/Obese Subjects With MASLD/MASH
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Metformin and Vaccine Response in Older Adults
Status: , Estimated PCD: 2025-07-01
Clinical trial
Semaglutide, 2.4mg, Once Weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth With Prediabetes (IGT)/Early Type 2 Diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Effect of Intravenous S-ketamine on Opioid Consumption and Postoperative Pain in Patients Undergoing Breast Cancer Surgery：a Multicenter, Randomised, Control Trial
Status: Recruiting, Estimated PCD: 2024-07-07
Clinical trial
Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers
Status: Recruiting, Estimated PCD: 2029-03-11
Clinical trial
Prophylactic Use of Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Operation for Biliary Atresia: Double Blinded Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients -a Randomised Placebo Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Sphenopalatine Ganglion Block With Bupivacaine on Postoperative Pain in Patients Undergoing Endoscopic Pituitary Adenoma Resection
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Effect of Metformin ER With Hypocaloric Diet on Weight Loss in Overweight/Obese Patients With Increased Waist Circumference
Status: Recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3, Clinical Study of QLG2198 in Haemodialysis Adult Subjects With Moderate-to-Severe Pruritus
Status: Recruiting, Estimated PCD: 2025-02-21
Clinical trial
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers
Status: Completed, Estimated PCD: 2017-12-28
Clinical trial
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Reduced Dose of Thrombolytic Treatment for Patients With Intermediate High-risk Acute Pulmonary Embolism: a Randomized Controled Trial
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Efficacy of Erenumab in Chronic Cluster Headache: A 10 Week Double-blind, Randomized, Placebo Controlled, Multicentric Trial.
Status: Completed, Estimated PCD: 2023-09-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
Status: Completed, Estimated PCD: 2023-07-30
Clinical trial
Effect of Perineural Dexamethasone on the Duration of Supraclavicular Brachial Plexus Block for Anesthesia After Pediatric Hand/Wrist Surgery
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Lifestyle Intervention Plus Metformin to Treat Frailty in Older Veterans With Obesity
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Cannabidiol in the Treatment of Opioid Use Disorder
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Effect of High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease Patients
Status: Completed, Estimated PCD: 2023-04-20
Clinical trial
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
Status: Not yet recruiting, Estimated PCD: 2028-12-31
Clinical trial
Metabolic Effects of Natriuretic Peptide Hormones
Status: Terminated, Estimated PCD: 2019-05-01
Clinical trial
A Randomized Controlled Trial of Oral Curcumin for the Treatment of Pain of CMC Arthritis
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Efficacy of Cetylated Fatty Acid for Alleviating Postoperative Pain After Total Knee Arthroplasty: A Randomized Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Randomized, Double-Blind Clinical Study Evaluating Efficacy of Intravenous Versus Enteric Acetaminophen in Donor Nephrectomy and Robot-Assisted, Laparoscopic Nephrectomy.
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Dexamethasone as a Novel Treatment for Obstructive Sleep Apnea in Children
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Renal Mechanistic Effects of Acute and Chronic Empagliflozin in Heart Failure
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
Status: Completed, Estimated PCD: 2023-08-02
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Status: Recruiting, Estimated PCD: 2028-07-31
Clinical trial
The Effect of Cannabidiol in Learning and Memory of Adults
Status: Completed, Estimated PCD: 2020-11-06
Clinical trial
Oral Corticosteroids for Post-infectious Cough in Adults: A Double-blind Randomised Placebo-controlled Trial in Swiss Family Practices (OSPIC Trial)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group, Phase 2b Study in Treatment-seeking Patients With Cannabis Use Disorder to Assess the Efficacy, Safety, and Tolerability of AEF0117 in Reducing Cannabis Use
Status: Active (not recruiting), Estimated PCD: 2024-04-11
Clinical trial
Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Effect of Opioid Infusion Rate on Abuse Liability Potential and Analgesic Efficacy of Intravenous Hydromorphone Among Inpatients With Cancer Pain: A Randomized Crossover Trial
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Multicentre Concealed-Allocation Parallel-Group Blinded Randomized Controlled Trial to Ascertain the Effect of High-Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic Intensive Care Unit Patients
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized Controlled Trial of Adjunctive D-Cycloserine to Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation in Fibromyalgia
Status: Active (not recruiting), Estimated PCD: 2026-12-01
Clinical trial
Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone
Status: Active (not recruiting), Estimated PCD: 2027-12-31
Clinical trial
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Treatment With Lorcaserin for Cocaine Use: The TLC Study
Status: Terminated, Estimated PCD: 2020-02-28
Clinical trial
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic Infection
Status: Completed, Estimated PCD: 2023-07-12
Clinical trial
Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients
Status: Active (not recruiting), Estimated PCD: 2023-08-14
Clinical trial
Clinical Evaluation of mTORC1 Inhibition for Geroprotection
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized, Double-Blinded, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Effect of DAPAglifozin and Stress ( i.v. ACTH) on the Development of DKA After Insulin Withdrawal in Adolescent and Adult Subjects With T1D
Status: Terminated, Estimated PCD: 2022-08-26
Clinical trial
Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial
Status: Withdrawn, Estimated PCD: 2022-05-01
Clinical trial
The Role of Vitamin D Supplementation in the Prevention of Cardiovascular Risk Factors
Status: Completed, Estimated PCD: 2013-12-01
Clinical trial
Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) of Limbic Brain Circuitry in Stress Modulation in a Healthy Population
Status: Withdrawn, Estimated PCD: 2023-04-10
Clinical trial
Simvastatin add-on to Escitalopram in Patients With Comorbid Obesity and Major Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase III Study of Ginseng for Cancer Related Fatigue
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer
Status: Withdrawn, Estimated PCD: 2026-12-01
Clinical trial
Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Efficacy of Probiotics for Non-steroidal Anti-inflammatory Drug-induced Enteropathy in Arthritis Patients: A Double-blinded Pilot Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
Status: Completed, Estimated PCD: 2020-06-07
Clinical trial
The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery
Status: Terminated, Estimated PCD: 2019-10-14
Clinical trial
Using Repetitive Transcranial Magnetic Stimulation (rTMS) to Explore Neural Mechanisms of Stress-Induced Opioid Use
Status: Withdrawn, Estimated PCD: 2023-04-10
Clinical trial
Efficacy of Naltrexone in Women's Smoking Cessation
Status: Completed, Estimated PCD: 2009-06-01
Clinical trial
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study
Status: Not yet recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery: A Double-Blind Randomized Trial
Status: Not yet recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3031185 Administered as Tablet to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Relative Bioavailability Comparison of BI 3031185 as Tablet With and Without Food in Healthy Male Subjects
Status: Recruiting, Estimated PCD: 2024-07-09
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled and Open Label Extension Study to Assess the Efficacy, Safety, and Pharmacokinetic Profile of of ATL1102 in Non-ambulatory Participants With Duchenne Muscular Dystrophy
Status: Recruiting, Estimated PCD: 2024-11-13
Clinical trial
A PHASE 3, RANDOMIZED OBSERVER-BLINDED STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Status: Completed, Estimated PCD: 2020-12-22
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Status: Not yet recruiting, Estimated PCD: 2027-06-08
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg Compared to Placebo for Relief of Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) After 4 Weeks and to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg for Relief of Heartburn in Subjects With NERD After 6 Months
Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Dupilumab Compared to Placebo in Japanese Patients With Atopic Dermatitis Aged 6 Months to
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Status: Completed, Estimated PCD: 2023-09-29
Clinical trial
A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS
Status: Completed, Estimated PCD: 2024-03-04
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
Status: Completed, Estimated PCD: 2023-03-01
Clinical trial
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Status: Active (not recruiting), Estimated PCD: 2028-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR.
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
Status: Active (not recruiting), Estimated PCD: 2023-07-25
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1920 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
Status: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Status: Terminated, Estimated PCD: 2020-05-07
Clinical trial
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2025-03-21
Clinical trial
A Phase I/II Study Of The Efficacy,Safety and Pharmacokinetics Of Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Alopecia Areata
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Monthly Subcutaneous Administration of ION904 in Patients With Uncontrolled Hypertension
Status: Completed, Estimated PCD: 2023-01-31
Clinical trial
A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-004 in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2025-02-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers
Status: Completed, Estimated PCD: 2011-06-01
Clinical trial
ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction
Status: Not yet recruiting, Estimated PCD: 2026-09-03
Clinical trial
A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
Status: Active (not recruiting), Estimated PCD: 2020-12-22
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Dose and Multiple Rising Oral Doses of BI 706321 in Healthy Japanese Male Subjects and Single Oral Dose of BI 706321 in Healthy Chinese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Recruiting, Estimated PCD: 2025-10-21
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Type 2 Diabetes
Status: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity
Status: Recruiting, Estimated PCD: 2025-05-07
Clinical trial
A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines in Toxin-Naïve Subjects
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Phase 2 Study of the Safety and Efficacy of JTM201 (Botulinum Toxin Type A) to Treat Moderate or Severe Glabellar Lines
Status: Not yet recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1323495 Versus Placebo in Healthy Male Japanese Subjects Genotyped as Poor and Extensive Metabolizers of UGT2B17 (Single-blind, Randomised, Placebo-controlled [Within Dose Groups] Trial), Including an Investigation of Drug-drug Interaction With Itraconazole in Healthy Male Subjects Genotyped as Poor Metabolizers of UGT2B17 (an Open-label, Two-period, Fixed Sequence Trial)
Status: Completed, Estimated PCD: 2021-07-30
Clinical trial
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Nebulized CSL787 in Healthy Subjects and Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB)
Status: Completed, Estimated PCD: 2023-03-12
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity
Status: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2017-06-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase II, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial to Assess Ongoing Pregnancy Rate With OXO-001 (200/300 mg) or Placebo at 10 Weeks Following Fresh Single Blastocyst Transfer From Donor Oocyte IVF/ICSI
Status: Completed, Estimated PCD: 2023-08-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Status: Not yet recruiting, Estimated PCD: 2028-08-14
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Status: Active (not recruiting), Estimated PCD: 2022-04-11
Clinical trial
A Phase 1, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamics of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA).
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis
Status: Terminated, Estimated PCD: 2023-02-01
Clinical trial
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
Status: Active (not recruiting), Estimated PCD: 2024-10-15
Clinical trial
A Phase III, Randomized，Double-blind Placebo-controlled Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-stage Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-10-13
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Single Rising Intravenous Doses of BI 765845 in Healthy Male Japanese Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2023-12-17
Clinical trial
A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults
Status: Completed, Estimated PCD: 2017-07-23
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for Additional 2 Years in Women With Hormone-receptor Positive Breast Cancer:
Status: Active (not recruiting), Estimated PCD: 2024-01-29
Clinical trial
A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Completed, Estimated PCD: 2016-04-04
Clinical trial
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes
Status: Completed, Estimated PCD: 2023-10-11
Clinical trial
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy
Status: Recruiting, Estimated PCD: 2024-11-28
Clinical trial
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
Status: Active (not recruiting), Estimated PCD: 2025-08-21
Clinical trial
A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2021-07-06
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-26
Clinical trial
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-09-16
Clinical trial
Effect of Trazodone on Obstructive Sleep Apnea Endotypes and Severity
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension
Status: Active (not recruiting), Estimated PCD: 2023-04-04
Clinical trial
A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD
Status: Recruiting, Estimated PCD: 2025-08-12
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Status: Completed, Estimated PCD: 2024-04-11
Clinical trial
HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Status: Recruiting, Estimated PCD: 2027-07-02
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-19
Clinical trial
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)
Status: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
Status: Recruiting, Estimated PCD: 2025-03-07
Clinical trial
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Zavegepant Intranasal (IN) for the Acute Treatment of Migraine in Asian Adults
Status: Recruiting, Estimated PCD: 2025-07-03
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity
Status: Recruiting, Estimated PCD: 2026-02-13
Clinical trial
A Randomized, Double-blinded, Placebo-controlled Phase 1 Study of a Single Dose of a Subcutaneous Ultra-Long-Acting Somatostatin Analog (TE-8214 Solution) to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-10-10
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
Status: Completed, Estimated PCD: 2022-03-24
Clinical trial
A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults With Progressive Systemic Sclerosis
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Two Part, Randomized, Participant and Investigator-blinded, 2-arm, Parallel-design, Placebo-controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles on Tendon Regeneration in Patients With Achilles Tendinopathy
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)
Status: Active (not recruiting), Estimated PCD: 2024-09-13
Clinical trial
A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy, Safety and PK Study of KX01 Ointment 1% in Japanese Adult Subjects With Actinic Keratosis on the Face or Scalp
Status: Completed, Estimated PCD: 2023-11-20
Clinical trial
A National, Multicenter, Randomized, Double-blind, Phase III, Crossover Clinical Trial to Assess the Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Clinical trial
A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)
Status: Active (not recruiting), Estimated PCD: 2025-09-19
Clinical trial
A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment
Status: Active (not recruiting), Estimated PCD: 2024-07-10
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China
Status: Recruiting, Estimated PCD: 2025-05-02
Clinical trial
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
Status: Completed, Estimated PCD: 2023-08-05
Clinical trial
A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous Injections of NNC0581-0001 in Healthy Adults
Status: Recruiting, Estimated PCD: 2025-01-22
Clinical trial
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin
Status: Recruiting, Estimated PCD: 2025-09-16
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Combined With Standard of Care Versus Standard of Care Alone in Outpatients With Worsening Heart Failure (WHF)
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Status: Completed, Estimated PCD: 2024-01-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-04-28
Clinical trial
A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Dose-Escalation, Drug-Interaction, and Food-Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
Status: Recruiting, Estimated PCD: 2025-02-09
Clinical trial
A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Randomized, Double-blind Study to Compare LNK01001 to Placebo in Adults With Rheumatoid Arthritis (RA) on a Stable Dose of csDMARDs Who Have an Inadequate Response or Intolerance to bDMARDs
Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks
Status: Active (not recruiting), Estimated PCD: 2024-03-06
Clinical trial
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
A Two-Part Study to Examine the Drug-Drug Interaction With Itraconazole and Safety of AZD4041 in Healthy Participants and the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 as an Adjunctive Treatment to Buprenorphine in Participants With Moderate to Severe Opioid Use Disorder
Status: Not yet recruiting, Estimated PCD: 2026-05-07
Clinical trial
Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging
Status: Recruiting, Estimated PCD: 2026-01-29
Clinical trial
A Single-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Doses in Japanese and Chinese Healthy Participants
Status: Not yet recruiting, Estimated PCD: 2024-10-04
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AG-181 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Status: Recruiting, Estimated PCD: 2025-04-09
Clinical trial
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Status: Active (not recruiting), Estimated PCD: 2024-02-08
Clinical trial
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older
Status: Completed, Estimated PCD: 2023-07-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-06-22
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)
Status: Terminated, Estimated PCD: 2021-03-31
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers and an Expansion Cohort in Patients With Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324
Status: Recruiting, Estimated PCD: 2025-01-02
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
Status: Completed, Estimated PCD: 2023-06-21
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Status: Recruiting, Estimated PCD: 2025-06-25
Clinical trial
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
Status: Completed, Estimated PCD: 2020-10-23
Clinical trial
A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of Ascending Single and Fixed Repeat Intravenous Doses of DMT in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
Status: Recruiting, Estimated PCD: 2027-07-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2023-12-11
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Multicenter Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder
Status: Completed, Estimated PCD: 2023-10-05
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
Status: Completed, Estimated PCD: 2019-08-02
Clinical trial
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants
Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ZnAg Liquid Solution to Treat COVID-19 in Acutely Symptomatic Non-Hospitalized Participants
Status: Completed, Estimated PCD: 2022-05-28
Clinical trial
A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-19
Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia
Status: Completed, Estimated PCD: 2023-05-12
Clinical trial
A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment
Status: Completed, Estimated PCD: 2016-07-01
Clinical trial
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
Status: Active (not recruiting), Estimated PCD: 2024-10-26
Clinical trial
A Randomised Double-blind Placebo-controlled Clinical Study Investigating the Effects of Semaglutide s.c. Once-weekly Versus Placebo on Central and Peripheral Inflammation in Participants With Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-05-16
Clinical trial
A Phase 2a Randomized Controlled Trial of MIB-626 (NAD-boosting Drug) vs. Placebo in Adults With COVID-19 Infection and Early Acute Kidney Injury
Status: Completed, Estimated PCD: 2023-08-17
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of 52 Weeks of Treatment With Basmisanil in Participants Aged 2 to 14 Years Old With Dup15q Syndrome Followed by a 2-Year Optional Open-Label Extension
Status: Completed, Estimated PCD: 2024-03-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Status: Recruiting, Estimated PCD: 2028-02-15
Clinical trial
A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Dose Escalation Study in Healthy Volunteers and an Expansion Cohort in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Two-Arm, Randomized, Double-Blind, Phase IIb Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants Plus Narrow-Band Ultraviolet B (NB-UVB) Light Source With Narrow-Band Ultraviolet B (NB-UVB) Light Source in the Treatment of Nonsegmental Vitiligo AND A Single-Arm, Open Label, Phase IIb Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants Plus Narrow-Band Ultraviolet B (NB-UVB) Light Source in the Treatment of Nonsegmental Vitiligo
Status: Completed, Estimated PCD: 2016-02-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II/III Trial Evaluating the Efficacy and Safety of Sufenidone (SC1011) Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) and to AKLIEF® Cream (Trifarotene 0.005%,Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Status: Completed, Estimated PCD: 2023-07-13
Clinical trial
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Status: Completed, Estimated PCD: 2023-10-05
Clinical trial
A Phase 2A, Placebo-controlled, Randomized, Dose Response Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C Spirulina GEBT in Patients With Moderate to Severe Gastroparesis
Status: Completed, Estimated PCD: 2022-09-29
Clinical trial
Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3
Status: Completed, Estimated PCD: 2017-12-28
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1% QD for the Treatment of Acute Exacerbations of Blepharitis (Mississippi)
Status: Completed, Estimated PCD: 2021-06-16
Clinical trial
A Phase II Seamless Design, Randomized, Double-blind, Placebo-controlled, Dose-exploration Study Evaluate the Efficacy and Safety of SHR-2010 Injection in Patients With Primary IgA Nephropathy
Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 1584862 Administered as Tablet to Healthy Male Subjects (SRD Part), and a Randomised, Open-label, Single-dose, Two-way Crossover Part Investigating Relative Bioavailability of BI 1584862 as Tablet With and Without Food in Healthy Male Subjects (FE Part)
Status: Completed, Estimated PCD: 2023-03-06
Clinical trial
A Double-blind, Randomized, Intra-patient Placebo- Controlled, Multiple Dose Study of PTW-002 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy, and Systemic Exposure in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa (DDEB / RDEB) Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Status: Not yet recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Status: Completed, Estimated PCD: 2020-12-18
Clinical trial
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial
Status: Completed, Estimated PCD: 2021-12-13
Clinical trial
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis
Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2019-02-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
Status: Completed, Estimated PCD: 2021-02-11
Clinical trial
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Status: Completed, Estimated PCD: 2019-11-20
Clinical trial
A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male and Female Adult Subjects
Status: Completed, Estimated PCD: 2021-08-01
Clinical trial
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effects of Food on the Pharmacokinetics of HRS-1893 Tablets After Single and Multiple Ascending Oral Doses in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
Status: Terminated, Estimated PCD: 2022-08-23
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects With Mild Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Prospective Multi-center Clinical Study Evaluating the Use of PD G 506 A and the Eagle V1.2 Imaging System for the Visualization of Carcinoma During Breast Conserving Surgery
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
Status: Not yet recruiting, Estimated PCD: 2023-08-01
Clinical trial
A Phase 2b, Double-blind, Randomised, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of VIT-2763 Multiple Doses in Adults With Transfusion-dependent Beta-thalassaemia
Status: Withdrawn, Estimated PCD: 2023-07-01
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of JnJ-64304500 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Completed, Estimated PCD: 2020-12-10
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX, an Antisense Inhibitor of Factor XI), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Status: Completed, Estimated PCD: 2019-07-10
Clinical trial
A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) in Subjects for Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Status: Completed, Estimated PCD: 2021-12-21
Clinical trial
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Pro-ocular™ 0.5% and 1% in Patients With Dry Eye Syndrome
Status: Completed, Estimated PCD: 2022-10-27
Clinical trial
A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)
Status: Completed, Estimated PCD: 2016-04-14
Clinical trial
Investigation of Safety, Tolerability and Pharmacokinetics of Subcutaneously Co-administered Single Doses of NNC0480-0389 and Semaglutide in Healthy Japanese Male Subjects
Status: Completed, Estimated PCD: 2021-07-20
Clinical trial
A Two-Part, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose (Part A) or Twice Daily Dose (Part B) Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Status: Completed, Estimated PCD: 2019-10-23
Clinical trial
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Status: Active (not recruiting), Estimated PCD: 2027-06-23
Clinical trial
A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)
Status: Completed, Estimated PCD: 2009-08-01
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2022-07-20
Clinical trial
Exploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
Status: Completed, Estimated PCD: 2021-02-28
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003002 in Single and Multiple Ascending Dose Randomized，Doubled-blind Phase 1 Study in Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
Status: Completed, Estimated PCD: 2019-08-07
Clinical trial
A Driving Performance Evaluation Study of TS-142 Using a Driving Simulator in Non-elderly and Elderly Healthy Subjects
Status: Completed, Estimated PCD: 2022-01-05
Clinical trial
Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-07-19
Clinical trial
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of QL1203 and Placebo Respectively Combined With Chemotherapy in Patients With Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Sintilimab (IBI308) in Combination With Gemcitabine and Platinum-Based Chemotherapy vs. Placebo in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Treatment for Patients With Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) (ORIENT-12)
Status: Completed, Estimated PCD: 2020-03-25
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Completed, Estimated PCD: 2017-04-21
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome
Status: Completed, Estimated PCD: 2013-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Abuse Potential of Sativex in Subjects With a History of Recreational Marijuana Use
Status: Completed, Estimated PCD: 2008-06-01
Clinical trial
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalating Study to Examine the Safety and Tolerability of Multiple Doses of KD025 (Formerly Called SLX-2119) in Healthy Male and Post- Menopausal Female Subjects
Status: Completed, Estimated PCD: 2014-03-06
Clinical trial
Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWKH
Status: Completed, Estimated PCD: 2022-12-09
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Status: Terminated, Estimated PCD: 2023-01-18
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma
Status: Completed, Estimated PCD: 2013-04-05
Clinical trial
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-12-04
Clinical trial
A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)
Status: Completed, Estimated PCD: 2023-07-25
Clinical trial
A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisinicline in Healthy Smokers
Status: Completed, Estimated PCD: 2022-12-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Status: Active (not recruiting), Estimated PCD: 2022-08-17
Clinical trial
A Study of the Safety, Tolerability, Microbial Kinetics and Effect on Urinary Oxalate Excretion of FB-001 in Healthy Volunteers Fed a High Oxalate/Low Calcium Diet and in Patients With Enteric Hyperoxaluria
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Status: Terminated, Estimated PCD: 2022-10-06
Clinical trial
A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome
Status: Terminated, Estimated PCD: 2022-07-25
Clinical trial
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase 1/2 Dose Escalation Study To Evaluate the Safety and Biologically Effective Dose of GEO-CM04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Double Blind, Double Dummy, Multicenter, Randomized, Placebo- and Active-controlled Clinical Trial to Evaluate Effectiveness of Tricortin 1000 in Patients Affected by Chronic Low Back Pain
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment
Status: Completed, Estimated PCD: 2020-07-31
Clinical trial
A Double-Blind, Randomized, Multicenter, Parallel-Group Study of Levalbuterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease
Status: Completed, Estimated PCD: 2003-03-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of n-Butylphthalide (NBP) Softgel Capsules Administered to Patients With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Status: Withdrawn, Estimated PCD: 2024-12-30
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of HEM1036 in Subjects With Low Anterior Resection Syndrome (LARS)
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase l, Single-blind, Placebo-controlled Trial Designed to Assess the Safety and Tolerability of a Single Intravenous Dose of MTx-COVAB36 in Healthy Volunteers.
Status: Completed, Estimated PCD: 2022-09-04
Clinical trial
A Phase 2, Factorial-Designed, Randomized, Double-Blind, Placebo-Controlled, Parallel- Cohort Study to Evaluate Efficacy and Safety of MELT-300 and the Contribution of Midazolam and Ketamine Components to Sedation and Intraoperative Ocular Analgesia in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Status: Completed, Estimated PCD: 2022-10-26
Clinical trial
A First-in-Human, Randomized, Double-Blind, Placebo/Active Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases
Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Status: Terminated, Estimated PCD: 2021-11-05
Clinical trial
A Phase III, Multicentre, Double-blind, Prospective, Randomized, Placebo-controlled Study, Assessing the Efficacy and Safety of Dysport® Used for the Treatment of Lower-limb Spasticity in Adult Subjects With Hemiparesis Due to Stroke or Traumatic Brain Injury
Status: Completed, Estimated PCD: 2013-12-01
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Status: Active (not recruiting), Estimated PCD: 2024-06-05
Clinical trial
Randomized, Double-blind and Placebo-controled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ZX-7101A and Its Food Effect in China Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2022-08-29
Clinical trial
A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease
Status: Completed, Estimated PCD: 2008-06-01
Clinical trial
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Divozilimab in Patients With Systemic Scleroderma
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-03-21
Clinical trial
ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT
Status: Completed, Estimated PCD: 2023-06-01
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 894416 Versus Placebo in Male Patients With Asthma (Single-blind, Randomised, Placebo-controlled, Parallel Group Design).
Status: Completed, Estimated PCD: 2020-10-26
Clinical trial
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Status: Terminated, Estimated PCD: 2020-09-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study of Hte Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of XmAb27564 in Patients With Plaque Psoriasis and Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Status: Terminated, Estimated PCD: 2021-08-30
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Status: Active (not recruiting), Estimated PCD: 2020-12-14
Clinical trial
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Status: Terminated, Estimated PCD: 2021-10-20
Clinical trial
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Terminated, Estimated PCD: 2023-09-15
Clinical trial
A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®.
Status: Completed, Estimated PCD: 2009-01-01
Clinical trial
Phase 2 Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women With Sexual Arousal Disorder
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)
Status: Terminated, Estimated PCD: 2022-09-14
Clinical trial
A Phase Ⅰb/Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Tolerability, Safety,Pharmacokinetics and Efficacy of an Intravenous Treatment Regimen of GR1603 in Subjects With Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2028-06-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain
Status: Completed, Estimated PCD: 2022-05-16
Clinical trial
A Randomized, Controlled, Partial-blind, Parallel-group Study Evaluating the Effect of Oral Administration of BAY 1834845 and BAY 1830839 Twice Daily for 7 Consecutive Days on Local and Systemic IRAK4 Pathway-related Challenges in Healthy Male Participants
Status: Completed, Estimated PCD: 2021-12-16
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
Status: Terminated, Estimated PCD: 2023-05-05
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of RCN3028 in Treatment of Drug-Induced Moderate to Severe Vasomotor Symptoms in Breast Cancer Subjects
Status: Terminated, Estimated PCD: 2022-03-14
Clinical trial
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2027-09-15
Clinical trial
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
Status: Completed, Estimated PCD: 2020-09-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure
Status: Terminated, Estimated PCD: 2020-06-05
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Acute Uncomplicated Influenza
Status: Completed, Estimated PCD: 2023-04-25
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Status: Completed, Estimated PCD: 2021-07-08
Clinical trial
Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb (UL) Spasticity.
Status: Completed, Estimated PCD: 2016-03-01
Clinical trial
GULLIVER-2 - A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C)
Status: Active (not recruiting), Estimated PCD: 2022-07-18
Clinical trial
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for HIV-1 Infection
Status: Withdrawn, Estimated PCD: 2025-10-02
Clinical trial
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas
Status: Active (not recruiting), Estimated PCD: 2024-07-23
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.
Status: Completed, Estimated PCD: 2022-06-08
Clinical trial
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Status: Completed, Estimated PCD: 2020-10-28
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia
Status: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS)
Status: Withdrawn, Estimated PCD: 2022-10-19
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2020-03-05
Clinical trial
A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Randomized, Double-Blind and Nested Crossover (For Placebo and Moxifloxacin) Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat, and Its Major Metabolites on Cardiac Repolarization in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-07-28
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)
Status: Terminated, Estimated PCD: 2022-08-25
Clinical trial
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.
Status: Terminated, Estimated PCD: 2022-06-04
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Phase IIb Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2021-06-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in an Autism Spectrum Disorder Population
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension
Status: Terminated, Estimated PCD: 2022-06-07
Clinical trial
A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy
Status: Completed, Estimated PCD: 2020-06-18
Clinical trial
A Phase III Confirmatory Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2019-04-29
Clinical trial
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and Fibrosis
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease
Status: Completed, Estimated PCD: 2023-07-11
Clinical trial
A Phase Ia/b Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Healthy Volunteers and Multiple Ascending Doses of AZD3427 in Patients With Heart Failure (HFrEF and HF With EF ≥ 41%)
Status: Completed, Estimated PCD: 2022-09-14
Clinical trial
A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy
Status: Terminated, Estimated PCD: 2023-05-16
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of SZEY-2108 Administreated as Single and Repeated Intravenous Doses in Chinese Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17
Status: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of Inhaled HH-120 Aerosol in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-05-26
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN04894 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-04-11
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Status: Completed, Estimated PCD: 2022-04-20
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)
Status: Terminated, Estimated PCD: 2023-05-02
Clinical trial
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Status: Completed, Estimated PCD: 2019-08-28
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of BMS-986325 in Healthy Japanese Participants
Status: Completed, Estimated PCD: 2023-10-02
Clinical trial
A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled, 5-Way Crossover Study Evaluating the Abuse Potential of Soticlestat (TAK-935) in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System Depressant Experience
Status: Completed, Estimated PCD: 2023-06-29
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Status: Completed, Estimated PCD: 2022-09-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Oral ASN51 in Healthy Young Adult and Elderly Subjects and Elderly Subjects With Alzheimer's Disease
Status: Terminated, Estimated PCD: 2022-08-01
Clinical trial
Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-17
Status: Terminated, Estimated PCD: 2019-07-15
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacokinetics Study of Single Ascending and Multiple Doses of GWP42006 in Healthy Volunteers
Status: Completed, Estimated PCD: 2013-12-01
Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection
Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2018-04-16
Clinical trial
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status: Completed, Estimated PCD: 2018-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Intramuscular Administration of a Single Dose of TNM002 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-02-24
Clinical trial
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of EP395 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed, Estimated PCD: 2023-11-24
Clinical trial
Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Status: Completed, Estimated PCD: 2009-03-01
Clinical trial
EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Status: Completed, Estimated PCD: 2012-04-10
Clinical trial
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Status: Terminated, Estimated PCD: 2022-09-05
Clinical trial
A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
Status: Active (not recruiting), Estimated PCD: 2022-01-04
Clinical trial
A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Multicenter, Phase 2a Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 Monotherapy in Patients With Gout or Hyperuricemia
Status: Completed, Estimated PCD: 2021-10-26
Clinical trial
A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age
Status: Active (not recruiting), Estimated PCD: 2026-03-12
Clinical trial
A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed, Estimated PCD: 2016-12-01
Clinical trial
A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
Status: , Estimated PCD: 2023-10-01
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of BI 655064 in Healthy Chinese Male Volunteers (Randomised, Double-blind, Placebo-controlled, Clinical Phase I Study)
Status: Completed, Estimated PCD: 2016-05-25
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-06-07
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
Status: Terminated, Estimated PCD: 2022-09-22
Clinical trial
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, Followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
Double-blind, Randomized, Placebo-controlled, Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of X243 After Single and Multiple Oral Administration in Healthy Volunteers.
Status: Completed, Estimated PCD: 2023-09-21
Clinical trial
Phase I FIH Phase I/IIa Randomized Placebocontrolled Doubleblind Trial Evaluating Safety and Tolerability of ExVivo Deceased Donor Kidney Allograft Treatment With TUM012 to Minimize Ischemic Reperfusion Injury After Kidney Transplantation
Status: Active (not recruiting), Estimated PCD: 2023-07-31
Clinical trial
A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Status: Withdrawn, Estimated PCD: 2023-09-01
Clinical trial
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-04136309 500 MG BID IN SUBJECTS WITH CHRONIC HCV INFECTION AND RAISED AMINOTRANSFERASES
Status: Terminated, Estimated PCD: 2012-02-09
Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Status: Completed, Estimated PCD: 2010-06-01
Clinical trial
A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
Status: Completed, Estimated PCD: 2020-04-01
Clinical trial
Prednisolone and Vitamin B1, B6, and B12 in Patients With Post-COVID-19-Syndrome (PC19S) - a Randomized Controlled Trial in Primary Care
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma
Status: Terminated, Estimated PCD: 2014-04-01
Clinical trial
Brain-Behavior Markers of Reward and Drug Effects in Young Adults
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases: A Randomized Placebo-controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study
Status: Not yet recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis Prophylaxis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Prospective Randomized Prehospital Trial Comparing Kcentra Plus Standard of Care to Standard of Care Alone in Trauma Patient With Hemorrhagic Shock
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS): A Pilot Study
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms
Status: Recruiting, Estimated PCD: 2026-03-24
Clinical trial
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE
Status: Recruiting, Estimated PCD: 2026-10-02
Clinical trial
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
COrticosteroids in acUte uRticAria in emerGency dEpartment
Status: Recruiting, Estimated PCD: 2025-03-28
Clinical trial
Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
Status: Completed, Estimated PCD: 2023-07-12
Clinical trial
Effectiveness and Safety of Methylene Blue for Prevention of Postoperative Neurocognitive Disorders in Patients Undergoing Pancreatic Tumor Surgery: A Prospective Randomized Controlled Clinical Trial
Status: Completed, Estimated PCD: 2023-04-30
Clinical trial
Targeting New Receptors in Dystonia: Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem, a Selective Agonist of Benzodiazepine Subtype Receptor alfa1, in Different Forms of Primary Focal Dystonia
Status: Completed, Estimated PCD: 2021-04-30
Clinical trial
Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
Effect of Intravenous Lignocaine Infusion on Intraoperative End Tidal Desflurane Concentration Requirements: A Randomised Double-Blinded Controlled Study
Status: Completed, Estimated PCD: 2021-11-19
Clinical trial
BOTOX® (Botulinum Toxin Type A) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Status: Recruiting, Estimated PCD: 2025-11-25
Clinical trial
Time to Healing, Loss of Fixation, and Loss of Alignment in Supracondylar Distal Femur Fractures Among a Geriatric Population Treated With Abaloparatide: A Double-Blind Placebo Controlled Study
Status: Withdrawn, Estimated PCD: 2025-06-01
Clinical trial
Transdermal Buprenorphine Patch for Postoperative Pain Control in Laparoscopic Cholecystectomy: a Prospective Randomized, Placebo-controlled, Study
Status: Completed, Estimated PCD: 2024-02-14
Clinical trial
ORBS: Ocular Rosacea Biome Study
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Status: Recruiting, Estimated PCD: 2026-08-23
Clinical trial
Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 Trial.
Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids on Plasma Reproductive Hormones, Fertility, Withdrawal Symptoms and Myocardial Function - The LUCAS Trial
Status: Terminated, Estimated PCD: 2023-08-15
Clinical trial
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy
Status: Not yet recruiting, Estimated PCD: 2027-08-31
Clinical trial
Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
NCCIH Development of Pregnenolone as a Treatment for Depression R61 Phase
Status: Completed, Estimated PCD: 2022-05-31
Clinical trial
A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Sustaining Skeletal Health in Frail Elderly
Status: Completed, Estimated PCD: 2023-08-01
Clinical trial
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase II Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effects of Ketamine Infusions in Clinically Depressed ICU Patients
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Anomalous Motor System Physiology in Attention Deficit Hyperactivity Disorder: Biomarker Validation and Modeling Domains of Function
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2018-12-11
Clinical trial
Cannabidiol (CBD) As A Pain Adjunct in Orthopedic Surgical Patients: A Randomized Control Trial
Status: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
Status: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
A Triple-blind Randomized Clinical Trial Comparing the Efficacy of a Desensitizing Agent Used With an At-home Bleaching Technique
Status: Completed, Estimated PCD: 2023-02-22
Clinical trial
Rituximab in Patients With ST-elevation Myocardial Infarction: A Phase 2 Placebo-controlled Randomized Clinical Trial: RITA-MI 2
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
The Use of Memantine for Prevention of Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
Misoprostol Effect on Second Trimester Abortion Blood Loss
Status: , Estimated PCD: 2025-04-15
Clinical trial
Escitalopram for Agitation in Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
The Role of Vitamin c Supplementation in the Prevention of CRPS Following Distal Radius Fractures: a Randomized Control Study
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Status: Completed, Estimated PCD: 2019-10-01
Clinical trial
Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
Impact of Progesterone on Stress Reactivity and Cannabis Use
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
Impact of the Efficacy of Diazepam 1% Oral Gel in Burning Mouth Syndrome
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
Status: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Status: Completed, Estimated PCD: 2013-07-18
Clinical trial
A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)
Status: Completed, Estimated PCD: 2014-04-14
Clinical trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Status: Active (not recruiting), Estimated PCD: 2023-09-14
Clinical trial
A Prospective Randomized Open-label Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and Short-and Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
Status: Completed, Estimated PCD: 2020-12-29
Clinical trial
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF) -a Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial
Status: Completed, Estimated PCD: 2024-02-14
Clinical trial
Ketamine Infusion for Pain Control in Severe Traumatic Injury: A Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-10-08
Clinical trial
Dexamethasone, Olanzapine, Flow-targeted Versus Pressure-targeted Hemodynamic Management, and Low Tidal Volume Ventilation in Patients Undergoing On-pump Cardiac Surgery - a Multifactorial Design Randomized Trial
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1a Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses of ABBV-141 in Healthy Adult Western and Asian Subjects
Status: Active (not recruiting), Estimated PCD: 2025-01-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Magnesium Vitamin B6 in Combination With Treatment as Usual in First Episode of Bipolar I Disorder
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Opioid/Benzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies - Study 3
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Status: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
Fecal Microbiota Transplantation to Reduce Immune Activation in ART-treated People Living With HIV With Low CD4/CD8 Ratio: The Gutsy Study
Status: Not yet recruiting, Estimated PCD: 2025-09-15
Clinical trial
Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study
Status: Active (not recruiting), Estimated PCD: 2018-12-01
Clinical trial
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer
Status: Active (not recruiting), Estimated PCD: 2021-02-28
Clinical trial
Perioperative Platelet Inhibition With Acetylsalicylic Acid Targeting Intraoperative Tumor Cell Seeding in Patients With Resectable Tumors of the Pancreatic Head - a Randomized, Controlled Multicenter Study
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Clinical trial
Randomized Trial Evaluating Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis - RELIEF-SCC
Status: Not yet recruiting, Estimated PCD: 2025-01-02
Clinical trial
Efficacy and Safety of Yinxingmihuan Oral Solution in Treatment of Chest Pain After PCI: A Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled Study
Status: Completed, Estimated PCD: 2023-12-25
Clinical trial
Pathophysiology of Uric Acid Nephrolithiasis
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk
Status: Active (not recruiting), Estimated PCD: 2019-04-11
Clinical trial
Prazosin for the Prophylaxis of Chronic Post-Traumatic Headaches in OEF/OIF/OND Service Members and Veterans With Mild TBI
Status: Completed, Estimated PCD: 2023-05-09
Clinical trial
Effect of Low-dose Aspirin for Stomach Cancer Prevention After Endoscopic Resection of Gastric Neoplasm (EASTERN): a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
Pilot Study to Evaluate Docosahexaenoic Acid as Treatment for Residual Amblyopia
Status: Withdrawn, Estimated PCD: 2024-07-01
Clinical trial
Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Clavulanic Acid
Status: Completed, Estimated PCD: 2018-05-25
Clinical trial
A Pilot Study on the Safety and Efficacy of Mavoglurant in Alcohol Drinking
Status: Completed, Estimated PCD: 2023-07-13
Clinical trial
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)
Status: Completed, Estimated PCD: 2008-04-01
Clinical trial
Barrow 5-ALA Intraoperative Confocal Evaluation Trial
Status: Completed, Estimated PCD: 2018-01-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years
Status: Completed, Estimated PCD: 2020-08-10
Clinical trial
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 2: PCSK9 Inhibitors - Alirocumab and Evolocumab
Status: Completed, Estimated PCD: 2021-04-07
Clinical trial
Clinical Efficacy of α-Mangostin Hydrogel Film With Chitosan Alginate Base for Recurrent Aphthous Stomatitis (RAS) Treatment
Status: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
Neuroinflammatory Mechanisms Linking Chronic Stress to Motivational Deficits
Status: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Sublingual Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting in Elective Gynaecological Patients at the University Hospital of the West Indies (UHWI)
Status: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Steroid Eye Drops Versus Placebo Eye Drops in Chronic Central Serous Chorioretinopathy Trial (PICS Trial)
Status: Recruiting, Estimated PCD: 2025-06-19
Clinical trial
Mood Effects of Serotonin Agonists Extended
Status: Completed, Estimated PCD: 2021-06-07
Clinical trial
Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo: A Randomized Controlled Double Blinded Study
Status: Not yet recruiting, Estimated PCD: 2025-12-30
Clinical trial
The Effect of Intravenous Non-steroidal Anti-inflammatory Drugs and Intravenous Corticosteroids on the Likelihood of Dysphagia and Dysphonia Following Anterior Cervical Discectomy and Fusion
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis.
Status: Not yet recruiting, Estimated PCD: 2025-02-27
Clinical trial
Controlling and Preventing Asthma Progression and Severity in Kids
Status: Active (not recruiting), Estimated PCD: 2028-01-31
Clinical trial
A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized Fc Receptor (FcR) Non-Binding Anti-cluster of Differentiation 3 (CD3) Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Antibacterial Prophylaxis for Prevention of Infections in Azacitidine Treated Myelodysplastic Syndrome Patients.
Status: Completed, Estimated PCD: 2022-07-30
Clinical trial
Effect of Pimavanserin on Aggression and Social Cognition.
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Sympathetic Regulation of Large Artery Stiffness in Humans With Age-Related Isolated Systolic Hypertension
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
AFFIRM-LITE: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults
Status: , Estimated PCD: 2024-06-01
Clinical trial
Multicenter, Randomized, Double-blind, Biomarker-guided, Phase II Trial With Adrecizumab (HAM 8101) to Improve proGNosis and outcomES in Patients With Moderate to Severe COVID-19
Status: Terminated, Estimated PCD: 2023-08-25
Clinical trial
Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults With Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART With Conserved Immune Function
Status: Active (not recruiting), Estimated PCD: 2024-11-11
Clinical trial
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Status: Recruiting, Estimated PCD: 2026-01-09
Clinical trial
Statins and CPAP in Adipose Tissue: A Randomized Clinical Trial in Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2023-12-12
Clinical trial
Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
Phase II Clinical Investigation of Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
Targeting Orexin to Treat Nicotine Dependence
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals - A Double-blind, Randomized, Placebo-controlled Cross-over Study
Status: Completed, Estimated PCD: 2023-06-08
Clinical trial
The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU
Status: Completed, Estimated PCD: 2022-02-01
Clinical trial
Effect of DAW2020 on Endotypic Traits in OSA
Status: , Estimated PCD: 2024-05-15
Clinical trial
Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Randomized, Double Blind, Placebo-Controlled Trial of Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Controlled, Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity in Population Aged 18 Years Old and Above
Status: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized Crossover Study of Propranolol Versus Ivabradine in Postural Tachycardia Syndrome (POTS)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Status: Active (not recruiting), Estimated PCD: 2028-05-31
Clinical trial
Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty. The RECIPE Randomized Clinical Trial
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial
Status: Completed, Estimated PCD: 2023-01-23
Clinical trial
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)
Status: Recruiting, Estimated PCD: 2030-04-30
Clinical trial
Serotonin-receptor Agonism in Reward Processing
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis- A Double Blind Randomized Controlled Trial.
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
Novel Probiotic Preparation With Gluten Degrading Activity and Gut Microbiota Modulating Effect
Status: Completed, Estimated PCD: 2021-04-30
Clinical trial
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Ureteral Stent Symptoms After Ureteroscopy: a Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease
Status: Terminated, Estimated PCD: 2021-04-29
Clinical trial
Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH): A Randomized Controlled Trial [EVER Study]
Status: Terminated, Estimated PCD: 2015-12-01
Clinical trial
A Study of STAtins for Reducing Events in the Elderly (STAREE)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency
Status: Recruiting, Estimated PCD: 2026-02-01
Abstract
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1900907
Abstract
https://www.nejm.org/doi/pdf/10.1056/NEJMc2300400
Abstract
https://ir.wavelifesciences.com/static-files/a3dbbb88-aebf-433d-8cb0-fcade9d43c23
Abstract
https://ir.ptcbio.com/static-files/b06f07d0-248f-404a-9041-2ec5aff2abce
Clinical trial
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living With HIV-1 (PLWH)
Status: Completed, Estimated PCD: 2023-08-14
Clinical trial
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Multiple Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Patients With Generalized Anxiety Disorder (GAD) and Patients With Bipolar Disorder (BPD)
Status: Recruiting, Estimated PCD: 2024-11-21
Clinical trial
EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Status: Recruiting, Estimated PCD: 2030-06-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Status: Completed, Estimated PCD: 2023-02-08
Clinical trial
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Chinese Participants With Active Non-radiographic Axial Spondyloarthritis.
Status: Active (not recruiting), Estimated PCD: 2024-04-08
Clinical trial
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
Status: Active (not recruiting), Estimated PCD: 2024-10-14
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Single-Center, Human Tick Kill Proof-of-Concept Study Evaluating the Safety, Tolerability, and Whole Blood Concentration of TP-05 (Lotilaner) in Healthy Volunteers
Status: Active (not recruiting), Estimated PCD: 2024-06-27
Clinical trial
A Phase 2, Two-Stage (Open-Label Run-in Followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled Study of Setmelanotide in Patients With Specific Gene Variants in the Melanocortin-4 Receptor Pathway
Status: Active (not recruiting), Estimated PCD: 2024-02-14
Clinical trial
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Status: Completed, Estimated PCD: 2023-08-17
Clinical trial
A Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E (Alpha/Beta/Delta/Omicron Variants S-Trimer COVID-19 Vaccine) in Population Aged ≥18 Years
Status: Active (not recruiting), Estimated PCD: 2023-05-10
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren's Syndrome
Status: Recruiting, Estimated PCD: 2026-09-03
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healthy Subjects Aged 4 to 60 Years in India
Status: Recruiting, Estimated PCD: 2024-11-26
Clinical trial
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-Part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-KHK in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-KHK in Obese Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2025-04-04
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Pregabalin Sustained-Release Tablets for the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2024-11-04
Clinical trial
A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema
Status: Terminated, Estimated PCD: 2022-09-09
Clinical trial
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN
Status: Active (not recruiting), Estimated PCD: 2024-02-18
Clinical trial
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 Tumor Area Positivity (TAP) ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
Status: Recruiting, Estimated PCD: 2025-08-18
Clinical trial
Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)
Status: Recruiting, Estimated PCD: 2028-03-21
Clinical trial
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Status: Recruiting, Estimated PCD: 2026-02-13
Clinical trial
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity
Status: Not yet recruiting, Estimated PCD: 2026-02-27
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Dose of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA
Status: Recruiting, Estimated PCD: 2025-10-10
Clinical trial
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled 60-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A First in Human, Double-blind, Placebo-controlled, Multicentre Phase I/II Study to Evaluate the Safety, Tolerability and Immune Modulatory Effects of MRx-4DP0004 in Participants Taking Long-term Control Medication for Their Asthma
Status: Terminated, Estimated PCD: 2023-04-26
Clinical trial
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Multinational Phase IV Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Status: Terminated, Estimated PCD: 2017-05-31
Clinical trial
A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib
Status: Active (not recruiting), Estimated PCD: 2012-09-24
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Status: Active (not recruiting), Estimated PCD: 2018-12-05
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status: Completed, Estimated PCD: 2016-11-11
Clinical trial
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2029-04-30
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
A PHASE 1B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ORAL PF-07054894 IN ADULT PARTICIPANTS AGED 18-75 YEARS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Status: Active (not recruiting), Estimated PCD: 2024-07-12
Clinical trial
A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort
Status: Terminated, Estimated PCD: 2022-06-30
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-09-06
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Status: Completed, Estimated PCD: 2023-04-19
Clinical trial
Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.
Status: Terminated, Estimated PCD: 2019-04-01
Clinical trial
A Double-Blind Clinical Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels
Status: Completed, Estimated PCD: 2022-05-29
Clinical trial
A Exploratory Phase II Clinical Trial, Double-blind, Randomized Placebo-controlled to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
Status: Completed, Estimated PCD: 2021-11-11
Clinical trial
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris
Status: Completed, Estimated PCD: 2008-09-01
Clinical trial
Pilot Study: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
Status: Completed, Estimated PCD: 2009-04-01
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2024-07-18
Clinical trial
A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of AGN-151586 for the Treatment of Moderate to Severe Glabellar Lines
Status: Recruiting, Estimated PCD: 2025-03-22
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
Status: Recruiting, Estimated PCD: 2025-08-29
Clinical trial
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase I Clinical Trial to Evaluate the Characteristics of the Safety, Tolerability and Pharmacokinetics of LEM-S401 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-10-18
Clinical trial
BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2018-01-21
Clinical trial
A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single and Multiple Ascending Dose First-Time-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity
Status: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
Status: Recruiting, Estimated PCD: 2025-06-28
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
An Interventional Randomized, Double-blind, Placebo and Active Comparator-controlled, Four-way Crossover Trial Investigating the Analgesic Properties of a Single Oral Dose of Lu AG06474 in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-05-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)
Status: Active (not recruiting), Estimated PCD: 2024-01-12
Clinical trial
A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients
Status: Completed, Estimated PCD: 2020-01-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.
Status: Completed, Estimated PCD: 2016-03-18
Clinical trial
A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
Status: Completed, Estimated PCD: 2019-10-28
Clinical trial
A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis
Status: Completed, Estimated PCD: 2021-08-11
Clinical trial
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Status: Completed, Estimated PCD: 2022-09-07
Clinical trial
A Multi-Center, Randomised, Double-blind, Placebo Controlled Phase II Clinical Study of Chiglitazar in Patients With Nonalcoholic Steatohepatitis Accompanied by Elevated Triglycerides and Insulin Resistance
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Status: Active (not recruiting), Estimated PCD: 2024-08-19
Clinical trial
A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes
Status: Completed, Estimated PCD: 2012-05-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma
Status: Completed, Estimated PCD: 2018-10-30
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
Status: Completed, Estimated PCD: 2021-08-21
Clinical trial
A Phase 3b, Multicentre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Status: Completed, Estimated PCD: 2022-01-03
Clinical trial
Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
Status: Completed, Estimated PCD: 2021-07-02
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial Studying the Efficacy and Safety of IP2018 in Young, Depressed, Erectile Dysfunction (ED) Patients
Status: Recruiting, Estimated PCD: 2023-07-30
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of SVT-15652 Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Otomycosis).
Status: Completed, Estimated PCD: 2021-10-19
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Oral AZD5055 Following Single and Multiple Ascending Doses
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection
Status: Completed, Estimated PCD: 2023-10-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2020-04-17
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Status: Completed, Estimated PCD: 2021-11-12
Clinical trial
A Multi-country, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of STA363 at Two Concentrations (60 mg/mL and 120 mg/mL) Compared to Placebo in Patients With Chronic Discogenic Low Back Pain
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176
Status: Completed, Estimated PCD: 2018-05-29
Clinical trial
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain
Status: Completed, Estimated PCD: 2020-05-15
Clinical trial
A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients
Status: Completed, Estimated PCD: 2013-06-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Terminated, Estimated PCD: 2021-10-17
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2028-05-23
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)
Status: Recruiting, Estimated PCD: 2023-11-24
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss
Status: Terminated, Estimated PCD: 2023-04-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension
Status: Active (not recruiting), Estimated PCD: 2023-01-12
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Status: Completed, Estimated PCD: 2020-07-28
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blinded and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects With Moderate and Severe Dry Eye
Status: Recruiting, Estimated PCD: 2022-12-31
Clinical trial
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of Single and Multiple Dose of HRS-5965 Tablets in Healthy Subjects, and the Food Effect on Pharmacokinetics, and Pharmacokinetics in Subjects With Impaired Renal Function
Status: Recruiting, Estimated PCD: 2023-04-10
Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess the Safety, Tolerability, PD and PK of RLS-0071 in Healthy Adult Subjects After Challenge With Inhaled Lipopolysaccharide (LPS)
Status: Completed, Estimated PCD: 2022-09-21
Clinical trial
Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough
Status: Completed, Estimated PCD: 2022-05-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg) as a Treatment for Moderate-to-Severe Acute Pain and the Prevention of Opioid-Induced Nausea and Vomiting (OINV) Following Orthopedic Surgery
Status: Completed, Estimated PCD: 2018-04-16
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity
Status: , Estimated PCD: 2023-04-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19
Status: Terminated, Estimated PCD: 2022-03-22
Clinical trial
A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)
Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
Randomized, Double-blind, Placebo-controlled, Dose Escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of IOA-289 in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2021-09-07
Clinical trial
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, Japanese Older Adults Aged ≥ 60 Years, and RSV-Seropositive Children Aged 12 to 59 Months
Status: Active (not recruiting), Estimated PCD: 2024-06-29
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2021-08-06
Clinical trial
A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults With Moderate-to-severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Completed, Estimated PCD: 2019-09-17
Clinical trial
A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
Status: Active (not recruiting), Estimated PCD: 2022-07-09
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Assess the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of TTI-0102 for the Treatment of Patients With Mild to Moderate COVID-19
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of TS-172 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-01-26
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Single Dose Regimen Study of LMN-101 in Healthy Volunteers Challenged With Campylobacter Jejuni
Status: Completed, Estimated PCD: 2022-10-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 Infection
Status: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus
Status: Recruiting, Estimated PCD: 2023-10-31
Clinical trial
A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.
Status: Completed, Estimated PCD: 2020-11-30
Clinical trial
A Phase I, Randomized, Observer-blinded, Placebo-controlled and Dose-escalation Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 60 Years and Over.
Status: Active (not recruiting), Estimated PCD: 2022-09-05
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2023-03-29
Clinical trial
A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants
Status: Completed, Estimated PCD: 2021-06-17
Clinical trial
A Multicenter, Randomized, Placebo-Controlled Investigator-Blind, Participant-Blind Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
Status: Terminated, Estimated PCD: 2022-05-04
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 157 in Healthy Subjects
Status: Completed, Estimated PCD: 2011-01-09
Clinical trial
Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells
Status: Terminated, Estimated PCD: 2022-08-29
Clinical trial
A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 Infection
Status: Terminated, Estimated PCD: 2021-05-16
Clinical trial
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Status: Completed, Estimated PCD: 2022-05-16
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Status: Terminated, Estimated PCD: 2022-02-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Chinese Participants
Status: Completed, Estimated PCD: 2022-09-28
Clinical trial
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
Status: Terminated, Estimated PCD: 2008-11-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-increasing Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Infusion of LPM3480392 Injection in Healthy Subject
Status: Completed, Estimated PCD: 2021-11-02
Clinical trial
Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Status: Completed, Estimated PCD: 2021-01-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of SAR443820 in Healthy Adult Participants.
Status: Completed, Estimated PCD: 2021-07-20
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Status: Completed, Estimated PCD: 2021-04-22
Clinical trial
A Phase Ib，Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety, Tolerability And Pharmacokinetics of HS-10345 In Chinese Adult Subjects With Treatment Resistant Depression
Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
Phase IIb/III Parallel-arm, Random., Active-controlled, Double-blind, Double-dummy, Multicenter, Non-inferiority Study in Patients With RVVC to Compare Efficacy, Safety and Tolerability of Topically Administered ProF-001 to Oral Fluconazole
Status: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Randomized, Positive and Placebo-Controlled Trial to Evaluate the Effects of Milademetan Administration on Cardiac Repolarization in Healthy Subjects
Status: Terminated, Estimated PCD: 2023-06-08
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis
Status: Terminated, Estimated PCD: 2022-10-28
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Efficacy and Safety of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration
Status: Completed, Estimated PCD: 2021-02-08
Clinical trial
A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Status: Terminated, Estimated PCD: 2022-10-04
Clinical trial
Randomized, Double-blinded, Placebo-controlled, Prospective, Multicenter Trial to Evaluate the Efficacy and Safety of SIC in Subjects With Mild/Moderate Asthma and Rhinitis/Rhinoconjunctivitis Sensitized to D.Pteronyssinus and/or D. Farinae
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)
Status: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Phase 1B, Multiple Ascending Dose Trial Examining The Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® for the Treatment of Chronic Sialorrhea in Pediatric Subjects
Status: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
Status: Completed, Estimated PCD: 2022-07-28
Clinical trial
A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Docetaxel to Placebo in Combination With Docetaxel in First Line Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2020-12-15
Clinical trial
A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2020-09-09
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-020572 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Multiple Doses in Subjects With Chronic Hepatitis B (Part 2)
Status: Terminated, Estimated PCD: 2022-07-18
Clinical trial
A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy
Status: Completed, Estimated PCD: 2017-03-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients With Negative Symptoms of Schizophrenia, Followed by a 40-Week Open-Label Extension
Status: Completed, Estimated PCD: 2020-05-26
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Status: Completed, Estimated PCD: 2022-06-16
Clinical trial
A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)
Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period
Status: Terminated, Estimated PCD: 2023-05-16
Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
Status: Completed, Estimated PCD: 2021-09-17
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants
Status: Completed, Estimated PCD: 2023-06-08
Clinical trial
Multicenter Double Blind Placebo-controlled Parallel-group Randomized Clinical Study of Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 12-18 Years Old
Status: Completed, Estimated PCD: 2023-07-21
Clinical trial
A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIAL
Status: Completed, Estimated PCD: 2022-06-23
Clinical trial
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL CHRONIC TREATMENT PERIOD TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE CROHN'S DISEASE
Status: Withdrawn, Estimated PCD: 2026-08-15
Clinical trial
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Status: Completed, Estimated PCD: 2019-08-12
Clinical trial
A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Status: Recruiting, Estimated PCD: 2023-07-31
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Status: Completed, Estimated PCD: 2022-05-21
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)
Status: Completed, Estimated PCD: 2021-12-10
Clinical trial
A Prospective Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of Three Intra-articular Injections of Ampion™ (4 mL) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care (SOC) Vs SOC in the Treatment of Hospitalized Patients With COVID-19
Status: Terminated, Estimated PCD: 2021-08-24
Clinical trial
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in China
Status: Active (not recruiting), Estimated PCD: 2022-12-05
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)
Status: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Phase III, Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-exploring Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).
Status: Completed, Estimated PCD: 2022-04-24
Clinical trial
A Randomized, Parallel-group, Double-blind and Open-label Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Status: Terminated, Estimated PCD: 2019-06-09
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ACP-044 for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy)
Status: Completed, Estimated PCD: 2022-02-11
Clinical trial
Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Status: Completed, Estimated PCD: 2019-12-12
Clinical trial
A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients
Status: Completed, Estimated PCD: 2005-10-01
Clinical trial
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis
Status: Completed, Estimated PCD: 2019-09-24
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
Status: Completed, Estimated PCD: 2022-04-20
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
Status: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2018-04-25
Clinical trial
A Dose-Ranging Safety, Tolerability, and Exploratory Efficacy Study of Adjunctive EQU-001 for Seizures in Adults With Epilepsy
Status: Active (not recruiting), Estimated PCD: 2022-10-11
Clinical trial
A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Noncarriers of the APOE4 Allele
Status: Withdrawn, Estimated PCD: 2023-12-31
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder
Status: Terminated, Estimated PCD: 2022-03-31
Clinical trial
A Randomized, Placebo-Controlled, Double-Blinded Single and Multiple Ascending Dose (SAD and MAD) Study of the Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-09-04
Clinical trial
A Randomized Double-blind Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-02-07
Clinical trial
Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217
Status: Completed, Estimated PCD: 2022-01-24
Clinical trial
ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Phase 2/3 Randomized Controlled Semi-blinded Trial to Investigate Safety and Effectiveness in Ureter Visualization With Intravenous Nizaracianine Triflutate, in up to 3 Divided Doses, in Adults Undergoing Abdominopelvic Surgery (TRIPHASE)
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care
Status: Recruiting, Estimated PCD: 2024-12-21
Clinical trial
A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Status: Completed, Estimated PCD: 2018-02-20
Clinical trial
The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator
Status: Completed, Estimated PCD: 2022-06-03
Clinical trial
A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 Following Single Ascending Dose Administration to Healthy Participants
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
Status: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously for 8 Weeks to Hypertensive Subjects With Uncontrolled Blood Pressure
Status: Completed, Estimated PCD: 2020-07-20
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® CGRP Immunotherapy (UB-313) in Healthy Participants
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Status: Completed, Estimated PCD: 2021-07-08
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses and the Open-Label Food Effect of a Single Dose of INS1007 in Healthy Japanese and Caucasian Subjects
Status: Completed, Estimated PCD: 2019-08-01
Clinical trial
A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant
Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
Efficacy and Safety of Intravenous HRS8179 on Brain Swelling After Large Hemispheric Infarction: a Randomised, Double-blind, Placebo-controlled Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2023-10-31
Clinical trial
A 4-arm, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Single Dose, Parallel Group Study Comparing Efficacy and Safety of a Fixed Combination of 500 mg Acetylsalicylic Acid + 4 mg Lidocaine With 500 mg Acetylsalicylic Acid and 4 mg Lidocaine Monotherapy as Well as Placebo in Adult Patients With Sore Throat Associated With a Common Cold.
Status: Completed, Estimated PCD: 2005-05-28
Clinical trial
A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology
Status: Terminated, Estimated PCD: 2022-11-28
Clinical trial
A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
Status: Recruiting, Estimated PCD: 2025-03-05
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
Status: Terminated, Estimated PCD: 2022-05-03
Clinical trial
A Phase 1, First-in-human, Randomized, Placebo Controlled, Double Blind, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AV-380 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-01-14
Clinical trial
A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of BG2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women.
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers
Status: Completed, Estimated PCD: 2020-08-28
Clinical trial
A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Status: Terminated, Estimated PCD: 2023-06-05
Clinical trial
A Phase 1, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenously Administered AVLX-144
Status: Completed, Estimated PCD: 2023-07-01
Clinical trial
The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2021-04-08
Clinical trial
A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD)
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Immunogenicity and Safety of Recombinant Human Papillomavirus Bivalent(Type 16 and 18) Vaccine (Yeast) in Healthy Females
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg, 20 mg, and 40 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Status: Completed, Estimated PCD: 2021-12-16
Clinical trial
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older as a Primary Series and Open-label Extension to Assess Immunogenicity, Safety, Efficacy of a Monovalent Booster Dose of SARS-CoV2 Adjuvanted Recombinant Protein Vaccine
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
Randomized, Delayed Start, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study of Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalation Phase I Clinical Study of Humanized Monoclonal Antibody Injection (SSGJ-613) in Healthy Adult Chinese Subjects
Status: Not yet recruiting, Estimated PCD: 2024-03-10
Clinical trial
Single-center, Randomised, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile of Single- and Multiple-dose Ascending Oral QG101-23-0 Capsules in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
Status: Completed, Estimated PCD: 2021-02-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, PK, PDand Randomized, Open-label，Crossover, Food Effect Study of HEC93077 in Healthy Chinese Subjects and Hyperuricemia Patients
Status: Recruiting, Estimated PCD: 2023-10-25
Clinical trial
A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status: Terminated, Estimated PCD: 2018-08-10
Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide
Status: Completed, Estimated PCD: 2021-08-17
Clinical trial
Effect of Testofen on Erectile Function in an Adult Male Population - A Double Blind, Randomised Controlled Trial.
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Status: Completed, Estimated PCD: 2013-04-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
Status: Completed, Estimated PCD: 2016-02-24
Clinical trial
Phase-1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Oral Doses in Japanese and Chinese Healthy Volunteers.
Status: Completed, Estimated PCD: 2023-12-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19
Status: Terminated, Estimated PCD: 2021-05-17
Clinical trial
Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
Status: Completed, Estimated PCD: 2021-06-16
Clinical trial
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-erosive Gastroesophageal Reflux Disease
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study of Telitacicept in Patients With Generalized Myasthenia Gravis
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
APEX-AMI - Pexelizumab in Conjunction With Angioplasty
Status: Completed, Estimated PCD: 2007-05-01
Clinical trial
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2019-06-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus
Status: Completed, Estimated PCD: 2019-12-20
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of GST-HG121 Tablets in Single and Multiple Administration in Chinese Adult Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-12-28
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
Status: Completed, Estimated PCD: 2022-09-09
Clinical trial
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
Status: Completed, Estimated PCD: 2021-11-01
Clinical trial
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
Status: Completed, Estimated PCD: 2022-01-10
Clinical trial
Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 6 Months Treatment With Hydroxycarbamide (Siklos®) or a Placebo in Adults With Sickle Cell Disease:
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Randomized, Single-blinded, Placebo Controlled, Single Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of KJ103 in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2023-03-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
Status: Completed, Estimated PCD: 2021-06-07
Clinical trial
A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients
Status: Completed, Estimated PCD: 2019-04-19
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
Status: Withdrawn, Estimated PCD: 2022-04-30
Clinical trial
A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)
Status: Not yet recruiting, Estimated PCD: 2025-11-15
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Status: Terminated, Estimated PCD: 2022-09-28
Clinical trial
A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of Vurolenatide in Adult Patients With Short Bowel Syndrome
Status: Terminated, Estimated PCD: 2022-08-05
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
Status: Completed, Estimated PCD: 2017-04-03
Clinical trial
A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression
Status: Completed, Estimated PCD: 2019-05-10
Clinical trial
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 Infection
Status: Completed, Estimated PCD: 2022-03-18
Clinical trial
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Status: Terminated, Estimated PCD: 2022-07-27
Clinical trial
A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
Status: Completed, Estimated PCD: 2023-08-03
Clinical trial
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
Status: Active (not recruiting), Estimated PCD: 2016-06-07
Clinical trial
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers
Status: Completed, Estimated PCD: 2022-02-23
Clinical trial
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Status: Terminated, Estimated PCD: 2023-09-15
Clinical trial
Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion : a Randomized, Double-blind Clinical Trial
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Status: Terminated, Estimated PCD: 2022-08-26
Clinical trial
A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-05-05
Clinical trial
A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Status: Completed, Estimated PCD: 2021-03-15
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Status: Completed, Estimated PCD: 2023-04-10
Clinical trial
Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Comparison Of Different Antiplaque Agents On Gingivitis In Patients Undergoing Fixed Orthodontic Treatment: A Double-Blind, Randomized Controlled Trial.
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age
Status: Active (not recruiting), Estimated PCD: 2020-09-21
Clinical trial
The Effects of Caffeine Supplementation on Training Intensity Quantification
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Influence of Hyperandrogenemia on the Sleep-associated Slowing of Follicular LH Frequency in Adult Polycystic Ovary Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer: A Randomized, Double-Blinded, Placebo Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
Safety for Home Administration of Microdose Psilocybin Use
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H6: PF-07304814)
Status: Terminated, Estimated PCD: 2022-04-06
Clinical trial
Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC
Status: Completed, Estimated PCD: 2023-08-14
Clinical trial
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
Effects of Antipsychotics on Brain Insulin Action in Females: A Randomised Placebo-Controlled, Crossover Multi-Modal Neuroimaging Study
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Topical Epidural Steroid Usage in Patients Undergoing Posterior Lumbar Decompression: A Randomized Control Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase III, Randomized, Multi-center Clinical Trial That Will Examine Whether Treatment With Intravenous TNK is Superior to Placebo in Patients Who Suffer a Non-large Vessel Occlusion Ischemic Stroke Within 4.5-12 Hours From Time Last Seen Well
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Subcutaneous Injections of Cultured Adipose-derived Stroma/ Stem Cells to Heal Refractory Ischemic Digital Ulcers in Patients With Scleroderma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide
Status: Recruiting, Estimated PCD: 2032-01-31
Clinical trial
Comparison of iv Paracetamol, iv Dexketoprofen and Topical Lidocaine in Scorpion Sting: a Placebo Randomized Controlled Trial
Status: Completed, Estimated PCD: 2021-10-01
Clinical trial
A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Status: Completed, Estimated PCD: 2017-09-15
Clinical trial
Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes
Status: Active (not recruiting), Estimated PCD: 2024-07-29
Clinical trial
Experimental Medicine Studies of Brain and Peripheral Immune Mechanisms for Sickness Behaviours in Patients With Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Effects of Serotonin Transporter Inhibition on the Subjective Response to LSD in Healthy Subjects
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
Cannabidiol for Reducing Drinking in Alcohol Use Disorder and Modifying the Effects of Alcohol on the Brain and the Liver: a Phase 2 Clinical Trial.-The CARAMEL Study
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Clinical trial
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD- the ESCAPE Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effects of Oxytocin Nasal Inhalation and Social Familiarity on Empathy Analgesia: a Factorial Randomized Controlled Trial
Status: Completed, Estimated PCD: 2024-01-21
Clinical trial
Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTI-CENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Status: Recruiting, Estimated PCD: 2026-08-08
Clinical trial
Behavioral Effects of Drugs (Inpatient): 42 (Cocaine and Zolmitriptan)
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial
Status: Completed, Estimated PCD: 2023-07-14
Clinical trial
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Morphine or Fentanyl for Refractory Dyspnea in COPD
Status: Active (not recruiting), Estimated PCD: 2024-05-24
Clinical trial
Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD: a Multicenter, Randomized, Controlled, Proof of Concept Study
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Human Cerebral Blood Flow Regulation: Sex, Mechanism, and Stress Differences (Phase 2)
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Multi-center, Randomized Clinical Trial of Chidamide Combined With Azacytidine and the HAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Patients
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
An Exploratory Study of the Efficacy and Safety of IBI311, a Modified Anti-IGF-1R Antibody, in Patients With Steroid-resistant, Thyroid Associated Ophthalmopathy
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes
Status: Completed, Estimated PCD: 2023-11-17
Clinical trial
Effects of NAD Restoration on Neurovascular Coupling in Community Dwelling Older Adults
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study of HSK21542 Injection for the Prevention of Postoperative Nausea and Vomiting (PONV)
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Comparing Single Versus Repeat Parent-to-Child Nasal Microbiome Transplant on Seeding, Engraftment, and Diversity of the Neonatal Nasal Microbiome
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients With Postoperative Lower Extremity Dyskinesia
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Flibanserin and Women With Hypoactive Sexual Desire Disorder: A Double-Blind, Randomized, Electrical Neuroimaging Study
Status: Terminated, Estimated PCD: 2021-12-21
Clinical trial
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)
Status: Recruiting, Estimated PCD: 2025-11-15
Clinical trial
Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial of Corfluvec Intranasal Vector Vaccine for the Prevention of COVID-19 in Healthy Volunteers Aged 18 to 60 Years
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
The Effect of 2mg Sub-acute Prucalopride on Cognition and Emotional Processing in Participants Recovered From Depression
Status: Completed, Estimated PCD: 2023-11-13
Clinical trial
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
Status: Completed, Estimated PCD: 2020-12-17
Clinical trial
Impact of Perioperative Dexmedetomidine on Long-term Survival in Older Patients After Cancer Surgery: a Multicenter Randomized Trial
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain.
Status: Active (not recruiting), Estimated PCD: 2027-06-30
Clinical trial
A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Naltrexone Treatment for Prolonged Grief Disorder: A Proof of Concept Study
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction
Status: Completed, Estimated PCD: 2023-11-15
Clinical trial
The Effect of Betaine in Refractory Syringomyelia（RS）
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58235) 10 mg in Addition to Atorvastatin Compared to Placebo in Subjects With Primary Hypercholesterolemia (Protocol P00692)
Status: Completed, Estimated PCD: 2001-07-27
Clinical trial
Descemet Endothelial Thickness Comparison Trials (DETECT I & II)
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Impact of Opioids on Heart Rate During Rapid Sequence Intubation: Double-blind Randomized Controlled Study
Status: Terminated, Estimated PCD: 2023-10-18
Clinical trial
Targeting the Beta-2-adrenergic Pathway to Improve Skeletal Muscle Glucose Uptake in Obese Humans
Status: Completed, Estimated PCD: 2024-03-01
Clinical trial
A Phase III Multi-center Randomized Placebo-controlled Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic
Status: Not yet recruiting, Estimated PCD: 2027-01-30
Clinical trial
Effects of Glucocorticoids on Cognition in HIV-infected Women
Status: Completed, Estimated PCD: 2023-09-08
Clinical trial
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Status: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations
Status: Terminated, Estimated PCD: 2008-05-01
Clinical trial
The Effect of Anti-IL17 in New-onset Type 1 Diabetes: a Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: a Feasibility Randomized Controlled Trial of Short-course Antibiotic Therapy
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease
Status: Completed, Estimated PCD: 2023-09-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study Evaluating Acetazolamide Efficacy in Ataxia in PMM2-CDG
Status: Terminated, Estimated PCD: 2024-01-24
Clinical trial
Functional Connectivity and Associated Neuropeptides Variations in Treatment Resistant Schizophrenia Patients: Treatment Efficacy of add-on Sodium Benzoate
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Status: Completed, Estimated PCD: 2023-08-25
Clinical trial
Evaluation of 5-fluorouracil and Low Molecular Weight Heparin Intraoperative Infusion in Preventing Proliferative Vitreoretinopathy in High Risk Pediatric Rhegmatogenous Retinal Detachment
Status: Completed, Estimated PCD: 2022-10-21
Clinical trial
Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomised, Multi-centre, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Dose Study to Assess Safety, Tolerability, PK, PD & Preliminary Efficacy of IV Doses of ONO-4685 in Patients With Plaque Psoriasis
Status: , Estimated PCD: 2024-10-24
Clinical trial
Pharmaceutical Interventions for Noise-Induced Hearing Loss-Acute Exposure Treatment
Status: Terminated, Estimated PCD: 2023-09-29
Clinical trial
Adjunctive Dexamethasone for Cerebral Toxoplasmosis: a Double-blinded Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Reducing Inflammation for Greater Health Trial: The RIGHT Study
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Effect of Celery Seed (Apium Graveolens L.) Administration on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1, First-in-human, 2-part Study (Part 1 is a Single Ascending Dose in Healthy Participants; Part 2 is a Multiple Ascending Dose Study in Participants With Autoimmune Disease) to Evaluate the Safety, PD and PK of VIS171
Status: Terminated, Estimated PCD: 2024-02-15
Clinical trial
Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Evaluating the Safety and Acceptability of Using Chinese Herbal Medicine in Patients With Primary Dysmenorrhea: A Randomized-controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis: a Randomized Controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With Significant/Advanced Fibrosis or Cirrhosis: a Randomized, Double-blind Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Efficacy of the Levonorgestrel Intrauterine Device With Norethindrone Acetate for Treatment of Endometriosis in Adolescents and Young Adults
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Clinical trial
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
Status: Completed, Estimated PCD: 2024-01-18
Clinical trial
Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative
Status: Withdrawn, Estimated PCD: 2025-08-01
Clinical trial
"Restoration of the Gut Microbiome After Cesarean Section (RestoreGut)" - A Double-blinded Randomized Controlled Feasibility Trial
Status: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-02-01
Clinical trial
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Status: Completed, Estimated PCD: 2022-10-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
Status: Terminated, Estimated PCD: 2022-12-31
Clinical trial
Neurobehavioral and Immune Effects of Citicoline in Youth Alcohol Use Disorder
Status: Not yet recruiting, Estimated PCD: 2029-02-01
Clinical trial
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
Status: Recruiting, Estimated PCD: 2024-11-16
Clinical trial
Effect of Simvastatin on Hepatic Decompensation and Death in Subjects With High-risk Compensated Cirrhosis
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Investigating the Use of EMLA Topical Cream for Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Cutaneous Cancers
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Immunosuppression in Biopsy-proven Virus Negative Myocarditis or Inflammatory Cardiomyopathy
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Regress-HFpEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
Status: Completed, Estimated PCD: 2023-04-28
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of ALN-ANG3 in Otherwise Healthy Adult Participants
Status: Not yet recruiting, Estimated PCD: 2025-11-02
Clinical trial
Mechanisms Underlying Oxytocin's Analgesia in Older Adults
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Status: Not yet recruiting, Estimated PCD: 2029-12-31
Clinical trial
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia Patients During Symptomatic Remission
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2018-02-16
Clinical trial
Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index
Status: Recruiting, Estimated PCD: 2023-12-12
Clinical trial
Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Double-blind, Placeboa-controlled, Randomized Clinical Trial of the Safety and Efficacy of Botulinum Toxin (BOTOX) in Bruxism.
Status: Completed, Estimated PCD: 2011-08-01
Clinical trial
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2028-01-31
Clinical trial
Cognitive Effects of Nimodipine in Patients With Schizophrenia
Status: Completed, Estimated PCD: 2023-05-12
Clinical trial
Trial to Assess Chelation Therapy 2
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Randomized, Double Blind, Placebo-Controlled Single Center Phase 2 Pilot Study to Assess the Safety and Efficacy of Off-label Subcutaneous Administration of Erenumab-aooe in Patients With Temporomandibular Disorder
Status: Completed, Estimated PCD: 2024-01-04
Clinical trial
Actions of Dietary Tocotrienols on Obesity
Status: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
Status: Terminated, Estimated PCD: 2023-06-18
Clinical trial
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (>=6 To <18 Years of Age)
Status: Active (not recruiting), Estimated PCD: 2023-07-19
Clinical trial
A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With Schizophrenia
Status: Completed, Estimated PCD: 2018-07-31
Document
DailyMed Label: 0.9% SODIUM CHLORIDE
Organization
HF Acquisition Co LLC, DBA HealthFirst
Clinical trial
A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study
Status: Terminated, Estimated PCD: 2023-10-20
Clinical trial
601-0018
Status:
Clinical trial
hzVSF-v13 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics After Intravenous and Subcutaneous Administration in Healthy Adults
Status: Completed, Estimated PCD: 2022-01-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Effects of Single Doses of AUT00201 in Patients With Myoclonus Epilepsy and Ataxia Due to Potassium (K+) Channel Mutation (MEAK)
Status: Completed, Estimated PCD: 2024-05-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of SRN-001 in Healthy Participants
Status: Active (not recruiting), Estimated PCD: 2024-03-15
Clinical trial
A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Status: Active (not recruiting), Estimated PCD: 2021-11-03
Clinical trial
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Healthy Chinese Subjects
Status: Completed, Estimated PCD: 2020-12-11
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY FOLLOWING SINGLE SUBCUTANEOUS DOSE OF PF-06480605 IN CHINESE HEALTHY PARTICIPANTS
Status: Completed, Estimated PCD: 2022-04-09
Clinical trial
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2019-01-23
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
Status: Completed, Estimated PCD: 2023-08-25
Clinical trial
Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0385-0434 in Healthy, Male Japanese Participants
Status: Completed, Estimated PCD: 2022-01-19
Clinical trial
A Phase 2 and Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Status: Recruiting, Estimated PCD: 2026-03-03
Clinical trial
Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.
Status: Completed, Estimated PCD: 2018-08-14
Clinical trial
A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC)
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de Novo Kidney Transplantation
Status: Completed, Estimated PCD: 2012-01-23
Clinical trial
A Single-and Multiple Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease
Status: Recruiting, Estimated PCD: 2024-07-05
Clinical trial
A Phase 1, Single-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Oral Administrations of TNP-2092 Capsules in Asymptomatic Healthy People With Helicobacter Pylori Infection
Status: Completed, Estimated PCD: 2017-08-15
Clinical trial
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON)
Status: Recruiting, Estimated PCD: 2025-06-04
Clinical trial
Phase 1/2 Clinical Study to Assess the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of HCR040, Allogeneic Adipose-derived Adult Mesenchymal Stem Cells, in Acute Respiratory Distress Syndrome
Status: Completed, Estimated PCD: 2021-08-16
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Status: Completed, Estimated PCD: 2024-01-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)
Status: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Status: Recruiting, Estimated PCD: 2025-04-26
Clinical trial
Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Observer-Blind, Placebo-Controlled Proof-of-Concept Trial to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1 Placebo-controlled Study of the Safety and Tolerability of Rectally Administered, Multiple-ascending Doses of IW-3300 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Status: Completed, Estimated PCD: 2023-04-03
Clinical trial
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of SOL-116 in Healthy Subjects and Patients With Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Status: Active (not recruiting), Estimated PCD: 2021-08-11
Clinical trial
A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus
Status: Not yet recruiting, Estimated PCD: 2025-02-17
Clinical trial
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study Evaluating Safety and Immunogenicity of Influenza A Hemagglutinin Stabilized Stem Nanoparticle Vaccine Candidate in Healthy Adults
Status: Completed, Estimated PCD: 2023-10-10
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Dose Escalating Study of TAS3731 in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period in Patients With Borderline Personality Disorder
Status: Completed, Estimated PCD: 2022-12-09
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETICS FOLLOWING SINGLE INTRAVENOUS DOSE OF PF-06823859 IN JAPANESE HEALTHY PARTICIPANTS
Status: Completed, Estimated PCD: 2022-03-27
Clinical trial
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 After Single and Multiple Ascending Doses to Healthy Participants.
Status: Recruiting, Estimated PCD: 2024-08-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (BMT CTN 1705)
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Status: Terminated, Estimated PCD: 2023-06-07
Clinical trial
A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
402-C-1201
Status: Withdrawn, Estimated PCD: 2012-10-31
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE_791 and Food Effect in Normal Healthy Volunteers
Status: Completed, Estimated PCD: 2024-02-01
Clinical trial
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Status: Completed, Estimated PCD: 2023-12-14
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Single Center, Single-blind, Randomized, Dose-escalation, Parallel, Placebo and Active-controlled, Single Dose, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults
Status: Recruiting, Estimated PCD: 2024-03-20
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Etrasimod for Induction and Maintenance Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Status: Completed, Estimated PCD: 2019-02-21
Clinical trial
Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial Glucose Excursions
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis
Status: Completed, Estimated PCD: 2022-02-17
Clinical trial
A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer.
Status: Active (not recruiting), Estimated PCD: 2023-12-08
Clinical trial
A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Status: Terminated, Estimated PCD: 2012-04-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of J2H-1702 for Non-alcoholic Steatohepatitis
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS)
Status: Active (not recruiting), Estimated PCD: 2024-12-10
Clinical trial
Pharmacokinetics, Pharmacodynamics and Safety of Ziltivekimab Versus Placebo in Chinese Participants With Chronic Kidney Disease and Systemic Inflammation
Status: Active (not recruiting), Estimated PCD: 2024-05-27
Clinical trial
A Phase I, First-in-human, Two-part, Randomized, Placebo-controlled, Double-blind, Single and Repeated Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of SAR442501 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Status: Active (not recruiting), Estimated PCD: 2022-05-31
Clinical trial
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-005 in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy Subjects
Status: Completed, Estimated PCD: 2018-07-16
Clinical trial
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
Status: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）
Status: Completed, Estimated PCD: 2017-12-15
Clinical trial
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Status: Recruiting, Estimated PCD: 2025-02-08
Clinical trial
A Phase 1, First-in-Human, Double-blind, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, PK and PD and Food Effect of CKD-508 After Single and Multiple Ascending Oral Dose Administration in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-07-02
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia
Status: Terminated, Estimated PCD: 2023-05-23
Clinical trial
A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)
Status: Completed, Estimated PCD: 2022-06-29
Clinical trial
A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment
Status: Completed, Estimated PCD: 2019-11-15
Clinical trial
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of Age
Status: Active (not recruiting), Estimated PCD: 2024-06-10
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Multiple Ascending Dose (MAD) Study To Evaluate The Safety, Tolerability, and Pharmacokinetics of TMP-301 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-12-22
Clinical trial
Phase Ib, Single-center, Randomized, Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, 3-arm Study to Evaluate the Safety, and Efficacy of AD17002 (LTh[αK]) Intranasal Spray in Male and Female Participants Aged 18 to 65 Years With Mild to Moderate COVID 19
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations (PROSPERO).
Status: Recruiting, Estimated PCD: 2025-07-19
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
Status: Completed, Estimated PCD: 2021-05-27
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS CoV 2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Participants ≥ 50 Years of Age
Status: Not yet recruiting, Estimated PCD: 2025-03-15
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Dose and Single Subcutaneous Dose of BI 655130 in Healthy Japanese Male Volunteers (Double-blind, Randomised, Placebo-controlled Design).
Status: Completed, Estimated PCD: 2018-01-04
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue Infection
Status: Terminated, Estimated PCD: 2023-01-19
Clinical trial
Open, Randomised, Two-way Crossover Study to Assess the Effect of a High Fat, High Caloric Meal on the Pharmacokinetics of BI 409306, Followed by a Fixed Sequence Period to Investigate the Pharmacokinetics of BI 409306 After a Single Oral Dose Given at Bed Time in Healthy Male and Female Volunteers
Status: Completed, Estimated PCD: 2014-10-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS)
Status: Completed, Estimated PCD: 2023-11-08
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ103 in Chinese Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2024-12-24
Clinical trial
A Phase 1 Randomized, A Phase 1 Randomized, Placebo Controlled, Double Blind, Two Part, Single- and Multiple-Ascending-Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered ABL301 in Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia With Long-Term Follow-Up
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1, Single-Ascending-Dose, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3410738 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2021-08-04
Clinical trial
An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status: Active (not recruiting), Estimated PCD: 2031-03-31
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of VSA006 Injection in Chinese Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Phase Ⅰ Study to Evaluate the Tolerability and Pharmacokinetics of HS-10509 in Chinese Adult Subjects
Status: Not yet recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IBI3002 in Healthy Participants and Participants With Mild to Moderate Asthma
Status: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
Phase 3, Double-blind, Placebo-controlled, Multicentre Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic
Status: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Status: Not yet recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
Status: Completed, Estimated PCD: 2024-01-03
Clinical trial
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Status: Completed, Estimated PCD: 2021-04-19
Clinical trial
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) Patients
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
An Open-Label Extension of the Study XEN496 in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Status: Terminated, Estimated PCD: 2023-11-17
Clinical trial
A Phase 1, Single-Dose, Randomized, Placebo- and Positive-Control, Four-Way, Crossover Study for the Evaluation of the Effect of Epetraborole on QT Intervals in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-07-26
Clinical trial
A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Empagliflozin (10 mg and 25 mg) Administered Orally Once Daily in Combination With Insulin With or Without up to Two Oral Anti-diabetic Agents for 24 Weeks in Chinese Type 2 Diabetic Patients With Insufficient Glycemic Control.
Status: Completed, Estimated PCD: 2022-03-03
Clinical trial
A Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-09-26
Clinical trial
Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multiple Ascending Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-05-16
Clinical trial
A Randomized, Double-blind, Controlled, Parallel-cohort Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
Status: Completed, Estimated PCD: 2023-11-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis
Status: Terminated, Estimated PCD: 2022-11-11
Clinical trial
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout
Status: Terminated, Estimated PCD: 2023-01-25
Clinical trial
A Randomised, Double-blind, Placebo-controlled Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone Stimulation Test Following Treatment With Baxdrostat for 8 Weeks in Participants With Uncontrolled Hypertension
Status: Not yet recruiting, Estimated PCD: 2024-11-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Patients With Rheumatoid Arthritis
Status: Withdrawn, Estimated PCD: 2011-04-28
Clinical trial
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose and Multi-Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
Status: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine With a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.
Status: Completed, Estimated PCD: 2023-02-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Pilot Stage Clinical Trial Evaluating CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study
Status: Completed
Clinical trial
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Status: Completed, Estimated PCD: 2024-03-14
Clinical trial
A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of OK-101 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP)
Status: Completed, Estimated PCD: 2023-11-14
Clinical trial
A Double-blind, Randomised, Placebo-controlled Study of Intravenous Doses of SPL026 (DMT Fumarate), a Serotonergic Psychedelic, in Healthy Subjects (Part A) and Patients With Major Depressive Disorder (Part B)
Status: Completed, Estimated PCD: 2022-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure
Status: Recruiting, Estimated PCD: 2025-03-06
Clinical trial
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
Status: Completed, Estimated PCD: 2023-11-14
Clinical trial
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Status: Completed, Estimated PCD: 2023-07-19
Clinical trial
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Status: Active (not recruiting), Estimated PCD: 2023-11-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AHB-137 With Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis
Status: Terminated, Estimated PCD: 2022-11-16
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma
Status: Recruiting, Estimated PCD: 2029-10-31
Clinical trial
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)
Status: , Estimated PCD: 2025-06-01
Clinical trial
Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)
Status: Completed, Estimated PCD: 2021-10-20
Clinical trial
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2027-05-06
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Double-blind, Multicenter, Randomized, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of Ingavirin®, 60 mg Capsules in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Children Aged 13-17 Years.
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE)
Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
First-in-man Single-dose Escalation Study in a Randomized, Single-blind, Placebo-controlled, Group-comparison Design to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY 2701250 After Single Short-time Intravenous Infusion or Subcutaneous Administration in Healthy Male Participants.
Status: Recruiting, Estimated PCD: 2025-01-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
Status: Completed, Estimated PCD: 2023-03-06
Clinical trial
A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-05-27
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, CROSSOVER, FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-06954522 IN HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
A Multicenter, Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Exploratory, First Time in Human (FTIH), Observer-blind, Randomized, Controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of Various Doses of GlaxoSmithKline Biologicals SA's (GSK) Investigational Omicron Variant S Glycoprotein (mRNA-CR-04) Vaccine When Administered Intramuscularly in Healthy Adults 18 to 49 Years of Age
Status: Active (not recruiting), Estimated PCD: 2023-11-09
Clinical trial
A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior Therapies
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 2 ,Multicentre, Randomised, Double Blind Double Simulation, Placebo and Positive Controlled Study to Evaluate the Efficacy and Safety of HSK31679 in Patients With Hypercholesterolemia With Non-alcoholic Fatty Liver Disease
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Uncontrolled Hypertension
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Tobramycin In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis
Status: Terminated, Estimated PCD: 2023-01-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2019-03-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia
Status: Active (not recruiting), Estimated PCD: 2024-04-15
Clinical trial
Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects
Status: Completed, Estimated PCD: 2018-12-27
Clinical trial
Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia
Status: Recruiting, Estimated PCD: 2024-05-27
Clinical trial
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2026-06-23
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Multidose Clinical Trial to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Status: Terminated, Estimated PCD: 2024-01-31
Clinical trial
A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)
Status: Recruiting, Estimated PCD: 2025-12-04
Clinical trial
B7451015
Status:
Clinical trial
A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis
Status: Terminated, Estimated PCD: 2024-02-02
Clinical trial
A Phase II, 8-week-treatment, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy, Tolerability and Safety of Orally Administered BI 1358894 in Patients With Post-Traumatic Stress Disorder (PTSD)
Status: Completed, Estimated PCD: 2023-10-12
Clinical trial
A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD
Status: Recruiting, Estimated PCD: 2025-09-10
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis
Status: Active (not recruiting), Estimated PCD: 2023-12-18
Clinical trial
Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Withdrawal, and Long-term Safety Study to Evaluate the Efficacy and Safety of Ulixacaltamide (PRAX-944) in Adults With Essential Tremor
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen
Status: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Observational Follow-up Study to Investigate the Duration of Treatment Effect With Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain
Status: Active (not recruiting), Estimated PCD: 2024-12-24
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
Status: Completed, Estimated PCD: 2019-01-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age
Status: Active (not recruiting), Estimated PCD: 2024-06-09
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1595043 (Single-blind, Partially Randomised, Placebo-controlled, Parallel (Sequential) Group Design) in Healthy Male Subjects
Status: Completed, Estimated PCD: 2021-03-19
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
An Open Clinical Trial to Evaluate the Immunity Persistence of Live Attenuated Varicella Vaccine at 5 and 8 Years After Primary Immunization With Live Attenuated Varicella Vaccine
Status: , Estimated PCD: 2021-12-19
Clinical trial
A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Status: Recruiting, Estimated PCD: 2034-03-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Candin for the Treatment of Common Warts (Verruca Vulgaris) in Adolescents and Adults
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects With Focal Onset Seizures With Suboptimal Response to Levetiracetam or Brivaracetam
Status: Completed, Estimated PCD: 2024-02-08
Clinical trial
A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH)
Status: Not yet recruiting, Estimated PCD: 2026-06-08
Clinical trial
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients
Status: Completed, Estimated PCD: 2013-02-26
Clinical trial
Interventional, Randomised, Partially Double-blind, Crossover, Positive-controlled, Single-dose Trial Investigating the Effect of LEO 152020 on Cardiac Repolarisation in Healthy Men and Women
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects With Schizophrenia
Status: Completed, Estimated PCD: 2024-03-15
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients With Enteric Hyperoxaluria
Status: Completed, Estimated PCD: 2023-01-17
Clinical trial
Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles Following Single and Multiple Doses and Food Effect of CS12192 Capsules in Healthy Adult Chinese Subjects
Status: Completed, Estimated PCD: 2024-02-01
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, and Clinical Efficacy of Seltorexant (JNJ-42847922) on Behavioral and Psychological Symptoms of Dementia in Patients With Probable Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-11-10
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects and Patients With Rheumatoid Arthritis.
Status: Completed, Estimated PCD: 2022-02-16
Clinical trial
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A First-in-human, Single-center, Placebo-controlled, Randomized, Double-blind Study in Healthy Subjects to Evaluate Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam After Oral Single and Multiple Ascending Dosing of KAND145
Status: Completed, Estimated PCD: 2024-04-08
Clinical trial
A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis
Status: Active (not recruiting), Estimated PCD: 2025-02-13
Clinical trial
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
Status: Recruiting, Estimated PCD: 2027-08-31
Clinical trial
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Status: Completed, Estimated PCD: 2023-03-09
Clinical trial
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2024-01-12
Clinical trial
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension
Status: Recruiting, Estimated PCD: 2025-01-22
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Status: Active (not recruiting), Estimated PCD: 2025-02-14
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 as an Adjunctive Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Status: Recruiting, Estimated PCD: 2024-06-26
Clinical trial
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Status: Terminated, Estimated PCD: 2023-02-13
Clinical trial
A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-08-11
Clinical trial
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
Status: Completed, Estimated PCD: 2019-05-15
Clinical trial
Randomized, Double-blind, Four Period, Six-treatment, Double-dummy, Placebo Controlled, Partial-crossover Study to Explore and Compare the Ventilatory Response to Hypercapnia (VRH) of Cebranopadol, Oxycodone, and Placebo in Healthy Subjects
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Status: Recruiting, Estimated PCD: 2027-04-25
Clinical trial
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Status: Recruiting, Estimated PCD: 2025-01-06
Clinical trial
A Phase 1/2, Observer-blind, Randomized, Placebo-controlled Multi-country Study to Assess Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age
Status: Active (not recruiting), Estimated PCD: 2025-05-23
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of JX11502MA Capsules in Patients With Schizophrenia.
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1B Multiple Ascending Dose Study of The Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients With Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
Status: Active (not recruiting), Estimated PCD: 2024-03-20
Clinical trial
A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, First-in-human, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
Status: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Status: Active (not recruiting), Estimated PCD: 2024-02-27
Clinical trial
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single and Multiple Doses of ENC1018 in Healthy Adult Subjects
Status: Not yet recruiting, Estimated PCD: 2024-08-20
Clinical trial
An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
A Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB004 in Healthy Volunteers
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Injections of NNC0247-0829 in Adults With Overweight or Obesity
Status: Completed, Estimated PCD: 2022-06-11
Clinical trial
A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-07-14
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Adaptative, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled, Clinical Trial, on the Efficacy and Tolerability of Different Escalating Doses of Intra-articular Clodronate in Patients With Painful Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK2982772 in Participants With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2021-09-13
Clinical trial
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label Sub-study to Evaluate the Safety, PK, and Neutralizing Activity of AZD3152 for Pre-exposure Prophylaxis of COVID-19
Status: Active (not recruiting), Estimated PCD: 2023-09-07
Clinical trial
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-02-13
Clinical trial
An Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY2287411 Injection, in Patients With Solid Tumors Known to Express Mesothelin
Status: Completed, Estimated PCD: 2021-09-29
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
Status: Active (not recruiting), Estimated PCD: 2023-08-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2028-06-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-08-02
Clinical trial
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BRII-297 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-11-21
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Status: Active (not recruiting), Estimated PCD: 2026-12-29
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
Status: Completed, Estimated PCD: 2024-03-13
Clinical trial
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
Status: Completed, Estimated PCD: 2024-02-06
Clinical trial
A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
Status: Completed, Estimated PCD: 2020-04-30
Clinical trial
A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics With Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of LY3848575 in Healthy Participants, Including First-generation Japanese Participants
Status: Completed, Estimated PCD: 2024-02-19
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Phase I, Double Blind, Placebo Controlled, Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of KBP-7072 in Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2020-10-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Five Strengths of a Fixed Combination of Acetaminophen/Naproxen Sodium in Postoperative Dental Pain
Status: Completed, Estimated PCD: 2021-04-09
Clinical trial
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age).
Status: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2022-09-21
Clinical trial
Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS
Status: Completed, Estimated PCD: 2024-02-29
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age
Status: Completed, Estimated PCD: 2024-03-13
Clinical trial
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)
Status: Active (not recruiting), Estimated PCD: 2023-07-10
Clinical trial
A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)
Status: Completed, Estimated PCD: 2023-10-16
Clinical trial
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Status: Completed, Estimated PCD: 2019-09-28
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Participants
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 2a, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults
Status: Recruiting, Estimated PCD: 2024-09-16
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Oral Doses of BI 1569912 (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel Group Design) With an Optional Posology (Uptitration) Part (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel Group Design) in Healthy Male Subjects
Status: Recruiting, Estimated PCD: 2024-07-04
Clinical trial
A Phase 1 Placebo-Controlled, Double-Blind Crossover Study to Assess Psychological Effects of MDMA When Administered to Healthy Volunteers
Status: Completed, Estimated PCD: 2022-08-05
Clinical trial
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With Recent Onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-11 in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)
Status: Recruiting, Estimated PCD: 2025-06-05
Clinical trial
A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human, Adaptive Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of Orally Administered ATH-1020 in Healthy Young and Elderly Subjects
Status: Completed, Estimated PCD: 2022-09-09
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
Status: Terminated, Estimated PCD: 2022-09-27
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP.
Status: Completed, Estimated PCD: 2015-11-01
Clinical trial
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Pilot Study to Evaluate the Efficacy and Safety of Recombinant Super-compound Interferon (rSIFN-co) Among Healthy Subjects in Close Contact With Confirmed COVID-19 Case(s) and Subjects With Mild or Asymptomatic COVID-19
Status: Active (not recruiting), Estimated PCD: 2023-04-05
Clinical trial
A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Status: Completed, Estimated PCD: 2021-10-06
Clinical trial
A Phase 3b, Randomized, Double-Blind, Placebo-Control, Multicenter, Evaluation of the Safety and Efficacy of N1539 Administered Preoperatively in Open Unilateral Total Knee Arthroplasty
Status: Completed, Estimated PCD: 2019-05-21
Clinical trial
IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding Study
Status: Recruiting, Estimated PCD: 2024-11-25
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects
Status: , Estimated PCD: 2024-11-13
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
Status: Not yet recruiting, Estimated PCD: 2024-12-23
Clinical trial
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Placebo-controlled, Randomized, Multicenter, Double-blind, Parallel-group Trial to Confirm the Superiority of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2028-05-31
Clinical trial
Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight
Status: Recruiting, Estimated PCD: 2025-11-07
Clinical trial
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants With Parkinson's Disease
Status: Active (not recruiting), Estimated PCD: 2025-10-30
Clinical trial
A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
An Exploratory, Prospective, Multicenter, Randomized, Double Blind, Placebo + Sham Device Controlled, Study to Assess the Safety, Usability, and Initial Efficacy of the ViXe Combination for Intravesical Administration of XEOMIN® in the Treatment of Female Patients With Idiopathic Overactive Bladder (OAB)
Status: Completed, Estimated PCD: 2024-02-01
Clinical trial
A Phase1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Status: Recruiting, Estimated PCD: 2026-06-25
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
Status: Terminated, Estimated PCD: 2023-03-23
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Inclisiran in Asian Patients With ASCVD or ASCVD High Risk and Elevated Low-density Lipoprotein Cholesterol as an Adjunct to Diet and Maximally Tolerated Statins With or Without Additional Lipid-lowering Therapy (ORION-18)
Status: Active (not recruiting), Estimated PCD: 2022-06-09
Clinical trial
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-09-21
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 894416 Versus Placebo in Healthy Male Japanese Subjects (Single-blind, Randomized, Placebo-controlled Within Dose Group)
Status: Terminated, Estimated PCD: 2020-11-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Study of Topical Pirenzepine or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel
Status: Recruiting, Estimated PCD: 2024-04-26
Clinical trial
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants With Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2023-01-23
Clinical trial
An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies
Status: Completed, Estimated PCD: 2016-10-05
Clinical trial
Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO Trial)
Status: Completed, Estimated PCD: 2023-09-15
Clinical trial
Efficacy and Safety of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients: A Multicenter, Randomized, Double-blind, Dose-finding, Placebo-controlled Study
Status: Completed, Estimated PCD: 2022-07-05
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2018-02-19
Clinical trial
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Bioavailability of Branebrutinib in a Tablet Formulation Relative to Branebrutinib (RBA) in a Capsule Formulation Including the Effect of Food (Low-fat/Low-calorie and a High-fat/High-calorie) on the Bioavailability of Branebrutinib From a Tablet Formulation and a Double-blind Study to Evaluate the Safety and Pharmacokinetics of Branebrutinib From a Tablet Formulation in a Multiple-dose Arm in Healthy Participants
Status: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2019-07-22
Clinical trial
A Phase I Single-Centre, Randomised, Double-Blind, Placebo-Controlled Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356
Status: Terminated, Estimated PCD: 2021-10-28
Clinical trial
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Status: Completed, Estimated PCD: 2020-12-22
Clinical trial
A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects
Status: Completed, Estimated PCD: 2021-12-31
Clinical trial
A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa Trial to Investigate the Efficacy of OM-85 Versus Matched Placebo in Reducing Disease Severity Children Aged 3 to 24 Months With Early Clinical Diagnosis of Moderate Atopic Dermatitis
Status: Terminated, Estimated PCD: 2023-07-13
Clinical trial
A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)
Status: Completed, Estimated PCD: 2021-09-23
Clinical trial
Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET Study)-Long Term Safety Follow-up
Status: Completed, Estimated PCD: 2019-09-20
Clinical trial
A 26-Wk, Phase 3, Open Label (OL) Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period and an OL Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in CKD Patients on Dialysis
Status: Completed, Estimated PCD: 2019-11-15
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Patients With Guillain-Barré Syndrome
Status: Withdrawn, Estimated PCD: 2026-03-19
Clinical trial
Phase 2, Double-Blind, Randomized, Placebo-Controlled Clinical Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Female Patients
Status: Not yet recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects
Status: Completed, Estimated PCD: 2018-10-15
Clinical trial
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy
Status: Completed, Estimated PCD: 2006-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Evaluation of Evoked Responses as Pharmacodynamic Biomarkers in Healthy Adults and Schizophrenic Patients
Status: Completed, Estimated PCD: 2022-09-23
Clinical trial
A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults
Status: Completed, Estimated PCD: 2022-11-14
Clinical trial
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
Status: Completed
Clinical trial
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma
Status: Terminated, Estimated PCD: 2022-04-28
Clinical trial
Phase 2a, Randomized, Double-blind (Double-dummy), Controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and a Quadrivalent Inactivated Influenza Vaccine Given Intramuscularly as 2 Separate Injections in the Same Arm, in Comparison to Co-administration of Quadrivalent Inactivated Influenza Vaccine and Placebo and to Co-administration of OVX836 and Placebo Given Intramuscularly in Healthy Subjects.
Status: Completed, Estimated PCD: 2022-07-19
Clinical trial
A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients With Friedreich's Ataxia
Status: Completed, Estimated PCD: 2020-08-13
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Assess Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis (Placebo-Controlled Double-Blind Study)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
Status: Completed, Estimated PCD: 2022-05-16
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Status: Completed, Estimated PCD: 2020-08-18
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2019-01-30
Clinical trial
A Randomised, Double-blind, Placebo-controlled, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Oral Doses of HSK31858 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-08-15
Clinical trial
An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression
Status: Completed, Estimated PCD: 2008-08-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect After the Oral Administration of NXC736 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment
Status: Terminated, Estimated PCD: 2023-07-24
Clinical trial
A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2009-09-01
Clinical trial
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo/Positive Parallel Phase III Clinical Trial to Evaluate the Efficacy and Safety of SAL067 in Type 2 Diabetes Patients Who Cannot Effectively Control Blood Glucose Through Diet and Exercise
Status: Completed, Estimated PCD: 2022-03-25
Clinical trial
A Randomized , Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Ulcerative Colitis
Status: Completed, Estimated PCD: 2020-12-10
Clinical trial
A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
Status: Completed, Estimated PCD: 2023-11-13
Clinical trial
A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, and Pharmacokinetics After Multiple-dose Administration of 25 mg Aprocitentan in Healthy Japanese and Caucasian Subjects
Status: Completed, Estimated PCD: 2018-09-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
Status: Active (not recruiting), Estimated PCD: 2025-01-29
Clinical trial
A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age, RSV-seropositive Toddlers 12 to 24 Months of Age
Status: Completed, Estimated PCD: 2020-04-21
Clinical trial
AM1476 - A Phase I, Double-blind, Placebo-controlled, Single- and Multiple-oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects
Status: Completed, Estimated PCD: 2022-01-26
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)
Status: Completed, Estimated PCD: 2023-03-03
Clinical trial
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation
Status: Completed, Estimated PCD: 2023-10-19
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1569912 in Healthy Male Japanese Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel-group Design)
Status: Active (not recruiting), Estimated PCD: 2023-10-24
Clinical trial
Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity
Status: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Placebo-Controlled, Double-Blind, Parallel, Randomized, Two-Part, Clinical Dose-Confirming Study Of Pulsed, Inhaled Nitric Oxide (iNO) In Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) On Long Term Oxygen Therapy (LTOT) INHALE 1
Status: Completed, Estimated PCD: 2014-06-01
Clinical trial
A Phase 1, First-in-human, Randomized, Double-blind，Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of 9MW3811 in Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) ≥ 20 mL/Min/1.73 m^2
Status: Completed, Estimated PCD: 2023-06-01
Clinical trial
Phase 3, A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2023-07-23
Clinical trial
A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection
Status: , Estimated PCD: 2024-07-16
Clinical trial
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Phase Ⅰb/Ⅱ, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia.
Status: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose CRB4101 Tablets in Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2023-04-05
Clinical trial
A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese Participants
Status: Completed, Estimated PCD: 2023-06-08
Clinical trial
A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis.
Status: Completed, Estimated PCD: 2005-12-01
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Allergen Challenge Trial of 6 Repeat Doses of IRL201104 in Adult Participants With Seasonal Allergic Rhinitis.
Status: Completed, Estimated PCD: 2023-03-27
Clinical trial
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)
Status: Terminated, Estimated PCD: 2019-09-24
Clinical trial
A Randomized, Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect Factor Xa (fXa) Inhibitors in Healthy Volunteers.
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
Four-part, Randomized, Double-blind (Parts 1, 2A, 3 and 4), Multi-center, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK3965193 Monotherapy in Healthy Participants and in Participants Living With Chronic Hepatitis B Infection; and GSK3965193 in Combination With Bepirovirsen in Participants Living With Chronic Hepatitis B Infection
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Status: Completed, Estimated PCD: 2017-07-18
Clinical trial
A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeated Doses of Orally Administered ZF874 in Healthy Volunteers and PiXZ Subjects
Status: Terminated, Estimated PCD: 2022-09-12
Clinical trial
A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2).
Status: Completed, Estimated PCD: 2017-02-28
Clinical trial
A Phase I，Randomized, Double-blind，Placebo Controlled，Dose Escalated, Single Adminstrated Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
Status: Completed, Estimated PCD: 2020-10-22
Clinical trial
International, Multi-Center, Double-blind, Randomized, Placebo-Controlled, Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
Status: Withdrawn, Estimated PCD: 2025-08-01
Clinical trial
Multicenter, Double-blind, Double-dummy, Randomized Parallel Group Study to Evaluate the Safety and Efficacy of SH D 00659 E for 6 Treatment Cycles in Female Patients With Acne Papulopustulosa in Comparison to SH D 00659 G and Placebo.
Status: Completed, Estimated PCD: 2005-05-21
Clinical trial
A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo
Status: Completed, Estimated PCD: 2020-12-15
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Status: Completed, Estimated PCD: 2022-09-12
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2010-06-18
Clinical trial
A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2015-11-01
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-02-27
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)
Status: Completed, Estimated PCD: 2022-08-04
Clinical trial
Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma
Status: Completed, Estimated PCD: 2023-06-26
Clinical trial
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-10-16
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN9933, a Monoclonal Antibody Against Factor XI, in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Phase 1/2 Randomized, Double-blind, Placebo-controlled Single Dose Study at Two Dose Levels of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
Status: Completed, Estimated PCD: 2018-12-18
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APNmAb005 in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-06-16
Clinical trial
Phase 2a Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Completed, Estimated PCD: 2016-07-05
Clinical trial
A Phase 1A, First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-08-18
Clinical trial
Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Status: Completed, Estimated PCD: 2019-12-17
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Completed, Estimated PCD: 2018-08-07
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2018-07-17
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)
Status: Completed, Estimated PCD: 2021-12-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CB06-036 in Subjects With Chronic Hepatitis B
Status: Not yet recruiting, Estimated PCD: 2024-03-27
Clinical trial
A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder (5 μg and 10 μg), Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® (18 μg Tiotropium) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: , Estimated PCD: 2006-06-04
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects With Insomnia Disorder
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease
Status: Completed, Estimated PCD: 2020-12-02
Clinical trial
A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF SELF-AMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS
Status: Completed, Estimated PCD: 2023-08-04
Clinical trial
Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Withdrawal Study of Pulmonary Arterial Hypertension(PAH) Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric Oxide (INO)
Status: Withdrawn, Estimated PCD: 2019-06-01
Clinical trial
A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects With Acute Uncomplicated Influenza A Infection
Status: Terminated, Estimated PCD: 2018-03-09
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲb Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Booster Dose in Adults Aged 18 Years and Above
Status: Withdrawn, Estimated PCD: 2023-02-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
Status: Completed, Estimated PCD: 2020-10-20
Clinical trial
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
Status: Completed, Estimated PCD: 2019-01-02
Clinical trial
A Two-Part 1b/2a Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
Status: Terminated, Estimated PCD: 2022-06-24
Clinical trial
Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Status: Completed, Estimated PCD: 2021-05-14
Clinical trial
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-06-26
Clinical trial
Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2019-12-03
Clinical trial
A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-05-30
Clinical trial
A Single-Center, Randomized, Placebo-Controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Nts-104 Tris in Healthy Adults
Status: Recruiting, Estimated PCD: 2023-07-27
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis
Status: Completed, Estimated PCD: 2023-09-11
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Single-Center Study to Evaluate Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
Phase 2 Efficacy & Safety Evaluation of Advantage Anti-Caries Varnish for Primary Prevention
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Completed, Estimated PCD: 2019-04-26
Clinical trial
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults
Status: Recruiting, Estimated PCD: 2025-06-02
Clinical trial
A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Status: Completed, Estimated PCD: 2018-06-06
Clinical trial
A Placebo-Controlled, Double-masked Phase-1 Study in Healthy Subjects Investigating the Safety and Tolerability of Laquinimod Eye Drops
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera
Status: Active (not recruiting), Estimated PCD: 2025-10-15
Clinical trial
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2020-08-31
Clinical trial
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-02-20
Clinical trial
A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Terminated, Estimated PCD: 2022-10-14
Clinical trial
A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
Status: Completed, Estimated PCD: 2022-06-08
Clinical trial
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)
Status: Completed, Estimated PCD: 2016-01-27
Clinical trial
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Status: Completed, Estimated PCD: 2016-10-24
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HS-10518 in Healthy Adult Premenopausal Females in China
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase IIa, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 50561 in Patients With Mild or Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Multicentre, Phase III, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Assess Efficacy and Safety of Early Administration of Ivermectin During 3 Consecutive Days to Prevent SARS CoV-2 (COVID-19) Hospitalisation in Adults Older Than 50 Years of Age
Status: Terminated, Estimated PCD: 2021-07-21
Clinical trial
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Double-Blind, Placebo-Controlled Study of Cariprazine as an Adjunct to Antidepressants in the Treatment of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to Antidepressants Alone
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection
Status: Recruiting, Estimated PCD: 2023-06-01
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine in Patients With a Dual Diagnosis of Migraine and Medication Overuse Headache
Status: Completed, Estimated PCD: 2022-05-23
Clinical trial
An Adolescent Sub-study Within FLUTE-2: A Randomized, Double-blind, Placebo-Controlled Study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), With an Open-label Extension, in Adolescent Subjects With Eosinophilic Esophagitis
Status: Completed, Estimated PCD: 2022-09-05
Clinical trial
Randomized, Double Blind, Placebo Controlled "First-in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses and Multiple Oral Doses of MBF-118 in Healthy Young Volunteers
Status: Completed, Estimated PCD: 2022-09-06
Clinical trial
A Phase II, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Cerebral Edema
Status: Withdrawn, Estimated PCD: 2022-11-17
Clinical trial
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection
Status: Terminated, Estimated PCD: 2022-04-18
Clinical trial
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects
Status: Completed, Estimated PCD: 2022-08-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of AXA1125 in Subjects With Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Status: Completed, Estimated PCD: 2022-06-21
Clinical trial
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of LY3885125 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Ascending Dose in Participants With Dyslipidemia and Repeat-Doses in Participants With NAFLD
Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip
Status: Terminated, Estimated PCD: 2020-08-25
Clinical trial
A 16-week Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Status: Not yet recruiting, Estimated PCD: 2023-12-21
Clinical trial
A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Pembrolizumab in Patients With Resectable Stage III and IV Melanoma
Status: Not yet recruiting, Estimated PCD: 2030-12-23
Clinical trial
A Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
Status: Completed, Estimated PCD: 2023-03-24
Clinical trial
Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers
Status: Completed, Estimated PCD: 2018-08-24
Clinical trial
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status: Completed, Estimated PCD: 2019-03-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Two-stage Phase II Study Evaluating the Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia
Status: Completed, Estimated PCD: 2021-01-05
Clinical trial
A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-180935 Following Topical Administration in Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-08-18
Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Assess Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
Status: Completed, Estimated PCD: 2022-07-13
Clinical trial
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Status: Terminated, Estimated PCD: 2023-10-18
Clinical trial
A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Status: Completed, Estimated PCD: 2022-04-18
Clinical trial
A Randomized, 2-Part, Crossover Trial to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
Status: Completed, Estimated PCD: 2023-09-21
Clinical trial
RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-09-26
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects With Moderate to Severe Psoriasis
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Status: Completed, Estimated PCD: 2020-07-21
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms
Status: Completed, Estimated PCD: 2023-08-21
Clinical trial
Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Status: Active (not recruiting), Estimated PCD: 2022-04-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Japan Local Phase II Clinical Study Comparing Eltrombopag Monotherapy Versus Placebo in Adult Lower-risk Myelodysplastic Syndromes (MDS) Patients With Platelet Transfusion Dependence
Status: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
A Phase 1, Double-blind (Investigator and Participant), First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CVL-354 in Healthy Participants
Status: Completed, Estimated PCD: 2023-01-23
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Status: Completed, Estimated PCD: 2021-10-21
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults With Acute Respiratory Syncytial Virus Infection Who Are at High Risk for Complications
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Status: Completed, Estimated PCD: 2022-08-08
Clinical trial
The Efficacy of Selumetinib in Chinese Paediatric Participants With Post-operative Neurofibromatosis Type 1 (NF1)-Associated PNs: A PhaseⅡ, Multicenter, Randomised, Double-Blinded, Placebo-Controlled Study
Status: Withdrawn, Estimated PCD: 2026-06-30
Clinical trial
A Multiple-dose, Randomized, Double-blind, Placebo-controlled, Active-Comparator, Parallel Study to Investigate the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Subjects
Status: Completed, Estimated PCD: 2020-01-22
Clinical trial
The Efficacy, Safety and Tolerability of Sativex as an Adjunctive Treatment to Existing Anti-spasticity Medications in Children Aged 8 to 18 Years With Spasticity Due to Cerebral Palsy or Traumatic Central Nervous System Injury Who Have Not Responded Adequately to Their Existing Anti-spasticity Medications: a Parallel Group Randomised, Double-blind, Placebo-controlled Study Followed by a 24-week Open Label Extension Phase
Status: Completed, Estimated PCD: 2016-09-01
Clinical trial
A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants
Status: Completed, Estimated PCD: 2023-03-27
Clinical trial
A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.
Status: Completed, Estimated PCD: 2022-05-05
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.
Status: Completed, Estimated PCD: 2008-03-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Status: Completed, Estimated PCD: 2016-09-05
Clinical trial
Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids
Status: Completed, Estimated PCD: 2018-07-25
Clinical trial
Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2022-01-19
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety and Efficacy of Preoperative N1539 In Colorectal Surgery
Status: Completed, Estimated PCD: 2018-09-26
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2020-08-07
Clinical trial
A Double-blind, Placebo-controlled, Randomised, First in Human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of C106 in Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2023-06-22
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of SAGE-217 With a Fixed, Repeated Treatment Regimen on Relapse Prevention in Adults With Major Depressive Disorder
Status: Terminated, Estimated PCD: 2020-01-06
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase III Clinical Trial to Examine the Clinical Efficacy and Safety of Ranquilon, 1 mg Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
Status: Completed, Estimated PCD: 2022-11-22
Clinical trial
Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
A Phase I, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Once-daily Oral Doses of NNC0560-0004 in Healthy Humans, With an Additional Open Label Single Dose Cohort of CYP2D6 Poor Metabolizers.
Status: Recruiting, Estimated PCD: 2024-09-09
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy
Status: Active (not recruiting), Estimated PCD: 2023-11-16
Clinical trial
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture
Status: Completed, Estimated PCD: 2022-04-29
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Characteristics of DISC-3405 in Adult Healthy Male and Female Volunteers
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Multicentre Randomized, Double-blind, Placebo Controlled, Dose-finding, Phase 2 Study (MARS-17) of GSK3858279 in Adult Participants With Moderate to Severe Pain Due to Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2025-07-07
Clinical trial
A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4-way Crossover Study to Evaluate the Effects of Aticaprant (JNJ-67953964) on Electrocardiogram Intervals in Healthy Adult Participants
Status: Completed, Estimated PCD: 2022-10-04
Clinical trial
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2019-10-23
Clinical trial
Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine
Status: Completed, Estimated PCD: 2022-08-09
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-10-27
Clinical trial
A Single-center, Open Label Study to Evaluate the Safety，Tolerability and Pharmacokinetics of Multiple Administration of Sufenidone (SC1011) Tablets in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2023-01-14
Clinical trial
A Single-Blind, Randomized Study Comparing The Efficacy And Safety Of A Single Dose Of TNX-1300 To Placebo With Usual Care For The Treatment Of Signs And Symptoms Of Acute Cocaine Intoxication In Emergency Department Subjects (CATALYST Study)
Status: Not yet recruiting, Estimated PCD: 2024-06-04
Clinical trial
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2011-03-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label Extension
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Intramuscular Administration of a Single Dose of TNM002 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects
Status: Completed, Estimated PCD: 2020-01-13
Clinical trial
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN)
Status: Completed, Estimated PCD: 2021-06-08
Clinical trial
A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects
Status: Completed, Estimated PCD: 2023-01-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Recently Diagnosed, Treatment Naïve Subjects With IPF
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease
Status: Completed, Estimated PCD: 2023-03-01
Clinical trial
A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Status: Completed, Estimated PCD: 2017-08-03
Clinical trial
A Randomized, Subject- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Patients With Bronchiectasis
Status: Terminated, Estimated PCD: 2023-06-15
Clinical trial
A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 2a Study of SLV213 in Ambulatory Individuals Positive for COVID-19
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2020-02-20
Clinical trial
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Status: Completed, Estimated PCD: 2020-07-08
Clinical trial
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
Status: Completed, Estimated PCD: 2023-07-25
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single Center Study to Assess the Angiogenesis and Blood Perfusion Effect of NL003 in Patients With Critical Limb Ischemia by PETCT-RGD and MIBI
Status: Recruiting, Estimated PCD: 2023-07-31
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Status: Completed, Estimated PCD: 2019-10-24
Clinical trial
BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2021-11-24
Clinical trial
A Phase 1 FIH, Randomized, Double Blind, Placebo Controlled, SAD/MAD Study to Assess Safety, Tolerability, PK/PD and Food Effect of Trichomylin in Healthy Adult Participants and Preliminary Efficacy in Management of Chronic OA Pain
Status: Completed, Estimated PCD: 2022-02-18
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2021-07-20
Clinical trial
The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
Status: Withdrawn, Estimated PCD: 2020-12-01
Clinical trial
Ibuprofen and Biomarkers of Acute Kidney Injury After Running in the Heat
Status: Completed, Estimated PCD: 2023-09-05
Clinical trial
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Status: Terminated, Estimated PCD: 2022-10-12
Clinical trial
5HTP Regulation Of Asthma In Children
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Status: Completed, Estimated PCD: 2022-07-26
Clinical trial
Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence
Status: Recruiting, Estimated PCD: 2026-09-28
Clinical trial
A Phase II, Randomised, Multi-centric, Multi-national Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for Adolescent Girls and Young Adult Women (AYAs) With Polycystic Ovary Syndrome (PCOS)
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia: a Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Compare The Efficacy And Safety Of High-Medium Molecular Weight Beta-Glucan As Add-On To Statin Therapy In Subjects With Hyperlipidemia.
Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial
Status: Completed, Estimated PCD: 2013-05-01
Clinical trial
Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation
Status: Completed, Estimated PCD: 2019-06-01
Clinical trial
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Immunogenicity of Twice-annual Vaccination Against Seasonal Influenza for Two Hemispheres in Older Adults in Hong Kong - a Randomised Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
REstoration With Calcifediol of VItamin D Deficiency in Pulmonary Arterial Hypertension Patients
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
Acute Effects of Prescription Stimulant Medication on Cognition and Mood in College Students With and Without ADHD
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized Placebo-controlled Trial Investigating the Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 by Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Pilot Study to Assess Safety and Biomarker Responses of the Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Status: Completed, Estimated PCD: 2023-09-30
Clinical trial
A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit
Status: Active (not recruiting), Estimated PCD: 2016-08-26
Clinical trial
The Impact of the Vasodilator, Sildenafil, on the Pulmonary Circulation During Exercise in Healthy Trained and Untrained Humans
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA)Nephropathy Course QUIgAN Study
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas. Prospective Monocentric Interventional Study With Blinded Evaluation
Status: Recruiting, Estimated PCD: 2024-08-05
Clinical trial
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Simplifying Hepatitis B Care in Pregnancy by Combining Birth-dose Vaccine and Tenofovir: The COMBAT HBV Feasibility Trial
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Behavioral Pharmacology of THC and Beta-Myrcene
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
Estrogen Receptor Alpha Signaling in Endothelial Cells Exacerbates Arterial Stiffening Via Upregulation of ENaC in Insulin Resistant Females
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Clonidine to Prevent Postictal Delirium After ElectroConvulsive Therapy: a Randomised, Placebo-controlled, Triple-blind, Single-centre Trial.
Status: Recruiting, Estimated PCD: 2025-04-27
Clinical trial
Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy: A Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD: A Pilot Double-blind, Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection
Status: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
The Effects of Hydrocortisone, Melatonin, and Placebo on Symptoms of Jet Lag
Status: Completed, Estimated PCD: 2006-01-06
Clinical trial
Effects of Botulinum Toxin Type a Treatment on Clinical and Biophysical Parameters in Patients With Erythematotelangiectatic Rosacea: A Prospective, Randomized, Placebo-controlled, Double-masked Study
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
Propranolol for the Treatment of Traumatic Brain Injury
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory Drugs
Status: Terminated, Estimated PCD: 2022-09-01
Clinical trial
Effect of Nigella Sativa on Blood Lipids as an add-on Therapy in Atorvastatin Treated Hyperlipidaemic Patients. A Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Clinical and Nutrigenetic Assessment of Zinc in Participants With Prediabetes
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Effect of 8-week Supplementation With Anthocyanin Compounds Contained in Black Chokeberry on Inflammation and Oxidative Stress Induced by Very Intense Exercise in Highly Trained Rowers
Status: Completed, Estimated PCD: 2023-06-10
Clinical trial
Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized Double Blind Controlled Comparison of Oral Dydrogesterone as Luteal Phase Support in Natural Cycle Frozen-thawed Embryo Transfer
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Nandrolone Decanoate Therapy and Therapy With Complex Physiotherapy and Diet in the Treatment of Sarcopenia
Status: Recruiting, Estimated PCD: 2026-06-12
Clinical trial
A Proof of Concept Randomized Controlled Trial of XEN1101 for the Treatment of Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair. A Randomized, Placebo-controlled, Double-blind Crossover Study
Status: Completed, Estimated PCD: 2015-12-14
Clinical trial
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation in Patients With Heart Failure With Reduced Ejection Fraction
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group
Status: Active (not recruiting), Estimated PCD: 2024-03-26
Clinical trial
Phosphate Binder Therapy and Chronic Kidney Disease in Children
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
Status: Terminated, Estimated PCD: 2021-08-13
Clinical trial
Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Optimizing Surgical Outcomes at UPMC
Status: Completed, Estimated PCD: 2022-09-23
Clinical trial
Role of Nitric Oxide Coupling in Muscle Dysfunction With COPD
Status: Withdrawn, Estimated PCD: 2022-08-01
Clinical trial
Quadratus Lumborum (QL) Nerve Block for Patients Undergoing Primary Total Hip Arthroplasty (THA)
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
Status: Withdrawn, Estimated PCD: 2023-08-01
Clinical trial
Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Two Long-Acting Broadly Neutralizing Antibodies at ART Initiation in Adults Living With HIV-1 in Sub-Saharan Africa: The ACACIA Study
Status: Not yet recruiting, Estimated PCD: 2029-02-16
Clinical trial
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes
Status: Terminated, Estimated PCD: 2023-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Double-blinded, Phase II, Randomized Control Trial to Study the Effects of Simvastatin in Patients With Uterine Leiomyoma
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Randomised-controlled Trial of Donepezil for Motor Recovery in Acute Stroke
Status: Withdrawn, Estimated PCD: 2013-11-01
Clinical trial
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Using Live Vaccines to Induce Beneficial Innate Immune Training and Reduce Systemic Inflammation in COPD Patients.
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Getting SMART for Pediatric Epilepsy (Sleep, Melatonin, and Research Trial, SMART)
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
Sciatic Block in Contralateral Limb for Treatment of Refractory Phantom and Residual Limb Pain; a Double-Blind Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Liraglutide in Type 1 Diabetes
Status: Completed, Estimated PCD: 2019-01-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients. A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism
Status: Not yet recruiting, Estimated PCD: 2025-10-15
Clinical trial
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain of Initial Orthodontic Wire Insertion: a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL)
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Opium Tincture Against Chronic Diarrhea - Patients An Investigator Initiated, Randomized Placebo-controlled, Double-blinded, Clinical Trial
Status: Completed, Estimated PCD: 2023-12-21
Clinical trial
The Efficacy and Safety of a Chinese Herbal Medicine for the Constipation-predominant Irritable Bowel Syndrome (IBS-C): a Double-blinded, Placebo-controlled, Randomized Pilot Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2024-08-31
Clinical trial
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Neuroimaging and CBD for Opiod Use Disorder
Status: Recruiting, Estimated PCD: 2025-11-12
Clinical trial
Safety, Tolerability, and Pharmacokinetics of MG-ZG122 in a Single Subcutaneous Injection in Chinese Healthy Adult Subjects: a Single-center, Randomized, Double-blind, Placebo-controlled, Dose-increasing Phase I Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-01-26
Clinical trial
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia: a Double-blinded Randomized Controlled Trial
Status: , Estimated PCD: 2025-12-31
Clinical trial
Prophylactic Tranexamic Acid Versus Adrenaline for Bleeding Prevention During Flexible Bronchoscopy: a Double Blind, Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-blind, Parallel Group, Single Centre, Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Orally Administered Doses of Enoxacin (200mg Twice Daily, 400mg Twice Daily and 600mg Twice Daily) in Adults With Amyotrophic Lateral Sclerosis
Status: Completed, Estimated PCD: 2023-11-15
Clinical trial
Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
The BE WELL Study: Black Raspberry Beverage Working to Prevent Lung Cancer
Status: Completed, Estimated PCD: 2021-05-13
Clinical trial
N of 1 Pilot Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)
Status: Recruiting, Estimated PCD: 2025-01-14
Clinical trial
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease: The GPAD-3 Study
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
Status: Completed, Estimated PCD: 2016-08-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis
Status: Completed, Estimated PCD: 2020-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Curcumin to Prevent Progression of Biopsy Proven, Low-risk Localized Prostate Cancer Patients Undergoing Active Surveillance
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa Trial
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
Proton Pump Inhibitors (PPI) as a New Strategy for Therapy in Sepsis: Clinical Trial to Reduce Severity of Organ Failure and in Vitro Experiments to Search Specific Hallmarks in Monocytes From Septic Patients and to Characterize the Mechanism of Action of PPI
Status: Completed, Estimated PCD: 2023-08-21
Clinical trial
Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children
Status: Active (not recruiting), Estimated PCD: 2020-05-04
Clinical trial
DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
The Effect of Colchicine on Food-related Effort-based Decision Making in Brain and Behaviour in Overweight and Obesity: the FLAIR-i Study
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2019-12-27
Clinical trial
A Multi-center, Randomized, Double-blinded, Active-controlled, Superiority, Phase 4 Trial to Evaluate the Efficacy and Safety of Atock Dry Syrup Sama With Acute Bronchitis Patients
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: A Randomized, Controlled Trial
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Age-descending, Randomized, Placebo-controlled Phase 2 Trial in Three Sites in Sub-Saharan Africa to Assess the Safety and Immunogenicity of a Parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) Versus Placebo
Status: Recruiting, Estimated PCD: 2025-04-05
Clinical trial
Trial of Propranolol in Older Adults With Primary Progressive Aphasia
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
the Impact of Statin on Cirrhotic Patients
Status: Completed, Estimated PCD: 2023-02-25
Clinical trial
Phase II Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Broccoli Seed and Sprout Extract (BSSE) to Evaluate Detoxification of Carcinogens in Firefighters
Status: , Estimated PCD: 2025-11-01
Clinical trial
A Pilot,Randomized Controlled-trial of Lipoprotein(a) Lowering for the Prevention of Aortic Valve Disease-translating Genomic Knowledge for Cardiovascular Prevention
Status: Withdrawn, Estimated PCD: 2017-01-01
Clinical trial
Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis An Investigator-initiated, Randomized, Placebo-controlled, Double-blind Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)
Status: Completed, Estimated PCD: 2022-07-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Status: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
A Phase III Confirmatory Study of K-237-Multi-regional, Multi-center, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Mild COVID-19
Status: Completed, Estimated PCD: 2022-08-26
Clinical trial
Obeticholic Acid for Prevention in Barrett's Esophagus
Status: Recruiting, Estimated PCD: 2025-09-29
Clinical trial
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Parkinson's Disease Patients With Constipation
Status: Not yet recruiting, Estimated PCD: 2026-05-31
Clinical trial
Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
Metformin in Alzheimer's Dementia Prevention
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder (AUD) and Comorbid Post-Traumatic Stress Disorder (PTSD)
Status: Terminated, Estimated PCD: 2022-05-02
Clinical trial
A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Lofexidine Combined With Buprenorphine for Reducing Symptoms of Post-Traumatic Stress Disorder (PTSD) and Opioid Use Relapse in Veterans
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial
Status: Completed, Estimated PCD: 2021-10-28
Clinical trial
The Effect of Combined Oral and Topical Analgesics to Reduce Pain Perception During Electromyography in Pediatric Population-A Randomized Controlled Trial
Status: Completed, Estimated PCD: 2022-06-27
Clinical trial
Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial
Status: Recruiting, Estimated PCD: 2028-05-31
Clinical trial
Neuroscience-Informed Treatment Development for Adolescent Alcohol Use
Status: Completed, Estimated PCD: 2022-03-01
Clinical trial
Hydroxychloroquine for Outpatients With Confirmed COVID-19
Status: Completed, Estimated PCD: 2021-10-30
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Efficacy and Safety of Sodium Oligomannate in the Prevention of Post-stroke Cognitive Impairment in Patients With Ischemic Stroke:a Randomized, Double-blind, Exploratory Controlled Study
Status: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
Effect of Ubiquinone (Coenzyme Q10) on Early Wound Healing Following Gingival Recession Coverage: a Pilot Study
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
Status: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
Effects of Montelukast Therapy on Alzheimer's Disease (EMERALD)
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.
Status: Terminated, Estimated PCD: 2010-03-01
Clinical trial
Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder
Status: Completed, Estimated PCD: 2020-11-05
Clinical trial
A Phase IV Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery (TRACTION): A Pragmatic Randomized Cluster Crossover Trial
Status: Active (not recruiting), Estimated PCD: 2024-03-05
Clinical trial
The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlodipine 5 mg Monotherapy
Status: Completed, Estimated PCD: 2013-04-22
Clinical trial
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of a Single Subcutaneous Dose of IMG-007 in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of ABBV-932 in Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2024-06-06
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Status: Completed, Estimated PCD: 2019-12-10
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Parallel-group, Double-blinded, proof-of Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren's Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
Status: Active (not recruiting), Estimated PCD: 2021-07-26
Clinical trial
Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.
Status: Completed, Estimated PCD: 2023-08-10
Clinical trial
Multicenter, Open Label, Randomized Comparative Trial of the Efficacy and Safety of a Single Bolus Recombinant Non-immunogenic Staphylokinase and Bolus-infusion of Alteplase in Patients With Massive Pulmonary Embolism (FORPE)
Status: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of AK1967 (Procizumab) in Healthy Male Volunteers
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation
Status: Completed, Estimated PCD: 2016-12-01
Clinical trial
A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis
Status: Completed, Estimated PCD: 2023-07-25
Clinical trial
A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered Zilganersen (ION373) in Patients With Alexander Disease
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis
Status: Completed, Estimated PCD: 2024-01-02
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07293893 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2024-03-22
Clinical trial
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-12-27
Clinical trial
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Clinical Study to Evaluate the Efficacy and Safety of Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
Status: Recruiting, Estimated PCD: 2028-06-20
Clinical trial
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease
Status: Completed, Estimated PCD: 2024-03-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients Following 12 Weeks of Oral Treatment
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Status: Terminated, Estimated PCD: 2023-11-03
Clinical trial
Motion Syros: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness During Travel
Status: Completed, Estimated PCD: 2023-04-12
Clinical trial
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Status: Terminated, Estimated PCD: 2022-09-13
Clinical trial
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 Posoleucel (ALVR105,Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Status: Terminated, Estimated PCD: 2024-01-31
Clinical trial
Prospective, Multicenter, First Part Randomized, Placebo-controlled, Parallel-group, Double-blind Period Followed by Open-label Trial Period to Evaluate Clinical Safety & Efficacy of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease: Proof-of-concept Study
Status: Recruiting, Estimated PCD: 2024-01-23
Clinical trial
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)
Status: Terminated, Estimated PCD: 2024-01-31
Clinical trial
A First-In-Human Phase I Study in 3 Parts: Randomized, Double-blind, Placebocontrolled, Sequential Group Investigation of the Safety, Tolerability, Pharmacokinetics of AEF0217 After Oral, Single and Multiple Ascending Doses, and an Open Label, Cross-over Investigation of the Effect of Food on the Bioavailability of AEF0217 in Healthy Volunteers.
Status: Completed, Estimated PCD: 2022-06-28
Clinical trial
Adaptive Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kratom in Healthy, Nondependent, Adult Recreational Polydrug Users With Opioid Experience
Status: Completed, Estimated PCD: 2024-01-17
Clinical trial
Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Prospective, Randomized, Placebo-controlled, Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy, for the Treatment of Allergy
Status: Terminated, Estimated PCD: 2023-10-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Three-period Two-treatment Incomplete-block Crossover Study to Investigate the Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Participants
Status: Terminated, Estimated PCD: 2021-09-16
Clinical trial
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period
Status: Active (not recruiting), Estimated PCD: 2025-05-09
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Status: Active (not recruiting), Estimated PCD: 2020-08-19
Clinical trial
A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
Status: Completed, Estimated PCD: 2016-04-04
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
Status: Active (not recruiting), Estimated PCD: 2024-01-07
Clinical trial
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Status: Completed, Estimated PCD: 2020-06-08
Clinical trial
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Status: Recruiting, Estimated PCD: 2025-11-24
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of NNC0519-0130 in Healthy Participants and Multiple Subcutaneous and Oral Doses of NNC0519-0130 in Participants With Overweight or Obesity and Participants With Type 2 Diabetes
Status: Completed, Estimated PCD: 2024-04-02
Clinical trial
Feasibility Study on the Use of Redormin® 500 (Ze 91019) on Day-time Cognition and Quality of Life in People With Occasional Sleep Problems
Status: Completed, Estimated PCD: 2023-12-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-02-28
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Status: Terminated, Estimated PCD: 2023-09-26
Clinical trial
A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions
Status: Completed, Estimated PCD: 2024-01-16
Clinical trial
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)
Status: Recruiting, Estimated PCD: 2024-12-16
Clinical trial
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma
Status: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva
Status: Recruiting, Estimated PCD: 2025-04-10
Clinical trial
A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE)
Status: Terminated, Estimated PCD: 2022-10-18
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Status: Completed, Estimated PCD: 2021-04-07
Clinical trial
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic Sclerosis
Status: Active (not recruiting), Estimated PCD: 2023-05-17
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
Status: Active (not recruiting), Estimated PCD: 2021-08-26
Clinical trial
A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Status: , Estimated PCD: 2027-06-01
Clinical trial
Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
Status: Active (not recruiting), Estimated PCD: 2017-01-31
Clinical trial
Randomized, Double-blind, Multicenter Pilot Clinical Trial to Evaluate the Use of a Mouthwash With Cetylpyridinium Chloride (CPC) in the Prevention and Reduction of Symptoms of Viral Upper Respiratory Tract Infections (vURTI)
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Status: Terminated, Estimated PCD: 2023-12-20
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.
Status: Active (not recruiting), Estimated PCD: 2026-12-30
Clinical trial
A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis
Status: Terminated, Estimated PCD: 2009-08-01
Clinical trial
Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, First-In-Patient Study Of AJ201 To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics In Adults With Spinal And Bulbar Muscular Atrophy (SBMA)
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency)
Status: Active (not recruiting), Estimated PCD: 2023-10-12
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
Status: Completed, Estimated PCD: 2023-07-25
Clinical trial
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2020-03-27
Clinical trial
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Multi-center, Randomized, Independent Evaluator-Subject Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate Safety and Efficacy of TPX-105 for Correction of Nasojugal Groove
Status: Completed, Estimated PCD: 2023-06-05
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Center, Multiple-Dose, Parallel Trial Evaluating the Impact of Apraglutide on Gastric Emptying of Liquids in Healthy Subjects
Status: Completed, Estimated PCD: 2023-07-24
Clinical trial
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
Status: Recruiting, Estimated PCD: 2026-03-02
Clinical trial
International, Multicenter, Randomized, Single Blind, Placebo-controlled Study of Efficacy and Safety of CITOFLAVIN® in the Acute Period of Head Injury in Adults
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Status: Completed, Estimated PCD: 2024-03-14
Clinical trial
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older
Status: Recruiting, Estimated PCD: 2026-03-10
Clinical trial
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age
Status: Active (not recruiting), Estimated PCD: 2025-08-25
Clinical trial
A Phase IIa Observer-blind, Randomized, Controlled, Age-de-escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, Including Dose-finding in Infants, in Africa
Status: Recruiting, Estimated PCD: 2026-04-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AP303 Following 2-week Oral Administration in Healthy Chinese Participants.
Status: Not yet recruiting, Estimated PCD: 2024-06-10
Clinical trial
A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2022-12-15
Clinical trial
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 52 Weeks in Postmenopausal Women
Status: Completed, Estimated PCD: 2023-03-29
Clinical trial
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity
Status: Recruiting, Estimated PCD: 2026-01-19
Clinical trial
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety and Immunogenicity in Infants Born to Vaccinated Mothers
Status: Recruiting, Estimated PCD: 2026-02-18
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 1 Study Evaluating the Effects of ARO-RAGE Injection for Subcutaneous Administration in Healthy Subjects
Status: Completed, Estimated PCD: 2024-02-08
Clinical trial
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Ten-week Prospective Study to Evaluate the Efficacy and Safety of NOE-105 in Adult Male Patients With Childhood Onset Fluency Disorder (Orpheus)
Status: Completed, Estimated PCD: 2023-10-20
Clinical trial
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Status: Active (not recruiting), Estimated PCD: 2025-04-11
Clinical trial
Addition of DLBS1033 to Standard Therapy for Acute Ischemic Stroke Patients
Status: Terminated, Estimated PCD: 2023-02-21
Clinical trial
A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Status: Completed, Estimated PCD: 2022-06-13
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo
Status: Completed, Estimated PCD: 2023-01-13
Clinical trial
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF-07817883 IN NON-HOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19
Status: Completed, Estimated PCD: 2023-09-13
Clinical trial
A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients With Hereditary Angioedema (HAE)
Status: Completed, Estimated PCD: 2023-11-06
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Status: Completed, Estimated PCD: 2019-01-25
Clinical trial
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Status: Completed, Estimated PCD: 2023-04-03
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 1323495 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Status: Completed, Estimated PCD: 2018-11-14
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
Status: Completed, Estimated PCD: 2023-12-07
Clinical trial
A Phase III Clinical Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Randomised, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study in Healthy Volunteers and Asymptomatic GRN Mutation Carriers to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001
Status: Recruiting, Estimated PCD: 2024-07-16
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)
Status: Recruiting, Estimated PCD: 2025-05-15
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 655130 (Double-blind, Partially Randomised Within Dose Groups, Placebo-controlled Parallel Group Design) and One Single Intravenous Dose of BI 655130 (Single-blind, Partially Randomised, Placebo-controlled) in Healthy Male Subjects
Status: Completed, Estimated PCD: 2017-08-01
Clinical trial
Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older
Status: Terminated, Estimated PCD: 2022-06-27
Clinical trial
Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections: a Multicenter, Randomized, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of 4P-004 Versus Placebo Injected in the Target Knee Joint of Patients With Grade 2 to 4 Osteoarthritis on the Kellgren and Lawrence Severity Index (KL 2-4)
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Status: Completed, Estimated PCD: 2022-08-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Ocular Hypertensive Subjects
Status: Withdrawn, Estimated PCD: 2023-08-01
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease
Status: Active (not recruiting), Estimated PCD: 2024-12-26
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
Status: Terminated, Estimated PCD: 2022-03-18
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis
Status: Recruiting, Estimated PCD: 2025-01-22
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)
Status: Active (not recruiting), Estimated PCD: 2025-11-28
Clinical trial
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-A)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Multi-center, Randomized, Double Blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy of ORE-001 in Preventing Gastrointestinal Disturbance/ Intolerance in Patients After Longitudinal Laparotomy
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers
Status: Completed, Estimated PCD: 2013-01-01
Clinical trial
A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3366 in Healthy Men and Women of Non-Childbearing Potential Following: Part A: Single Ascending Dose Administration (Including Populations of Japanese and Chinese Subjects) Part B: Single Dose Administration of AZD3366 at One Dose Level or Placebo With Concomitant Repeated Dosing of Ticagrelor and Acetylsalicylic Acid
Status: Completed, Estimated PCD: 2022-01-19
Clinical trial
A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants
Status: Completed, Estimated PCD: 2024-01-11
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 3-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Status: Terminated, Estimated PCD: 2023-01-06
Clinical trial
A Two-part, Randomized Partially-blinded, Parallelgroup, Placebo- and Active Comparatorcontrolled Phase 1 Study to Evaluate the Photosafety of Repeated Oral Dose of SAR441566 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-10-15
Clinical trial
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
Status: Not yet recruiting, Estimated PCD: 2026-07-19
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study
Status: Completed, Estimated PCD: 2023-08-10
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
Status: Terminated, Estimated PCD: 2020-11-05
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue Fever
Status: Terminated, Estimated PCD: 2022-09-24
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Multicenter Phase 2, 12-week Double-blind, Placebo-controlled, Randomized, Parallel-group Study of JZP150 for the Treatment of Posttraumatic Stress Disorder
Status: Completed, Estimated PCD: 2023-12-05
Clinical trial
A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2031-05-23
Clinical trial
A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine
Status: Completed, Estimated PCD: 2023-05-03
Clinical trial
2021-PT054: A Randomized Phase I Open-Label, Placebo-Controlled, Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Hutrukin Via Intravenous Administration in Healthy Subjects.
Status: Active (not recruiting), Estimated PCD: 2023-10-24
Clinical trial
A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Controlled, Double-blind, Double-dummy Study to Evaluate the Safety and Efficacy of Subcutaneous Progesterone Compared to Vaginal Progesterone for Luteal Phase Supplementation in Modified Natural Frozen Euploid Blastocyst Transfer.
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults
Status: Active (not recruiting), Estimated PCD: 2029-06-19
Clinical trial
A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 4, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 100 mg Once Weekly as an add-on to Insulin Therapy in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Treatment With Insulin Preparations in Addition to Diet and/or Exercise Therapy
Status: Completed, Estimated PCD: 2016-12-28
Clinical trial
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia
Status: Completed, Estimated PCD: 2011-10-01
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)
Status: Recruiting, Estimated PCD: 2024-07-08
Clinical trial
A Phase 1 Placebo-and Active-Controlled Crossover Study of the Potential for Cardiac Repolarization Effects Following Single Dose of ABBV-CLS-7262 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Who Are Treatment-naïve or Untreated for at Least 6 Months
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0487-0111 in Japanese Participants With Obesity
Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 3000202 in Healthy Male and Female Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design) and Evaluation of Midazolam Interaction in Healthy Male and Female Subjects (Nested, Open, Fixed-sequence, Intra-individual Comparison)
Status: Recruiting, Estimated PCD: 2024-09-27
Clinical trial
A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered YN001 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-04-29
Clinical trial
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)
Status: Completed, Estimated PCD: 2017-11-02
Clinical trial
An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
Status: Terminated, Estimated PCD: 2022-09-23
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect, and Ethnicity Effect of SB17170 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2024-02-29
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status: Active (not recruiting), Estimated PCD: 2016-08-01
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed, Estimated PCD: 2023-12-27
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder
Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With Single Blind Sentinel Period to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGNX001 in Peanut-Allergic Participants
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 1, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PRA023 in Healthy Caucasian and Japanese Adult Volunteers
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D): A Multicenter, Randomized, Prospective, Placebo-Controlled, Double-Blind, Phase IV Clinical Study
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Single Center, Randomized, Double-Blind, Parallel Placebo-Controlled Study of the Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
Status: Withdrawn, Estimated PCD: 2010-06-01
Clinical trial
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Status: Terminated, Estimated PCD: 2023-02-28
Clinical trial
An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2020-08-21
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
Status: Completed, Estimated PCD: 2023-03-14
Clinical trial
A Randomized, Single-blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Trial, to Evaluate the Efficacy and Safety of a Single Intra-articular Injection of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Status: Completed, Estimated PCD: 2021-09-15
Clinical trial
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CEL383 When Administered Intravenously to Healthy Adult Subjects
Status: Completed, Estimated PCD: 2024-01-17
Clinical trial
A Placebo-controlled, Phase 1, Participant- and Investigator-blinded, Single- and Multiple- Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Status: Active (not recruiting), Estimated PCD: 2027-10-13
Clinical trial
A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2)
Status: Completed, Estimated PCD: 2021-11-30
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of Subcutaneous ALXN1830 in Healthy Participants
Status: Terminated, Estimated PCD: 2021-01-22
Clinical trial
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
Status: Terminated, Estimated PCD: 2023-09-13
Clinical trial
Motion Serifos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age
Status: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Status: Active (not recruiting), Estimated PCD: 2019-07-15
Clinical trial
A Prospective, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Adaptive Phase 3 Study With Open-label Extension to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Status: Terminated, Estimated PCD: 2023-12-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2024-10-17
Clinical trial
A Multi-center, Prospective, Randomized, Double-blind, Flexible-dose, Placebo-controlled, Parallel Group Clinical Trial of Sildenafil Oral Film 25 mg, 50 mg, 75 mg and 100 mg for the Treatment of Erectile Dysfunction (ED)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Meta-Analysis of Amputation Risk in Empagliflozin Studies (1245.25, 1245.110, 1245.121)
Status: Completed, Estimated PCD: 2021-07-13
Clinical trial
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
Status: , Estimated PCD: 2025-04-16
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Adults 18 to 55 Years of Age
Status: Active (not recruiting), Estimated PCD: 2026-02-04
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CB03-154 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-11-09
Clinical trial
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Status: Active (not recruiting), Estimated PCD: 2022-12-12
Clinical trial
A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia
Status: Active (not recruiting), Estimated PCD: 2025-04-28
Clinical trial
A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Subcutaneous Single Ascending Doses of NNC0650-0013 in Healthy Male Participants
Status: Recruiting, Estimated PCD: 2025-03-22
Clinical trial
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multi-center, Fixed-dose, Parallel Group Efficacy and Safety in Pediatrics (6-17) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase I/II, First-in-Human Study to Assess the Safety and Efficacy of Two Doses of SX600 Administered by Lumbosacral Transforaminal Epidural Injection in Patients With Radicular Pain Secondary to Lumbar Intervertebral Disc Herniation
Status: Terminated, Estimated PCD: 2022-02-21
Clinical trial
Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants
Status: Recruiting, Estimated PCD: 2025-06-06
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Oral Doses of BI 1323495 Versus Placebo in Healthy Subjects, Including an Investigation of Drug-drug Interaction With Microdose Midazolam (Double-blind, Randomised, Placebo-controlled [Within Dose Groups] Trial)
Status: Completed, Estimated PCD: 2021-03-05
Clinical trial
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
Status: Recruiting, Estimated PCD: 2025-03-21
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Status: Completed, Estimated PCD: 2023-03-22
Clinical trial
A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2022-10-19
Clinical trial
An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder
Status: Recruiting, Estimated PCD: 2024-10-26
Clinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)
Status: Active (not recruiting), Estimated PCD: 2024-03-13
Clinical trial
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Are Not Eligible for Tissue Pasminogen Activator or Thrombectomy
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-09-21
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING ORAL DOSES OF PF-07328948 IN HEALTHY ADULT PARTICIPANTS
Status: Recruiting, Estimated PCD: 2024-07-10
Clinical trial
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 Injection in Healthy Subjects
Status: Completed, Estimated PCD: 2023-11-01
Clinical trial
A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase 2, Observer-Blind, Placebo-Controlled, Proof-of-Concept Trial to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
Status: Withdrawn, Estimated PCD: 2027-02-14
Clinical trial
Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity (OASIS 1)
Status: Completed, Estimated PCD: 2023-03-24
Clinical trial
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Terminated, Estimated PCD: 2012-10-31
Clinical trial
A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Hybrid Decentralized Study to Evaluate the Safety and Efficacy of Daily Subcutaneous (SC) Injection of TXA127 in Post-ischemic Stroke Patients
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dexlansoprazole 60 mg Delayed Release Capsules and Esomeprazole 40 mg Delayed Release Capsules on Bone Homeostasis in Healthy Postmenopausal Female Subjects
Status: Completed, Estimated PCD: 2014-08-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2022-04-24
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
Status: Active (not recruiting), Estimated PCD: 2023-08-10
Clinical trial
A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease Who Have the PNPLA3 I148M Genotype
Status: Recruiting, Estimated PCD: 2024-11-05
Clinical trial
A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral VX-993 in Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A 12-Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Participants With Migraine
Status: Completed, Estimated PCD: 2022-02-07
Clinical trial
A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
Status: Terminated, Estimated PCD: 2024-02-07
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women
Status: Completed, Estimated PCD: 2024-01-13
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Status: Active (not recruiting), Estimated PCD: 2024-12-20
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-09-09
Clinical trial
A Phase 3, Randomised, 2-arm, Parallel-group, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Subcutaneous Methotrexate Versus Placebo in Moderate to Severe Atopic Dermatitis.
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer
Status: Terminated, Estimated PCD: 2009-11-01
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Status: Completed, Estimated PCD: 2021-03-05
Clinical trial
Can Vitamin C Reduce the Risk of Postoperative Shoulder Stiffness? A Multi-center, Double-blinded, Randomized and Placebo-controlled Study
Status: Active (not recruiting), Estimated PCD: 2023-05-16
Clinical trial
A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Status: Terminated, Estimated PCD: 2023-11-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Status: Completed, Estimated PCD: 2023-07-14
Clinical trial
A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)
Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-04-22
Clinical trial
ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A First-in-Human, Phase 1a, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-11-17
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Subcutaneous Doses and Multiple Subcutaneous Doses Over 6 Weeks of BI 3006337 in Healthy Male Japanese Subjects (Single-blind, Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)
Status: Recruiting, Estimated PCD: 2024-10-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Intravenous Doses of BI 765080 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel-group Design)
Status: Completed, Estimated PCD: 2021-08-25
Clinical trial
A Phase I, Double-blind, Placebo-controlled, Single and Multiple Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study of KBP-7072 in Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2023-06-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of Leramistat in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2026-02-25
Clinical trial
A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Status: Active (not recruiting), Estimated PCD: 2023-10-30
Clinical trial
National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BALI Association in the Treatment of Aphthous Ulcerations
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder of Moderate or Greater Severity
Status: Completed, Estimated PCD: 2022-10-30
Clinical trial
A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Exposure
Status: Completed, Estimated PCD: 2023-11-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Status: Active (not recruiting), Estimated PCD: 2024-05-17
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Status: Recruiting, Estimated PCD: 2027-10-05
Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY
Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Status: Completed, Estimated PCD: 2023-09-08
Clinical trial
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2027-11-08
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles Following Single and Multiple Doses and Food Effect of CS32582 Capsules in Healthy Adult Subjects
Status: Not yet recruiting, Estimated PCD: 2025-01-02
Clinical trial
Evaluation of the Safety and Efficacy of Silmitasertib (CX-4945) in Combination With Standard of Care (SOC) for Treating Patients With Community-Acquired Pneumonia (CAP) Associated With SARS-CoV-2 and Influenza Viral Infections
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Placebo-Controlled, Ascending Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of MGTA-145 in Healthy Subjects Administered as a Single Agent, as Well as in Combination With Plerixafor
Status: Completed, Estimated PCD: 2020-02-25
Clinical trial
Multi-Center, Randomized, Double-Blind, Placebo (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Recruiting, Estimated PCD: 2025-11-05
Clinical trial
Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: , Estimated PCD: 2021-02-16
Clinical trial
A Multiple Dose, Randomised, Double Blinded, Double Dummy Trial Investigating Efficacy and Safety of NNC0268-0965 Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2021-12-10
Clinical trial
A Phase 1, Randomised, Double Blind Placebo-controlled, First Time in Human Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Oral Doses and Food Effect of GSK4024484 in Healthy Adult Participants.
Status: Recruiting, Estimated PCD: 2025-08-14
Clinical trial
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
Status: Active (not recruiting), Estimated PCD: 2024-03-18
Clinical trial
A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2031-03-26
Clinical trial
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Terminated, Estimated PCD: 2021-04-27
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of ATX01 (Topical Amitriptyline Hydrochloride 10% and 15% w/w) in Comparison to Placebo, in Cancer Survivor Adult Patients With Chemotherapy-induced Peripheral Neuropathy (CIPN)
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2018-10-14
Clinical trial
A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)
Status: Completed, Estimated PCD: 2023-09-14
Clinical trial
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder
Status: Recruiting, Estimated PCD: 2025-03-23
Clinical trial
A Phase 2 Study to Evaluate the Safety and Efficacy of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis
Status: Completed, Estimated PCD: 2022-11-24
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed by Coronary Computed Tomography Angiography (CCTA) in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (VICTORION-PLAQUE)
Status: Recruiting, Estimated PCD: 2027-01-07
Clinical trial
Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of the Administration of RUTI® Immunotherapy With the Standard Treatment in Patients With Tuberculosis
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 1, Randomized, Participant- and Investigator-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3541860 in Healthy Japanese and Non-Japanese Participants
Status: Completed, Estimated PCD: 2023-12-27
Clinical trial
A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
Status: Completed, Estimated PCD: 2020-12-29
Clinical trial
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Status: Terminated, Estimated PCD: 2022-03-17
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Status: Completed, Estimated PCD: 2022-05-17
Clinical trial
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
Status: Recruiting, Estimated PCD: 2030-01-16
Clinical trial
A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
Status: Recruiting, Estimated PCD: 2026-06-12
Clinical trial
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Status: Completed, Estimated PCD: 2022-06-20
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-01-02
Clinical trial
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease (AD)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Safety and Efficacy of ST-100 Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease
Status: Completed, Estimated PCD: 2021-10-11
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Using Two Different Titration Schemes
Status: Completed, Estimated PCD: 2007-06-29
Clinical trial
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status: Active (not recruiting), Estimated PCD: 2017-06-28
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants.
Status: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose and an Open-Label Fixed-Dose Study in Patients With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RGLS8429
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) in Healthy Adults
Status: Active (not recruiting), Estimated PCD: 2023-06-05
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Parallel Group, Multicenter 12-week Study With a 52-week Extension to Evaluate the Efficacy and Safety of Two Doses of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid and/or Obeticholic Acid Treatment
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Double-blind, Active- and Placebo-controlled, 6-way Crossover Study to Evaluate the Abuse Potential of Orally Administered Gabapentin Enacarbil Immediate Release Capsules Taken Alone and in Combination With Oxycodone in Healthy, Nondependent, Recreational Opioid Users
Status: Completed, Estimated PCD: 2023-04-25
Clinical trial
Phase III Clinical Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay the Progression of Myopia and Axial Ocular Elongation in Children.
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Parenterally Administered Suspension of Investigational Capsid Inhibitors in Healthy Adults
Status: Recruiting, Estimated PCD: 2026-05-05
Clinical trial
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures
Status: Recruiting, Estimated PCD: 2024-06-19
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Status: Active (not recruiting), Estimated PCD: 2024-04-24
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2023-11-17
Clinical trial
A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058), Administered Subcutaneously in Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (COMPOSE)
Status: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes
Status: Active (not recruiting), Estimated PCD: 2024-09-24
Clinical trial
Multicenter, Randomised, Double-blind, Placebo-controlled, 48-week, Phase III Trial to Evaluate the Efficacy and Safety of Survodutide Administered Subcutaneously in Participants With Overweight or Obesity and Presumed or Confirmed Nonalcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2026-02-16
Clinical trial
A Phase 1, 2-Part Study to Evaluate the Relative Bioavailability of and Food-Effect on Pharmacokinetics of Different Formulations of S-337395, and to Assess the Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of S-337395 in Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
Status: Terminated, Estimated PCD: 2022-11-15
Clinical trial
A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Participants With Delayed Sleep-Wake Phase Disorder (DSWPD)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Status: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Sequential, 3-Part, Double-Blind, Randomized, Placebo-Controlled, Single-Rising-Dose and Rising-Multiple-Dose Study in Healthy Subjects and Mild or Moderate Asthmatic Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled MK-0476
Status: Completed, Estimated PCD: 2008-09-01
Clinical trial
Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease
Status: Active (not recruiting), Estimated PCD: 2024-10-07
Clinical trial
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis
Status: Active (not recruiting), Estimated PCD: 2028-12-01
Clinical trial
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo
Status: Recruiting, Estimated PCD: 2025-09-11
Clinical trial
A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants.
Status: Recruiting, Estimated PCD: 2025-08-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Antimicrobial Efficacy Of Topically Once Or Twice Daily Applied Bisphosphocin® Nu-3 Gel At 5% And 10% Concentrations To Infected Diabetic Foot Ulcers (iDFU)
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Status: Recruiting, Estimated PCD: 2029-01-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of Subcutaneous Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Status: Recruiting, Estimated PCD: 2025-12-10
Clinical trial
A Multicenter, Randomized, Double-Blind Study to Compare the Effects of VI-0521,Phentermine, and Placebo on Ambulatory Blood Pressure in Overweight or Obese Subjects
Status: Completed, Estimated PCD: 2023-04-11
Clinical trial
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE
Status: Completed, Estimated PCD: 2023-10-19
Clinical trial
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927 in Healthy Adults
Status: , Estimated PCD: 2024-12-31
Clinical trial
A Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit Vaccine (HZ/su) GSK1437173A on a Two-dose Schedule in Adults ≥ 50 Years of Age With a Prior Episode of Herpes Zoster
Status: Active (not recruiting), Estimated PCD: 2024-02-21
Clinical trial
A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Luspatercept (ACE-536) in Chinese Adult Subjects Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia
Status: Recruiting, Estimated PCD: 2025-02-03
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants
Status: Recruiting, Estimated PCD: 2025-09-04
Clinical trial
A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)
Status: Completed, Estimated PCD: 2021-03-26
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension
Status: Terminated, Estimated PCD: 2024-03-07
Clinical trial
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial Study Evaluating Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring Anxiety
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 3, Randomised, Double-blind, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Brodalumab Treatment Compared to Placebo and Ustekinumab in Adolescent Subjects With Moderate-to-severe Plaque Psoriasis
Status: Terminated, Estimated PCD: 2023-05-05
Clinical trial
Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2025-10-02
Clinical trial
A Phase I Dose Escalation Trial to Investigate the Safety, Tolerability, and Explorative Efficacy, Following Environmental Allergen Exposure in a Chamber, of DM-101PX in Participants With Birch Pollen Allergy
Status: Completed, Estimated PCD: 2024-03-06
Clinical trial
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)
Status: Recruiting, Estimated PCD: 2025-04-10
Clinical trial
Pharmacokinetics and Pharmacodynamic Effects of Different Single Oral Doses of BI 474121 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2021-07-01
Clinical trial
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
Status: Recruiting, Estimated PCD: 2026-01-20
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients With Septic Shock and Elevated Adrenomedullin
Status: Completed, Estimated PCD: 2019-12-20
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, 2-Period, Cross-over, Double- Blind, Single-Dose Study to Evaluate the Effects of LY3532226 on Insulin- Induced Hypoglycemia in Participants With Type 1 Diabetes Mellitus
Status: Completed, Estimated PCD: 2024-02-21
Clinical trial
Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD Patients
Status: Recruiting, Estimated PCD: 2024-09-20
Clinical trial
A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
Status: Terminated, Estimated PCD: 2024-02-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication
Status: Active (not recruiting), Estimated PCD: 2023-09-18
Clinical trial
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Status: Completed, Estimated PCD: 2022-07-11
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
Status: Terminated, Estimated PCD: 2022-08-12
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants With Mild to Moderate COVID-19
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
A Double-Blind, Randomized,Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 for the Treatment of Pain in Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2012-01-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-10-28
Clinical trial
A Phase 3 Japanese Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention
Status: Completed, Estimated PCD: 2020-03-16
Clinical trial
A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)
Status: Active (not recruiting), Estimated PCD: 2023-10-02
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia
Status: Completed, Estimated PCD: 2022-04-18
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Status: Not yet recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Doses of Kylo-0603 Capsules in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis
Status: Recruiting, Estimated PCD: 2024-11-22
Clinical trial
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-05-21
Clinical trial
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera: a Phase II, Randomized, Placebo-controlled, Double-blinded Efficacy and Safety Trial
Status: Recruiting, Estimated PCD: 2024-05-15
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
A first-time-in Human (FTIH), Phase I/II, Randomized, Multi-centric, Single-blind, Controlled Dose-escalation Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GSK Biologicals' HBV Viral Vector Vaccines Given in a Prime-boost Schedule With Sequential or Co-administration of Adjuvanted Proteins Therapeutic Vaccine (GSK3528869A) in Chronic Hepatitis B Patients (18-65 Years Old) Well Controlled Under Nucleo(s)Tide Analogue (NA) Therapy
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL-2)
Status: Recruiting, Estimated PCD: 2025-10-28
Clinical trial
Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines
Status: Completed, Estimated PCD: 2023-10-16
Clinical trial
A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Subjects
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2025-06-13
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-2) With an Open-Label Extension
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 474121 Administered as Oral Solution and Tablets to Healthy Male Subjects (SRD Part), and a Randomised, Open-label, Single-dose, Three-way Cross-over Bioavailability Comparison of BI 474121 as Tablet Versus Oral Solution and Tablet With and Without Food (BA Part)
Status: Completed, Estimated PCD: 2021-03-25
Clinical trial
A Two-part, Randomized, Double-blind, Placebo Controlled, Ascending Dose Study to Assess the Safety and Tolerability of Single and Multiple Doses of Neumifil (a Novel Drug Candidate With Potential for Treatment of COVID-19)
Status: Completed, Estimated PCD: 2022-04-05
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of QLG1074 With Placebo in Achieving Renal Remission in Subjects With Active Lupus Nephritis
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Phase 2, Multi-country, Randomized, Double-blind, Placebo-controlled Trial to Evaluate Safety and Immunogenicity When HIL-214 is Concomitantly Administered With Routine Pediatric Vaccines in Healthy Infants
Status: Active (not recruiting), Estimated PCD: 2024-01-19
Clinical trial
A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)
Status: Active (not recruiting), Estimated PCD: 2026-05-22
Clinical trial
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S003 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-07-30
Clinical trial
A Two-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics and Preliminary Efficacy Study of CA-008 in Patients Undergoing Total Knee Arthroplasy
Status: Completed, Estimated PCD: 2020-10-26
Clinical trial
A Single Center, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Escalating Doses Of HSK7653 In Healthy Subjects
Status: Completed, Estimated PCD: 2019-07-03
Clinical trial
Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects
Status: Terminated, Estimated PCD: 2022-03-23
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate QL1706 Plus Paclitaxel-Cisplatin/Carboplatin With or Without Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa
Status: Terminated, Estimated PCD: 2023-02-28
Clinical trial
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Status: Completed, Estimated PCD: 2022-06-06
Clinical trial
A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2020-07-01
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Randomized, Open-label or Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect After Oral Administration of HSG4112 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled Study of AGN-151586 in the Treatment of Japanese Subjects With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2024-04-03
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315 IN HEALTHY PARTICIPANTS
Status: Active (not recruiting), Estimated PCD: 2024-04-22
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus Who Have Poor Glycemic Control After Dietary and Exercise Interventions
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Status: Completed, Estimated PCD: 2021-04-15
Clinical trial
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Status: Active (not recruiting), Estimated PCD: 2026-01-31
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Status: Terminated, Estimated PCD: 2020-03-11
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACOKINETIC INTERACTION WITH MIDAZOLAM OF MULTIPLE ASCENDING ORAL DOSES OF PF-07258669 IN HEALTHY NON-JAPANESE AND JAPANESE ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
Status: Terminated, Estimated PCD: 2021-01-08
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (the Olympia Study)
Status: Completed, Estimated PCD: 2023-01-27
Clinical trial
A Phase 1b Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 4 Weeks Treatment With BAY 2413555 in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices
Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3
Status: Active (not recruiting), Estimated PCD: 2020-08-31
Clinical trial
Phase III Study of AJM300 in Patients With Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2020-11-09
Clinical trial
Tau PET Longitudinal Substudy Associated With: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-randomized, Placebo-treated Non-carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-04-19
Clinical trial
A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Ketoconazole Shampoo, 2% to Ketoconazole Shampoo, 2% (RS) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Versicolor.
Status: Completed, Estimated PCD: 2024-02-10
Clinical trial
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis
Status: Terminated, Estimated PCD: 2018-11-09
Clinical trial
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS
Status: Completed, Estimated PCD: 2021-12-09
Clinical trial
A Phase 1 Randomized, Single-blind, Placebo-controlled, First-in-Human and Sequential Group Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 Following Single Ascending Doses Via Oral Administration
Status: Terminated, Estimated PCD: 2023-05-10
Clinical trial
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
Status: Active (not recruiting), Estimated PCD: 2024-07-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of Imatinib Inhalation Solution (AER-901) in Adult Healthy Volunteers
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Phase 1, Randomized, Placebo Controlled, Double-Blind, Single Dose Escalation Study of NoNO-42 in Healthy Adults
Status: Recruiting, Estimated PCD: 2023-10-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CFTX-1554 in Healthy Subjects, With Comparison of Intake of CFTX-1554 as Liquid Formulation and as Capsule, and After a High-fat Breakfast Versus Fasted
Status: Completed, Estimated PCD: 2023-02-10
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RAY1225
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Healthy Subjects and in Subjects With Type 1 Diabetes
Status: Completed, Estimated PCD: 2021-06-23
Clinical trial
A Two-part Exploratory Study Combining a Pilot Study in Healthy Subjects and Chronic Spontaneous Urticaria Patients (Part 1) and a Randomized, Subject, Investigator and Sponsor-blinded, Placebo Controlled, Study (Part 2) to Assess the MechAniSm of acTion of ligElizumab (QGE031) in Patients With Chronic uRticaria (MASTER)
Status: Terminated, Estimated PCD: 2022-07-19
Clinical trial
A Double-blind, Randomized, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-88260237 in Healthy Participants
Status: Completed, Estimated PCD: 2023-05-09
Clinical trial
A Phase I, Placebo-controlled, Double-blind, First-in-human Study to Investigate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-248 Solution in Healthy Subjects and Patients With Systemic Sclerosis (SSc)
Status: Completed, Estimated PCD: 2019-12-20
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Crossover Study to Explore the Effects of ACD440 in Patients With Peripheral Neuropathic Pain With Sensory Hypersensitivity.
Status: Completed, Estimated PCD: 2023-03-10
Clinical trial
Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial of Efficacy and Safety of the Drug Cytoflavin®, Administered Intravenously Followed by Oral Intake, in Patients With Diabetic Polyneuropathy
Status: Completed, Estimated PCD: 2021-03-29
Clinical trial
A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese Adults
Status: Completed, Estimated PCD: 2021-11-27
Clinical trial
A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis
Status: Withdrawn, Estimated PCD: 2024-09-18
Clinical trial
A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
Status: Completed, Estimated PCD: 2020-04-20
Clinical trial
Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in Children and Adolescents With Tourette's Syndrome
Status: Completed, Estimated PCD: 2021-09-23
Clinical trial
A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL
Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
Status: Completed, Estimated PCD: 2022-02-16
Clinical trial
A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)
Status: Completed, Estimated PCD: 2021-05-07
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris.
Status: Completed, Estimated PCD: 2023-04-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Primary Efficacy of HS-10517 in Chinese Adult Participants
Status: Recruiting, Estimated PCD: 2023-05-31
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
Status: Completed, Estimated PCD: 2021-10-18
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double--Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment
Status: Completed, Estimated PCD: 2019-07-05
Clinical trial
Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities
Status: Withdrawn, Estimated PCD: 2020-08-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Three-Part Phase 1 Study of Safety, Tolerability, Pharmacokinetics, and Food Effect of MRX-4 Administered Orally to Healthy Volunteers in Single and Multiple Ascending Dose Cohorts to Evaluate Drug Interactions With Omeprazole
Status: Completed, Estimated PCD: 2017-02-01
Clinical trial
A First-in Human, Randomized, Double-blind, Placebo Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-11-14
Clinical trial
A Comparative, Multicenter, Placebo-Controlled, Double-Blind Phase II Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Inhaled Aviptadil in Patients 18 Years and Older With COVID-19 Pulmonary Involvement - HOPE
Status: Completed, Estimated PCD: 2022-06-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Status: Completed, Estimated PCD: 2022-07-05
Clinical trial
A Phase 3, Placebo-controlled, Double-blind Comparative Study of KHK4827 With an Open-label Extension Period in Subjects With Systemic Sclerosis Who Have Moderate to Severe Skin Thickening
Status: Active (not recruiting), Estimated PCD: 2020-10-16
Clinical trial
This Was a Phase 1/2, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study Conducted at a Single Center for the Healthy Volunteer Cohorts in up to 56 Participants. It Consisted of 1 Single-dose Cohort and 3 Multiple-dose Cohorts (n = 12 Per Cohort, 10 Active:2 Placebo). The Open-label, hATTR Patient Cohort Portion of the Study Was Conducted at Multiple Centers.
Status: Completed, Estimated PCD: 2020-02-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients With Peripheral Neuropathy
Status: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2022-03-15
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Status: Completed, Estimated PCD: 2023-01-10
Clinical trial
A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis.
Status: Completed, Estimated PCD: 2005-10-01
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.
Status: Not yet recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset
Status: Completed, Estimated PCD: 2023-03-27
Clinical trial
A Cohort Study to Evaluate Safety and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in China
Status: Active (not recruiting), Estimated PCD: 2022-12-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Orally Administered BEBT-503 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) in Healthy Subjects
Status: Completed, Estimated PCD: 2023-05-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple-dose HH-003 Injection in Treatment Naïve Participants With HBeAg-positive Chronic HBV Infection
Status: Completed, Estimated PCD: 2022-03-15
Clinical trial
A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia
Status: Completed, Estimated PCD: 2019-04-18
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Status: Completed, Estimated PCD: 2021-07-01
Clinical trial
Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis
Status: Completed, Estimated PCD: 2020-03-02
Clinical trial
A Placebo-controlled, Double-blind Evaluation of Safety, Tolerability, and Efficacy of XT- 150 for the Treatment of Facet Joint Osteoarthritis Pain
Status: Completed, Estimated PCD: 2023-09-20
Clinical trial
A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Treatment of Prevention of Stress Ulcer Bleeding (Ilaprazole i.v. vs Esomeprazole, i.v.)
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection
Status: Terminated, Estimated PCD: 2022-11-17
Clinical trial
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)
Status: Completed, Estimated PCD: 2017-07-07
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Status: Active (not recruiting), Estimated PCD: 2024-06-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ABBV-181 in HIV-1 Infected Adults
Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
A Phase 1, Randomised, Placebo-controlled, Double-blind, Sequential Ascending-dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine (Gamma-PN3) in Healthy Adults
Status: Recruiting, Estimated PCD: 2023-09-30
Clinical trial
A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2022-04-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Status: Completed, Estimated PCD: 2022-03-30
Clinical trial
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2021-05-26
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase
Status: Terminated, Estimated PCD: 2017-04-10
Clinical trial
A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G), With an Open-label Extension
Status: Completed, Estimated PCD: 2019-12-11
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Clinical Pharmacology Study to Evaluate the Prevention Effect and the Recovery-Promoting Effect of a Single Subcutaneous Administration of GYM329 on Disuse Muscle Atrophy in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2022-06-03
Clinical trial
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Status: Completed, Estimated PCD: 2022-03-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Status: Terminated, Estimated PCD: 2023-11-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-07-31
Clinical trial
A Randomized, Observer-blinded, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Immunogenicity and Safety of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Healthy Participants Aged 18 Years or More
Status: Active (not recruiting), Estimated PCD: 2023-01-12
Clinical trial
a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.
Status: Active (not recruiting), Estimated PCD: 2022-12-07
Clinical trial
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder
Status: Completed, Estimated PCD: 2020-05-21
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Intravenous Doses of CM-101 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2018-02-18
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
Status: Terminated, Estimated PCD: 2023-07-20
Clinical trial
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Status: Recruiting, Estimated PCD: 2023-04-20
Clinical trial
A Phase 1, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABX1100 in Normal Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
Status: Terminated, Estimated PCD: 2022-06-06
Clinical trial
A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12 Week, Phase 2 Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Patients With Fuchs Endothelial Corneal Dystrophy
Status: Completed, Estimated PCD: 2021-09-22
Clinical trial
A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
Status: Completed, Estimated PCD: 2021-02-15
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants With Recent Onset Chronic Cough
Status: Completed, Estimated PCD: 2021-10-19
Clinical trial
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment.
Status: Completed, Estimated PCD: 2021-01-19
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF PF-07328948 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2023-05-03
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2022-07-15
Clinical trial
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease
Status: Terminated, Estimated PCD: 2022-09-02
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of HSK7653 as Monotherapy in Chinese Patients With Type 2 Diabetes
Status: Completed, Estimated PCD: 2022-01-10
Clinical trial
A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
Status: Terminated, Estimated PCD: 2022-04-27
Clinical trial
A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older
Status: Completed, Estimated PCD: 2021-08-07
Clinical trial
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Safety and Pharmacokinetics of AV-1 in Healthy Male and Female Adult Subjects
Status: Completed, Estimated PCD: 2021-07-08
Clinical trial
A Multicentric, Randomized, Double-Blind, Comparative, Prospective, Placebo-controlled, Phase-II/III Clinical Trial (ACCROS-III)
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
Stop Oral Dysbiosis. Study on the Effects of a Toothpaste in the Inflammatory Profile, Microbiome and Other Oral Dysbiosis Parameters: A Controlled, Randomized, Double-blind Study. This Study is Part of the Stop Dysbiosis Project
Status: Active (not recruiting), Estimated PCD: 2023-02-28
Clinical trial
A Phase 1, 2-Part Study in Healthy Male and Female Participants; Part 1 - A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose-Escalation Study of Inhaled DMC-IH1; Part 2 - An Open-Label, 3-Arm Study Assessing the Carryover Effects of Inhaled (DMC-IH1) and Intramuscular (EpiPen®) Epinephrine
Status: Not yet recruiting, Estimated PCD: 2024-01-18
Clinical trial
A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels.
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2018-10-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Status: Terminated, Estimated PCD: 2021-11-01
Clinical trial
A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention
Status: Completed, Estimated PCD: 2017-08-29
Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 in China
Status: Recruiting, Estimated PCD: 2023-04-15
Clinical trial
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2016-05-24
Clinical trial
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia
Status: Completed, Estimated PCD: 2021-07-18
Clinical trial
A 36-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-08-12
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
Status: Completed, Estimated PCD: 2019-12-03
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Completed, Estimated PCD: 2020-08-31
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Status: Terminated, Estimated PCD: 2022-07-28
Clinical trial
A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.
Status: Completed, Estimated PCD: 2022-04-22
Clinical trial
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation
Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19
Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)
Status: Active (not recruiting), Estimated PCD: 2020-06-22
Clinical trial
: A Randomised, Double-blind, Placebo-controlled, Dose-response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee:
Status: Completed, Estimated PCD: 2023-08-16
Clinical trial
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of Oral CDI-988 in Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Status: Completed, Estimated PCD: 2020-08-07
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers
Status: Completed, Estimated PCD: 2021-12-23
Clinical trial
AdvanTIG-306: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118/BGB-A1217) Combined With Tislelizumab (VDT482/BGB-A317) Plus Platinum-based Doublet Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Platinum-based Doublet Chemotherapy as First-line Therapy for Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Status: Withdrawn, Estimated PCD: 2027-12-24
Clinical trial
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2019-03-15
Clinical trial
A Randomized, Placebo-controlled, 2-way Crossover, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder Without Psychiatric Comorbidity
Status: Completed, Estimated PCD: 2015-12-02
Clinical trial
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Status: Completed, Estimated PCD: 2022-09-05
Clinical trial
Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis
Status: Completed, Estimated PCD: 2021-04-22
Clinical trial
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Pharmacodynamic Evaluation of ZT-01 in a Stepped Hypoglycemic Clamp Model in Subjects With Type 1 Diabetes Mellitus
Status: Terminated, Estimated PCD: 2022-04-12
Clinical trial
A Phase I Study of TS-142 in Non-Elderly Healthy Participants (Repeated Doses) (A Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TS-142 in Non-Elderly Participants)
Status: Completed, Estimated PCD: 2016-10-08
Clinical trial
A First-in-human, Randomized, Double-blinded, Placebo- Controlled, Two-part Study to Assess Safety/Tolerability and Pharmacokinetics of Single- and Multiple-ascending Doses and Food Effect of GFH312 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women With Endometriosis Experiencing Endometrial Related Pain
Status: Completed, Estimated PCD: 2021-05-13
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase Ib Study in Overweight/Obese Subjects Without Diabetes to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of TG103 Injection
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo and Active Controlled Parallel-group Trial to Assess the Efficacy and Safety of the Fixed Combination Medicinal Product Mometasone Furoate + Azelastine Hydrochloride Nasal Spray (50 + 140 mcg) in the Treatment of Seasonal Allergic Rhinitis
Status: Completed, Estimated PCD: 2023-06-20
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-06-29
Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Status: Completed, Estimated PCD: 2017-04-21
Clinical trial
A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2017-11-05
Clinical trial
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Status: Completed, Estimated PCD: 2022-09-05
Clinical trial
Randomized, Placebo-controlled, Single-blind, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics After Single and Multiple Nasal Doses of BAY 2586116 in Japanese Healthy Male Participants
Status: Completed, Estimated PCD: 2021-08-04
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel
Status: Completed, Estimated PCD: 2017-09-22
Clinical trial
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Terminated, Estimated PCD: 2023-09-29
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Subunit Rotavirus Vaccine in Healthy Infants Aged 6-12 Weeks and Healthy Toddlers Aged 7-71 Months
Status: Active (not recruiting), Estimated PCD: 2023-04-29
Clinical trial
A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Single-Dose or Open-Label Multiple-Dose Study of KHK4083 in Healthy Adults and Subjects With Ulcerative Colitis
Status: Completed, Estimated PCD: 2017-12-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1/2a, Multi-center Clinical Trial for Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain Due to Lumbar Intervertebral Disc Degeneration
Status: Completed, Estimated PCD: 2023-04-17
Clinical trial
A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2015-09-21
Clinical trial
A Phase I, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-04-13
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of APT Phage Bank Phage Therapy Versus Placebo in Conjunction With Debridement, Antibiotics, and Implant Retention (DAIR) in Subjects With Chronic Prosthetic Joint Infection (PJI)
Status: Withdrawn, Estimated PCD: 2025-07-01
Clinical trial
A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Status: Completed, Estimated PCD: 2022-03-17
Clinical trial
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER
Status: Active (not recruiting), Estimated PCD: 2020-08-31
Clinical trial
A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study.
Status: Completed, Estimated PCD: 2009-01-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2
Status: Terminated, Estimated PCD: 2022-02-11
Clinical trial
A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of MK-4305 (Suvorexant) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium
Status: Completed, Estimated PCD: 2022-12-23
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Completed, Estimated PCD: 2012-10-31
Clinical trial
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS
Status: Terminated, Estimated PCD: 2022-07-25
Clinical trial
A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects With an Alcohol Use Disorder Who Are Experiencing Insomnia Associated With Alcohol Cessation
Status: Completed, Estimated PCD: 2020-11-06
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Status: Completed, Estimated PCD: 2022-05-30
Clinical trial
A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants With Type 1 Diabetes
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Phase 1, Randomized, Double-blind, Multi-center, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Healthy Japanese Infants 5 Months of Age at First Trial Vaccine Administration
Status: Active (not recruiting), Estimated PCD: 2024-09-23
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Status: Terminated, Estimated PCD: 2022-06-29
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Status: Terminated, Estimated PCD: 2022-10-13
Clinical trial
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Telitacicept in Patients With IgA Nephropathy
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)
Status: Terminated, Estimated PCD: 2022-04-18
Clinical trial
A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled Hypertension
Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers
Status: Completed, Estimated PCD: 2022-09-20
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)
Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Status: Completed, Estimated PCD: 2022-02-17
Clinical trial
A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker
Status: Terminated, Estimated PCD: 2016-10-20
Clinical trial
A Randomized, Double-blind, Open for Active Comparator, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Three Different Doses of P2X3 Antagonist (BAY1817080) Versus Placebo and Elagolix 150 mg in Women With Symptomatic Endometriosis
Status: Terminated, Estimated PCD: 2022-01-17
Clinical trial
A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients With Chronic Hepatitis B
Status: Completed, Estimated PCD: 2022-07-12
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind and Open-label, Extension Study of TAS-205 in Patients With Duchenne Muscular Dystrophy
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females
Status: Completed, Estimated PCD: 2020-04-30
Clinical trial
A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Single-blind (Patient-blind), Randomized, Placebo-controlled, Intranasal Administration Study on Mechanisms and Potential Efficacy of AD17002 in Subjects With Poorly Controlled, Moderate to Severe Eosinophilic Asthma
Status: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
Status: Completed, Estimated PCD: 2022-07-30
Clinical trial
A Multicenter, Placebo-controlled, Double-blind, Randomized Clinical Trial in Parallel Groups to Evaluate the Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
Status: , Estimated PCD: 2024-12-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SLN124 in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-03-23
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Participants With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2023-10-06
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With C2202 and C2204
Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
Status: Active (not recruiting), Estimated PCD: 2024-11-13
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, and PK Characteristics of SIM1910-09 After Single/Multiple Dosing in Healthy Chinese Volunteers
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
A Randomized, Double-blind, Placebo Controlled, Single and Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed, Estimated PCD: 2023-07-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis
Status: Recruiting, Estimated PCD: 2023-10-30
Clinical trial
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate Its Efficacy and Safety Profile in Atopic Dermatitis Patients
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Completed, Estimated PCD: 2022-02-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets n Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Completed, Estimated PCD: 2018-09-10
Clinical trial
A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease
Status: Completed, Estimated PCD: 2021-10-08
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 in Healthy Adults
Status: Active (not recruiting), Estimated PCD: 2024-06-27
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza
Status: Completed, Estimated PCD: 2011-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2023-06-02
Clinical trial
A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia
Status: Recruiting, Estimated PCD: 2023-06-01
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of Intravenous PCN-101 in Treatment Resistant Depression
Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Chinese Adults With Familial Chylomicronemia Syndrome
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Study to Evaluate the Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin in Healthy Adult Participants
Status: Completed, Estimated PCD: 2021-10-30
Clinical trial
A Multi-Center ,Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of TPN171H in Patients With Erectile Dysfunction
Status: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Niclosamide in Healthy Adults
Status: Completed, Estimated PCD: 2021-10-13
Clinical trial
A Phase Ⅱ/Ⅲ Study to Evaluate Efficacy and Safety of Antaitavir Hasophate Capsules in Combination With Yiqibuvir Tablets in Adult Subject With Chronic HCV Infection
Status: , Estimated PCD: 2023-04-22
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Status: Terminated, Estimated PCD: 2023-04-12
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX1502 in Normal Healthy Volunteer
Status: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
Double-Blind, Randomized, Placebo-Controlled, Phase IIb Clinical Trial to Investigate the Efficacy of RUTI® Therapeutic Vaccination as Adjuvant of Tuberculosis Chemotherapy
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Status: Completed, Estimated PCD: 2022-10-13
Clinical trial
A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy
Status: Completed, Estimated PCD: 2018-09-11
Clinical trial
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
Status: Completed, Estimated PCD: 2023-10-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
A Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of PM8002(Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With EGFR-mutant Advanced Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx
Status: Completed, Estimated PCD: 2021-05-14
Clinical trial
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Status: Completed, Estimated PCD: 2023-01-27
Clinical trial
Safety, Tolerability and Pharmacokinetic Characteristics of Singletine(DC407) in Healthy Adult Subjects After Single and Multiple Doses: a Single-center, Randomized, Double-blind, Placebo-controlled, Phase 1 Trial
Status: Completed, Estimated PCD: 2021-01-30
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Status: Terminated, Estimated PCD: 2022-08-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Status: Active (not recruiting), Estimated PCD: 2024-07-26
Clinical trial
A Trial to Evaluate the Efficacy and Safety of HRS-5965 Tablets in Primary IgA Nephropathy
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005
Status: Active (not recruiting), Estimated PCD: 2023-09-19
Clinical trial
A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder
Status: Completed, Estimated PCD: 2017-10-04
Clinical trial
A Double-Blind, Placebo-Controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A First-in-Human Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Single Ascending Dose in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of the Product Vitamins B1 (100mg), B6 (100 mg), Plus B12 (5 mg) in Tablets in Subjects With Clinically Diagnosed PerIpheral Sensory polyNeuropathy of Different etiologieS (PINS Study)
Status: Completed, Estimated PCD: 2023-11-02
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Multiple Dose Study to Assess the Efficacy, Safety and Pharmacokinetics of Oral Nalbuphine, an Oral Soft Capsule, for Post-hemorrhoidectomy Pain Management
Status: Completed, Estimated PCD: 2014-09-21
Clinical trial
A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease
Status: Not yet recruiting, Estimated PCD: 2026-03-13
Clinical trial
A Phase 1 FIH, Randomized, Double Blind, Placebo Controlled, SAD/MAD Study to Assess Safety, Tolerability and PK in Healthy Participants and in Atopic Dermatitis Patients
Status: Recruiting, Estimated PCD: 2024-09-27
Clinical trial
Randomized Control Trial of Micronized Purified Flavonoid Fraction for Post Operative Treatment in Anal Fistula Surgery
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
Topical Tacrolimus for the Amelioration of Breast Cancer-related Lymphedema: a Randomized, Double-blind, Placebo-controlled Phase II/III Trial
Status: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
Status: , Estimated PCD: 2024-06-01
Clinical trial
A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV
Status: Terminated, Estimated PCD: 2022-04-04
Clinical trial
RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone (REST)
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Repeat Dosing of Psilocybin in Headache Disorders
Status: Completed, Estimated PCD: 2023-11-05
Clinical trial
Randomization to EndoVascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Acute Ischemic Stroke Due to Large Intracranial VEssel OcclusioN Trial - DIRECT Thrombectomy vs. Intravenous TNK Plus Thrombectomy
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Study on the Efficacy of in Office Steroid-eluting Sinus Stent Implantation in Chronic Rhinosinusitis Patients With Uncontrolled Postoperative Symptoms
Status: Recruiting, Estimated PCD: 2026-01-10
Clinical trial
Glucocorticoid Antagonists in Heavy Drinkers: Effects on fMRI Connectivity, Withdrawal and Drinking
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
A Phase 2 Study to Compare the Efficacy and Safety of Orally Administered Xiflam™ Therapy With Orally Administered Placebo in Patients With Ocular and Systemic Manifestations of Post COVID Sequelae Known as "Long" COVID
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Identifying Neurobiological Mechanisms That Underlie Acute Nicotine Withdrawal and Drive Early Relapse in Smokers
Status: Completed, Estimated PCD: 2020-03-30
Clinical trial
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Effect of Krill Oil Supplementation on Red Blood Cell Physiology Against Changes in Markers of Iron Metabolism.
Status: Recruiting, Estimated PCD: 2024-06-24
Clinical trial
Single and Multiple Dose Clinical Trial to Study the Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants With Primary Mitochondrial Myopathy
Status: Terminated, Estimated PCD: 2024-04-09
Clinical trial
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport Syndrome
Status: Recruiting, Estimated PCD: 2025-01-27
Clinical trial
Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension
Status: Recruiting, Estimated PCD: 2026-05-19
Clinical trial
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Status: Active (not recruiting), Estimated PCD: 2024-09-15
Clinical trial
Impact of Topical Pentoxifylline and Tocopherol in Treatment and Prevention of Medically-related Osteonecrosis of the Jaws: a Randomized Clinical Trial
Status: Completed, Estimated PCD: 2023-12-17
Clinical trial
Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder - a Randomized Double-blind Placebo-controlled Parallel-group Trial
Status: Completed, Estimated PCD: 2023-07-15
Clinical trial
Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II Trial
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Liposomal Bovine Lactoferrin (LbLf) and Liposomal Zn (LZn)) and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19
Status: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
Status: Terminated, Estimated PCD: 2020-11-01
Clinical trial
Evaluating a Neuromodulator Medical Device (Bridge Device) for Opioid Use Disorder Treatment
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Indacaterol
Status: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
BOTOX® (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Status: Recruiting, Estimated PCD: 2026-01-06
Clinical trial
A Phase 1 / 2 Clinical Trial to Assess the Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis
Status: Completed, Estimated PCD: 2017-09-28
Clinical trial
Effect of Gabapentin and Tizanidine on Insomnia in Chronic Pain Patients: A Randomized, Double-blind, Placebo-controlled Crossover Trial.
Status: , Estimated PCD: 2024-07-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Kinetic Effects in Healthy Volunteers With Normal or Mildly Elevated Triglycerides
Status: Recruiting, Estimated PCD: 2024-06-29
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)
Status: Recruiting, Estimated PCD: 2026-10-23
Clinical trial
Efficacy and Tolerability of Ramelteon in Patients With REM Behavior Disorder and Parkinsonism: A Placebo Controlled, Double Blind, Randomized, Prospective Pilot Study
Status: Terminated, Estimated PCD: 2009-12-01
Clinical trial
A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 1 Multiple Ascending Intradermal Dose Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites
Status: Active (not recruiting), Estimated PCD: 2022-12-22
Clinical trial
Double-blind Randomized Acetazolamide Trial in Normal Pressure Hydrocephalus
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill: a Randomised Double Blind Clinical Trial
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability: A Double-Blind Randomized Control Trial
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Safety and Efficacy of Oral Semaglutide in Hyperglycaemic Patients After Renal Transplantation
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
Phase I/II Study to Determine the Safety, Immunogenicity and Efficacy of the Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Effect of High Dose Intravenous Vitamin C as an Adjunct in the Treatment of Patients With Severe Pneumonia in Intensive Care Unit: a Multi-center, Double-blinded, Two-arm, Placebo-controlled, Randomized Trial
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy
Status: Active (not recruiting), Estimated PCD: 2024-10-18
Clinical trial
Pilot Studies Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
Status: Completed, Estimated PCD: 2024-01-04
Clinical trial
Angiotensin II Receptor Inhibition to Improve Microvascular Function in Women Who Have Had Preeclampsia
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
COLSIO Trial: Phase II Randomized, Controlled Trial of Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
CSP #590 - Lithium for Suicidal Behavior in Mood Disorders
Status: Terminated, Estimated PCD: 2019-08-13
Clinical trial
Photodynamic Therapy-Induced Immune Modulation: Part III
Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
Clinical and Imaging Biomarker Trial of Uridine for Veterans With Suicidal Ideation
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Double Blind, Single-Center, Randomized, Within Subject Placebo, Phase I Study Evaluating the Effects of Novel Topical Gel in Prevention of Hypertrophic Scar Formation
Status: Terminated, Estimated PCD: 2020-02-26
Clinical trial
Study to Evaluate if Androgen-receptor Blockade (Spironolactone) Improves Progesterone-suppression of Wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
Status: Completed, Estimated PCD: 2024-03-13
Clinical trial
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2024-10-30
Clinical trial
The Effectiveness of Tranexamic Acid in Breast Esthetic Surgery.
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent Grade-II Chemotherapy-induced Polyneuropathy (CIPN), to Reduce Symptoms Typical of CIPN, and to Improve the Quality of Life of Patients With CIPN
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
Long-Term, Safety and Tolerability Study of SCH 58235 or Placebo in Addition to Atorvastatin in Subjects With Primary Hypercholesterolemia
Status: Completed, Estimated PCD: 2002-08-08
Clinical trial
The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and Pharmacokinetics
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD)
Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
Study of Nasal Insulin to Fight Forgetfulness - Combination Intranasal Insulin and Empagliflozin Trial
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study.
Status: Completed, Estimated PCD: 2019-12-01
Clinical trial
NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection
Status: Completed, Estimated PCD: 2021-12-09
Clinical trial
Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Status: Recruiting, Estimated PCD: 2025-01-19
Clinical trial
Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder: A Randomized, Group Sequential, Adaptive Design, Controlled Clinical Trial
Status: Completed, Estimated PCD: 2023-09-30
Clinical trial
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Phase I Randomized, Single-blind, Placebo-controlled, Single-center Study of the Effect of Postoperative Administration of Single Dose Ketamine on Pain and Recovery After Robotic Removal of Endometriosis in Patients With Chronic Pelvic Pain
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Doxapram Versus Placebo in Preterm Newborns: An International Double Blinded Multicenter Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
The Phosphodiesterase 3 Inhibitor Cilostazol as Adjunct to Methotrexate in Patients With Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Cannabidiol (CBD) for the Management of Emergency Dental Pain
Status: Completed, Estimated PCD: 2023-03-02
Clinical trial
A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects
Status: Completed, Estimated PCD: 2023-09-07
Clinical trial
A Phase I/II, Prospective, Randomized, Double-Blind, PlAcebo-ControLled Trial to EvAluate the Efficacy of Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.(ALAUNUS)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
Status: Completed, Estimated PCD: 2023-08-21
Clinical trial
A Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3873862 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Clinical Study Evaluating the Role of Coenzyme Q10 as Adjuvant Therapy to Angiotensin Converting Enzyme Inhibitor on Blood Pressure, Proteinuria and Bone Metabolism in Patients With Chronic Kidney Disease
Status: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
Behavioral Pharmacology of THC and D-limonene
Status: Completed, Estimated PCD: 2022-06-28
Clinical trial
Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric Patients
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma: Multicenter Randomized Double-blind Placebo Controlled Trial (SOMAPROTECT01)
Status: Completed, Estimated PCD: 2024-04-30
Clinical trial
Effect of Probiotics on Grade 1 Primary Hypertension and Prehypertension and the Underlying Mechanism: a Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-06-02
Clinical trial
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide: a Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ⩾60 Years
Status: Completed, Estimated PCD: 2020-10-30
Clinical trial
Chiropractic Spinal Manipulative Therapy for Acute Neck Pain: a 4- Arm Clinical Placebo Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Status: Completed, Estimated PCD: 2023-09-13
Clinical trial
Treatment of Immune Related Adverse Events With CD24Fc (TIRAEC)
Status: Terminated, Estimated PCD: 2021-02-03
Clinical trial
Monotherapy of an NMDA Enhancer for Schizophrenia
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Cross-over Trial of Zibotentan in Microvascular Angina
Status: Completed, Estimated PCD: 2023-06-08
Clinical trial
PeriOperative ISchemic Evaluation-3 Trial
Status: Completed, Estimated PCD: 2021-11-08
Clinical trial
A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Colchicine on Pain and Inflammation in Subjects With Knee Osteoarthritis
Status: Completed, Estimated PCD: 2024-01-11
Clinical trial
A Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Brief Stresses and DNA Integrity: An Experimental Analysis
Status: Terminated, Estimated PCD: 2022-01-27
Clinical trial
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke. A Phase IIB Multicenter Double Blind Placebo Controlled Clinical Trial
Status: , Estimated PCD: 2023-07-15
Clinical trial
The Estrogen Replacement and Atherosclerosis Trial
Status: Completed, Estimated PCD: 2001-01-01
Clinical trial
Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain
Status: Terminated, Estimated PCD: 2016-05-01
Clinical trial
The Impact of Vitamin D Supplementation on Gestational Diabetes Mellitus Risk in Pakistani Females: A Randomized Controlled Trial.
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 3 Different HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) With MVA-CMDR Boosts in Healthy, HIV-1-Uninfected Adults
Status: Completed, Estimated PCD: 2016-11-01
Clinical trial
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis
Status: Active (not recruiting), Estimated PCD: 2022-03-07
Clinical trial
A Single-centre, Pilot, Randomized Controlled Trial of Oral Cannabinoids for Improving Pain Disability in Patients With Chronic Pain
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Examining the Effect of Salbutamol Use in Asthma and/or Exercise Induced Bronchoconstriction Whilst Exercising in Ozone Air Pollution
Status: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension
Status: Withdrawn, Estimated PCD: 2022-12-30
Clinical trial
A Phase II Placebo-Controlled Trial of Urolithin a Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury in Patients With ST-Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: Study on NLRP3, ASC, Caspase, and Troponin
Status: , Estimated PCD: 2023-03-31
Clinical trial
Safety and Protective Efficacy of Repeated Controlled Human Schistosoma Mansoni Infection
Status: Completed, Estimated PCD: 2023-01-11
Clinical trial
N-Acetylcysteine for Youth Cannabis Use Disorder
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease
Status: Active (not recruiting), Estimated PCD: 2024-06-05
Clinical trial
A Randomized, Controlled Study to Evaluate the Sensitizing Potential of BAY H006689, Naproxen 10% Topical Gel in Healthy Subjects Using a Repeat Insult Patch Test Design
Status: Not yet recruiting, Estimated PCD: 2024-07-20
Clinical trial
Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease
Status: Completed, Estimated PCD: 2022-10-28
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Decompensated Cirrhosis Patients(MSC-DLC-2)
Status: Not yet recruiting, Estimated PCD: 2025-07-18
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10421
Clinical trial
Effect of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at Risk for Developing Allergic Disease
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-05-21
Clinical trial
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
Status: Completed, Estimated PCD: 2022-03-03
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Subcutaneous Doses of SAR444336 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-12-12
Clinical trial
A Phase I Randomized, Double-blind, Placebo-controlled, Dose-increasing Single Dose Study Evaluating the Safety, Tolerability，Pharmacokinetics and Pharmacodynamics Analysis of Pegloticase in Subjects With Asymptomatic Hyperuricemia
Status: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Clinical Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
Status: Active (not recruiting), Estimated PCD: 2024-01-20
Clinical trial
A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of Single and Multiple Administration of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2022-05-17
Clinical trial
Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
Status: Active (not recruiting), Estimated PCD: 2023-05-30
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3996401 Following Single and Multiple Ascending Doses of GSK4347859 in Healthy Participants
Status: Not yet recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Status: Active (not recruiting), Estimated PCD: 2024-09-20
Clinical trial
A First-in-human, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single Doses of SAR443809 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-05-05
Clinical trial
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Status: Terminated, Estimated PCD: 2023-05-30
Clinical trial
A Randomised, Double Blind (Sponsor Unblinded), Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses and the Food Effect of GSK2556286 in Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2024-07-04
Clinical trial
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Status: Recruiting, Estimated PCD: 2027-08-07
Clinical trial
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain
Status: Completed, Estimated PCD: 2020-03-27
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 Following Subcutaneous Administration in Healthy Participants and Otherwise Healthy Participants With Obesity
Status: Completed, Estimated PCD: 2024-01-04
Clinical trial
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101, an Anti-DNABII Monoclonal Antibody, in Healthy Subjects (Part 1) and Hospitalized Subjects With Suspected or Confirmed Community-Acquired Bacterial Pneumonia of Moderate Severity (Part 2)
Status: Recruiting, Estimated PCD: 2024-05-11
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety
Status: Completed, Estimated PCD: 2022-08-02
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression
Status: Completed, Estimated PCD: 2018-11-15
Clinical trial
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-B)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers
Status: Active (not recruiting), Estimated PCD: 2023-09-03
Clinical trial
A Randomized, Double Blind, Active and Placebo Controlled, 5 Way Crossover Study to Determine the Abuse Potential of Orally Administered Gabapentin Enacarbil Immediate Release Capsules in Healthy, Nondependent Recreational Drug Users With Sedative Experience
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Phase 1, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Epetraborole Tablets Administered for up to 28 Days in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-02-26
Clinical trial
Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men
Status: Completed, Estimated PCD: 2018-10-29
Clinical trial
Randomised, Double-blind, Placebo-controlled Parallel-group Proof of Mechanism Study to Assess the Pharmacokinetics and to Evaluate the Pharmacodynamic Effect of Different Single Oral Doses of BI 409306 in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2012-02-01
Clinical trial
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension
Status: Completed, Estimated PCD: 2023-09-18
Clinical trial
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of the Recurrences of Chronic Bacterial Cystitis
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Proof-of-concept Study Evaluating Efficacy and Safety of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Who Are Inadequate Responders or Intolerant to Topical Corticosteroids
Status: Completed, Estimated PCD: 2023-06-23
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Status: Completed, Estimated PCD: 2022-08-26
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk Factors
Status: Recruiting, Estimated PCD: 2027-09-08
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Nighttime Doses of JZP441 in Sleep-Deprived Healthy Participants: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects
Status: Completed, Estimated PCD: 2023-12-03
Clinical trial
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Orally Administered DA-7503 After Single and Multiple Ascending Dose Regimens in Healthy Adult and Elderly Participants
Status: Not yet recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Thorough QT Study to Evaluate the Effects of BI 1015550 as Single Doses Following Oral Administration on Cardiac Safety Parameters (Double-blind, Randomized, Placebo-controlled, Five-period Crossover, With Open-label Moxifloxacin as Positive Control) in Healthy Male and Female Subjects
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
The ENCALM Trial: A Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients With Generalized Anxiety Disorder
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy
Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD
Status: Active (not recruiting), Estimated PCD: 2024-01-30
Clinical trial
A Phase Ib, Randomized, Double-Blind, Placebo Controlled, Sequential Study of Single Oral Doses of M5717 to Explore the Chemoprophylactic Activity of M5717 in a Controlled PISPZ Challenge Model in Healthy Participants
Status: Completed, Estimated PCD: 2021-08-18
Clinical trial
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-09
Clinical trial
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine Candidate in Adult Participants 60 Years and Older
Status: Recruiting, Estimated PCD: 2025-03-12
Clinical trial
Phase 1 Single-Dose Double-Blind Vehicle-Controlled 3-Way Crossover Study Using Thermography to Assess the Pharmacodynamics and Pharmacokinetics of L-Arginine and Sildenafil Contained in Sildenafil Cream 3.6% in Normal Healthy Premenopausal Women
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations
Status: Not yet recruiting, Estimated PCD: 2029-04-28
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers and in APOE4 Carriers
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Status: Active (not recruiting), Estimated PCD: 2022-04-01
Clinical trial
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
Status: Recruiting, Estimated PCD: 2028-05-16
Clinical trial
Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers
Status: Completed, Estimated PCD: 2021-06-19
Clinical trial
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Placebo-Controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Ascending Subcutaneous Doses of GS-0272 in Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus (MARASLE)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
Status: Active (not recruiting), Estimated PCD: 2022-01-12
Clinical trial
A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients With Inflammatory Lung Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
Status: Recruiting, Estimated PCD: 2025-09-26
Clinical trial
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-Response Study of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
Status: Active (not recruiting), Estimated PCD: 2024-08-28
Clinical trial
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Status: Active (not recruiting), Estimated PCD: 2024-02-08
Clinical trial
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Oral Doses Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of TAK-279 in Healthy Chinese Subjects
Status: Not yet recruiting, Estimated PCD: 2024-12-12
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Recruiting, Estimated PCD: 2026-02-06
Clinical trial
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Status: Recruiting, Estimated PCD: 2030-03-11
Clinical trial
Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
Status: Completed, Estimated PCD: 2022-12-29
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial of ADX-914 for the Treatment of Severe Alopecia Areata
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2016-01-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder
Status: Completed, Estimated PCD: 2020-01-14
Clinical trial
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Completed, Estimated PCD: 2015-02-20
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Status: Terminated, Estimated PCD: 2022-05-24
Clinical trial
A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
A Placebo-controlled Study of MD-120 in Patients With Depression
Status: Completed, Estimated PCD: 2022-07-21
Clinical trial
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer
Status: Completed, Estimated PCD: 2021-10-25
Clinical trial
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluation the Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) in a Population Aged 3 Months-50 Years Old
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment
Status: Recruiting, Estimated PCD: 2024-07-25
Clinical trial
A Phase 2 Trial to Evaluate Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients With Chronic Kidney Disease at Risk of Rapid Progression
Status: Completed, Estimated PCD: 2021-10-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
Status: Recruiting, Estimated PCD: 2030-04-24
Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Recruiting, Estimated PCD: 2026-09-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis
Status: Recruiting, Estimated PCD: 2024-10-23
Clinical trial
A Phase 3, Multi-center, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Moderate to Severe Forehead Lines in China
Status: Active (not recruiting), Estimated PCD: 2024-09-18
Clinical trial
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-01-22
Clinical trial
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Status: , Estimated PCD: 2024-12-01
Clinical trial
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
Prospective, Multi-center, Double-blind, Randomized, Active-controlled, Triple-dummy, Parallel-group, Group-sequential, Adaptive Phase 3 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed Dose Combination in Subjects With Pulmonary Arterial Hypertension (PAH), Followed by an Open-label Treatment Period With Macitentan and Tadalafil Fixed Dose Combination Therapy
Status: Active (not recruiting), Estimated PCD: 2022-08-23
Clinical trial
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy
Status: , Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Status: Active (not recruiting), Estimated PCD: 2024-10-04
Clinical trial
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
Status: Recruiting, Estimated PCD: 2029-02-15
Clinical trial
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Status: Active (not recruiting), Estimated PCD: 2024-03-14
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG)
Status: Terminated, Estimated PCD: 2023-02-21
Clinical trial
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Status: Terminated, Estimated PCD: 2023-10-26
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2019-05-17
Clinical trial
A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612
Status: Completed, Estimated PCD: 2015-04-26
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
Status: Completed, Estimated PCD: 2021-03-11
Clinical trial
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 Years of Age) Participants With Hypophosphatasia Who Have Not Received Previous Treatment With Asfotase Alfa
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
Status: Recruiting, Estimated PCD: 2025-02-27
Clinical trial
Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Status: Completed, Estimated PCD: 2012-03-09
Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SHR-1707 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2025-11-07
Clinical trial
A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Status: Completed, Estimated PCD: 2023-09-19
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Status: Recruiting, Estimated PCD: 2025-10-13
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10501 Tablets After Single and Multiple Oral Doses in Healthy Subjects
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2021-12-29
Clinical trial
A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2016-12-19
Clinical trial
A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids
Status: Not yet recruiting, Estimated PCD: 2025-11-22
Clinical trial
A 3-part Study of ABCI: A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Phase 1a Study in Healthy Volunteers (Part A), a Randomized, Double-blind, Placebo-controlled, 14- and 28-day Multiple-ascending Dose Phase 1a Study in Healthy Volunteers (Part B), and a 28-day Open-Label Phase 1b Study in Subjects With Cystic Fibrosis (Part C)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase 1 Single and Multiple Ascending Dose and Drug Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Status: Recruiting, Estimated PCD: 2024-10-17
Clinical trial
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VIT-2763 in Subjects With Non-transfusion Dependent β-thalassaemia
Status: Completed, Estimated PCD: 2021-10-11
Clinical trial
A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination
Status: Active (not recruiting), Estimated PCD: 2023-12-28
Clinical trial
A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels
Status: Recruiting, Estimated PCD: 2024-03-08
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
Status: Completed, Estimated PCD: 2016-04-29
Clinical trial
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
Status: Completed, Estimated PCD: 2024-02-26
Clinical trial
A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-07-05
Clinical trial
VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Status: Active (not recruiting), Estimated PCD: 2025-07-26
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study
Status: Active (not recruiting), Estimated PCD: 2024-03-22
Clinical trial
A Phase 1 Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of GS1-144 Tablets
Status: Recruiting, Estimated PCD: 2024-12-17
Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy, Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants With Cirrhosis
Status: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
Status: , Estimated PCD: 2003-06-01
Clinical trial
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Status: Terminated, Estimated PCD: 2024-01-31
Clinical trial
A Phase III Study Evaluating the Efficacy and Safety of ASKB589 Combined With CAPOX and PD-1 Inhibitor as First-Line Treatment in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee
Status: Active (not recruiting), Estimated PCD: 2023-07-30
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis
Status: Completed, Estimated PCD: 2022-04-06
Clinical trial
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
Status: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension
Status: Recruiting, Estimated PCD: 2025-03-20
Clinical trial
A Randomized, Intra-patient, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Food Effect After Single and Multiple Oral Doses of ARTS-011 In Chinese Health Subjects
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
Status: Completed, Estimated PCD: 2023-12-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of SI-722 Intravesical Instillation in Interstitial Cystitis/Bladder Pain Syndrome Subjects
Status: Completed, Estimated PCD: 2021-01-12
Clinical trial
A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years With Wheezing Lower Respiratory Illness
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
Status: Active (not recruiting), Estimated PCD: 2025-02-14
Clinical trial
A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients With Parkinson's Disease
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo, Positive Drug Parallel Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery
Status: Completed, Estimated PCD: 2023-07-04
Clinical trial
A Randomized, Double-blind, Positive Drug/Placebo Parallel Controlled, Multicenter, Phase III Clinical Trial of L-oxiracetam Injection to Improve Memory and Cognitive Impairment in Patients With Craniocerebral Injury
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Status: Terminated, Estimated PCD: 2023-11-08
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Completed, Estimated PCD: 2016-03-07
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Patients With COPD
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia
Status: Completed, Estimated PCD: 2020-09-29
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of IcBD-01 Enema for the Treatment of Active Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Multicenter, Randomized, Single-Blind, Placebo-Parallel-Controlled Research of REGEND001 Cell Therapy for Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee
Status: Active (not recruiting), Estimated PCD: 2024-03-06
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes
Status: Active (not recruiting), Estimated PCD: 2026-12-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Status: Active (not recruiting), Estimated PCD: 2023-07-19
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
Status: Completed, Estimated PCD: 2020-10-02
Clinical trial
A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer
Status: Completed, Estimated PCD: 2020-04-03
Clinical trial
A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
Status: Completed, Estimated PCD: 2023-07-10
Clinical trial
Interventional, Randomized, Double-blind, Sequential Cohort, Placebo-controlled, Multiple-dose Trial Investigating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of Lu AG06474 in Healthy Young Men and Women, With an Open-label, Cross-over, Single-dose Part Investigating the Relative Bioavailability of a Capsule Formulation
Status: Recruiting, Estimated PCD: 2024-08-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445, a Factor Xa (fXa) Inhibitor Antidote
Status: Completed, Estimated PCD: 2012-09-01
Clinical trial
A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3739937 in Healthy Participants
Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)
Status: Recruiting, Estimated PCD: 2027-08-23
Clinical trial
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
Status: Active (not recruiting), Estimated PCD: 2021-09-02
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral VX-708 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-04-14
Clinical trial
A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of NM-101 in Healthy Male and Female Subjects
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655088 Administered by Intravenous Infusion in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2019-02-14
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2018-06-01
Clinical trial
A PHASE 1 FIRST IN HUMAN, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF 07242813 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of ASC10 Tablets and an Open-label, Crossover Design to Evaluate the Food Effect on PK of ASC10 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effects of VX-150 on C-Nociceptor Action Potentials in Healthy Subjects
Status: Completed, Estimated PCD: 2022-09-14
Clinical trial
A Randomized, Double-blind, Placebo-controled, Multi-center Phase II Clinical Trial for Evaluation of the Efficacy and Safety of Jitongning Tablet in Patients With Active Axial Spondyloarthritis(SpA)
Status: Completed, Estimated PCD: 2021-06-20
Clinical trial
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Status: Active (not recruiting), Estimated PCD: 2023-06-28
Clinical trial
COVID-19: A MULTIPART, PHASE 1 STUDY WITH RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07817883 AND OPTIONAL OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF SOLID ORAL FORMULATION AND OPTIONAL OPEN-LABEL, NON-RANDOMIZED STUDY TO EVALUATE METABOLISM AND EXCRETION OF PF-07817883 AND OPTIONAL RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFECT OF PF-07817883 ON PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2023-09-15
Clinical trial
A Prospective, Randomised, Double-blinded, Placebo-controlled Study Investigating the Safety and Tolerability of STA363 in Patients With Radiculopathy Caused by Lumbar Disc Herniation
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI
Status: Active (not recruiting), Estimated PCD: 2023-04-17
Clinical trial
A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730357 Administered as Oral Solution and Tablets to Healthy Subjects, and a Randomized, Open-label, Single-dose, Three-way Cross-over Bioavailability Comparison of BI 730357 as Tablet Versus Oral Solution and Tablet With and Without Food
Status: Completed, Estimated PCD: 2017-08-15
Clinical trial
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia
Status: Terminated, Estimated PCD: 2012-09-01
Clinical trial
Phase 3, Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status: Completed, Estimated PCD: 2015-05-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2017-04-13
Clinical trial
A Double-Blind Randomized, Placebo-Controlled, Single and Repeated Oral Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect) of GSK3882347 in Healthy Participants
Status: Completed, Estimated PCD: 2021-05-14
Clinical trial
An Adaptive, Randomized, Double Blind, Placebo Controlled Three Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX-8 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts
Status: Completed, Estimated PCD: 2021-12-01
Clinical trial
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-01-17
Clinical trial
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Status: Completed, Estimated PCD: 2023-05-23
Clinical trial
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
Status: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc)
Status: Completed, Estimated PCD: 2020-12-14
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707 in Healthy Young Adult and Elderly Subjects
Status: Completed, Estimated PCD: 2022-01-13
Clinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
Status: Completed, Estimated PCD: 2022-05-31
Clinical trial
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
Status: Completed, Estimated PCD: 2017-06-26
Clinical trial
A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD
Status: Completed, Estimated PCD: 2022-10-28
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Multicenter, Randomized, Double-blind Recommended Dose-finding Study of SI-6603 in Patients With Lumbar Disc Herniation (Phase II/III Study)
Status: Completed, Estimated PCD: 2009-11-01
Clinical trial
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Status: Active (not recruiting), Estimated PCD: 2025-05-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®27564 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Status: Completed, Estimated PCD: 2020-11-16
Clinical trial
Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness
Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
A Multi-center, Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, PK and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis
Status: Recruiting, Estimated PCD: 2023-12-21
Clinical trial
A Single-dose, Randomised, Double-blind, Controlled, 2-way Cross-over Study to Assess the Potential for Bronchoconstriction of the New Propellant HFA-152a Versus the Marketed HFA-134a Propellant, in Adult Subjects With Mild Asthma
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Terminated, Estimated PCD: 2023-01-19
Clinical trial
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Status: Completed, Estimated PCD: 2021-06-20
Clinical trial
A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris
Status: Completed, Estimated PCD: 2017-07-19
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation
Status: Completed, Estimated PCD: 2012-06-30
Clinical trial
A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
Status: Completed, Estimated PCD: 2019-11-11
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase
Status: Completed, Estimated PCD: 2021-03-10
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2017-10-02
Clinical trial
COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)
Status: Completed, Estimated PCD: 2022-06-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Phase II/III Trial of Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease
Status: Active (not recruiting), Estimated PCD: 2023-08-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HS-10380 in Chinese Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
Status: Completed, Estimated PCD: 2021-08-24
Clinical trial
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEB-1170 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2018-08-24
Clinical trial
A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of CSX-1004 Injection in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity
Status: Completed, Estimated PCD: 2019-12-16
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Status: Terminated, Estimated PCD: 2022-05-06
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Oral QPX2015 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2019-10-06
Clinical trial
A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Status: Completed, Estimated PCD: 2021-09-09
Clinical trial
A Multicenter, Randomized, Double-blind, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
Status: Completed, Estimated PCD: 2023-01-23
Clinical trial
A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Status: Completed, Estimated PCD: 2022-06-21
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Dose Platform Study Investigating the Immunopharmacology of EDP1815 and EDP2939.
Status: Completed, Estimated PCD: 2022-10-14
Clinical trial
A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1
Status: Completed, Estimated PCD: 2016-07-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Two-cohort, Three-way Crossover Clinical Trial to Evaluate the Pharmacodynamic Effect of Different Doses of TPN171H Tablets in Mild to Moderate Male Erectile Dysfunction
Status: Completed, Estimated PCD: 2023-01-04
Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Effects of Overnight Intravenous TAK-925 in Patients With Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2022-11-23
Clinical trial
SYNERGY-1: A Phase 1 First-in-human, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-05-04
Clinical trial
A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis
Status: Completed, Estimated PCD: 2023-01-10
Clinical trial
Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Status: Completed, Estimated PCD: 2021-07-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study
Status: Completed, Estimated PCD: 2021-07-27
Clinical trial
OPSIS: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Status: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, PK and the Immunosuppressive Effects of p38 MAPK Inhibitor POLB 001 on the Intradermal and Intravenous LPS Challenge Response in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-12-14
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Comparative, Multicenter Phase III Clinical Trial to Study the Clinical Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2027-07-21
Clinical trial
A Study to Investigate the Safety and Tolerability of a Wearable On-body Delivery System, and Exploratory Assessment of Participant Response With an Autoinjector, Following Subcutaneous Injections of Placebo in Healthy Participants
Status: Completed, Estimated PCD: 2022-07-22
Clinical trial
A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Subjects With Molluscum Contagiosum
Status: Completed, Estimated PCD: 2018-11-03
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer
Status: Terminated, Estimated PCD: 2021-09-21
Clinical trial
A Phase 2 Open-Label Study in Infants With REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebocontrolled Part, to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of RV521 (REVIRAL 1)
Status: Terminated, Estimated PCD: 2022-12-05
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Status: Completed, Estimated PCD: 2019-06-13
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Randomized, Double-Blind Study of the Time Course of Response to Biphentin® Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting
Status: Completed, Estimated PCD: 2011-06-18
Clinical trial
An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia
Status: Completed, Estimated PCD: 2017-12-13
Clinical trial
A Randomized, Observer-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of One Dose Booster by A Lyophilized COVID-19 mRNA Vaccine in Adults Aged 18 to 60 Years
Status: Withdrawn, Estimated PCD: 2022-09-01
Clinical trial
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Status: Completed, Estimated PCD: 2020-04-16
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, FTIH Study to Investigate the Safety, Tolerability, PK and PD of ECC4703 in Healthy Volunteers and Participants With Treatment-Unnecessary LDL-C Under 160 mg/dL
Status: Recruiting, Estimated PCD: 2023-07-05
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older
Status: Completed, Estimated PCD: 2022-07-08
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Status: Active (not recruiting), Estimated PCD: 2021-01-24
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Multicenter, Interventional, Two-arm, Parallel-group, Randomized, Double-blinded, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Symptomatic Diabetic Polyneuropathy in Egypt
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
A Two-part, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Dose-range, Safety and Efficacy of 4 and 12 Weeks of Treatment With AP1189 in Adult Rheumatoid Arthritis (RA) Patients With an Inadequate Response to Methotrexate (MTX) Alone - (RESOLVE)
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin Nanoparticle Albumin Bound (Nab)-Paclitaxel) vs Chemotherapy (Carboplatin Nab-Paclitaxel) as First-Line Therapy for Locally Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment
Status: Completed, Estimated PCD: 2019-09-04
Clinical trial
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects With Beta Thalassemia
Status: Terminated, Estimated PCD: 2022-03-11
Clinical trial
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
Status: Completed, Estimated PCD: 2015-10-16
Clinical trial
A Phase 1, Double-blind, Single-dose, Randomized, Placebo and Active-Controlled, Four-Way Crossover Study Evaluating the Effects of Bemnifosbuvir on Cardiac Repolarization in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Status: Active (not recruiting), Estimated PCD: 2023-07-10
Clinical trial
A Multi-center, Phase 1b, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
Status: Completed, Estimated PCD: 2023-11-01
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With Chronic Hepatitis B
Status: Completed, Estimated PCD: 2023-11-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
Status: Completed, Estimated PCD: 2021-12-05
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Completed, Estimated PCD: 2018-09-04
Clinical trial
Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI
Status: Completed, Estimated PCD: 2022-12-16
Clinical trial
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Status: Completed, Estimated PCD: 2020-06-30
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist, in Obese Subjects With Prader-Willi Syndrome (PWS) on Safety, Weight Reduction, and Food-Related Behaviors
Status: Completed, Estimated PCD: 2016-10-26
Clinical trial
Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Study in Healthy Volunteers to Assess Immunogenicity, & Acceptability of a Single-dose of Live Oral Cholera Vaccine, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR
Status: Completed, Estimated PCD: 2015-02-01
Clinical trial
A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy
Status: Completed, Estimated PCD: 2019-10-21
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of NM8074 Administered Intravenously to Healthy Subjects
Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Completed, Estimated PCD: 2019-05-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2023-10-06
Clinical trial
A Phase 1, Randomzied, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Intravenous And Multiple Subcutaneous And Intravenous Doses Of Pf-06480605 In Healthy Subjects
Status: Completed, Estimated PCD: 2015-03-01
Clinical trial
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)
Status: Active (not recruiting), Estimated PCD: 2025-06-15
Clinical trial
Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2023-07-18
Clinical trial
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
Status: Completed, Estimated PCD: 2021-07-02
Clinical trial
A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-12-05
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients
Status: Completed, Estimated PCD: 2013-09-28
Clinical trial
VML 251 00/02
Status: Completed, Estimated PCD: 2002-06-01
Clinical trial
A Prospective, Multicenter, Randomized, Single Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)
Status: Completed, Estimated PCD: 2019-01-07
Clinical trial
A Phase 1, Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-01-12
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis
Status: Completed, Estimated PCD: 2021-06-14
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 IV Infusion in Healthy Subjects
Status: Terminated, Estimated PCD: 2021-08-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus
Status: Terminated, Estimated PCD: 2021-07-30
Clinical trial
A Phase III, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition
Status: Recruiting, Estimated PCD: 2023-03-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Status: Terminated, Estimated PCD: 2020-09-28
Clinical trial
A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II
Status: Completed, Estimated PCD: 2022-09-23
Clinical trial
A Phase Ib Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine Efficacy, Pharmacokinetics and Safety of BXCL501 in Agitation Associated With Schizophrenia
Status: Completed, Estimated PCD: 2019-07-31
Clinical trial
A Study to Assess the Effect of Single Doses of MK -5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial Hypertension
Status: Completed, Estimated PCD: 2020-12-11
Clinical trial
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia in Chinese Patients
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms
Status: Terminated, Estimated PCD: 2019-05-29
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial on the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (Ad5-nCoV-IH) in Adults Aged 18 Years and Above Who Have Received One Dose of Intramuscular Ad5-nCoV
Status: Withdrawn, Estimated PCD: 2022-04-15
Clinical trial
A Phase 1, Single-blind, Partially Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of AntiBKV in Healthy Adult Volunteers.
Status: Completed, Estimated PCD: 2022-12-05
Clinical trial
A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), in Patients With Hyperkalemia-HARMONIZE Asia
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)
Status: Completed, Estimated PCD: 2023-08-02
Clinical trial
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
Status: Completed, Estimated PCD: 2023-09-04
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Tablets Administered Randomly, Double-blind, Placebo-controlled Single and Multiple Times in Healthy Adult Subjects, as Well as the Effects of Randomized, Open, and Two Cycle Crossover Foods
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
Status: Active (not recruiting), Estimated PCD: 2023-07-18
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Status: Terminated, Estimated PCD: 2022-04-15
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Status: Completed, Estimated PCD: 2017-09-25
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Status: Completed, Estimated PCD: 2022-02-09
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 609 in Subjects With Non-alcoholic Fatty Liver Disease
Status: Completed, Estimated PCD: 2023-07-19
Clinical trial
A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
Status: Completed, Estimated PCD: 2021-11-17
Clinical trial
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
Status: Active (not recruiting), Estimated PCD: 2023-06-05
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease
Status: Active (not recruiting), Estimated PCD: 2023-03-14
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
Status: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2021-04-22
Clinical trial
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model
Status: Completed, Estimated PCD: 2017-10-31
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
Status: Terminated, Estimated PCD: 2023-03-28
Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous NKTR-358 in Patients With Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2019-08-29
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects With Focal Onset Seizures (FOS)
Status: Completed, Estimated PCD: 2023-08-21
Clinical trial
A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics
Status: Terminated, Estimated PCD: 2023-08-29
Clinical trial
A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis
Status: Completed, Estimated PCD: 2018-12-24
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Status: Completed, Estimated PCD: 2019-08-02
Clinical trial
A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome
Status: Terminated, Estimated PCD: 2022-11-24
Clinical trial
A Phase 1 Safety, Tolerability and Pharmacokinetic Study of R-Idazoxan HCl Extended-Release (TR-01-XRR), S-Idazoxan HCl Extended-Release (TR-01-XRS) and Racemic Idazoxan HCl Extended-Release (TR-01-XR) in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Reversing Microvascular Dysfunction in Heart Failure With Ejection Fraction > 40% Using Colchicine (The COL-Micro-HF Study)
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Bone Sarcoma
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging: SMArT-HS
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis
Status: Completed, Estimated PCD: 2021-12-03
Clinical trial
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
Status: Completed, Estimated PCD: 2024-03-07
Clinical trial
Adjuvant Capecitabine Metronomic Chemotherapy Plus Endocrine Therapy for HR-positive, HER2-negative, Primary Breast Cancer: a Multicenter, Randomized, Double-blind Phase III Clinical Trial
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Canadian Phase II, Placebo-controlled Randomized Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
Status: Withdrawn, Estimated PCD: 2024-01-31
Clinical trial
A Prospective, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Curcuvail® of K Patel Phyto Extractions Pvt. Ltd. in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Status: Completed, Estimated PCD: 2021-11-25
Clinical trial
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Status: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
Status: Completed, Estimated PCD: 2022-05-16
Clinical trial
Citicoline in Ischemic Stroke, a Randomized Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2024-06-29
Clinical trial
Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity
Status: Terminated, Estimated PCD: 2023-07-11
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Aspirin in Adults With Nonalcoholic Fatty Liver Disease
Status: Completed, Estimated PCD: 2023-02-23
Clinical trial
Patient Perception of Pain Following Extraction and Bone Graft Surgery With or Without Preemptive Ibuprofen: A Randomized Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Topical Tranexamic Acid as a Adjunct to Intravenous Tranexamic Acid in Adult Spinal Deformity Surgery
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2012-01-01
Clinical trial
Immunogenicity and Safety of the Inactivated Rotavirus Vaccine (Vero Cells) in Toddlers and Infants Aged From 2 to 71 Months: A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2025-02-17
Clinical trial
The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
Personalized Immunotherapy in Sepsis: a Multicentre and Multinational, Double-blind, Double-dummy Randomized Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2025-01-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept, Antipruritic Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Status: Completed, Estimated PCD: 2015-02-19
Clinical trial
Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
Epirubicin for the Treatment of Sepsis & Septic Shock
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care: A Randomized Controlled Phase II Feasibility Trial
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Investigate the Safety and Exploratory Efficacy of a Subdermal Implant-bioabsorbable Gestrinone Pellet for Pelvic Pain Secondary to Endometriosis Treatment
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
DON in Pediatric Cerebral Malaria: A Phase I/IIa Dose-Escalation Safety Study
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Double-blind Clinical Trial to Evaluate the Safety and Efficacy of Two Doses of Prolonged Release Pirfenidone, Compared Against Placebo Plus Conventional Therapy in Patients With Compensated Liver Cirrhosis.
Status: Completed, Estimated PCD: 2021-12-30
Clinical trial
Pharmacological Modulation of Hippocampal Activity in Psychosis 2
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents
Status: Active (not recruiting), Estimated PCD: 2024-07-10
Clinical trial
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients ≥65 Years of Age Not Eligible for Intensive Chemotherapy
Status: Terminated, Estimated PCD: 2020-12-26
Clinical trial
Ketones, Muscle Metabolism, and SGLT2 Inhibitors
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Pilot Study of Memantine for Enhanced Stroke Recovery
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Benefit of a Subacromial Injection Combining Corticosteroid and Hyaluronic Acid Versus Corticosteroid Alone in Supraspinatus Tendinopathy
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A 15 Months, Double-Blind, Randomized Controlled Trial Comparing 20 Weeks of Two Dosages of Omalizumab to Placebo to Accelerate a Symptom-driven Oral Immunotherapy Schedule in Subjects Aged 6 to 25 Years With Multiple Food Allergies
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Impact of Tamsulosin on Duration of Post-Operative Urinary Retention in Women Undergoing Pelvic Reconstructive Surgery- A Double Blind, Randomized, Placebo-Controlled Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
ERTU-SODIUM: Double-blind, Prospective, Randomized, Crossover, Placebo-control Study on the Effects of the SGLT2 Inhibitor Ertugliflozin on the Regulation of Interstitial Volume, Plasma Volume, Subcutaneous Sodium Storage, and the Functionality of the Subcutaneous Glycosaminoglycan Network in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome
Status: Completed, Estimated PCD: 2020-11-02
Clinical trial
A Four-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of JZP441 in Healthy Adult Participants: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Status: Completed, Estimated PCD: 2023-05-12
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of 3 Doses of INV-202 With an Optional Open-Label Extension in Patients With Obesity and Metabolic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults ≥60 Years of Age
Status: Active (not recruiting), Estimated PCD: 2023-03-13
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of WPV01 in Patients With Mild to Moderate COVID-19
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis
Status: Completed, Estimated PCD: 2023-07-27
Clinical trial
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Status: Completed, Estimated PCD: 2023-02-23
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Participants With Active Ulcerative Colitis
Status: Terminated, Estimated PCD: 2021-07-22
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous Coronary Intervention
Status: Terminated, Estimated PCD: 2022-08-23
Clinical trial
A Pilot Study to Assess the Use of Methylone in the Treatment of PTSD IMPACT-1 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study
Status: Recruiting, Estimated PCD: 2025-06-09
Clinical trial
A Phase 1, Double-Blinded, Randomised, Placebo-Controlled, Single Ascending Dose (SAD) Study in Healthy Subjects to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of AB801
Status: Completed, Estimated PCD: 2024-02-15
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Titration Schedules of Subcutaneous Doses of BI 1820237 Alone or Together With Either Semaglutide or BI 456906 in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Multiple Dose, Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
Status: Completed, Estimated PCD: 2023-10-12
Clinical trial
A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and Older
Status: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week Extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the Treatment of Moderate to Severe Dry Eye Disease
Status: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Based on Standard Treatment to Evaluate the Effect of Injectable Neucardin on Cardiac Function and Reverse Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Three-Part, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-PNP siRNA in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a PNPLA3 Genetic Risk Factor
Status: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of Subcutaneous and Intravenous ALXN1820 in Healthy Participants
Status: Completed, Estimated PCD: 2022-09-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants With Overall Good Health and Without HIV
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single, Repeat Dose Escalation and Indomethacin Challenge Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK4381406 in Healthy Participants
Status: Withdrawn, Estimated PCD: 2024-12-05
Clinical trial
A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis
Status: Completed, Estimated PCD: 2022-10-12
Clinical trial
A Phase 2, Double-blind, Randomized, Multicenter, Placebo-controlled, Three Arm Parallel Study to Evaluate the Efficacy and Safety of TNX-1900 (Intranasal Oxytocin) in Patients With Chronic Migraine (PREVENTION Study)
Status: Completed, Estimated PCD: 2023-10-08
Clinical trial
A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Status: Completed, Estimated PCD: 2023-09-04
Clinical trial
A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke
Status: Withdrawn, Estimated PCD: 2023-12-18
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Status: Completed, Estimated PCD: 2021-02-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY® (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy
Status: Completed, Estimated PCD: 2024-03-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Status: Terminated, Estimated PCD: 2023-03-09
Clinical trial
Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study
Status: Completed, Estimated PCD: 2023-10-12
Clinical trial
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RTA 1701 in Healthy Adults
Status: Completed, Estimated PCD: 2019-06-28
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder
Status: Completed, Estimated PCD: 2019-04-03
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SNP318 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-11-29
Clinical trial
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Local Administration of EXPAREL for Postsurgical Analgesia in Pediatric Subjects 12 to Less Than 17 Years of Age
Status: Completed, Estimated PCD: 2019-02-12
Clinical trial
A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers
Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Status: Completed, Estimated PCD: 2017-06-20
Clinical trial
Temelimab as a Disease Modifying Therapy in Patients With Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID 19 or Postacute Sequelae of COVID-19 (PASC) Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Status: Active (not recruiting), Estimated PCD: 2024-03-05
Clinical trial
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2016-01-24
Clinical trial
Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment-naïve Patients and Treated Patients With Chronic Hepatitis B
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A First-in-Human, Phase I, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects, Including Food-Effect and Drug-drug Interaction With Itraconazole
Status: Completed, Estimated PCD: 2022-04-21
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients
Status: Terminated, Estimated PCD: 2022-12-12
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-02-04
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2023-12-29
Clinical trial
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II
Status: , Estimated PCD: 2024-06-30
Clinical trial
Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects
Status: Completed, Estimated PCD: 2024-01-19
Clinical trial
Efficacy and Safety of Low-Dose Interleukin 2 for Behçet's Syndrome: a Phase 2, Randomised, Double-blind, Placebo-controlled Trial
Status: Completed, Estimated PCD: 2023-04-20
Clinical trial
Transabdominal Plane (TAP) Blocks for Inguinal Hernia Repairs
Status: Completed, Estimated PCD: 2023-08-03
Clinical trial
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
Evaluation of the Efficacy and Safety of Anti-angiogenic Therapy With Intravenous Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
REFOCUS: Refined Fecal Microbiota Transplantation (FMT) Delivered by Oral Capsules for Induction of Remission in Mild to Moderate Ulcerative Colitis - a Phase I Study
Status: Terminated, Estimated PCD: 2022-08-22
Clinical trial
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
In Vivo Targeting of Neuroactive Steroid and Immune Networks for Depression in People Living With HIV
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Phase 1 Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
Status: , Estimated PCD: 2025-12-01
Clinical trial
Pilot Study on Effects of Hydrogen Rich Water on Quality of Life of Patients Treated With Radiotherapy for High Grade Gliomas.
Status: Active (not recruiting), Estimated PCD: 2025-07-05
Clinical trial
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Status: Completed, Estimated PCD: 2024-05-30
Clinical trial
Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
" Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia " The pediaPREM Study.
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Ability of Oral Oxandrolone to Aid in Rehabilitation and Outcomes of Multiligament Knee Reconstructions: A Double-Blind, Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase Ib, Double-Blind, Placebo-Controlled, Single-site Trial to Determine the Safety and Efficacy of a Novel Renal-Specific Peptide, ANX-042, in Enhancing GFR Without Significant Hypotension in Human Cardiorenal Syndrome (CRS): ANX-042 Aim #1
Status: , Estimated PCD: 2024-12-01
Clinical trial
Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.
Status: Withdrawn, Estimated PCD: 2018-12-15
Clinical trial
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM): Can it Increase the Success of Transition to Naltrexone?
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine (RIVA-AP): a Randomized, Placebo-controlled Trial
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Trial of Micronutrient Supplementation in Patients With Heart Failure
Status: Completed, Estimated PCD: 2013-08-01
Clinical trial
Safety and Feasibility of Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Effect of Donepezil on Glycemic Control in Type II Diabetics
Status: Terminated, Estimated PCD: 2023-09-12
Clinical trial
Pharmacological Treatment of ADHD in Young Children
Status: Completed, Estimated PCD: 2008-08-01
Clinical trial
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
Status: Completed, Estimated PCD: 2023-08-29
Clinical trial
The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement
Status: Completed, Estimated PCD: 2023-09-22
Clinical trial
Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing in Vitro Fertilization Embryo Transfer: A Prospective, Multicentre, Randomised, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control - a Randomized, Double-blind, Placebo-controlled, Non-inferiority Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial
Status: Completed, Estimated PCD: 2023-12-20
Clinical trial
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects (11038)
Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
NMDA Receptor Modulation for the Treatment of Cognitive Impairment and Perceived Stress in Bipolar I Disorder
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
Low Dose Thyroid Hormone, Mitochondrial Fatty Acid Oxidation, and Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2029-03-31
Clinical trial
Ertugliflozin to Reduce Arrhythmic Burden in Implantable Cardioverter-defibrillators (ICD)/Cardiac Resynchronisation Therapy(CRT) patientS (ERASe-Trial) - a Phase III Study
Status: Terminated, Estimated PCD: 2023-06-23
Clinical trial
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy: A Phase II Randomized Study by UNICANCER With the Cooperation of AFSOS
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Status: Completed, Estimated PCD: 2022-03-23
Clinical trial
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia
Status: , Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Status: Recruiting, Estimated PCD: 2025-07-16
Clinical trial
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Peripheral Modulation of Muscle Stiffness and Spasticity
Status: Recruiting, Estimated PCD: 2024-11-16
Clinical trial
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Status: Withdrawn, Estimated PCD: 2023-09-27
Clinical trial
The Effect of Delta-8-THC vs Delta-9-THC on Simulated Driving Performance and Measures of Impairment
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Immune Mechanisms of Vitamin D in a Randomized Controlled Trial to Reduce Chronic Pain After Burn
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Use of Single-Dose Oral Methadone for Pain Management in Outpatient Arthroscopic Hip and Knee Procedures
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Microdosing Psychedelics to Improve Mood
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
An Inflammatory Challenge Using Endotoxin
Status: Completed, Estimated PCD: 2023-11-14
Clinical trial
Effects of a Single Dose of Amisulpride on Functional Brain Changes During Reward- and Motivation-related Processing
Status: Completed, Estimated PCD: 2023-09-18
Clinical trial
Study to Evaluate Safety, Tolerability, and Early Efficacy of Oral E-B-FAHF-2 in Subjects With Mild-To-Moderate Crohn's Disease
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Safety and Efficacy of Multiple Doses of the PAINLESS Nerve Growth Factor CHF6467 in Paediatric Subjects With Optic Pathway Glioma (OPG). A Randomized Clinical Trial (RCT)
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
An Adaptive, Randomized, doublE-blind, Placebo-controlled, Prospective, Pharmacological interVention Study In Participants With Long COVID-19 Syndrome: REVIVE-TOGETHER Trial
Status: Recruiting, Estimated PCD: 2024-10-18
Clinical trial
Effects of the Orexin Receptor Antagonist Suvorexant on Sleep Architecture and Delirium in the Intensive Care Unit: A Multi-Centric Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Clinical Study of hAESCs on Prevention of Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
Status: Not yet recruiting, Estimated PCD: 2025-07-31
Clinical trial
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates (CTOT-44)
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Drugs Brain and Behavior
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Decentralized Phase II Randomized Controlled Trial of Atorvastatin in Resected High-Risk Melanoma
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
Master Protocol for Early Treatment and Post-Exposure Prophylaxis of COVID-19 Adaptive Platform Trial PROTECT-APT 1
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis
Status: Terminated, Estimated PCD: 2024-01-04
Clinical trial
Motor Plasticity Enhancement of Spaced iTBS Trains: a Randomized, Placebo-controlled, Crossover Trial of D-cycloserine.
Status: Completed, Estimated PCD: 2021-10-06
Clinical trial
Randomized, Placebo-controlled Crossover Trial Evaluating Topical Lidocaine Patch(es) for Mechanical Neck Pain.
Status: Completed, Estimated PCD: 2023-06-02
Clinical trial
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
Status: Completed, Estimated PCD: 2023-09-08
Clinical trial
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Status: Not yet recruiting, Estimated PCD: 2028-08-30
Clinical trial
Recovery of Joint Cartilage in Adults With Knee Osteoarthritis by Use of Mesenchymal Stromal Cells Derived From Human Umbilical Cord: Randomized Controlled Clinal Trial With Clinical and Radiologic Outcomes
Status: Not yet recruiting, Estimated PCD: 2026-07-31
Clinical trial
Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen
Status: Completed, Estimated PCD: 2021-11-29
Clinical trial
Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study
Status: Completed, Estimated PCD: 2023-01-16
Clinical trial
A Split-Face, Double-Blind, Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage
Status: Not yet recruiting, Estimated PCD: 2023-08-31
Clinical trial
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea
Status: Completed, Estimated PCD: 2019-11-25
Clinical trial
Hormonal Mechanisms of Sleep Restriction - Axis Study
Status: Active (not recruiting), Estimated PCD: 2020-10-30
Clinical trial
Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Laser-assisted in Situ Keratomileusis (LASIK)
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
Ibuprofen With or Without Acetaminophen for Acute, Non-radicular Low Back Pain: A Randomized Trial
Status: Completed, Estimated PCD: 2019-09-30
Clinical trial
A Randomized, Double Blind, Placebo-Controlled Trial to Investigate the Effect of Vitamin C, Hydrocortisone and Thiamine on the Outcome of Patients With Septic Shock
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled, Intervention Study for the Efficacy and Safety of "BST104" (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects
Status: Completed, Estimated PCD: 2018-07-02
Clinical trial
Prospective Randomized Controlled Trial Analyzing the Efficacy of Oral Administration of Tranexamic Acid in Spine Surgery.
Status: Completed, Estimated PCD: 2021-12-30
Clinical trial
A Multicenter Trial of Autologous Bone Marrow Mononuclear Cells for the Treatment of Adult Severe Traumatic Brain Injury
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO
Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
Influence of Orexin Antagonism on Motivation for Cocaine
Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
Status: Recruiting, Estimated PCD: 2032-12-31
Clinical trial
OMEGA-3 FATTY ACIDS AS FIRST-LINE TREATMENT IN PAEDIATRIC DEPRESSION. A Phase III, 36-week, Multi-centre, Double-blind, Placebo-controlled Randomized Superiority Study
Status: Completed, Estimated PCD: 2022-03-24
Clinical trial
Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy: a 12-month, Double-blind, Randomized, Placebo-controlled Trial With a 12-month, Double-blind, Placebo-free Extension Phase.
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of THB335 in Healthy Participants
Status: Recruiting, Estimated PCD: 2025-03-15
Clinical trial
Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Status: Completed, Estimated PCD: 2023-04-03
Clinical trial
A Phase 1b Multiple Oral Dose Study to Evaluate the Pharmacological Effect, Safety and Tolerability of ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Status: Terminated, Estimated PCD: 2022-12-16
Clinical trial
A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)
Status: Active (not recruiting), Estimated PCD: 2023-01-18
Clinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Randomized, Participant- and Investigator-blinded, Sponsor Open-label, Placebo-controlled, Single and Multiple Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
Status: Completed, Estimated PCD: 2024-01-18
Clinical trial
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose MK-5475 in Participants With Pulmonary Hypertension Associated With COPD
Status: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Deuremidevir Hydrobromide for Suspension in Hospitalized Infants Infected With Respiratory Syncytial Virus.
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Multicentre, SAD, and MAD Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV Treatment of CALY-002 in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
Status: Completed, Estimated PCD: 2024-04-02
Clinical trial
A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Overactive Bladder Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Status: Recruiting, Estimated PCD: 2025-08-05
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19.
Status: Completed, Estimated PCD: 2022-08-16
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-Way Crossover Phase I Thorough QTc Study to Investigate the Effect on QTcF of Single Doses of Baxdrostat Compared With Placebo, Using Open-label Moxifloxacin as a Positive Control, in Healthy Participants
Status: Active (not recruiting), Estimated PCD: 2024-05-13
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Ic Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Participants With Overweight or Obesity
Status: , Estimated PCD: 2024-08-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy
Status: Completed, Estimated PCD: 2024-03-15
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3872386 in Healthy Participants, a Multiple-Ascending Dose Study of LY3872386 in Patients With Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Healthy Participants.
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, And Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Participants
Status: Recruiting, Estimated PCD: 2024-09-24
Clinical trial
A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability and Pharmacokinetics of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase I, Single Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-site, Parallel-group, Dose-finding Trial to Evaluate the Efficacy and Safety of Different Doses of Subcutaneously Administered LEO 138559 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-12-09
Clinical trial
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2026-11-25
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF EFFICACY AND SAFETY OF ENZALUTAMIDE IN COMBINATION WITH EXEMESTANE IN PATIENTS WITH ADVANCED BREAST CANCER THAT IS ESTROGEN OR PROGESTERONE RECEPTOR-POSITIVE AND HER2-NORMAL
Status: Active (not recruiting), Estimated PCD: 2016-09-23
Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) for the Prevention of SARS-CoV-2 Infection in a Population of 18 Years of Age and Older.
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
Status: Completed, Estimated PCD: 2020-02-06
Clinical trial
A Randomized, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses as Well as the Food Effect of Orally Administered ATH-399A in Healthy Adult Participants
Status: Completed, Estimated PCD: 2024-04-24
Clinical trial
Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of ART-123
Status: Completed, Estimated PCD: 2018-02-01
Clinical trial
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2025-07-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy: Amended Protocol to Include a Lutikizumab Open-Label Sub-study in Subjects Naïve to Biologic Therapy
Status: Recruiting, Estimated PCD: 2026-01-24
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2020-03-16
Clinical trial
A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2023-09-20
Clinical trial
A Multi-Center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CTAP101 Extended-release Capsules to Treat Secondary Hyperparathyroidism in Pediatric Subjects of Ages 8 to <18 Years With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2025-12-19
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects.
Status: Completed, Estimated PCD: 2017-11-01
Clinical trial
A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-3595 in Subjects With Insulin Resistance
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Double-Blind, Placebo-Controlled, Crossover Study of Sacrosidase for the Treatment of Subjects With Fructan Intolerance
Status: Completed, Estimated PCD: 2024-01-22
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-03-07
Clinical trial
A Phase 2, Two-Stage, Serial Cohort Dose Escalation and Expansion Study of a Single Intravenous Infusion of HBI 3000 for the Conversion of Atrial Fibrillation (AF) of Recent Onset
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-11-22
Clinical trial
A Double-blind, Placebo-controlled, Exploratory Randomised Clinical Trial to Assess the Safety and Efficacy of IFB-088 Plus Riluzole 100 mg vs Placebo Plus Riluzole 100 mg in Patients With Bulbar-onset Amyotrophic Lateral Sclerosis.
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
Status: Completed, Estimated PCD: 2023-12-21
Clinical trial
A Multicenter Randomized Double-blinded Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of SCT-I10A or Placebo Plus Docetaxel in Treating Advanced Squamous Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-02-23
Clinical trial
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Status: Terminated, Estimated PCD: 2021-11-03
Clinical trial
A Phase 1/1b, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Subjects With Chronic Hepatitis B (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)
Status: Terminated, Estimated PCD: 2023-06-15
Clinical trial
A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of LP-001 Injection in Healthy Subjects Following Single and Multiple Doses
Status: Active (not recruiting), Estimated PCD: 2024-01-02
Clinical trial
A Multicenter, Randomized, Double-blind, Double Dummy，Placebo and Positive Controlled，Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Ankylosing Spondylitis (AS)
Status: Not yet recruiting, Estimated PCD: 2025-02-27
Clinical trial
A Blinded, Randomized Controlled Study Investigating the Safety of Ortho-R® for Rotator Cuff Repair Compared With Standard of Care
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Status: Terminated, Estimated PCD: 2023-12-12
Clinical trial
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of VRG50635 in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Status: Active (not recruiting), Estimated PCD: 2024-01-11
Clinical trial
A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia
Status: Terminated, Estimated PCD: 2023-03-30
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Status: Active (not recruiting), Estimated PCD: 2025-05-05
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Status: Active (not recruiting), Estimated PCD: 2023-08-24
Clinical trial
Multicentre, Double-blind, Randomised Clinical Trial to Evaluate and Compare the Efficacy and Safety of Hemorrane Plus (Hemorrane® + Benzocaine) With Hemorrane® and With Placebo in Patients With Uncomplicated Haemorrhoids
Status: Terminated, Estimated PCD: 2024-01-04
Clinical trial
A Phase I, Open Label, First In Humans (FIH), Single Dose Level Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 1, 3-Part, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lu AG22515 (APB-A1) in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-08-05
Clinical trial
A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Post-Traumatic Stress Disorder
Status: Terminated, Estimated PCD: 2022-08-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed, Estimated PCD: 2019-10-03
Clinical trial
Randomized, Double-Blind, Study to Assess Low-Dose Naltrexone and Acetaminophen Combination in the Prevention of Episodic Migraine in Adults
Status: Completed, Estimated PCD: 2018-07-26
Clinical trial
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azeliac Acid Gel and Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea.
Status: Completed, Estimated PCD: 2017-03-31
Clinical trial
A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia
Status: Active (not recruiting), Estimated PCD: 2023-08-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Efficacy and Safety of ATX01 (Topical Amitriptyline Hydrochloride 15% w/w) in Adult Patients With Pain Due to Erythromelalgia (EM)
Status: Completed, Estimated PCD: 2024-02-29
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Oral Norovirus Vaccine Expressing GI.1 VP1 Administered Orally to Health Stable Older Adult Volunteers 55-80 Years of Age
Status: Completed, Estimated PCD: 2022-01-04
Clinical trial
A Phase III, Multicenter, Randomized, Active Reference, Double Blind, Double-dummy Study in Japanese Female Participants to Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Status: Recruiting, Estimated PCD: 2023-09-11
Clinical trial
Multicenter Double-blind Placebo-controlled Randomized Clinical Trial of the Efficacy and Safety of Tenoten for Children in 12-week Treatment of Children With Anxiety Disorders
Status: Completed, Estimated PCD: 2011-10-28
Clinical trial
Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2024-05-08
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus With an up to 52-Week Long-term Extension
Status: Terminated, Estimated PCD: 2024-02-29
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability, Pharmacokinetics of AHB-137 With Single Ascending Doses and Multiple Ascending Doses in Healthy Volunteers and Initial Efficacy With Multiple Ascending Doses in Chronic Hepatitis B Patients
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.
Status: Completed, Estimated PCD: 2021-08-01
Clinical trial
Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS)
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of ZX-7101A Tablets to Evaluate the Efficacy and Safety in the Treatment of Uncomplicated Influenza in Adolescents
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects
Status: Completed, Estimated PCD: 2011-10-01
Clinical trial
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
Status: Completed, Estimated PCD: 2022-07-21
Clinical trial
A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677
Status: Completed, Estimated PCD: 2023-06-27
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
Status: Terminated, Estimated PCD: 2022-04-11
Clinical trial
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD)
Status: Recruiting, Estimated PCD: 2024-05-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum
Status: Terminated, Estimated PCD: 2018-06-28
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Severe Alopecia Areata
Status: Not yet recruiting, Estimated PCD: 2025-06-24
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Status: Completed, Estimated PCD: 2021-07-15
Clinical trial
A Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
A Phase 1, First Time in Man Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST-1024 in Healthy Subjects and Otherwise Healthy Subjects With Elevated Triglycerides
Status: Completed, Estimated PCD: 2022-06-20
Clinical trial
A Phase 1, Single-blind, Dose-escalation Study to Assess the Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV)
Status: Withdrawn, Estimated PCD: 2024-05-31
Clinical trial
A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older
Status: Completed, Estimated PCD: 2021-10-28
Clinical trial
A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2017-12-15
Clinical trial
A Randomized Double-blind Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study II)
Status: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age
Status: Completed, Estimated PCD: 2023-06-19
Clinical trial
A Multi-center, Randomized, Double-Blind Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
Status: Not yet recruiting, Estimated PCD: 2025-02-28
Clinical trial
Randomized, Controlled, Double-blind, Placebo-controlled, Multi-center Hypothesis-finding Trial to Compare the Efficacy and Safety of a 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel and Placebo in the Treatment of Acute Soft Tissue Injuries of the Lower Extremities
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
Status: Terminated, Estimated PCD: 2022-08-12
Clinical trial
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Biological Activity, Safety, and Pharmacokinetics of PU-AD in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Withdrawn, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects
Status: Active (not recruiting), Estimated PCD: 2022-08-20
Clinical trial
International, Multicenter, Double Blind, Placebo-controlled, Randomized Clinical Study of Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344
Status: Completed, Estimated PCD: 2023-03-29
Clinical trial
A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Completed, Estimated PCD: 2012-02-01
Clinical trial
A Randomized Double-blind Placebo-controlled Comparative Multicenter Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg (Sandoz dd, Slovenia) in the Treatment of Patients With Acute Uncomplicated Respiratory Tract Infections
Status: Completed, Estimated PCD: 2022-12-18
Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics After 2-weeks Administration of CPL207280 (GPR40 Agonist) in Subjects With Type 2 Diabetes (T2D)
Status: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)
Status: Completed, Estimated PCD: 2018-09-19
Clinical trial
A Randomized, Double-Blind, Placebo-controlled Single-Dose Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Administration of Budigalimab in Adult People Living With HIV-1 (PLWH)
Status: Completed, Estimated PCD: 2022-10-11
Clinical trial
An Exploratory Phase 2, 2-part, Randomized, Double-blind, Placebo-controlled Study With a Long-term, Open-label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
Status: Completed, Estimated PCD: 2020-10-09
Clinical trial
A Clinical Trial Collecting Data From Routine Ophthalmological Examinations of Patients Who Were Randomized to Either Finerenone or Placebo in the Two Bayer-sponsored Phase 3 Clinical Trials FIDELIO-DKD and FIGARO-DKD to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic Retinopathy
Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Phase 3,Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy and Safety of Pyrotinib Plus Trastuzumab and Docetaxel Versus Placebo Plus Trastuzumab and Docetaxel in Patients With HER2 Positive MBC.
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain
Status: Completed, Estimated PCD: 2012-08-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (TBI).
Status: Completed, Estimated PCD: 2022-08-22
Clinical trial
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Status: Terminated, Estimated PCD: 2021-05-20
Clinical trial
Partially-blind, Randomized, Parallel Group, Placebo and Active Comparator-controlled Phase I Clinical Trial to Evaluate the Photosensitivity Potential of BI 730357
Status: Completed, Estimated PCD: 2020-09-09
Clinical trial
Phase 2b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of IV VIS410 in Addition to Oseltamivir Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support
Status: Completed, Estimated PCD: 2018-11-22
Clinical trial
A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
Status: Terminated, Estimated PCD: 2020-11-25
Clinical trial
Comparison Between the Effect of Dexmedetomidine, Melatonin and Pregabalin on Hypotensive Anesthesia in Patients Undergoing Functional Endoscopic Sinus Surgery
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers
Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
Status: Terminated, Estimated PCD: 2020-10-29
Clinical trial
A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Voclosporin (23.7 mg Twice Daily) With Placebo in Subjects With Lupus Nephritis
Status: Completed, Estimated PCD: 2021-10-07
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNM005 and to Characterize the Pharmacodynamics of TNM005 and VARIZIG in Healthy Adult Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A 2-Part, Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
Status: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2012-05-16
Clinical trial
Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan Cream
Status: Completed, Estimated PCD: 2006-05-01
Clinical trial
A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)
Status: Terminated, Estimated PCD: 2022-03-12
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Therapeutic Effect and Safety of LPTAT in Children With Myopia
Status: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia - A PhaseⅠb/Ⅱ Randomized, Double-Blind, Placebo-Controlled Clinical Study
Status: Completed, Estimated PCD: 2020-12-22
Clinical trial
A Randomised, Double Blind, Placebo Controlled, Parallel Group Comparative Study of the Efficacy, Safety and Tolerability of Sublingual Cannabis Based Medicine Extracts and Placebo in Patients With Intractable Neuropathic Pain Associated With Spinal Cord Injury
Status: Completed, Estimated PCD: 2005-01-01
Clinical trial
A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-Blind, Placebo- and Positive Controlled, Crossover, Thorough QT/QTc Study to Evaluate the Effects of a Therapeutic and Supratherapeutic Dose of Ecopipam (EBS-101) on Cardiac Repolarization in Healthy Subjects
Status: Completed, Estimated PCD: 2023-05-07
Clinical trial
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia
Status: Withdrawn, Estimated PCD: 2025-10-14
Clinical trial
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
A Phase 1, Placebo-Controlled, Double-Blind Study to Examine the Safety, Tolerability, and Pharmacokinetics of 500 mg KD025 Administered Twice Daily in Healthy Male and Post-Menopausal Female Subjects
Status: Completed, Estimated PCD: 2014-06-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus
Status: Completed, Estimated PCD: 2020-05-29
Clinical trial
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaine Sterile Topical Ophthalmic Solution
Status: Completed, Estimated PCD: 2022-12-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of BMB-101 in Fed and Fasted Adult Healthy Human Volunteers
Status: Completed, Estimated PCD: 2023-05-04
Clinical trial
FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis
Status: Completed, Estimated PCD: 2019-01-03
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single- and Multiple-ascending Doses of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
Status: Terminated, Estimated PCD: 2023-08-22
Clinical trial
A Phase 2 Safety Study of L1-79 for the Treatment of Autism
Status: Completed, Estimated PCD: 2017-12-01
Clinical trial
A Phase II 6-week, Randomized, Double-blinded, Placebo Controlled, Parallel Group Decentralised Clinical Trial to Evaluate Efficacy and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants
Status: Terminated, Estimated PCD: 2022-04-19
Clinical trial
A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects
Status: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-05-12
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Status: Terminated, Estimated PCD: 2017-08-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
Status: Terminated, Estimated PCD: 2022-08-05
Clinical trial
Proof-of-concept, Multi-center, Randomized, Double-blind, Placebo-controlled, Two-way Crossover Study to Investigate the Effect Strength of BAY 2586116 on the Apnea-hypopnea-index After Repetitive Nasal Doses Compared to Placebo in 80 Valid Participants With Moderate to Severe Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2021-08-17
Clinical trial
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease
Status: Completed, Estimated PCD: 2010-06-01
Clinical trial
A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder
Status: Completed, Estimated PCD: 2020-07-02
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Recruiting, Estimated PCD: 2026-12-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Status: Completed, Estimated PCD: 2019-12-02
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2023-08-30
Clinical trial
A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
Status: Terminated, Estimated PCD: 2021-09-23
Clinical trial
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease
Status: Completed, Estimated PCD: 2020-07-22
Clinical trial
A Multicenter, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AXER-204 in Subjects With Chronic Spinal Cord Injury
Status: Completed, Estimated PCD: 2022-06-21
Clinical trial
A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects
Status: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Doses Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic/Pharmacodynamics Characteristics of MY008211A Tablets in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2023-06-04
Clinical trial
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children:A Multi-centre, Double-blind, Randomized, Placebo-controlled, Clinical Trial
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Randomized, Double Blind, Parallel-groups, Non-inferiority Versus Flector® and Superiority Versus Placebo, Phase III Clinical Trial With Diclofenac Sodium 140 mg Medicated Plaster in Patients With Impact Injuries of the Limbs
Status: Completed, Estimated PCD: 2018-10-27
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Nasal Spray, 50 mcg With Flonase® Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
Status: Terminated, Estimated PCD: 2014-07-14
Clinical trial
A Phase 1, Single and Multiple Ascending Dose Study of NEU-723 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Status: Terminated, Estimated PCD: 2023-06-30
Clinical trial
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Status: Completed, Estimated PCD: 2022-10-12
Clinical trial
A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Study to Investigate the Safety and Pharmacokinetics of Single Ascending Supratherapeutic Doses of Elinzanetant in Healthy Participants
Status: Completed, Estimated PCD: 2023-02-07
Clinical trial
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Status: Completed, Estimated PCD: 2022-01-18
Clinical trial
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0472-0147 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2020-09-25
Clinical trial
Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension
Status: Completed, Estimated PCD: 2002-07-01
Clinical trial
A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled, Parallel Group Basket Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjögren's Syndrome or Mixed Connective Tissue Disease
Status: Terminated, Estimated PCD: 2023-02-07
Clinical trial
A Phase 3, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Chinese Population
Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase 2A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms (VMS) Associated With Menopause
Status: Completed, Estimated PCD: 2023-03-04
Clinical trial
A Controlled Phase 2 Study for Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
Status: Completed, Estimated PCD: 2019-08-30
Clinical trial
Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis
Status: Completed, Estimated PCD: 2020-05-29
Clinical trial
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Status: Completed, Estimated PCD: 2021-12-27
Clinical trial
A Multicenter, Randomized, Subject-assessor Blind, Placebo Controlled Phase Ⅱ Study to Determine the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat
Status: Completed, Estimated PCD: 2022-10-21
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
Status: , Estimated PCD: 2025-02-01
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active Rheumatoid Arthritis Failing Treatment With Methotrexate and TNF-alpha Blocking Agents
Status: Terminated, Estimated PCD: 2003-03-31
Clinical trial
Multiple Dose Escalation Study in a Randomized, Double-blind, Placebo-controlled Design to Investigate Safety, Tolerability, Pharmacokinetics, Drug-drug Interaction and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1830839 in Healthy Male Participants
Status: Completed, Estimated PCD: 2022-01-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
Status: Completed, Estimated PCD: 2022-06-06
Clinical trial
A Randomized, Placebo- and Active-controlled 4-way Crossover Study in Healthy Subjects to Evaluate the Effect of E4 on the QTc Interval
Status: Completed, Estimated PCD: 2021-07-14
Clinical trial
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation
Status: Completed, Estimated PCD: 2021-07-16
Clinical trial
A Randomized, Double-blind Phase III Clinical Study of ZSP1273 Tablets Compared With Placebo or Oseltamivir Patients With Acute Uncomplicated Influenza A
Status: Completed, Estimated PCD: 2023-04-01
Clinical trial
A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 Following Multiple Dose Administrations in Participants With Mild-to-Moderate SLE
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Status: Terminated, Estimated PCD: 2017-08-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group, 6-Month Study to Evaluate the Safety, Tolerability, and Potential Efficacy of Monthly Trappsol® Cyclo™ Infusions in Patients With Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection
Status: Completed, Estimated PCD: 2019-09-05
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
A Double Blind, Placebo Controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain
Status: Terminated, Estimated PCD: 2022-09-27
Clinical trial
A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Three Intra-articular Injections of Ampion™ (4 mL) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2015-04-01
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine
Status: Recruiting, Estimated PCD: 2024-10-22
Clinical trial
A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Daily Bedtime TNX-102 SL in Participants With PTSD
Status: Withdrawn, Estimated PCD: 2022-11-08
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Sequential Therapy With CYTOFLAVIN® (NTFF POLYSAN, Russia), Solution for Intravenous Infusion and Enteric-coated Tablets, in the Complex Rehabilitation of Patients With Acute Stroke
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics Following a Single Oral Dose of IA-14069 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 171 in Subjects With Obesity
Status: Terminated, Estimated PCD: 2021-09-10
Clinical trial
Interventional, Randomized, Double-blind, Crossover, Placebo-controlled, Multiple-dose Lu AG06466 Phase 1 B Study in Patients With Focal Epilepsy Using EEG and PSG to Investigate Its Pharmacodynamic Effects on Prolonged Period of Inter- Icterical Spikes, Sleep and Neuroinflammation
Status: Terminated, Estimated PCD: 2022-04-14
Clinical trial
A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis
Status: Completed, Estimated PCD: 2023-10-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
Status: Terminated, Estimated PCD: 2009-12-22
Clinical trial
A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
Status: Completed, Estimated PCD: 2022-02-24
Clinical trial
A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy
Status: Completed, Estimated PCD: 2013-12-01
Clinical trial
Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid/Chronic Cutaneous Lupus Erythematosus
Status: Completed, Estimated PCD: 2023-05-25
Clinical trial
Beta-glucans as Immune Modulators Amongst Hospitalised Patients With COVID-19: A Pilot Randomised Trial
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short-term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport and Dysport NG) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport NG Following Repeated Treatments of Subjects With Cervical Dystonia
Status: Completed, Estimated PCD: 2012-05-01
Clinical trial
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-Controlled Induction Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Subjects in China With Moderately to Severely Active Crohn's Disease
Status: Recruiting, Estimated PCD: 2030-03-08
Clinical trial
A Single Center, Randomized, Placebo Controlled Phase Ⅱ Study to Determine the Dosing Interval and the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943
Status: Completed, Estimated PCD: 2023-07-27
Clinical trial
A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
Status: Completed, Estimated PCD: 2022-05-27
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
A Phase I, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0491-6075 Following Single Dose Administration to Healthy Participants and Multiple Doses to Participants With Dyslipidaemia
Status: Recruiting, Estimated PCD: 2025-02-03
Clinical trial
A Staged, Phase 1b/Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Efficacy of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients Using a Once or Twice Daily Sub-Cutaneous Injection Formulation
Status: Completed, Estimated PCD: 2014-08-01
Clinical trial
A Double-Blind, Placebo-Controlled Phase Followed by An Open-Label Phase to Evaluate the Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
Status: Completed, Estimated PCD: 2022-10-20
Clinical trial
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)
Status: Terminated, Estimated PCD: 2023-10-26
Clinical trial
A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Status: Completed, Estimated PCD: 2022-11-01
Clinical trial
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HIB210 in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Status: Completed, Estimated PCD: 2009-04-13
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of BxC-I17e Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
"A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"
Status: Completed, Estimated PCD: 2023-10-30
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of SVT-15652 Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Otomycosis)
Status: Completed, Estimated PCD: 2021-10-25
Clinical trial
A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) With an Optional Open Label Extension in Subjects With IgA Nephropathy
Status: Terminated, Estimated PCD: 2023-11-09
Clinical trial
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome
Status: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Control, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in Type 2 Diabetes Mellitus Patients
Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2023-09-20
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Status: Completed, Estimated PCD: 2022-10-17
Clinical trial
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
Status: Completed, Estimated PCD: 2022-07-05
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of AK102 in Patients With Heterozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2022-09-26
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
Status: Terminated, Estimated PCD: 2022-11-22
Clinical trial
A Phase 1 Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-457 in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-08-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 - The "EMPATHY" Trial
Status: Terminated, Estimated PCD: 2021-11-18
Clinical trial
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Bioavailability of ORG-129 After Single and Multiple Ascending Oral Doses (Including Food Interaction Effect) in Healthy Young Volunteers
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Completed, Estimated PCD: 2014-03-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-09-25
Clinical trial
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
A Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in Adult Women With Intrahepatic Cholestasis of Pregnancy and Elevated Serum Bile Acid Concentrations (OHANA).
Status: Terminated, Estimated PCD: 2022-12-07
Clinical trial
Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection
Status: Active (not recruiting), Estimated PCD: 2022-08-14
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study in 60 to 80-Year-Old Adults to Assess the Safety and Immunogenicity of BARS13
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1b/2a, Double-blinded, Placebo-controlled, Multiple Doses, 2 Step-up Study Evaluating the Safety, Tolerability, PK/PD and Efficacy of Systemic NS101 in Healthy Volunteers and SSNHL Patients
Status: Recruiting, Estimated PCD: 2025-06-19
Clinical trial
A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of Various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older
Status: Terminated, Estimated PCD: 2023-01-16
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY)
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis
Status: Withdrawn, Estimated PCD: 2026-01-16
Clinical trial
A First-in-Human, Single Ascending Dose and Pharmacokinetic/Pharmacodynamic Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2025 in Healthy Subjects
Status: Completed, Estimated PCD: 2024-01-30
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Safety and Immunogenicity Study of a Zoster Vaccine in Healthy Adults >= 40 Years
Status: Completed, Estimated PCD: 2020-04-30
Clinical trial
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Investigation of the Safety and Efficacy of Semaglutide s.c. in Combination With NNC0480-0389 in Participants With Type 2 Diabetes - a Dose Finding Study
Status: Completed, Estimated PCD: 2023-02-13
Clinical trial
A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
Multi-centre, Double-blind, Randomised, Active- and Placebo-Controlled, Confirmatory Trial to Demonstrate Efficacy and Safety of Traumed® Gel in Patients Having Acute Ankle Sprain
Status: Completed, Estimated PCD: 2020-11-18
Clinical trial
A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-06-24
Clinical trial
A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
Status: Completed, Estimated PCD: 2022-07-28
Clinical trial
A Phase 3, Double-blind, Randomized, Multicenter, Parallel Group, Placebo-controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjects From 5 to < 18 Years of Age With Overactive Bladder
Status: Terminated, Estimated PCD: 2023-07-07
Clinical trial
A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Status: Active (not recruiting), Estimated PCD: 2023-03-06
Clinical trial
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease
Status: Completed, Estimated PCD: 2023-12-04
Clinical trial
A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of JY09 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis
Status: Terminated, Estimated PCD: 2023-09-13
Clinical trial
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Parallel Treatment, Phase 2a, Double-blind, Randomized, Placebo-controlled, 4-arm Study to Evaluate the Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adult Aged 20 to 70 Years With Mild to Moderate COVID-19
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2019-09-24
Clinical trial
A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
A Phase IIa/IIb, Randomised, Double Blind, Placebo-controlled, Parallel-group Dose-finding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-week Treatment Period in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough
Status: Not yet recruiting, Estimated PCD: 2025-07-21
Clinical trial
Safety and Tolerability Study of Single Dose Escalations of TR02 (SLIT™ Amikacin) by Inhalation in Cystic Fibrosis Study Patients With Chronic Infections of Pseudomonas Aeruginosa
Status: Completed, Estimated PCD: 2005-02-08
Clinical trial
A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
Status: Terminated, Estimated PCD: 2022-09-06
Clinical trial
A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP.
Status: Completed, Estimated PCD: 2022-11-23
Clinical trial
A First in Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LC542019 in Healthy Subjects and Subjects With T2DM
Status: Completed, Estimated PCD: 2023-12-14
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Status: Terminated, Estimated PCD: 2022-09-02
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein HIV-1 Vaccines (PDPHV-201401) Co-administered With or Without Adjuvant GLA-SE in Repeated Doses, in Healthy, HIV-1 Uninfected Adult Participants
Status: Completed, Estimated PCD: 2023-12-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Status: Recruiting, Estimated PCD: 2029-09-18
Clinical trial
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Status: Active (not recruiting), Estimated PCD: 2024-08-19
Clinical trial
A Phase 1a Randomized, Double-blind, Placebo-controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Kindolor Tosylate in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Status: Completed, Estimated PCD: 2021-02-05
Clinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of a Single, Ascending Dose of WAL0921 in Healthy Subjects
Status: Completed, Estimated PCD: 2024-01-09
Clinical trial
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD)
Status: Recruiting, Estimated PCD: 2028-09-29
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ARINA-1 in Adult Participants With Non-CF Bronchiectasis (NCFBE) With Excess Mucus and Cough
Status: Completed, Estimated PCD: 2024-01-11
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old
Status: Active (not recruiting), Estimated PCD: 2018-07-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Status: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase I/IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effects After Intravenous Transplantation of Human Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Cerebral Infarction Disease
Status: Completed, Estimated PCD: 2017-04-01
Clinical trial
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Completed, Estimated PCD: 2018-01-19
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Study to Investigate the Efficacy & Safety of MBS2320 in Participants With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response to Methotrexate Alone
Status: Completed, Estimated PCD: 2023-12-28
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Status: Completed, Estimated PCD: 2024-01-03
Clinical trial
A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
Status: Withdrawn, Estimated PCD: 2025-07-07
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Status: Completed, Estimated PCD: 2015-07-01
Clinical trial
A Multi-Center, Randomized, Double-Blind, Placebo- (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain
Status: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ101 in Chinese Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2024-04-28
Clinical trial
A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2025-10-14
Clinical trial
A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight
Status: Recruiting, Estimated PCD: 2024-11-29
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Completed, Estimated PCD: 2018-09-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AX-158 Following Administration of Single and, Multiple Ascending Oral Doses and Food Effect Sub-study in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2022-11-16
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of S-217622 in the Prevention of Symptomatic SARS-CoV-2 Infection in Household Contacts of an Individual With Symptomatic COVID-19
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients With Diabetic Kidney Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-03
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Completed, Estimated PCD: 2015-12-14
Clinical trial
Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain After Abdominal Surgery - a Multicenter, Randomized, Double-blind, Placebo-parallel Controlled, Phase III Clinical Trial
Status: Completed, Estimated PCD: 2023-07-11
Clinical trial
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
Status: Recruiting, Estimated PCD: 2017-07-14
Clinical trial
A Dose-blocked-randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of DDN-A-0101 in Healthy Adults and Elderly Subjects
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
An Exploratory Study to Evaluate the Efficacy and Safety of TYNADOTE® Combined N-acetylcysteine in the Treatment of Acetaminophen Overdose
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma
Status: Completed, Estimated PCD: 2021-04-09
Clinical trial
A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
Status: Completed, Estimated PCD: 2023-04-12
Clinical trial
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung Disease
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Palmoplantar Pustulosis in Japan
Status: Completed, Estimated PCD: 2021-01-18
Clinical trial
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia
Status: Active (not recruiting), Estimated PCD: 2024-03-19
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Status: Completed, Estimated PCD: 2017-08-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
Status: Active (not recruiting), Estimated PCD: 2023-10-06
Clinical trial
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
Status: , Estimated PCD: 2024-01-31
Clinical trial
A Phase 1b-2, Multicenter, Trial To Evaluate The Efficacy, Safety, Pharmacokintetics, And Pharmacodynamics Of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects With Active Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment
Status: Recruiting, Estimated PCD: 2026-03-20
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
Status: Completed, Estimated PCD: 2022-11-27
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2019-10-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
Status: Active (not recruiting), Estimated PCD: 2022-01-05
Clinical trial
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2014-06-30
Clinical trial
A Phase I, Single-Dose, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, 3-Way Crossover Study to Evaluate the Effect of LOXO-305 on QTc Interval in Healthy Subjects
Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis
Status: Not yet recruiting, Estimated PCD: 2025-12-17
Clinical trial
A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Status: Recruiting, Estimated PCD: 2024-11-29
Clinical trial
A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-859)
Status: Active (not recruiting), Estimated PCD: 2022-10-03
Clinical trial
A Phase 1 Randomised, Double-Blind, Placebo-Controlled 3 Part Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7798 Following Single Ascending Dose Administration and Repeat Dose Administration in Healthy Subjects (Including Japanese and Chinese Subjects), and Patients With Crohn's Disease
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2021-01-06
Clinical trial
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Status: Completed, Estimated PCD: 2021-10-08
Clinical trial
A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia
Status: Completed, Estimated PCD: 2024-02-22
Clinical trial
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 474121 in Young and Elderly Healthy Male and Female Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design) and Evaluation of Midazolam Interaction in Young Healthy Male and Female Subjects (Nested, Open, Fixed-sequence, Intra-individual Comparison)
Status: Completed, Estimated PCD: 2021-10-07
Clinical trial
A Randomized, Single-blind, Placebo-controlled, Single/Multiple Dose, Dose Escalation, Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of CKR-051 After Transdermal Administration in Healthy Male Subjects.
Status: Completed, Estimated PCD: 2024-01-08
Clinical trial
Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Status: Recruiting, Estimated PCD: 2026-05-13
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures (REALIZE Trial)
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
Status: Active (not recruiting), Estimated PCD: 2024-07-06
Clinical trial
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-11-19
Clinical trial
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (MIRANDA)
Status: Recruiting, Estimated PCD: 2026-09-10
Clinical trial
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 2b, Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Status: Recruiting, Estimated PCD: 2025-11-25
Clinical trial
Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
Status: Recruiting, Estimated PCD: 2030-05-05
Clinical trial
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Status: Completed, Estimated PCD: 2020-09-23
Clinical trial
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
Status: Active (not recruiting), Estimated PCD: 2027-10-07
Clinical trial
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Randomized, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Single-Dose, Randomized, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age
Status: Active (not recruiting), Estimated PCD: 2025-07-05
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's Disease
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2025-10-02
Clinical trial
A Double-blind, Randomized, Placebo-controlled, 4-week, Phase 1/2 Trial in Young Adult Participants With Down Syndrome to Assess the Safety, Tolerability, Plasma Exposure, and Preliminary Indications of Pharmacodynamic Activity of AEF0217
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts
Status: Recruiting, Estimated PCD: 2024-05-11
Clinical trial
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Status: Recruiting, Estimated PCD: 2025-09-26
Clinical trial
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of PF-07899895 Administered as Immediate and Modified Release Formulations in Healthy Adult Participants
Status: Active (not recruiting), Estimated PCD: 2024-08-02
Clinical trial
A Phase III, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus (SLE) While on Background Standard of Care Therapy
Status: Recruiting, Estimated PCD: 2029-07-25
Clinical trial
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Terminated, Estimated PCD: 2021-04-27
Clinical trial
A Multi-Part, Phase 1 Study With Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single- And Multiple-Dose Escalation To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-07976016 In Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2024-09-05
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Status: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-05-19
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-1) With an Open-Label Extension
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are ≥18 to ≤ 65 Years
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2027-04-16
Clinical trial
A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children
Status: Recruiting, Estimated PCD: 2024-09-14
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Ascending Doses in Healthy Subjects, an Open-label Study to Assess the Relative Bioavailability and Food Effect of a Tablet Formulation of AZD6793 in Healthy Subjects and a Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Tablet Formulation of AZD6793 in Patients With Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2024-10-08
Clinical trial
A Phase III Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-2)
Status: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
A Phase 2a Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Burfiralimab(hzVSF-v13) Added to Disease-modifying Antirheumatic Drugs in Participants With Moderate to Severe RA
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-01-04
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 in Subjects Undergoing Complete Abdominoplasty
Status: Completed, Estimated PCD: 2019-05-16
Clinical trial
Clinical Protocol REN-007E - Extension Study: An Evaluation of Patient Reported Outcomes and Clinical Outcomes Through 12 Months Post-Cardiac Surgery in Patients Enrolled in Study REN-007
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis
Status: Not yet recruiting, Estimated PCD: 2027-08-27
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 474121 in Healthy Japanese Male Subjects (Doubleblind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2021-11-11
Clinical trial
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Participants (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder
Status: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
A Multicentre, Late Phase Clinical Trial to Establish the Efficacy and Safety of Repeat Dosing of Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase (eNOS) in Patients With Pulmonary Arterial Hypertension (PAH) on Top of Conventional Treatments
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 3, Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Immune Response and Safety of the Herpes Zoster Subunit Vaccine When Administered Intramuscularly on a 2-dose Schedule in Adults Aged 50 Years and Older in India
Status: Completed, Estimated PCD: 2022-10-11
Clinical trial
A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease
Status: Recruiting, Estimated PCD: 2027-04-26
Clinical trial
A Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Sleep Latency Effects of MK-6552 in Participants With Narcolepsy Type 1
Status: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Phase 1 Clinical Trial to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous GH002 in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-11-29
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Escalating Single and Multiple Doses of FB1003 in the Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-03-15
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients
Status: Completed, Estimated PCD: 2022-11-07
Clinical trial
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of PF-06954522 in Adult Participants With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2020-10-08
Clinical trial
A Randomized, Double-blinded，Multicenter，Phase II Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Placebo in Combination With Trastuzumab and Chemotherapy (XELOX) for Treatment of Locally Advanced or Metastatic Gastric Cancer (GC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Efficacy, and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
Status: Active (not recruiting), Estimated PCD: 2026-11-16
Clinical trial
A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants With Dyslipidemia
Status: Recruiting, Estimated PCD: 2024-11-13
Clinical trial
A Phase 2A Randomized, Placebo-Controlled Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
Status: Withdrawn, Estimated PCD: 2024-07-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia
Status: Active (not recruiting), Estimated PCD: 2024-02-20
Clinical trial
A Phase 3, Multi-Center, Double-Blind, Randomized, Efficacy and Safety Study of M108 Monoclonal Antibody Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Status: Recruiting, Estimated PCD: 2027-01-11
Clinical trial
VP-VLY-686-1301: A Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-09-24
Clinical trial
(AURORA) A Randomized, Double-blind, Placebo-Controlled Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX (PPIX) Concentrations in Participants With Erythropoietic Protoporphyria (EPP)
Status: Active (not recruiting), Estimated PCD: 2024-02-20
Clinical trial
A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Two Part, Phase I/II, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of the Safety and Efficacy of Topically Applied AMTX-100 CF in Adult Patients With Mild to Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
Status: Active (not recruiting), Estimated PCD: 2023-02-02
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Status: Recruiting, Estimated PCD: 2024-05-22
Clinical trial
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Status: Recruiting, Estimated PCD: 2029-06-25
Clinical trial
A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE
Status: Active (not recruiting), Estimated PCD: 2024-04-23
Clinical trial
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2019-05-28
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Completed, Estimated PCD: 2019-04-10
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 730357 in Japanese Healthy Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2019-04-26
Clinical trial
Multicenter Double-blinded Randomized Phase 2a Clinical Trial to Evaluate the Efficacy of SA001 for Dry Eye and Mouth Dryness in the Patients With Primary Sjögren's Syndrome
Status: Completed, Estimated PCD: 2022-02-25
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Status: Recruiting, Estimated PCD: 2025-03-17
Clinical trial
A Randomized, Multi-Center, Double Blinded, Self-Initiated, Single Treatment Study Comparing Sitavig® (Acyclovir) 50 mg Muco-adhesive Buccal Tablet to Placebo in the Treatment of Herpes Labialis in Immunocompetent Adults
Status: Active (not recruiting), Estimated PCD: 2023-07-19
Clinical trial
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Status: Active (not recruiting), Estimated PCD: 2023-10-13
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGA2115 in Adult Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-10-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Status: Active (not recruiting), Estimated PCD: 2022-02-07
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Completed, Estimated PCD: 2014-10-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.
Status: Terminated, Estimated PCD: 2023-04-19
Clinical trial
In Silico Non Interventional Secondary Use of Data Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
Status: Recruiting, Estimated PCD: 2026-05-03
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-15
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)
Status: Completed, Estimated PCD: 2016-05-01
Clinical trial
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2028-01-08
Clinical trial
A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events
Status: Recruiting, Estimated PCD: 2029-01-01
Clinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary Embolism
Status: Completed, Estimated PCD: 2019-08-05
Clinical trial
Analgesic Efficacy and Pharmacokinetic-pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 After Impacted Mandibular Third Molar Extraction - A Double-blind, Randomised, Placebo-controlled Study
Status: Completed, Estimated PCD: 2023-10-05
Clinical trial
A Phase 1, Randomized, Double-Blind, First-In-Human, Dose Escalation Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Status: Completed, Estimated PCD: 2019-11-01
Clinical trial
A Placebo-controlled, Participant, Investigator and Sponsor Blinded, Randomized Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Inclisiran Treatment Given as Single Subcutaneous Injection in Chinese Participants With Elevated Low-density Lipoprotein Cholesterol (LDL-C) Despite Treatment With LDL-C Lowering Therapies (ORION-14)
Status: Completed, Estimated PCD: 2021-10-18
Clinical trial
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Status: Completed, Estimated PCD: 2021-12-02
Clinical trial
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Status: Completed, Estimated PCD: 2023-06-05
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)
Status: Completed, Estimated PCD: 2022-06-14
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Status: Completed, Estimated PCD: 2021-01-11
Clinical trial
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)
Status: Active (not recruiting), Estimated PCD: 2027-10-31
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis
Status: , Estimated PCD: 2026-03-15
Clinical trial
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19
Status: Completed, Estimated PCD: 2021-05-07
Clinical trial
The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2
Status: Completed, Estimated PCD: 2022-02-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency
Status: Terminated, Estimated PCD: 2010-01-01
Clinical trial
Multiple-dose Safety, Pharmacokinetic and Pharmacodynamic Trial, in Subjects With Allergic Rhinitis
Status: Completed, Estimated PCD: 2022-07-12
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients
Status: Completed, Estimated PCD: 2021-04-16
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase Ib/IIa Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TNM001 Injection in Chinese Healthy Preterm and Term Infants
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of Subcutaneous ALXN1830 in Healthy Participants
Status: Terminated, Estimated PCD: 2021-12-14
Clinical trial
A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Etripamil in Healthy Chinese Subjects
Status: Completed, Estimated PCD: 2023-03-26
Clinical trial
The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial
Status: Terminated, Estimated PCD: 2023-02-13
Clinical trial
Interventional, Randomized, Double-Blind, Crossover, Placebo-Controlled, Exploratory Study Investigating the Effects of Lu AG06466 on BOLD fMRI Signals and Sleep Parameters in Patients With PTSD
Status: Completed, Estimated PCD: 2023-02-13
Clinical trial
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study
Status: Completed, Estimated PCD: 2017-12-04
Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN-151607) Injections Into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac Surgery
Status: Completed, Estimated PCD: 2022-03-24
Clinical trial
Single-center, Randomized, Double-blind, Single-dose, 3-way Crossover Study to Compare the Effects of Daridorexant and Placebo on Postural Stability, the Auditory Awakening Threshold, and Cognitive Function in the Middle-of-the-night Following Evening Administration to Healthy Adult and Elderly Subjects
Status: Completed, Estimated PCD: 2023-04-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
Status: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Multiple-Dose, Randomized, Double-Blind, Placebo- and Active-Controlled, Four-Arm, Parallel Group Thorough QT/QTc Study to Evaluate the Electrophysiologic Effects of Sativex.
Status: Completed, Estimated PCD: 2008-06-01
Clinical trial
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Status: Completed, Estimated PCD: 2022-05-04
Clinical trial
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Study Following Multiple Subcutaneous Injections of SHR-1222 in Postmenopausal Osteoporosis Patients
Status: Completed, Estimated PCD: 2022-07-18
Clinical trial
Randomized, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of TQB3616 Combined With Endocrine Therapy Versus Placebo Combined With Endocrine Therapy in Hormone Receptors (HR)-Positive and Human Epidermal GrowthFactor Receptor-2 (HER2) -Negative Breast Cancer Adjuvant Therapy
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function.
Status: Completed, Estimated PCD: 2002-08-01
Clinical trial
A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis.
Status: Completed, Estimated PCD: 2002-08-01
Clinical trial
A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)
Status: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab
Status: Completed, Estimated PCD: 2021-05-09
Clinical trial
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression (the "ACLR8-LR" Study)
Status: Not yet recruiting, Estimated PCD: 2024-04-27
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2012-01-31
Clinical trial
Exploring the Pharmacokinetic Characteristics of Different Doses of Naltrexone Implants in Patients With Alcohol Use Disorders
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-01-01
Clinical trial
A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.
Status: Completed, Estimated PCD: 2022-06-06
Clinical trial
A Double Blind, Randomized, Parallel Group, Placebo Controlled, Comparative Study of the Efficacy, Safety and Tolerability of Cannabis Based Medicine (CBM) Extracts in Patients With Cancer-related Pain.
Status: Completed, Estimated PCD: 2004-02-01
Clinical trial
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Status: Active (not recruiting), Estimated PCD: 2022-06-04
Clinical trial
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China
Status: Active (not recruiting), Estimated PCD: 2022-12-19
Clinical trial
A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single and Repeat-Dose, Multicenter, Exploratory Efficacy Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
Status: Completed, Estimated PCD: 2020-10-06
Clinical trial
A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-919 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)
Status: Completed, Estimated PCD: 2022-02-22
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX9003 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-07-14
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Single Administration of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
Status: Completed, Estimated PCD: 2022-07-13
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months
Status: Completed, Estimated PCD: 2022-01-26
Clinical trial
A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients
Status: Terminated, Estimated PCD: 2022-03-24
Clinical trial
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers
Status: Terminated, Estimated PCD: 2023-04-19
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Status: Completed, Estimated PCD: 2018-10-12
Clinical trial
VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China
Status: Completed, Estimated PCD: 2020-11-09
Clinical trial
A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy
Status: Completed, Estimated PCD: 2014-02-01
Clinical trial
A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause
Status: Completed, Estimated PCD: 2019-11-21
Clinical trial
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Status: Terminated, Estimated PCD: 2021-12-23
Clinical trial
A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Cross-over Study to Evaluate the Efficacy, Safety, and Immunogenicity of S-268019 for the Prevention of COVID-19
Status: Completed, Estimated PCD: 2022-12-19
Clinical trial
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Status: Terminated, Estimated PCD: 2021-07-12
Clinical trial
Masked, Placebo Controlled, Phase I Trial to Assess the Safety of Bosentan 5 mg/ml Ophthalmic Eyewash in Type II Diabetic Patients
Status: Completed, Estimated PCD: 2022-05-20
Clinical trial
A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age
Status: Terminated, Estimated PCD: 2022-09-08
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
Status: Completed, Estimated PCD: 2022-06-27
Clinical trial
Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A Multicenter, Double-blind, Placebo-controlled, Cross-over, Multiple (n=1) Trial.
Status: Active (not recruiting), Estimated PCD: 2023-04-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled Proof-of-pharmacology Study of EP395 in Healthy Adults
Status: Completed, Estimated PCD: 2023-06-21
Clinical trial
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis
Status: Completed, Estimated PCD: 2019-10-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of CU104 in Patients With Moderate to Severe Ulcerative Colitis
Status: Not yet recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
Status: Terminated, Estimated PCD: 2023-02-13
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD)
Status: Completed, Estimated PCD: 2017-11-02
Clinical trial
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
Status: Completed, Estimated PCD: 2018-07-24
Clinical trial
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19
Status: Terminated, Estimated PCD: 2023-06-12
Clinical trial
A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial With a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Status: Completed, Estimated PCD: 2022-04-05
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.
Status: Completed, Estimated PCD: 2020-03-02
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Status: Completed, Estimated PCD: 2023-10-19
Clinical trial
A Pharmacodynamic Study of Measured Glomerular Filtration Rate Assessed by Tc99m-DTPA in Patients With Chronic Kidney Disease and Type 2 Diabetes
Status: Terminated, Estimated PCD: 2012-11-01
Clinical trial
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis
Status: Active (not recruiting), Estimated PCD: 2026-11-30
Clinical trial
A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.
Status: Completed, Estimated PCD: 2016-05-13
Clinical trial
A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 1815368 Administered as Oral Solution to Healthy Male Subjects (SRD Part), and a Randomised, Open-label, Single-dose, Three-way Cross-over Part Investigating Relative Bioavailability of BI 1815368 as Tablet Versus Oral Solution and Tablet With and Without Food in Healthy Male Subjects (BA Part)
Status: Completed, Estimated PCD: 2022-10-18
Clinical trial
ALTERNATIVE SCHEDULE STUDY FOR VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY.
Status: Completed, Estimated PCD: 2020-04-07
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Status: Completed, Estimated PCD: 2014-09-25
Clinical trial
A Double-blind, Multicentre, Multiple-dose, Enriched Enrolment, Randomized-withdrawal, Parallel-group Phase III Study With Lido-Patch and Corresponding Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)
Status: Completed, Estimated PCD: 2004-06-30
Clinical trial
A PhaseⅠRandomised, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Characteristics of the Oral Topical Use of GB001 Recombinant Peptide Spray in Chinese Healthy Adult Subjects
Status: Active (not recruiting), Estimated PCD: 2022-11-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU-5937 for the Treatment of Chronic Pruritus in Adult Subjects With Atopic Dermatitis
Status: Completed, Estimated PCD: 2021-10-04
Clinical trial
A Phase Ia, Randomized, Parallel-group, Double-blind, Placebo-controlled, Single-center, Multiple Dose Safety and Tolerability Study of Ascending Doses of BL-001 Oral Capsules Administered for 28 Days to Healthy Volunteers
Status: Completed, Estimated PCD: 2023-05-19
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2022-06-22
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.
Status: Completed, Estimated PCD: 2019-12-18
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Ankylosing Spondylitis
Status: Completed, Estimated PCD: 2022-12-06
Clinical trial
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Status: Completed, Estimated PCD: 2022-04-04
Clinical trial
A Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of ALXN2050 in Healthy Participants of Japanese Descent
Status: Completed, Estimated PCD: 2021-09-07
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multi- Centre, Adaptive Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For SARS-CoV-2 Infection
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Terminated, Estimated PCD: 2014-03-03
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2022-02-20
Clinical trial
A First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
A Double-blind, Randomised, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple-ascending Doses of Intravenously Administered STT-5058 in Otherwise Healthy Subjects With Elevated Triglyceride Levels and Single-ascending and Multiple Doses of Subcutaneously Administered STT-5058 in Otherwise Healthy Subjects With Elevated Triglyceride Levels and Patient Volunteers With Hypertriglyceridemia.
Status: Terminated, Estimated PCD: 2022-12-23
Clinical trial
The Effect of DLBS1033 in Patients With ST Elevation Acute Coronary Syndrome (STE-ACS) After Primary Percutaneous Coronary Intervention
Status: Terminated, Estimated PCD: 2023-01-01
Clinical trial
A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Tolerability and Safety of Hydrocodone Bitartrate Controlled-Release Capsules in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
Status: Completed, Estimated PCD: 2011-10-01
Clinical trial
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Status: Completed, Estimated PCD: 2017-04-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
Status: Active (not recruiting), Estimated PCD: 2020-10-08
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime-Boost Regimen of Ad26.ZEBOV and MVA-BN®-Filo in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2016-06-07
Clinical trial
A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2022-06-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)
Status: Completed, Estimated PCD: 2010-02-01
Clinical trial
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Status: Terminated, Estimated PCD: 2022-08-09
Clinical trial
A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simvastatin Pharmacokinetics in Healthy Male Japanese Participants
Status: Withdrawn, Estimated PCD: 2022-12-08
Clinical trial
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY
Status: Completed, Estimated PCD: 2023-09-13
Clinical trial
A Phase I Study of TS-142 in Non-Elderly Healthy Participants (Single Doses) (A Single Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TS-142 in Non-Elderly Participants)
Status: Completed, Estimated PCD: 2016-02-06
Clinical trial
A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease
Status: Completed, Estimated PCD: 2022-06-13
Clinical trial
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed
Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2019-03-27
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-and-Multiple-Ascending Subcutaneous Doses of DR10624
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Subcutaneous Administered SHR-1905 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-11-12
Clinical trial
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Completed, Estimated PCD: 2018-05-01
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of ARRY-502 in Adults With Persistent Asthma
Status: Completed, Estimated PCD: 2013-05-31
Clinical trial
A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Status: Completed, Estimated PCD: 2023-03-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Dose and Multiple Ascending Dose, Single Center Phase1 Study of Safety, Tolerability, Pharmacokinetics, and Electroencephalography of Intravenous GATE-202 in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2021-02-04
Clinical trial
A 2 Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA), and to Characterize the Effect of Food on the Pharmacokinetics in Healthy Male and Female Subjects
Status: Active (not recruiting), Estimated PCD: 2023-10-07
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Status: Completed, Estimated PCD: 2021-08-24
Clinical trial
A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity
Status: Recruiting, Estimated PCD: 2024-11-13
Clinical trial
A Multiple-dose, Single-centre, Randomised, Double-blind, Placebo-controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Chinese Subjects
Status: Completed, Estimated PCD: 2021-01-23
Clinical trial
A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines
Status: Completed, Estimated PCD: 2015-04-01
Clinical trial
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19
Status: Completed, Estimated PCD: 2022-04-12
Clinical trial
A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
Status: Completed, Estimated PCD: 2022-08-13
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis
Status: Completed, Estimated PCD: 2021-06-21
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154
Status: Completed, Estimated PCD: 2023-07-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, and Food Effect Evaluation Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of AQ280 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-07-10
Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain
Status: Terminated, Estimated PCD: 2021-04-29
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC
Status: Not yet recruiting, Estimated PCD: 2025-09-28
Clinical trial
A Long-Term Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase 1B Study to Examine the Pharmacokinetic and Pharmacodynamic Effects of INV-202 in Subjects With Metabolic Syndrome as Defined by Hypertriglyceridemia, Abdominal Obesity, and Impaired Glucose Tolerance Over 28 Days.
Status: Completed, Estimated PCD: 2022-09-11
Clinical trial
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease
Status: Terminated, Estimated PCD: 2023-08-01
Clinical trial
A Double-blind, Multi-center, Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 Weeks Extended Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients naïve to DMARD Treatment
Status: Completed, Estimated PCD: 2023-07-20
Clinical trial
A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection
Status: Completed, Estimated PCD: 2021-02-17
Clinical trial
Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction
Status: Completed, Estimated PCD: 2019-10-24
Clinical trial
A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)
Status: Completed, Estimated PCD: 2014-10-01
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of HH-120 Nasal Spray for Post-exposure Prophylaxis of SARS-CoV-2
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
Status: Terminated, Estimated PCD: 2019-07-17
Clinical trial
The Effect of Oral Semaglutide 50 mg Once-daily on Energy Intake, Gastric Emptying, Appetite, Control of Eating and Pharmacokinetics in Participants With Obesity
Status: Completed, Estimated PCD: 2022-09-29
Clinical trial
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4011499 in Healthy Participants
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
A RANDOMISED, PHASE 1B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RV299 AGAINST RESPIRATORY SYNCYTIAL VIRUS IN THE VIRAL CHALLENGE MODEL
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression
Status: Completed, Estimated PCD: 2019-07-05
Clinical trial
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Who Are at High Risk for RSV-related Disease Progression
Status: Terminated, Estimated PCD: 2022-03-31
Clinical trial
Use the Protocol Title. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect on the Pharmacokinetics of HRS-7085 in Healthy Participants
Status: Completed, Estimated PCD: 2023-03-16
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Status: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Phase 1, Randomized, Blinded, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PRS 220 Administered by Oral Inhalation in Healthy Subjects.
Status: Completed, Estimated PCD: 2023-08-11
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending-Dose Study to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of UPB-101 in Subjects With Asthma
Status: Completed, Estimated PCD: 2023-08-15
Clinical trial
A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
Status: Completed, Estimated PCD: 2017-11-03
Clinical trial
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Status: Terminated, Estimated PCD: 2021-10-29
Clinical trial
A Randomized, Double-Blind, Multiple Dose, 3-way Crossover, Exploratory Study to Assess the Pharmacodynamic Effects of SAGE-217 Capsules in Healthy Adults Using a 5-hour Phase Advance Model of Insomnia
Status: Completed, Estimated PCD: 2017-12-04
Clinical trial
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults
Status: Active (not recruiting), Estimated PCD: 2025-06-18
Clinical trial
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants
Status: Active (not recruiting), Estimated PCD: 2022-11-17
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Dose of NKTR-358 in Healthy Volunteers
Status: Completed, Estimated PCD: 2019-01-20
Clinical trial
A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Status: Completed, Estimated PCD: 2021-12-21
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Status: Terminated, Estimated PCD: 2023-06-27
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Terminated, Estimated PCD: 2010-11-18
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-67835989 in Healthy Participants
Status: Completed, Estimated PCD: 2022-05-18
Clinical trial
A US, Phase 3 Multicenter, Randomized, Double-blind, Placebo Controlled Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder (PaliSADe-2)
Status: Terminated, Estimated PCD: 2022-08-16
Clinical trial
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants With Dyslipidemia
Status: Completed, Estimated PCD: 2021-09-29
Clinical trial
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Status: Completed, Estimated PCD: 2016-06-01
Clinical trial
ZG-801 Phase III Trial - Randomized, Double-blind, Placebo-controlled Trial of ZG-801 in Patients With Hyperkalemia -
Status: Completed, Estimated PCD: 2022-12-26
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance
Status: Completed, Estimated PCD: 2021-11-08
Clinical trial
A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.
Status: Completed, Estimated PCD: 2015-07-10
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2022-04-08
Clinical trial
A Multiple-dose, Steady-state, Double-blind, Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Mild to Moderate Alzheimer's Disease and Healthy Adult Subjects ("MAD Study")
Status: Completed, Estimated PCD: 2023-04-14
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Participants With Moderate to Severe Asthma (VECTOR)
Status: Completed, Estimated PCD: 2022-03-21
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Completed, Estimated PCD: 2013-11-15
Clinical trial
A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes
Status: Completed, Estimated PCD: 2016-02-01
Clinical trial
A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A First-in-human, Randomised Double-blind, Placebo-controlled 2-part Study to Evaluate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single Ascending Doses of AX-202 in Healthy Subjects and Multiple Ascending Doses of AX-202 in Patients With Mild to Moderate Chronic Plaque Psoriasis.
Status: Recruiting, Estimated PCD: 2024-07-11
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Subcutaneous Doses of Cendakimab in Chinese Healthy Participants
Status: Completed, Estimated PCD: 2023-06-27
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
Status: Completed, Estimated PCD: 2016-04-01
Clinical trial
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression
Status: Terminated, Estimated PCD: 2023-09-08
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2021-12-15
Clinical trial
Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of CPL-01 in the Management of Postoperative Pain After Unilateral Distal First Metatarsal Bunionectomy With Osteotomy
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase I Clinical Study of CCX168 in Japanese and Caucasian Healthy Adult Males
Status: Completed, Estimated PCD: 2018-01-26
Clinical trial
A Phase 1, Multicentre, 2-Part, Randomised, Parallel-arm, Placebo-controlled, Partially Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Participants With Mild to Moderate Crohn's Disease
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
Status: Not yet recruiting, Estimated PCD: 2031-12-09
Clinical trial
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)
Status: Terminated, Estimated PCD: 2023-10-18
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study)
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Randomized, Double Blind, Placebo Controlled "First-in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses and Multiple Oral Doses of MBF-015 in Healthy Young Volunteers
Status: Completed, Estimated PCD: 2023-08-24
Clinical trial
A Single-blind, Randomised, Placebo-controlled, Parallel Group Design Phase I Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Different Doses (Part A) and Different Treatment Regimens (Part B) of BI 765845 Administered to Healthy Male Subjects and Female Subjects of Non-childbearing Potential
Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
Status: Completed, Estimated PCD: 2023-11-09
Clinical trial
To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.
Status: Not yet recruiting, Estimated PCD: 2024-08-12
Clinical trial
A Phase II, Blinded, Randomised, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (TRAIT)
Status: , Estimated PCD: 2026-11-01
Clinical trial
Efficacy and Safety of Topical Statin Eye Drop in the Management of Dry Eye Associated With Meibomian Gland Dysfunction
Status: Active (not recruiting), Estimated PCD: 2025-01-04
Clinical trial
A Multi-center, Random, Double Blind and Placebo Control Phase III Clinical Study on the Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Low-dose Naltrexone for Bladder Pain Syndrome: A Randomized Placebo-controlled Prospective Pilot Trial
Status: , Estimated PCD: 2024-07-01
Clinical trial
Impact of Lofexidine on Stress, Craving and Opioid Use
Status: Completed, Estimated PCD: 2024-01-30
Clinical trial
Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
Status: Active (not recruiting), Estimated PCD: 2025-07-18
Clinical trial
Influence of Orexin Antagonism on Motivation for Alcohol
Status: Recruiting, Estimated PCD: 2027-03-15
Clinical trial
A Randomized Placebo-controlled Trial of Adjunctive D-Cycloserine and Accelerated Intermittent Theta Burst Stimulation for Emerging Adults With Suicidal Ideation
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
Status: Completed, Estimated PCD: 2022-05-17
Clinical trial
Metformin as a Novel, Mechanistic Treatment of Fibromyalgia; a Proof of Concept RCT
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Painful Inflammatory Carpometacarpal-1 Osteoarthritis Treated With Intraarticular Steroids, Saline or an Occupational Therapy Intervention: the PICASSO Trial.
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Evaluating the Efficacy of Intranasal Oxytocin on Pain and Function Among Individuals Who Experience Chronic Pain: A Multisite, Placebo-controlled, Blinded, Sequential, Within-subjects Crossover Trial
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Effect of CBD on the GABAergic System in Patients With Fragile X Syndrome.
Status: Not yet recruiting, Estimated PCD: 2027-08-15
Clinical trial
Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRI
Status: Recruiting, Estimated PCD: 2028-03-30
Clinical trial
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Double-blind, Placebo-controlled Randomized Study Comparing the Effectiveness of a Single Dose of Betamethasone vs Placebo in Children With Symptomatic Adenovirus Infection
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
Efficacy of Preoperative Administration of Gabapentin in Managing Intraoperative and Postoperative Pain From Third Molar Extractions.
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Status: Recruiting, Estimated PCD: 2032-12-01
Clinical trial
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Status: Active (not recruiting), Estimated PCD: 2022-03-29
Clinical trial
Pre-operative Tamsulosin After Minimally Invasive Hysterectomy and Time to Spontaneous Void: A Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-06-24
Clinical trial
Assessment of Pain After Intra-articular Botulinum Toxin Injections in Carpometacarpal Osteoarthritis of the Thumb
Status: Recruiting, Estimated PCD: 2025-05-15
Clinical trial
A Prospective, Randomized, Double-blind Controlled Trial of Chlorpheniramine Pretransfusion Medication for Allergic Transfusion Reactions
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Angiotensin II as a First-line Vasopressor for Distributive Shock During or After Heart Transplantation or Durable Left Ventricular Assist Device Implantation: A Pilot Study
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in Post-Traumatic Stress
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
The Neural Correlates of and Effects of Methylphenidate on Acute Pain Dynamics
Status: Completed, Estimated PCD: 2024-04-26
Clinical trial
Randomized Double-blind Cross-over Placebo-controlled Trial to Study the Impact on Behavioral and Psychological Symptoms of Dementia of Medical Cannabinoids (CBD/THC) in Patients With Severe Dementia in Long-term Care Facilities in Geneva
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis
Status: Recruiting, Estimated PCD: 2028-08-26
Clinical trial
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Ketamine for The Rapid Treatment of Major Depression and Alcohol Use Disorder
Status: Completed, Estimated PCD: 2023-10-30
Clinical trial
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants
Status: Recruiting, Estimated PCD: 2025-10-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free Diet
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Children and Adolescents With ADHD
Status: Withdrawn, Estimated PCD: 2028-12-01
Clinical trial
Effects of LSD on Perceptual Decision-making in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Immunomodulation Therapy for Primary Prevention of Urinary Tract Infections in Patients With Spinal Cord Injury During First Rehabilitation: a Randomized Controlled Pilot Study
Status: Completed, Estimated PCD: 2023-09-04
Clinical trial
The Role of Hemolysis in Promoting Thrombosis During Mechanical Circulatory Support With Continuous Flow Pumps (Aim 2)
Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
A Phase II Placebo Controlled Study of the Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant/Intolerant Meniere's Disease (CR-MD) and Corticosteroid-Resistant/Intolerant Autoimmune Inner Ear Disease Disease (CR-AIED)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Slow-release CArvedilol in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure (CARE-preserved HF): A Prospective Randomized, Double-Blinded, Multicenter Study
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder
Status: Completed, Estimated PCD: 2023-03-14
Clinical trial
A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Subarachnoid Hemorrhage
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Clinical trial
Reducing Pain and Opioid Use With CBD
Status: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
A Pilot, Randomized, Placebo-Controlled Trial Evaluating the Treatment of Premenstrual Dysphoric Disorder With Oral Contraceptives in Bipolar Disorder.
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
Gulf War Illness Inflammation Reduction Trial
Status: Completed, Estimated PCD: 2023-10-19
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Adaptive, First-in-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Avenanthramide
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
The Impact of Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment
Status: Not yet recruiting, Estimated PCD: 2027-08-01
Clinical trial
Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
Investigation of Pregabalin Therapy and Complex Rehabilitation in Treating Chronic Fatigue Associated With Post-COVID Syndrome
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Placebo Controlled Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without Human Immunodeficiency Virus (HIV) Infection and Their Infants
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)
Status: Completed, Estimated PCD: 2022-10-01
Clinical trial
Autonomic Determinants of Postural Tachycardia Syndrome (Chronic Pilot Study 2)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Cannabinoids, Learning, and Memory
Status: Active (not recruiting), Estimated PCD: 2018-08-10
Clinical trial
Targeting Neural, Behavioral and Pharmacological Mechanisms of Drug Memories in Drug Addiction With Methylphenidate
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs: A Randomized Controlled Trial in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Randomized Double Blinded Placebo-Controlled Trial of Semaglutide to Prevent Weight Gain Following Liver Transplantation
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Impact of Perioperative Maintenance or Interruption of Low-dose Aspirin on Recurrence Rate and Thrombotic Events After Burr-hole Drainage of Chronic Subdural Hematoma: a Randomized, Placebo Controlled, Double Blinded Study
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Autonomic Determinants of Postural Tachycardia Syndrome (Acute Pilot Study 1)
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis Associated With Acute Necrotizing Soft Tissue Infections, The NASTI HAT Trial
Status: Terminated, Estimated PCD: 2023-05-16
Clinical trial
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy Humans
Status: Completed, Estimated PCD: 2023-01-17
Clinical trial
Combination of Curcumin and Berberine Therapy in the Treatment of Post Acute Diverticulitis (AD) Symptomatic Uncomplicated Diverticular Disease (SUDD)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Sit Less, Interact and Move More (SLIMM) 2 Study
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Topical Nitroglycerin Prior to Trans-radial Coronary Angiography: a Phase 2, Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Arterial Stiffness, Cognition and Equol
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 1: Interleukin-5 Antagonists - Mepolizumab and Reslizumab
Status: Completed, Estimated PCD: 2021-04-04
Clinical trial
Efficacy and Safety of Oral Semaglutide Versus Placebo Both in Combination With Metformin and/or Basal Insulin in Children and Adolescents With Type 2 Diabetes
Status: Recruiting, Estimated PCD: 2025-02-17
Clinical trial
A New Intervention to Improve Function in Veterans With Anxiety and Depression
Status: Not yet recruiting, Estimated PCD: 2028-06-30
Clinical trial
Triheptanoin's Effect on Fatty Acid Oxidation and Exercise Tolerance in Patients With Debrancher Deficiency, Glycogenin-1 Deficiency and Phosphofructoinase Deficiency at Rest and During Exercise. A Randomized, Double-blind, Placebo-controlled, Cross-over Study
Status: Completed, Estimated PCD: 2019-08-28
Clinical trial
Effect of Pyridoxine as Add-on Therapy With Standard Treatment in Obsessive Compulsive Disorder Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus
Status: Active (not recruiting), Estimated PCD: 2022-11-11
Clinical trial
Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Cobimetinib for BRAF-wild-type or Mutated Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study
Status: Completed, Estimated PCD: 2021-10-05
Clinical trial
A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Metformin as add-on Therapy in Non-diabetic Patients With Abdominal Aortic Aneurysm (MetAAA Study)
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Prebiotic Inulin to Limit Antimicrobial-Resistant Infections During Critical Illness: A Phase II Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2023-11-23
Clinical trial
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial
Status: Terminated, Estimated PCD: 2022-06-20
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19
Status: Completed, Estimated PCD: 2021-05-12
Clinical trial
Salicylic Augmentation in Depression
Status: Terminated, Estimated PCD: 2021-02-16
Clinical trial
Cardiovascular Consequences of Hypogonadism in Men
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Prospective, Multi-center, Double Blind Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule Versus Placebo in Severe Irritable Bowel Syndrome (IBS).
Status: Not yet recruiting, Estimated PCD: 2028-07-15
Clinical trial
Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled Trial
Status: Completed, Estimated PCD: 2021-09-10
Clinical trial
Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients: a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2027-05-12
Clinical trial
Effect of Topical CBD Oil on Pain Scores for Hallux Disorders: A Randomized Controlled Trial
Status: Terminated, Estimated PCD: 2023-05-15
Clinical trial
Medication Development for Protracted Abstinence in Alcoholism: Suvorexant Versus Placebo
Status: Completed, Estimated PCD: 2022-11-08
Clinical trial
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma
Status: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
PAciFy Cough: A Multicentre, Double Blind, Placebo Controlled, Crossover Trial of Morphine Sulfate for the Treatment of PulmonAry Fibrosis Cough
Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD
Status: Terminated, Estimated PCD: 2018-07-27
Clinical trial
Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans
Status: Completed, Estimated PCD: 2021-11-18
Clinical trial
Hypomania, Amphetamine, and Preferences for Sweets
Status: Completed, Estimated PCD: 2018-08-09
Clinical trial
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Status: Completed, Estimated PCD: 2022-01-05
Clinical trial
The Effect of Donepezil on Wound Healing
Status: Recruiting, Estimated PCD: 2023-07-30
Clinical trial
MitoQ for the Treatment of Metabolic Dysfunction in Asthma
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
Milrinone in Congenital Diaphragmatic Hernia
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder
Status: Completed, Estimated PCD: 2024-02-26
Clinical trial
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Status: Recruiting, Estimated PCD: 2024-08-20
Clinical trial
The Effect of Preoperative Maltodextrin on Cardiac Function in Cardiac Surgery Patients With Reduced Left Ventricular Ejection Fraction: A Randomized, Controlled, Double-blind, Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2)
Status: Recruiting, Estimated PCD: 2025-04-23
Clinical trial
A Single Center, Randomized, Double-masked, Vehicle-controlled Phase 2b Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora CAC®) Model
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Status: Active (not recruiting), Estimated PCD: 2023-11-08
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Terminated, Estimated PCD: 2023-03-20
Clinical trial
A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2021-06-24
Clinical trial
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Suppositories for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Status: Terminated, Estimated PCD: 2024-01-30
Clinical trial
Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3839840 Following Oral Dosing in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-06-13
Clinical trial
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
Status: Recruiting, Estimated PCD: 2025-09-08
Clinical trial
A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure
Status: Not yet recruiting, Estimated PCD: 2025-11-24
Clinical trial
Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.
Status: Completed, Estimated PCD: 2022-03-14
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single-ascending Dose, Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics, and Immunogenicity of STSA-1301 Subcutaneous Injection in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase I-II, Dose-escalation, Double-blinded, Placebo-controlled, and Dose-finding Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Osteoarthritis of the Knee
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Status: Terminated, Estimated PCD: 2016-02-22
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-09-17
Clinical trial
Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder
Status: Completed, Estimated PCD: 2024-01-17
Clinical trial
A Randomised, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of 5-grass Mix SLIT-drops in Adults With Grass Pollen-induced Rhinoconjunctivitis
Status: Completed, Estimated PCD: 2023-09-26
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of XG005 Tablets in Subjects Undergoing Bunionectomy
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of LIV001 in Healthy Subjects and Multiple Doses of LIV001 in Subjects With Mild-to-Moderate Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-05-29
Clinical trial
International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants S Trimer Protein Vaccine (SCTV01E) in a Vaccinated Population
Status: Completed, Estimated PCD: 2024-01-15
Clinical trial
A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Subjects With Mild-to-moderate Asthma and in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-11-14
Clinical trial
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Healthy Adults, 60 to 75 Years of Age
Status: Completed, Estimated PCD: 2024-01-24
Clinical trial
A Phase I/Ⅱ Randomized Controlled Proof-of-concept Study to Evaluate the Safety and Efficacy of JINZHEN Granules for Oral Solution in Participants With Mild to Moderate COVID-19
Status: Completed, Estimated PCD: 2023-05-12
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
Status: Completed, Estimated PCD: 2022-11-16
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Mechanism of Action and Clinical Effect of BI 655130 in Patients With Fistulizing Crohn's Disease
Status: Completed, Estimated PCD: 2021-12-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe HS
Status: Completed, Estimated PCD: 2022-12-23
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-02-14
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated HR-positive, HER2-negative Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Intra-articular Injections of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Status: Active (not recruiting), Estimated PCD: 2025-10-03
Clinical trial
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
Status: Completed, Estimated PCD: 2023-11-09
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Status: Completed, Estimated PCD: 2023-01-19
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies
Status: Completed, Estimated PCD: 2023-11-16
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
Status: Recruiting, Estimated PCD: 2025-02-22
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients With Active Psoriatic Arthritis
Status: Terminated, Estimated PCD: 2024-01-02
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
Status: Active (not recruiting), Estimated PCD: 2024-01-26
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Status: Active (not recruiting), Estimated PCD: 2021-01-21
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3888130B in Healthy Participants Aged 18-55 Inclusive
Status: Completed, Estimated PCD: 2023-10-12
Clinical trial
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients With Systemic Lupus Erythematosus
Status: Terminated, Estimated PCD: 2022-12-14
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM310 Under Background Treatment in Patients With Seasonal Allergic Rhinitis Inadequately Controlled With Current Recommended Therapies
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Dosing, Dose-Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect After Oral Administration of HGR4113 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo Controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in Acutely Psychotic Patients With Schizophrenia, Followed by an Open-label Extension Phase
Status: Terminated, Estimated PCD: 2023-10-12
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Status: Recruiting, Estimated PCD: 2029-10-31
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Five-part Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2020 in Healthy Participants
Status: Completed, Estimated PCD: 2023-12-24
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
Status: Terminated, Estimated PCD: 2017-07-03
Clinical trial
Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.
Status: Completed, Estimated PCD: 2023-11-09
Clinical trial
Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Status: Recruiting, Estimated PCD: 2025-05-07
Clinical trial
ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation
Status: Recruiting, Estimated PCD: 2025-09-24
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneously Administered ALN-TTRSC04 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Two-part, Randomized, Investigator- and Participant- Blinded, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MHS552 in Adult Participants With Systemic Lupus Erythematosus (SLE)
Status: Terminated, Estimated PCD: 2023-06-04
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Status: Terminated, Estimated PCD: 2023-06-14
Clinical trial
AN INTERVENTIONAL, PHASE 1b, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, MULTI-CENTER, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SISUNATOVIR IN PEDIATRIC PARTICIPANTS UP TO AGE 60 MONTHS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT INFECTION (LRTI)
Status: Recruiting, Estimated PCD: 2024-10-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered HEC96719 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis
Status: Completed, Estimated PCD: 2023-09-05
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2023-09-29
Clinical trial
A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A First-In-Human, Two-Part Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Subjects
Status: Completed, Estimated PCD: 2024-01-18
Clinical trial
A Phase Ib, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of M5049 Administered Orally in SLE and CLE Participants Treated With Standard of Care
Status: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin™) In Stable Cystic Fibrosis Patients
Status: Completed, Estimated PCD: 2012-05-07
Clinical trial
A Phase 1b Multiple Ascending Dose (MAD) Study of EC5026 in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects With Presbyopia
Status: Completed, Estimated PCD: 2024-04-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Multi-center, Randomized, Placebo- and Active-controlled, Parallel-group, 24-week Proof of Concept and Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Heart Failure
Status: Recruiting, Estimated PCD: 2025-10-27
Clinical trial
A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia
Status: Completed, Estimated PCD: 2010-09-01
Clinical trial
Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb
Status: Completed, Estimated PCD: 2023-04-26
Clinical trial
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2024-01-20
Clinical trial
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 Gel to Clinically Noninfected Chronic Diabetic Foot Ulcers (cDFU)
Status: Terminated, Estimated PCD: 2022-05-18
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and PK of LY3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
Status: Recruiting, Estimated PCD: 2024-09-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2023-08-02
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Double-Blind, Placebo/Active Controlled, Single Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Patients With Various Allergic Diseases
Status: Recruiting, Estimated PCD: 2024-08-26
Clinical trial
An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
Status: Terminated, Estimated PCD: 2013-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression
Status: Completed, Estimated PCD: 2023-11-28
Clinical trial
A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Randomized Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Pelacarsen (TQJ230) in US Black/African American & Hispanic Patient Populations With Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Status: Not yet recruiting, Estimated PCD: 2027-06-21
Clinical trial
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2023-03-23
Clinical trial
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults
Status: Completed, Estimated PCD: 2022-02-25
Clinical trial
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Apremilast 30 mg Twice Daily in Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Recruiting, Estimated PCD: 2025-03-17
Clinical trial
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-634
Status: Completed, Estimated PCD: 2023-05-24
Clinical trial
A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Phase 1/2 Prospective Randomized Placebo Controlled Study to Assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Administered Sublingual and in Inhalation Concomitantly With BAT (Best Available Care) as Compared to Placebo and BAT for the Treatment of Moderate to Severe COVID-19 Patients.
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Status: Recruiting, Estimated PCD: 2025-05-07
Clinical trial
A Phase 1, Single And Multiple Ascending Dose, Food Effect, and Drug-Drug Interaction Study With Itraconazole, Midazolam and Fexofenadine Of Orally Administered AV078 In Healthy Adults
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-Blind, Controlled Phase 2 Pilot Study of Manualized 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in 12 Subjects With Treatment-Resistant Posttraumatic Stress Disorder (PTSD) - Canada
Status: Terminated, Estimated PCD: 2015-09-10
Clinical trial
A Phase 2A, Randomized, Double-blind, Placebo-controlled, Single Dose, Sequential Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 With Ticagrelor Pretreatment in Older and Elderly Subjects and With High-Dose Ticagrelor Pretreatment in Healthy Younger Subjects
Status: Completed, Estimated PCD: 2019-10-09
Clinical trial
A Phase 3 Trial of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Status: Terminated, Estimated PCD: 2023-08-08
Clinical trial
APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Status: Active (not recruiting), Estimated PCD: 2022-06-20
Clinical trial
A Single-Dose Study Evaluating Different Dose Levels and Subcutaneous Infusion Durations on Safety, Pharmacokinetics, and Pharmacodynamics of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour
Status: Not yet recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2015-11-01
Clinical trial
A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients With Brain Contusion
Status: Terminated, Estimated PCD: 2023-06-27
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Status: Not yet recruiting, Estimated PCD: 2026-08-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
An Adaptive, Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of add-on Eptinezumab Treatment to Brief Educational Intervention for the Preventive Treatment of Migraine in Patients With Dual Diagnosis of Migraine and Medication Overuse Headache
Status: Recruiting, Estimated PCD: 2024-10-23
Clinical trial
A Phase Ib/III Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
Status: Terminated, Estimated PCD: 2023-08-29
Clinical trial
Post-surgical Scars After the Use of CACIPLIQ20: A Randomized, Double-blind, Placebo -Controlled Trial
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1, First-in-Human, Single-center, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MDI-1228_mesylate Ophthalmic Solution by Local Instillation in Adult Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)
Status: Recruiting, Estimated PCD: 2026-05-27
Clinical trial
A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia
Status: Withdrawn, Estimated PCD: 2023-12-01
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses of BI 765423 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2024-03-19
Clinical trial
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution - A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial (Whistler)
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Solriamfetol in Subjects With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
Status: Recruiting, Estimated PCD: 2024-07-26
Clinical trial
Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects With Episodic Migraine
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-07-23
Clinical trial
A Phase 2a, Randomized, Double-blind, Study of TAS5315 in Chronic Spontaneous Urticaria Patients With an Inadequate Response to H1-antihistamines
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Clinical trial
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Status: Completed, Estimated PCD: 2020-10-07
Clinical trial
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects
Status: Completed, Estimated PCD: 2022-05-26
Clinical trial
Phase II Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study
Status: , Estimated PCD: 2026-12-31
Clinical trial
An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 3 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Status: Recruiting, Estimated PCD: 2026-05-15
Clinical trial
A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.
Status: Recruiting, Estimated PCD: 2027-09-11
Clinical trial
A Safety and Immunogenicity Extension Study of GPNV-001
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Multicenter, Randomized Double-blind Study to Compare the Safety and Performance of a Combination of A-PRP and XLHA Prepared With the RegenMatrix Medical Device, to Hylan G-F 20 XLHA and Placebo to Treat Moderate/Severe Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2025-02-21
Clinical trial
Phase 2 Multi-Center, Double-Masked, Randomized, 28-Day Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients With Ocular Hypertension (OHT) or Open Angle Glaucoma (OAG)
Status: Completed, Estimated PCD: 2020-11-05
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LMT503 in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Double-blind, Placebo-controlled, Phase 2b, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients With Tourette Syndrome
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Status: Recruiting, Estimated PCD: 2029-09-30
Clinical trial
A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-03-22
Clinical trial
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Status: Completed, Estimated PCD: 2012-08-01
Clinical trial
US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise
Status: Recruiting, Estimated PCD: 2025-08-12
Clinical trial
Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Status: Active (not recruiting), Estimated PCD: 2012-06-06
Clinical trial
BOTOX® (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Status: Recruiting, Estimated PCD: 2025-12-27
Clinical trial
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers Following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2027-05-19
Clinical trial
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or Obesity
Status: Recruiting, Estimated PCD: 2024-11-27
Clinical trial
A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence
Status: Completed, Estimated PCD: 2022-08-18
Clinical trial
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With SoRbitol Dehydrogenase (SORD) DEficiency
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
Status: Active (not recruiting), Estimated PCD: 2024-07-10
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients
Status: , Estimated PCD: 2023-12-31
Clinical trial
Study in Male / Postmenopausal Female Participants With Mild to Moderate Arterial Hypertension to Investigate Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of BAY 3283142 in a Randomized, Multi-center, Placebo-controlled, Single-blind, Group Comparison Design
Status: Completed, Estimated PCD: 2023-01-03
Clinical trial
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-11-12
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of ABX464 Capsules in Healthy Japanese Volunteers.
Status: Completed, Estimated PCD: 2022-02-18
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Examine the Safety, Tolerability and Pharmacokinetic Profile of Single Oral Doses of SLx-2119 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2009-12-09
Clinical trial
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN
Status: Completed, Estimated PCD: 2018-07-19
Clinical trial
Prospective, Randomised, DBPC, Double-dummy, Multicenter CT of Efficacy and Safety With IT in Patients With Controlled Mild to Moderate Allergic Asthma and Rhinitis/Rhinoconjunctivitis, Allergic to D. Pteronyssinus and/or D. Farinae.
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered VMX-C001 in Healthy Subjects (Part 1) and in Combination With Selected Direct Oral Anticoagulants (DOACs) in Healthy Older Subjects (Part 2)
Status: Completed, Estimated PCD: 2023-02-03
Clinical trial
A Phase 1, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single and Multiple Ascending Doses of MBX 2109 in Healthy Participants
Status: Completed, Estimated PCD: 2023-06-20
Clinical trial
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Status: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, and Efficacy of RV521 in the Treatment of Adult Subjects Who Have Undergone Hematopoietic Cell Transplantation (HCT) With a Documented Upper Respiratory Tract Infection (URTI) With Respiratory Syncytial Virus (RSV)
Status: Withdrawn, Estimated PCD: 2023-06-30
Clinical trial
A Phase 2, Placebo-Controlled, Randomized, Blinded Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ARD-101 in Adults With Obesity
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects With Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Status: Completed, Estimated PCD: 2019-11-27
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase III Clinical Trial for the Efficacy and Safety of Fugliglitinate Benzoate Tablets in Patients With Type 2 Diabetes Who Cannot be Effectively Controlled by Metformin
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Status: Completed, Estimated PCD: 2019-01-12
Clinical trial
A Phase III, Multicentre, Prospective, Double Blind, Randomised, Placebo Controlled Study, Assessing the Efficacy and Safety of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury
Status: Completed, Estimated PCD: 2013-09-01
Clinical trial
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
Status: Completed, Estimated PCD: 2006-09-01
Clinical trial
Multi-centre, Randomised, Double Blind, Placebo-controlled, Parallel, Phase III Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Two-part, Phase I, Double-blind, Placebo- and Positive-controlled Crossover Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Subjects
Status: Completed, Estimated PCD: 2022-10-07
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2)
Status: Active (not recruiting), Estimated PCD: 2024-05-17
Clinical trial
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Status: Completed, Estimated PCD: 2019-07-30
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Status: Completed, Estimated PCD: 2023-08-23
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects With Moderate to Severe Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate to Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2024-01-19
Clinical trial
A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)
Status: , Estimated PCD: 2025-12-01
Clinical trial
A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2023-01-11
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2022-05-16
Clinical trial
Efficacy and Safety of Recombinant Human Thymosin β4(NL005) for Injection in Patients With Acute Myocardial Infarction: a Phase IIb Clinical Study
Status: Completed, Estimated PCD: 2023-05-26
Clinical trial
A Randomized, Blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Potential Interaction of Tunodafil Hydrochloride Tablets and Alcohol in Healthy Chinese Male Participants
Status: Completed, Estimated PCD: 2023-03-08
Clinical trial
A Randomized, Multi-regional, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study to Assess the Safety and Efficacy of 6 Months Treatment With Tigulixostat in Gout Patients With Hyperuricemia
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients With Systemic Lupus Erythematosus
Status: Active (not recruiting), Estimated PCD: 2023-09-22
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled First-in-Human Study of Single and Multiple Doses of ALXN2080 in Healthy Participants
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma
Status: Completed, Estimated PCD: 2019-04-05
Clinical trial
A Prospective, Randomized, Placebo-controlled, Double-blinded, Multi-center, Phase IV, Exploratory Clinical Trial to Demonstrate the Effect of Improving the Walking Distance by GNX80 in Patients With Intermittent Claudication
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults
Status: , Estimated PCD: 2022-11-30
Clinical trial
A Phase 1, Randomized, Blinded, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALXN1210 Administered Intravenously to Healthy Subjects
Status: Completed, Estimated PCD: 2015-03-13
Clinical trial
Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL
Status: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy
Status: Completed, Estimated PCD: 2017-01-12
Clinical trial
A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung Disease
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection
Status: Completed, Estimated PCD: 2021-01-05
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IA-14069 in Healthy Subjects, With an Extension to Explore Any Drug-Drug Interaction Potential With Methotrexate (Part 1), and in Patients With Rheumatoid Arthritis, With Preliminary Assessment of Efficacy in Patients (Part 2)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Two-Stage, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19
Status: Terminated, Estimated PCD: 2022-08-12
Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients With Uncontrolled Blood Pressure
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Status: Completed, Estimated PCD: 2022-05-19
Clinical trial
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
Status: Completed, Estimated PCD: 2023-02-18
Clinical trial
A Phase 2, Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
Status: Withdrawn, Estimated PCD: 2022-10-01
Clinical trial
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency
Status: Completed, Estimated PCD: 2023-02-02
Clinical trial
A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Terminated, Estimated PCD: 2022-09-13
Clinical trial
Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women With NILM, ASC-US, LSIL or Low-grade CIN
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
Status: Terminated, Estimated PCD: 2022-09-28
Clinical trial
A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease
Status: Terminated, Estimated PCD: 2023-03-10
Clinical trial
Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants
Status: Completed, Estimated PCD: 2021-04-08
Clinical trial
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Cohort Study Investigating the Effect of EDP1815 in Participants for the Treatment of Mild, Moderate and Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2023-03-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment
Status: Completed, Estimated PCD: 2022-09-05
Clinical trial
A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Multiple Ascending Doses of CM326 Injection by Subcutaneous Administration in Healthy Subjects
Status: Completed, Estimated PCD: 2022-10-11
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
Status: , Estimated PCD: 2023-12-31
Clinical trial
A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label Extension
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Status: Completed, Estimated PCD: 2019-08-13
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of BXCL501 For The Treatment of Agitation Associated With Dementia
Status: Terminated, Estimated PCD: 2022-04-01
Clinical trial
GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor Administered Via a Dry Powder Inhaler Over 52 Weeks
Status: Completed, Estimated PCD: 2023-05-17
Clinical trial
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease
Status: Completed, Estimated PCD: 2016-02-01
Clinical trial
A Phase 1, 2-Part, Randomized, Double-Blind, Placebo-controlled, Multiple Dose Study to Test the Potential Interaction of a PDE5 Inhibitor With BMS-986278 and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986278 in Healthy Adult Participants (Part 1) and in Japanese Participants (Part 2)
Status: Completed, Estimated PCD: 2023-05-02
Clinical trial
A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee
Status: Completed, Estimated PCD: 2022-04-26
Clinical trial
A Phase Ib/IIa, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral Treatment With OST-122 in Patients With Moderate to Severe Ulcerative Colitis
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2018-04-24
Clinical trial
A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Status: Active (not recruiting), Estimated PCD: 2027-02-26
Clinical trial
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell Disease
Status: Terminated, Estimated PCD: 2022-03-02
Clinical trial
A Phase 1, Randomized, Double-blind，Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of 9MW3811 in Healthy Participants
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years
Status: Terminated, Estimated PCD: 2023-03-23
Clinical trial
A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3337641 in Japanese and Caucasian Healthy Subjects
Status: Completed, Estimated PCD: 2017-05-25
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07612577 (PF-06264006 [CTB] + PF-07338233 [AVP]) IN HEALTHY ADULT PARTICIPANTS
Status: Completed, Estimated PCD: 2023-06-23
Clinical trial
A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
Status: Completed, Estimated PCD: 2021-11-12
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Confirmatory Study For Intracordal Administration Of KP-100LI In Patients With Vocal Fold Scar
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults
Status: Completed, Estimated PCD: 2019-12-10
Clinical trial
A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1703 Injection Administered Subcutaneously in Healthy Subjects
Status: Completed, Estimated PCD: 2021-09-21
Clinical trial
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
Status: Terminated, Estimated PCD: 2021-03-11
Clinical trial
A Single and Multiple Assending Doses Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Characteristics and Food Effect After Administration of HHT120 Capsule in Healthy Subjects
Status: Withdrawn, Estimated PCD: 2023-02-15
Clinical trial
A Phase II, Double-blind, Parallel-group Comparative Study 2 of TS-091 in Patients With Narcolepsy
Status: Completed, Estimated PCD: 2018-12-13
Clinical trial
A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis
Status: Completed, Estimated PCD: 2021-06-21
Clinical trial
A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1, Double-Blinded, Placebo- and Active-Controlled, Randomized Study to Investigate the Potential of Soticlestat to Prolong the QTc Interval in Healthy Adult Participants
Status: Withdrawn, Estimated PCD: 2022-12-06
Clinical trial
Multicentre,Randomized,Double-Blind,Double-Dummy,3period,6Seq,Crossover,Active&Placebo,SD PD Study to Evaluate Therapeutic Equivalence of Test Tiotropium Bromide Inh. Powder to Reference SPIRIVA® HANDIHALER in Subjects w/COPD*
Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa
Status: Terminated, Estimated PCD: 2022-02-02
Clinical trial
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Status: Terminated, Estimated PCD: 2021-11-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing the Efficacy, Safety and Dose-response of Quinagolide Extended-release Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate to Severe Endometriosis-related Pain
Status: Completed, Estimated PCD: 2022-02-14
Clinical trial
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Terminated, Estimated PCD: 2021-12-30
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of B001 in Subjects With Aquaporin-4 Antibody (AQP4-IgG) Positive Neuromyelitis Optic Spectrum Disorder (NMOSD)
Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
Status: Terminated, Estimated PCD: 2008-11-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Withdrawn, Estimated PCD: 2024-08-01
Clinical trial
A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of LEO 153339 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-07-18
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo, Parallel-controlled Phase Ⅱ Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Patients With Active Ankylosing Spondylitis
Status: Completed, Estimated PCD: 2022-08-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of FTP 198 in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-02-26
Clinical trial
A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Efficacy, Tolerability and Safety of ESO-101 in Adult Patients With Active Eosinophilic Esophagitis
Status: Completed, Estimated PCD: 2023-10-09
Clinical trial
A Phase 1b, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Safety and Efficacy of Oral Zavegepant in Subjects With Mild Allergic Asthma
Status: Terminated, Estimated PCD: 2023-03-29
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2019-08-19
Clinical trial
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Status: Active (not recruiting), Estimated PCD: 2025-03-12
Clinical trial
Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Status: Completed, Estimated PCD: 2018-07-30
Clinical trial
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4004280 in Healthy Participants
Status: Completed, Estimated PCD: 2023-06-21
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above
Status: Completed, Estimated PCD: 2021-05-19
Clinical trial
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis
Status: Terminated, Estimated PCD: 2018-11-09
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
Status: Completed, Estimated PCD: 2023-07-03
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects With Heart Failure With Reduced Ejection Fraction
Status: Terminated, Estimated PCD: 2022-09-19
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Status: Active (not recruiting), Estimated PCD: 2025-06-18
Clinical trial
A Phase 1, Single-center, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TNP-2092 Capsules, and the Food Effect on the Pharmacokinetics of TNP-2092 Capsules After Single-dose Oral Administration in Healthy Subjects
Status: Completed, Estimated PCD: 2016-07-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.
Status: Terminated, Estimated PCD: 2022-07-12
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Response Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Status: Completed, Estimated PCD: 2020-05-01
Clinical trial
A Phase 1B, Repeated Dose Study, to Evaluate the Safety, PD and PK Profile of CM-101 in NAFLD Patients With Normal Liver Function Tests and Stable NAFLD/NASH Patients With NAFLD Activity Score (NAS) < 3-The SPARK Study
Status: Completed, Estimated PCD: 2020-04-27
Clinical trial
A Multicenter, Randomized, Double-Blind, Active-Controlled (BOTOX®) and Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines in Subjects of Chinese Origin
Status: Completed, Estimated PCD: 2023-01-29
Clinical trial
A Phase I, Single-center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK's Clostridium Difficile Investigational Vaccine Based on the F2 Antigen With or Without AS01B Adjuvant, When Administered Intramuscularly According to a 0, 1-month Schedule to Healthy Adults Aged Between 18-45 Years and Between 50-70 Years, Followed by an Additional Dose Administered in a Partial Blind Manner Within an Interval of Approximately 15 Months After Dose 2, in a Subcohort of Subjects Aged 50-70 Years
Status: Completed, Estimated PCD: 2022-05-10
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Status: Completed, Estimated PCD: 2018-08-01
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CT-996 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
Status: Terminated, Estimated PCD: 2023-05-18
Clinical trial
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers
Status: Completed, Estimated PCD: 2023-12-12
Clinical trial
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Completed, Estimated PCD: 2012-05-14
Clinical trial
A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
Status: Completed, Estimated PCD: 2022-04-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Chronic Cough
Status: Completed, Estimated PCD: 2023-04-13
Clinical trial
A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-12-15
Clinical trial
A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation
Status: Withdrawn, Estimated PCD: 2023-10-26
Clinical trial
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women
Status: Completed, Estimated PCD: 2015-07-03
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Status: Completed, Estimated PCD: 2020-03-12
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-11-02
Clinical trial
A Phase I Single-blind, Randomised, Placebo-controlled, Parallelgroup Design Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Harmacodynamics of Single Rising Doses of BI 3032950 Administered as Intravenous Infusion (Part A) or Subcutaneous Injection (Part B) to Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-09-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
Status: Terminated, Estimated PCD: 2020-11-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy
Status: Recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain
Status: Completed, Estimated PCD: 2022-02-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis
Status: Terminated, Estimated PCD: 2022-09-09
Clinical trial
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Multiple Ascending Dose Administration to Healthy Male Participants of Sub-Saharan West African Ancestry
Status: Completed, Estimated PCD: 2023-07-06
Clinical trial
A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
Status: Completed, Estimated PCD: 2006-12-01
Clinical trial
A Study to Evaluate the Efficacy and Safety of AK101 in Subjects With Moderate-to-severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2022-09-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Notalgia Paresthetica
Status: Completed, Estimated PCD: 2022-05-18
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Status: Terminated, Estimated PCD: 2021-09-28
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Completed, Estimated PCD: 2019-11-15
Clinical trial
A Phase 2a, Multi-center, Placebo-Controlled, Randomized, Assessor-blind Study to Assess the Safety & Efficacy of Parenteral TK-90 or Parenteral TK-90 Placebo to Patients Receiving Radiotherapy for Non-Metastatic Squamous Cell Carcinoma of Head and Neck.
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
Prospective, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Type 1 Diabetes Patients With Celiac Disease While Undergoing Periodic Gluten Exposure
Status: Terminated, Estimated PCD: 2022-12-19
Clinical trial
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Status: Completed, Estimated PCD: 2021-09-09
Clinical trial
A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients With Mild to Severe Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-10-13
Clinical trial
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel Phase IIb Clinical Trial for the Efficacy Assessment and Safety Evaluation by Treating CU01-1001 for 24 Weeks in Type 2 Diabetic Nephropathy Patients With Albuminuria
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase I, Randomized, Observer-blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV211 in Adult Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multisite, Phase 3 Study to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P) in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures
Status: Terminated, Estimated PCD: 2023-09-28
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Pivotal Study Assessing the Efficacy and Safety of 15 mg Twice a Day (BID) of SER150 in Well-controlled Type 2 Diabetic Patients With Diabetic Kidney Disease and Albuminuria in Treatment With an Angiotensin Converting Enzyme Inhibitor or an Angiotensin Receptor Antagonist
Status: Recruiting, Estimated PCD: 2025-01-26
Clinical trial
A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia
Status: Withdrawn, Estimated PCD: 2025-08-18
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2025-03-08
Clinical trial
Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH
Status: Completed, Estimated PCD: 2019-11-25
Clinical trial
A Randomised, Blinded, Parallel-controlled Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a COVID-19 mRNA Vaccine in Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-14 (NCT02960204)
Status: Completed, Estimated PCD: 2019-04-08
Clinical trial
A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 Administered as Multiple Intravenous Doses to Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-04-08
Clinical trial
A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19
Status: Completed, Estimated PCD: 2020-10-29
Clinical trial
A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection
Status: Terminated, Estimated PCD: 2022-05-10
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Status: Completed, Estimated PCD: 2021-06-04
Clinical trial
A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
Status: Completed, Estimated PCD: 2006-09-01
Clinical trial
Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes
Status: Completed, Estimated PCD: 2023-01-06
Clinical trial
A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF 04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE.
Status: Completed, Estimated PCD: 2011-08-16
Clinical trial
A Phase 1b, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, 2-Period Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Oral Administration of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease (NAFLD) And Hyperoxaluria
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase I/II Observer-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Hong Kong/125/2017-like (H7N9) Virus Vaccine With AS03 Adjuvant System, Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
Status: Completed, Estimated PCD: 2022-09-12
Clinical trial
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Completed, Estimated PCD: 2014-11-24
Clinical trial
A Phase I Urodynamic Study of the Opioid Antagonist, Naloxone and Intravenous Methylnaltrexone Reverse Opioid Effects on Bladder Function in Healthy Volunteers
Status: Completed, Estimated PCD: 2003-05-01
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2001 After a Single Subcutaneous Injection in Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-12-20
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers Followed by Open Label Treatment in Patients With PNH to Evaluate the Safety, Tolerability, PK and PD of ADX-038
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD)
Status: Completed, Estimated PCD: 2022-10-17
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability After Oral Administration of AJH-2947 in Healthy Korean or Caucasian Male Subjects
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2022-10-13
Clinical trial
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
Status: Completed, Estimated PCD: 2008-01-01
Clinical trial
Anti Viral Treatment in Mild Cognitive Impairment
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics
Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Management Of Pain After Cesarean Trial
Status: Completed, Estimated PCD: 2023-09-30
Clinical trial
The Effect of Lipoic Acid Natural Supplement on Cystine Stone Formation
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Clinical trial
A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months
Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Pulse Reduction On Beta-blocker and Ivabradine Therapy
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation
Status: Terminated, Estimated PCD: 2023-09-27
Clinical trial
Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers
Status: Active (not recruiting), Estimated PCD: 2027-12-31
Clinical trial
Brain Research in Aggression and Irritability Network (BRAIN): Building Evidence-Based Approaches to Managing Traumatic Brain Injury
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness
Status: Recruiting, Estimated PCD: 2025-01-10
Clinical trial
Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA) A Phase II, Prospective, Double-Blind Randomized Trial
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Noradrenergic Biomarkers in PTSD: Precision Medicine & Mechanisms
Status: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2018-03-19
Clinical trial
The Role of Cannabidiol in Anandamide-Related Improvement in Alexithymia and Health Outcomes
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
The Mechanism of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
Status: Recruiting, Estimated PCD: 2025-02-02
Clinical trial
A Phase 1, Randomized, 2-part, 7-way Cross-over (Part 1) and 7-way Cross-over (Part 2), Active Device Blinded, Single Dose Study in Mild Asthmatics Aged 18-65 to Assess the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152a (Test) and HFA-134a (Reference) Via Methacholine Bronchoprovocation and Systemic Pharmacodynamic Effects
Status: Not yet recruiting, Estimated PCD: 2024-10-15
Clinical trial
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-42X in Subjects With Obstructive Sleep Apnoea Who Are Intolerant, Non-Compliant, or Naïve to Positive Airway Pressure
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Clinical Evaluation of NMDA Modulator NYX-783 for OUD: Randomized, Double-blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of NYX-783 in Combination With Oxycodone (Study 1)
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Clinical and Biochemical Evaluation of the Use of Locally Delivered Metformin as an Adjunctive Therapy to Non Surgical Periodontal Treatment of Periodontitis Patients (Randomized Controlled Study)
Status: Completed, Estimated PCD: 2021-06-01
Clinical trial
Comparison of Postoperative Pain Score Between Perioperative Intravenous Ketamine and Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty Under General Anesthesia, A Prospective Randomized Controlled Trial Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized Controlled Trial of RyR2 Inhibition With Dantrolene and Susceptibility to Ventricular Arrhythmias in Patients With Structural Heart Disease.
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Cannabidiol on reward-and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder: A Double-blind, Placebo-controlled, Cross-over Trial
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
Effect of Pioglitazone on Mitochondrial Metabolism in Pulmonary Hypertension Due to Chronic Lung Disease
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
The Canadian Study of Arterial Inflammation in Patients With Diabetes and Recent Vascular Events: EvaluatioN of Colchicine Effectiveness (CADENCE)
Status: Recruiting, Estimated PCD: 2024-08-14
Clinical trial
A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Effect of Vitamin D Supplementation on Rate of Partial Clinical Remission in Children and Adolescents With Type 1 Diabetes
Status: Completed, Estimated PCD: 2014-06-01
Clinical trial
The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Effect of Oral Cimetidine in the Protoporphyrias
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders - A Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Prospective Multi-Center Randomized Study to Evaluate the Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 2b, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine, MTBVAC, Against TB Disease in Interferon Gamma Release Assay Positive Adolescents and Adults Aged 14-45 Years, Living in a TB Endemic Region.
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H2: VIR-7831 (GSK4182136))
Status: Completed, Estimated PCD: 2021-06-09
Clinical trial
A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1
Status: Recruiting, Estimated PCD: 2026-04-29
Clinical trial
A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)
Status: Recruiting, Estimated PCD: 2024-07-16
Clinical trial
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/∆NS1, Lot RSV#018A, or RSV 6120/F1/G2/∆NS1, Lot RSV#016A, Delivered as Nose Drops to RSV-seropositive Children 12 to 59 Months of Age and RSV-seronegative Infants and Children 6 to 24 Months of Age
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Comparative, Investigator-initiated Clinical Trial to Evaluate the Efficacy of Carnitine Orotate Complex _Godex® in Patients With Nonalcoholic Fatty Liver Disease
Status: , Estimated PCD: 2026-06-30
Clinical trial
A Clinical Trial Using Ganwei (HepatoKeeper) Herbal Essentials to Treat Non-Alcoholic Fatty Liver Disease
Status: Completed, Estimated PCD: 2023-03-14
Clinical trial
Glutamatergic Mechanisms in Opioid and Cocaine Co-Use
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Iraqi Traditional Medicine for Urinary Tract Symptoms: The Effect of Cinnamon on Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome; a Pilot Study
Status: Completed, Estimated PCD: 2019-06-30
Clinical trial
Efficacy and Safety of Moxidectin-albendazole Combination for Trichuris Trichiura Infections in School-aged Children: a Double-blind Randomised Controlled Superiority Trial
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study to Assess Safety and Efficacy of Anti-Human CD38 Monoclonal Antibody CM313 in the Treatment of Primary Immune Thrombocytopenia
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Inflammation-Induced CNS Glutamate Changes in Depression
Status: Terminated, Estimated PCD: 2019-11-27
Clinical trial
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-PCSK9 Monoclonal Antibody Injection in Subjects With Heterozygous Familial Hypercholesterolemia
Status: Completed, Estimated PCD: 2023-05-08
Clinical trial
Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
Status: Not yet recruiting, Estimated PCD: 2031-06-30
Clinical trial
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Status: Not yet recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Status: Terminated, Estimated PCD: 2024-03-21
Clinical trial
Role of Mitochondrial Dysfunction in the Response to Exercise in Patients With Advance Kidney Disease
Status: Recruiting, Estimated PCD: 2027-06-20
Clinical trial
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
Status: Recruiting, Estimated PCD: 2025-08-15
Clinical trial
Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study
Status: Active (not recruiting), Estimated PCD: 2024-10-25
Clinical trial
Multi Ethnic Study of Atherosclerosis Individualized Response to Vitamin D Treatment Study
Status: Completed, Estimated PCD: 2021-11-30
Clinical trial
The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Department for Renal Colics
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Canagliflozin Targeting Vascular Inflammation: An Ottawa Imaging Study - A Pilot Study
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Status: Completed, Estimated PCD: 2022-11-20
Clinical trial
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity
Status: Recruiting, Estimated PCD: 2025-10-13
Clinical trial
Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Preeclampsia Intervention 4 - A Triple Blind Phase III Randomised Controlled Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia
Status: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
Status: Recruiting, Estimated PCD: 2031-04-01
Clinical trial
A Single Center, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.
Status: Completed, Estimated PCD: 2024-04-16
Clinical trial
A Clinical Trial to Assess Whether Dexamethasone Addition to Standard Protocols for Non-Traumatic Rhabdomyolysis of Unknown or Genetic Etiologies Improves Patient Outcomes
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
Status: , Estimated PCD: 2027-02-02
Clinical trial
Inhibition of Small Conductance Calcium-Activated Potassium Current: A New Therapeutic Approach for Atrial Fibrillation
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery: a Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD: a Double-blind Multicentre Prospective Randomized Study.
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study
Status: Completed, Estimated PCD: 2022-03-21
Clinical trial
Aprepitant vs. Placebo for the Prevention of Postoperative Nausea and Vomiting: a Randomized, Double-blind Study in Patients Undergoing Laparoscopic Cholecystectomy
Status: Completed, Estimated PCD: 2010-11-01
Clinical trial
A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis Versus Oxycodone
Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
The Effect of Gabapentin on Post-Operative Pain in Minimally Invasive Sacrocolpopexy: A Randomized Controlled Pilot Study
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD
Status: Completed, Estimated PCD: 2023-11-20
Clinical trial
Influence of Medication on Functional Connectivity
Status: Completed, Estimated PCD: 2022-06-02
Clinical trial
An Oral Methylprednisolone Taper Within a Multimodal Analgesic Regimen After Total Knee Arthroplasty: a Double-Blind Randomized Placebo-Controlled Trial
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
Status: Not yet recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria With Inadequate Controll to Second Generation H1-antihistamines
Status: Not yet recruiting, Estimated PCD: 2026-03-30
Clinical trial
Effectiveness of a Curcumin Mouthwash in Preventing Traumatic Ulcers in Patients With Fixed Orthodontic Appliances: a Randomized Clinical Trial
Status: Completed, Estimated PCD: 2023-08-07
Clinical trial
Bupropion for the Prevention of Postpartum Smoking Relapse
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Hormonal Mechanisms of Sleep Restriction
Status: Completed, Estimated PCD: 2017-11-01
Clinical trial
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD
Status: Completed, Estimated PCD: 2008-10-01
Clinical trial
Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)
Status: Completed, Estimated PCD: 2022-04-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Effect of Akkermansia Muciniphila WST01 Strain in Patients With Type 2 Diabetes
Status: Active (not recruiting), Estimated PCD: 2022-11-09
Clinical trial
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Status: Active (not recruiting), Estimated PCD: 2024-03-10
Clinical trial
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
Status: Active (not recruiting), Estimated PCD: 2022-07-24
Clinical trial
Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.
Status: Withdrawn, Estimated PCD: 2022-06-01
Clinical trial
A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
Insulin Resistance in Men With Prostate Cancer on Androgen Deprivation Therapy
Status: Withdrawn, Estimated PCD: 2023-01-18
Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics After a Single Oral Administration of ID110521156 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
Effect of Highly Bioavailable Curcumin on Subjective Tinnitus
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy
Status: Recruiting, Estimated PCD: 2030-05-31
Clinical trial
The Effects of Behavioral Counseling Plus Nicotine Replacement Therapy (NRT) or Varenicline on Smoking Cessation Among Smokers High and Low in Intrinsic Reward Sensitivity
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)
Status: Completed, Estimated PCD: 2023-08-15
Clinical trial
A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Status: Terminated, Estimated PCD: 2021-06-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia
Status: Terminated, Estimated PCD: 2019-12-20
Clinical trial
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomised, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2693 Following Multiple Subcutaneous Dose Administration in Healthy Participants
Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status: A Randomized Controlled Trial (BBTBBT)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2, Randomized, Active and Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children Aged 6 Months to 2 Years With Influenza and Other Acute Respiratory Viral Infections Against Standard Therapy
Status: Completed, Estimated PCD: 2022-04-29
Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS
Status: Completed, Estimated PCD: 2022-04-04
Clinical trial
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2014-07-26
Clinical trial
Multicenter Randomized Parallel-Group 6-Week Treatment Clinical Study to Assess BE of Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Comparison With Reference Product, Symbicort® in Adult Asthma Patients
Status: Completed, Estimated PCD: 2023-08-15
Clinical trial
A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers
Status: Completed, Estimated PCD: 2018-09-24
Clinical trial
A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-06-12
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma
Status: Active (not recruiting), Estimated PCD: 2024-10-04
Clinical trial
A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor
Status: Completed, Estimated PCD: 2017-11-22
Clinical trial
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Difamilast Ointment 1% in Children, Adolescents, and Adults With Mild to Moderate Atopic Dermatitis
Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
A 16-Week Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy (DSP) in Patients With HIV (PWH)
Status: Completed, Estimated PCD: 2023-01-18
Clinical trial
The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke
Status: Completed, Estimated PCD: 2013-09-01
Clinical trial
PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
Status: Completed, Estimated PCD: 2021-05-26
Clinical trial
Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
Status: Completed, Estimated PCD: 2023-10-17
Clinical trial
Cilostazol for HFpEF (Heart Failure With a Preserved Ejection Fraction)
Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 [The MIND Study]
Status: Withdrawn, Estimated PCD: 2024-07-01
Clinical trial
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of Group B Streptococcus Vaccine (GBS NN/NN2 With Alhydrogel®) in Elderly Participants Aged 55 to 75
Status: Completed, Estimated PCD: 2023-12-14
Clinical trial
Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Trial on the Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Opioid Withdrawal
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial.
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Study of the Efficacy and Safety of Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Restoring Gut Health With INF108F in Infants With Food Protein Induced Allergic Proctocolitis
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Apply the Pharmacodynamic Model of Peripheral Oxytocin Action to a Multimodal Stimulus That Increases (Heat) or Decreases (Vibration) Pain Perception
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
Status: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Ability of Androgen-receptor Blockade to Normalize Progesterone-induced Augmentation of Gonadotropin Secretion in PCOS (CRM010)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Does Mirabegron Increase the Body Heat Generated by the Nervous System
Status: Completed, Estimated PCD: 2024-01-17
Clinical trial
AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS
Status: Recruiting, Estimated PCD: 2025-08-30
Clinical trial
Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Partnership for Research on Ebola VACcinations (PREVAC)
Status: Active (not recruiting), Estimated PCD: 2019-12-24
Clinical trial
Mechanisms for Activation of Beige Adipose Tissue in Humans
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Efficacy of Certolizumab in Women With Unexplained Recurrent Implantation Failure: a Double-blind Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
Phase II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2023-09-22
Clinical trial
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase III, Double-blind, Placebo-controlled, Randomized Trial
Status: Not yet recruiting, Estimated PCD: 2026-03-14
Clinical trial
An Exploratory, Randomized, Double-Blind, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of TI-0010 Vaccine to Prevent COVID-19 Caused by SARS-CoV-2 in Healthy Adults Aged 18-59 Years
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
OSU6162 as add-on in SSRI/SNRI-resistant Depression (ODEN): a Double-blind, Placebo-controlled Evaluation of Efficacy and Safety
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Status: Active (not recruiting), Estimated PCD: 2024-09-17
Clinical trial
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H1: LY3819253 (LY-CoV555))
Status: Completed, Estimated PCD: 2021-02-01
Clinical trial
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Inhaled N,N-Dimethyltryptamine: a Safety and Tolerability Study in Healthy Adults
Status: Completed, Estimated PCD: 2023-07-17
Clinical trial
Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Tadalafil Versus Placebo in Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology (TRIUMPH Trial)
Status: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients
Status: Completed, Estimated PCD: 2023-09-01
Clinical trial
Effect on Contrast Induced Acute Kidney Injury of APX-115 in Subjects Undergoing Percutaneous Coronary Intervention A Randomized, Double-blind, Parallel Group, Multicenter, Multi-national Trial
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. The RESUS Proof of Concept Study
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Evaluation of Combination Zinc and Green Tea Extract Supplementation on Reduction in Symptom Duration and Severity Associated With Community Respiratory Viral Infections: a Randomized Control Trial (ZiPhenol Study)
Status: Terminated, Estimated PCD: 2023-10-31
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Status: Active (not recruiting), Estimated PCD: 2024-04-19
Clinical trial
A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia
Status: Completed, Estimated PCD: 2022-02-18
Clinical trial
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Optimal Treatment of Inflammation Following Acute Skeletal Muscle Injury
Status: Not yet recruiting, Estimated PCD: 2025-07-31
Clinical trial
Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium Among Elderly Patients With Type 2 Diabetes Undergoing Cardiac Surgery: A Single-Center Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Clinical trial
EMPagliflozin After Aortic Valve Replacement - The EMPAVR Study - A Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke
Status: Recruiting, Estimated PCD: 2025-02-22
Clinical trial
Prospective Comparison of ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
Status: Terminated, Estimated PCD: 2023-03-01
Clinical trial
Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy: A Multicenter, Randomized Controlled Trial.
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer
Status: Withdrawn, Estimated PCD: 2026-08-01
Clinical trial
Letrozole Plus Misoprostol Versus Misoprostol Alone in Induction of Abortion of Anembryonic Pregnancy:
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma
Status: Completed, Estimated PCD: 2014-06-01
Clinical trial
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients in Remission to Reduce Recurrence Regardless of HPV Status
Status: Active (not recruiting), Estimated PCD: 2025-04-06
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
Status: , Estimated PCD: 2025-04-29
Clinical trial
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Status: Recruiting, Estimated PCD: 2030-06-01
Clinical trial
A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Status: Completed, Estimated PCD: 2022-06-13
Clinical trial
Randomised Controlled Trial of Intravenous Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Pediatric Emergency Department
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative Atrial Fibrillation and Kidney Injury (STENOTYPE Trial)
Status: Recruiting, Estimated PCD: 2027-12-04
Clinical trial
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy for Individuals Living With Opioid Use Disorder: A Phase II, Placebo-controlled, Blinded, Pilot Study to Assess Safety and Feasibility (THC-MMT)
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
Status: Terminated, Estimated PCD: 2023-02-10
Clinical trial
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
Status: Active (not recruiting), Estimated PCD: 2026-07-31
Clinical trial
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
Efficacy and Safety of 24 Weeks Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder With Comorbid Opioid Use Disorder - A Multicenter Randomized, Double-blind, Placebo-controlled Study
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-973 in Healthy Adults
Status: Completed, Estimated PCD: 2024-04-04
Clinical trial
A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-07-15
Clinical trial
Losartan Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Multicenter, Double-blinded, Randomized, Placebo-controlled Trial to Compare the Effectiveness of Intratympanic Injections methylPREDnisolon Versus Placebo in the Treatment of Vertigo Attacks in MENière's Disease (PREDMEN Trial).
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Prophylactic Antibiotics Following Treatment of Neurogenic Overactive Bladder With Intradetrusor onabotulinumtoxinA for the Reduction of Postoperative UTI: a Randomized Blinded Placebo-controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-31
Clinical trial
Contribution of an Antiviral Drug (Valaciclovir) in the Treatment of Generalized Periodontitis (Stage III or IV and Grade A, B or C): Prospective, Randomized and Double Blind Clinical Trial
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Mechanisms by Which HA35 Regulates Muscle Protein Homeostasis in Healthy Controls
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
Status: Completed, Estimated PCD: 2022-11-02
Clinical trial
A Double-blind Randomized Controlled Trial of 6-month of Abatacept vs Placebo as Adjuvant to Peanut Oral Immunotherapy to Induce Immunologic Changes in Patients With Severe Persistent Peanut Allergy
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2023-06-13
Clinical trial
Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Efficacy and Safety of Dietary Supplementation of Diamine Oxidase (DAO) to Improve Symptoms in Patients With Irritable Bowel Syndrome
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2025-06-17
Clinical trial
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Status: Recruiting, Estimated PCD: 2026-06-27
Clinical trial
Effect of Perioperative Continuous Intravenous Infusion of Lidocaine on Postoperative Pain in Elderly Patients Undergoing Colorectal Cancer Surgery: a Prospective, Randomized Controlled Trial
Status: , Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Double-blind Clinical Trial of TCM in Reducing CRF Caused by Chemotherapy in Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
Effect of Metformin as Add-on Therapy to Ibuprofen on Disease Activity in Knee Osteoarthritis Patients: A Randomized Controlled Trial.
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia: a Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
The MUFFIN-PTS Trial: Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial
Status: Completed, Estimated PCD: 2020-01-01
Clinical trial
Testing the Ability of JNJ(Janssen and Janssen)18038683, a Selective Serotonin (5-HT)7 Antagonist, to Improve Cognition and Reduce Residual Depressive Symptoms in Stable Bipolar Patients (18038683BCD2001)
Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
Addition of Pyridostigmine to Conventional Management of Postdural Puncture Headache
Status: Completed, Estimated PCD: 2024-01-03
Clinical trial
Preventing Adverse Cardiac Events in Chronic Obstructive Pulmonary Disease
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of 4 g/d Prescription Omega-3 Acid Ethyl Esters on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects With Hypertriglyceridemia
Status: Completed, Estimated PCD: 2010-12-01
Clinical trial
A Study of Cardiovascular Events iN Diabetes Plus
Status: Recruiting, Estimated PCD: 2028-08-17
Clinical trial
Midodrine for the Early Liberation From Vasopressor Support in the ICU - The LIBERATE Multi-Site Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Alpha-Lipoic Acid Supplementation on the Incidence of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Novel Combination Therapy for Osteoporosis in Men
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Smoking Cessation and Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Status: Not yet recruiting, Estimated PCD: 2029-04-01
Clinical trial
M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
Status: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
VE416 and Low-dose Peanut Oral Immunotherapy for Treatment of Persistent Peanut Allergy
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
Status: Completed, Estimated PCD: 2019-09-18
Clinical trial
Evaluating the Effect of a Mixture of Lactobacillus Brevis and Lactobacillus Plantarum on the Management of Periodontitis Stage III Grade C Molar-incisor Pattern in Egyptian Patients ( Randomize Control Trial)
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Randomized, Placebo-controlled, Double-blinded, Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment
Status: Recruiting, Estimated PCD: 2026-07-21
Clinical trial
Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)
Status: Completed, Estimated PCD: 2023-07-05
Clinical trial
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
The Effect of Aromatherapy on the Incidence and Severity of Post Procedure Pain and Discomfort in Patients
Status: Not yet recruiting, Estimated PCD: 2023-09-01
Clinical trial
Prospective Randomized, Double-blind Controlled Clinical Study of N-acetylcysteine for Treatment of Dryness Symptoms Due to Primary Sjogren's Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease
Status: Completed, Estimated PCD: 2022-10-09
Clinical trial
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients
Status: Withdrawn, Estimated PCD: 2023-04-21
Clinical trial
Canakinumab for the Treatment of Postprandial Hypoglycemia - CanpHy Study
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis
Status: Completed, Estimated PCD: 2023-06-13
Clinical trial
Targeting Branched-chain Amino Acid Oxidation to Improve Glycaemic Control in Patients With Type 2 Diabetes
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Status: Recruiting, Estimated PCD: 2029-04-16
Clinical trial
Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial
Status: Withdrawn, Estimated PCD: 2026-03-01
Clinical trial
A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia: a Double-blind Placebo-controlled Randomized Multicenter Study: The "SwissHandSpasm" Study
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)
Status: Completed, Estimated PCD: 2013-02-01
Clinical trial
Use of a Weight Loss Aid in a Population Exposed to Polybrominated Biphenyls (PBB)
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
Musculoskeletal Resiliency and Adaptation to Sex Steroid Suppression and Replacement During Multi-Stressor Training
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study of the Safety and Efficacy of ADC189 Tablets in the Treatment of Influenza A Virus Infection/Influenza B Virus Infection in Adolescents and Adults
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single Dose, Dose-ranging Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccine Administered Orally to Healthy Volunteers Aged Greater Than or Equal to 18 Years and Less Than or Equal to 80 Years Old.
Status: Active (not recruiting), Estimated PCD: 2023-10-16
Clinical trial
A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.
Status: Completed, Estimated PCD: 2023-12-18
Clinical trial
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Status: Recruiting, Estimated PCD: 2025-04-09
Clinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3
Status: Completed, Estimated PCD: 2024-01-23
Clinical trial
A Phase 1b, Randomised, Double-Blind, Parallel Treatment Group Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RMC-035 in Subjects Undergoing Non-Emergent On-Pump Coronary Artery Bypass Graft and/or Valve Surgery
Status: Completed, Estimated PCD: 2021-07-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease
Status: Active (not recruiting), Estimated PCD: 2026-01-12
Clinical trial
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox-Gastaut Syndrome
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Status: Active (not recruiting), Estimated PCD: 2024-07-24
Clinical trial
A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3152 in Healthy Japanese Adults
Status: Active (not recruiting), Estimated PCD: 2024-12-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.
Status: Terminated, Estimated PCD: 2018-01-24
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis
Status: Terminated, Estimated PCD: 2023-12-06
Clinical trial
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)
Status: Active (not recruiting), Estimated PCD: 2025-09-19
Clinical trial
A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
Status: Completed, Estimated PCD: 2023-11-08
Clinical trial
A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy
Status: Completed, Estimated PCD: 2023-09-18
Clinical trial
A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2031-01-01
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease
Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety and Pharmacokinetics of Intravenous VX-993 in Healthy Adults
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Completed, Estimated PCD: 2014-12-05
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
Status: Recruiting, Estimated PCD: 2027-04-29
Clinical trial
A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Randomised, Double-blind, Placebo-controlled and Parallel Group Trial to Investigate the Effects of One Dose (Up-titration to a Fixed Dose Regimen) of Oral BI 685509 on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Decompensated Cirrhosis After Their First Decompensation Event, Who Are Stabilized CTP 5-7
Status: Recruiting, Estimated PCD: 2024-07-29
Clinical trial
A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
Status: Recruiting, Estimated PCD: 2026-02-19
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-02-28
Clinical trial
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: , Estimated PCD: 2025-12-01
Clinical trial
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase II, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2025-05-10
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation
Status: Recruiting, Estimated PCD: 2026-09-17
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety and Efficacy of Subcutaneous Injections of Elamipretide in Subjects With Genetically Confirmed Barth Syndrome Followed by Open-Label Treatment
Status: Completed, Estimated PCD: 2018-10-05
Clinical trial
A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.
Status: Recruiting, Estimated PCD: 2024-10-17
Clinical trial
A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate Postsurgical Dental Pain
Status: Completed, Estimated PCD: 2024-01-25
Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study)
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Phase 2, Study for the Treatment of Anemia With Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents
Status: Recruiting, Estimated PCD: 2025-11-05
Clinical trial
Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Status: Terminated, Estimated PCD: 2017-01-17
Clinical trial
BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia
Status: Terminated, Estimated PCD: 2023-05-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects With Hyperphosphatemia
Status: Completed, Estimated PCD: 2019-07-17
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects
Status: Completed, Estimated PCD: 2019-08-13
Clinical trial
ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Alone
Status: Completed, Estimated PCD: 2023-09-05
Clinical trial
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single Ascending-Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1201 Injection in Healthy Subjects
Status: Completed, Estimated PCD: 2024-03-14
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Status: Recruiting, Estimated PCD: 2026-04-10
Clinical trial
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Status: Completed, Estimated PCD: 2022-03-21
Clinical trial
A Phase 2, Single-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Adolescent and Adult Dental Subjects
Status: Completed, Estimated PCD: 2017-03-29
Clinical trial
A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder
Status: Completed, Estimated PCD: 2014-01-01
Clinical trial
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa
Status: Recruiting, Estimated PCD: 2025-09-22
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus With an up to 52-Week Long-term Extension
Status: Terminated, Estimated PCD: 2024-02-26
Clinical trial
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze
Status: Recruiting, Estimated PCD: 2028-12-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients With Severe Community-Acquired Pneumonia.
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex®]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered 83-0060 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E8001 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-08-18
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously Over 12 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Status: Completed, Estimated PCD: 2022-10-19
Clinical trial
EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction
Status: Completed, Estimated PCD: 2023-11-05
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus
Status: Terminated, Estimated PCD: 2016-11-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
Status: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Double-Blind, Placebo-Controlled Evaluation of the Dexmedetomidine Transdermal Systems for Agitation Associated With Dementia of the Alzheimer's Type
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Status: Terminated, Estimated PCD: 2021-12-09
Clinical trial
A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
A Phase 1 Randomized, Double-Blind, Two Part Study of the Safety, Tolerability, Pharmacokinetics, Analgesic and Respiratory Effect of KUR-101 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2022-10-12
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD
Status: Completed, Estimated PCD: 2019-11-25
Clinical trial
A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years
Status: Completed, Estimated PCD: 2023-03-29
Clinical trial
A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH)
Status: Withdrawn, Estimated PCD: 2024-11-10
Clinical trial
An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)
Status: Terminated, Estimated PCD: 2021-11-23
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of SBS-1000 Administered by Intravenous Infusion to Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Combination With Electroporation in Healthy Volunteers in Ghana
Status: Completed, Estimated PCD: 2022-10-14
Clinical trial
Efficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes
Status: Completed, Estimated PCD: 2020-09-18
Clinical trial
A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease
Status: Completed, Estimated PCD: 2018-08-18
Clinical trial
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease
Status: Completed, Estimated PCD: 2022-11-07
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese Participants
Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal Function
Status: Completed, Estimated PCD: 2019-06-24
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-708 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-03-07
Clinical trial
A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants
Status: Completed, Estimated PCD: 2021-03-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Status: Completed, Estimated PCD: 2020-04-23
Clinical trial
A Phase 2, Double Blind, Randomized, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of DWRX2003 in Combination With Remdesivir Following Intramuscular Administration in Moderate-Severe COVID-19 Patients
Status: Terminated, Estimated PCD: 2022-12-16
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults
Status: Active (not recruiting), Estimated PCD: 2024-04-25
Clinical trial
A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2019-12-06
Clinical trial
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis
Status: Completed, Estimated PCD: 2016-02-12
Clinical trial
A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.
Status: Completed, Estimated PCD: 2021-10-08
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-arm, Parallel-group, Adaptive Study to Investigate the Efficacy and Safety of OPL-0301 in Patients With Post-myocardial Infarction Left Ventricular Dysfunction (RESTORE)
Status: Withdrawn, Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects With PAH (Part 1 and Part 2)
Status: Terminated, Estimated PCD: 2018-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)
Status: Terminated, Estimated PCD: 2020-12-28
Clinical trial
A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
A Randomized, Partial-Blind, Placebo and Positive-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HSK36273 in Healthy Subjects.
Status: Completed, Estimated PCD: 2022-09-12
Clinical trial
Randomized, Double-blind, Placebo-controlled Phase Ib/Ⅱa Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of XW001 Inhalation in Children With Respiratory Syncytial Virus (RSV) Infection in China
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Evaluation of the Efficacy and Safety of DEX-IN Following Painful Outpatient Procedures
Status: Completed, Estimated PCD: 2018-01-18
Clinical trial
International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis
Status: Completed, Estimated PCD: 2016-11-21
Clinical trial
Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.
Status: Completed, Estimated PCD: 2020-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)
Status: Terminated, Estimated PCD: 2023-03-30
Clinical trial
A Parallel-group Treatment, Phase 1, Participant- and Investigator-Blind, Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Dose of Donanemab Compared With Placebo in Healthy Chinese Participants
Status: Completed, Estimated PCD: 2023-01-05
Clinical trial
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase Ia, Randomized Double-Blinded, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 Following a Single Dose Administration in Normal Health Volunteers.
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients With Duchenne Muscular Dystrophy (DMD)
Status: Terminated, Estimated PCD: 2022-09-04
Clinical trial
A Phase 2/3 Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Evaluate the Efficacy and Safety of Brexpiprazole (OPC-34712) in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2023-04-21
Clinical trial
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
Status: Completed, Estimated PCD: 2018-03-05
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma
Status: Completed, Estimated PCD: 2018-06-22
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Status: Withdrawn, Estimated PCD: 2026-11-01
Clinical trial
A Randomized, Double-blind, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 9MW1911 Injection in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
A Phase 1 Randomized, Double-blind, Single and Multiple-dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of S-309309 in Healthy and Obese Adult Study Participants
Status: Completed, Estimated PCD: 2022-10-20
Clinical trial
A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Doses of CFZ533 in Patients With Moderately Active Proliferative Lupus Nephritis
Status: Completed, Estimated PCD: 2023-06-29
Clinical trial
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Status: Completed, Estimated PCD: 2022-04-11
Clinical trial
A Phase 1, Randomised, Single-blind, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Elarekibep Given Twice Daily as Inhaled or a Single IV Formulation in Healthy Japanese Subjects
Status: Terminated, Estimated PCD: 2023-07-08
Clinical trial
Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain After Mini-abdominoplasty Surgery
Status: Completed, Estimated PCD: 2020-02-28
Clinical trial
A Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray, Among Close Contact With COVID-19 People
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status: Active (not recruiting), Estimated PCD: 2019-10-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Status: Completed, Estimated PCD: 2020-04-29
Clinical trial
A Double-Blind, Placebo-Controlled Study of Cariprazine as an Adjunct to Antidepressants in the Treatment of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to Antidepressants Alone
Status: Completed, Estimated PCD: 2021-09-06
Clinical trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, Multi-part, Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Double-Blinded, Randomized, Placebo-Controlled, Phase 2B Trial of IMC-1 for the Treatment of Fibromyalgia
Status: Completed, Estimated PCD: 2022-08-05
Clinical trial
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-03-02
Clinical trial
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Status: Terminated, Estimated PCD: 2023-02-13
Clinical trial
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Status: Completed, Estimated PCD: 2022-03-18
Clinical trial
Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication
Status: Completed, Estimated PCD: 2015-10-01
Clinical trial
A Clinical Pharmacological Study of TS-142 in Non-Elderly and Elderly Healthy Participants (A Repeated-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TS-142 in Elderly and Non-Elderly Participants)
Status: Completed, Estimated PCD: 2019-11-30
Clinical trial
Phase I/II Study of PTX-9908 Injection as an Inhibitor of Cancer Progression in Patients With Non-resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors
Status: Completed, Estimated PCD: 2019-08-20
Clinical trial
A Multicenter,Randomized,Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Poorly Controlled Severe Asthma
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Status: Completed, Estimated PCD: 2022-11-11
Clinical trial
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder
Status: Completed, Estimated PCD: 2022-10-10
Clinical trial
A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension
Status: Recruiting, Estimated PCD: 2024-10-02
Clinical trial
A Randomized, Placebo-controlled, Participant-and-investigator- Blinded, Sponsor Open-label Study to Evaluate the Safety, Tolerability, and Efficacy With Different Dosing Regimens of Subcutaneously Administered MBL949 in Obese Participants With or Without Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
A Multi-center, Randomized, Double Blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation With an Intramedullary Nail
Status: Completed, Estimated PCD: 2012-03-06
Clinical trial
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function
Status: Completed, Estimated PCD: 2022-09-19
Clinical trial
A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibodies, Brii-196 and BRII-198, Administered Intravenously to Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2021-09-16
Clinical trial
A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, PK and the Effect of MK-8189 on QTc in Participants With Schizophrenia
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of ASC11/RTV Tablets and Study to Evaluate the Effects of Food on the PK of ASC11/RTV Tablets in Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-04-04
Clinical trial
An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Status: Completed, Estimated PCD: 2009-01-19
Clinical trial
A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients Without Diabetes With Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure
Status: Completed, Estimated PCD: 2023-07-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Status: Completed, Estimated PCD: 2022-12-29
Clinical trial
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis
Status: Terminated, Estimated PCD: 2021-09-03
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Status: Terminated, Estimated PCD: 2022-05-18
Clinical trial
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Terminated, Estimated PCD: 2019-07-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Terminated, Estimated PCD: 2017-06-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Study in Healthy Chinese Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HBM9378 (SKB378) After Subcutaneous Administration.
Status: Recruiting, Estimated PCD: 2023-09-22
Clinical trial
A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Multicenter, Single and Multiple Ascending Dose Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy Followed by an Open-Label Extension
Status: Completed, Estimated PCD: 2023-07-26
Clinical trial
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Basket Study to Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1, Two Part, Placebo-controlled, Single Dose Study in Healthy Volunteers and Multiple Dose Study in Patients With Refractory Chronic Cough to Assess the Safety, Tolerability, and PK of NTX-1175 Administered Via Nebulizer (NOC-100) and Dry Powder Inhaler (NOC-110)
Status: Completed, Estimated PCD: 2022-10-25
Clinical trial
A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis
Status: Active (not recruiting), Estimated PCD: 2023-02-01
Clinical trial
A Phase 1/2, Randomized, Stratified, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults 18 Years and Older
Status: Completed, Estimated PCD: 2022-09-27
Clinical trial
A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2021-08-19
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets After Oral Administration in Adult Subjects With Binge Eating Disorder
Status: Completed, Estimated PCD: 2022-08-30
Clinical trial
China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2022-11-18
Clinical trial
A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Status: Completed, Estimated PCD: 2016-04-01
Clinical trial
A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for the Prevention of COVID-19 in Adults Aged 18 Years and Above
Status: Active (not recruiting), Estimated PCD: 2022-04-22
Clinical trial
A Single and Multiple Dose Study of Rodatristat Ethyl in Healthy Subjects to Evaluate the Effect of Food, and the Safety, Tolerability, and Pharmacokinetics of a Supratherapeutic Dose of Rodatristat Ethyl
Status: Completed, Estimated PCD: 2023-01-17
Clinical trial
An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2016-01-04
Clinical trial
A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547 Administered Subcutaneously to Healthy Subjects
Status: Completed, Estimated PCD: 2022-09-14
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2021-05-28
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers
Status: Completed, Estimated PCD: 2015-09-01
Clinical trial
Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants
Status: Active (not recruiting), Estimated PCD: 2026-05-05
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet
Status: , Estimated PCD: 2023-12-05
Clinical trial
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Terminated, Estimated PCD: 2016-11-03
Clinical trial
A Single-center, Randomized, Placebo-controlled, Parallel-group, Double-blind Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of BAY 1817080 in Chinese Healthy Adult Male Participants.
Status: Completed, Estimated PCD: 2021-07-19
Clinical trial
A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
Status: Completed, Estimated PCD: 2021-12-02
Clinical trial
A Randomized, Double-blind (Sponsor Unblinded), Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) and Repeat Doses of GSK3186899 in Healthy Participants
Status: Terminated, Estimated PCD: 2019-10-17
Clinical trial
A Randomized, Controlled, Double-Masked Adaptive Design Evaluation of the Safety and Preliminary Efficacy of IVMED-85 on Pediatric Myopia
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2011-01-05
Clinical trial
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
Status: Completed, Estimated PCD: 2021-10-11
Clinical trial
A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults
Status: Completed, Estimated PCD: 2020-07-03
Clinical trial
Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study Part Investigating the Safety, Tolerability, and Pharmacokinetic and -Dynamic Properties of Lu AF90103 and a Double-Blind, Cross-Over Study Part Investigating the Safety Profile After Infusion of Lu AF90103 at Two Rates to Healthy Men
Status: Terminated, Estimated PCD: 2021-11-23
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 4 Study of the Efficacy & Safety of Patiromer for Oral Suspension in Combination With Standard of Care Treatment in ED Patients With Hyperkalemia
Status: Terminated, Estimated PCD: 2023-03-09
Clinical trial
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior
Status: Completed, Estimated PCD: 2016-09-13
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity Disorder
Status: Completed, Estimated PCD: 2011-06-20
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO -CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING IN HEALTHY ADULT MALE PARTICIPANTS AND OPEN-LABEL AFTER SINGLE SUBCUTANEOUS DOSING IN MALE AND FEMALE PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA
Status: Terminated, Estimated PCD: 2023-01-06
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis
Status: Terminated, Estimated PCD: 2022-11-07
Clinical trial
A Phase 2, Open-label and Single-Blind Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip Administered in Multiple Doses to Adolescent and Adult Dental Subjects
Status: Completed, Estimated PCD: 2017-11-22
Clinical trial
A Phase Ia Dose Escalation, Randomized, Double-Blinded, and Placebo- Controlled Clinical Study of Single Dose and Multiple Doses of XW001 Inhalation Solution in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-06-20
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19
Status: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Dose-Finding Phase II Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo Following a Single Intramuscular Injection in Chinese Adult Volunteers
Status: Completed, Estimated PCD: 2022-05-29
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19
Status: Recruiting, Estimated PCD: 2023-03-01
Clinical trial
A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Mild COVID-19
Status: Completed, Estimated PCD: 2022-08-26
Clinical trial
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects With Moderate to Advanced Diabetic Kidney Disease
Status: Completed, Estimated PCD: 2021-09-03
Clinical trial
A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Ascending Doses of M5717 to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Doses, and to Assess the Antimalarial Activity of M5717 Against Plasmodium Falciparum in Healthy Male and Female Adult Subjects
Status: Completed, Estimated PCD: 2019-06-14
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of EN3835 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Completed, Estimated PCD: 2022-04-14
Clinical trial
A Phase II, Single Center, Randomized, Blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
Phase 2, Double-Blind, Placebo-Controlled, Randomized Efficacy, Safety and Tolerability Study of Lymfactin in Combination With Surgical Lymph Node Transfer To Patients With Secondary Lymphedema Associated With the Treatment of Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2019-12-16
Clinical trial
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects With Diabetic Kidney Disease
Status: Completed, Estimated PCD: 2023-05-16
Clinical trial
Z-338 Phase III Trial - Evaluation of Pharmacokinetics, Efficacy and Safety in Paediatric Patients With Functional Dyspepsia
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 3, Double-Blind, Placebo-Controlled, 40-Week Extension Study to Assess the Efficacy and Safety of Etrasimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Status: Terminated, Estimated PCD: 2020-09-03
Clinical trial
A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).
Status: Completed, Estimated PCD: 2015-02-01
Clinical trial
A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects
Status: Terminated, Estimated PCD: 2019-12-23
Clinical trial
A Phase 2 Study to Assess the Efficacy and Safety of AX-8 in Patients With Chronic Cough
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis (NASH) in People Living With Human Immunodeficiency Virus (HIV) in the US
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia
Status: Completed, Estimated PCD: 2020-12-22
Clinical trial
A Phase 1a, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Overlapping Single and Multiple Ascending Dose Escalation Study of WP1122 to Establish Maximum Tolerated Dose and Evaluate Pharmacokinetics
Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Exploratory Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis
Status: Completed, Estimated PCD: 2021-11-15
Clinical trial
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ILB-202 Administered Intravenously as Single Ascending Doses to Healthy Participants
Status: Completed, Estimated PCD: 2023-09-05
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status: Completed, Estimated PCD: 2018-10-05
Clinical trial
Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers
Status: Completed, Estimated PCD: 2023-04-13
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status: Terminated, Estimated PCD: 2016-12-01
Clinical trial
Phase 1/2a Study of KH001 in Dentin Hypersensitivity Patients
Status: Completed, Estimated PCD: 2023-03-02
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of a Repeat Dose of G03-52-01 in Adult Subjects
Status: Active (not recruiting), Estimated PCD: 2024-12-03
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)
Status: Completed, Estimated PCD: 2020-01-14
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2021-12-07
Clinical trial
An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Status: Completed, Estimated PCD: 2023-06-15
Clinical trial
A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS
Status: Completed, Estimated PCD: 2022-02-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of CB1 Antagonist ANEB-001 in Healthy Occasional Cannabis Users in a THC Challenge Test.
Status: Completed, Estimated PCD: 2023-08-26
Clinical trial
Double-blind, Randomized, Dose Escalation Study of the Efficacy and Safety of ZK 245186 Ointment in Concentrations of 0.01%, 0.03%, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2010-09-15
Clinical trial
A Phase 1 Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Effects of a Single Dose of VSA001 Injection in Chinese Healthy Adult Volunteers
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Double Blind, Randomized, Three Arm, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of RZL-012 in Subjects Seeking for Submental Fat Reduction
Status: Completed, Estimated PCD: 2022-04-20
Clinical trial
Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A FTIH Phase I/II Randomized and Controlled Study
Status: Completed, Estimated PCD: 2022-09-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass
Status: Completed, Estimated PCD: 2008-12-02
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Status: Completed, Estimated PCD: 2019-02-08
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
Status: Completed, Estimated PCD: 2023-08-10
Clinical trial
A Phase IIa, Randomized, Double-blind (Participant and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Participants With Chronic Hepatitis C Virus Genotype 1
Status: Completed, Estimated PCD: 2012-03-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Status: Completed, Estimated PCD: 2021-11-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection (INTEGRITY)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease
Status: Completed, Estimated PCD: 2021-09-07
Clinical trial
A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older
Status: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Target Engagement and Immunogenicity of a Single Subcutaneous Dose of GSK3858279 Administered to Healthy Caucasian, Chinese and Japanese Participants
Status: Completed, Estimated PCD: 2023-06-02
Clinical trial
A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age
Status: Completed, Estimated PCD: 2021-11-02
Clinical trial
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Status: Active (not recruiting), Estimated PCD: 2024-04-09
Clinical trial
AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2019-11-26
Clinical trial
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Terminated, Estimated PCD: 2023-09-29
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status: Completed, Estimated PCD: 2012-10-11
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Randomized, 6-Week, Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Terminated, Estimated PCD: 2022-12-23
Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection
Status: Completed, Estimated PCD: 2020-10-14
Clinical trial
A Phase 1, Randomized, Placebo-controlled, Participant- and Investigator-blind, Single-dose Study of the Pharmacokinetics of LY3471851 Following Subcutaneous Dosing of LY3471851 in Healthy Participants
Status: Completed, Estimated PCD: 2023-02-23
Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients With Mild to Moderate COPD With Chronic Bronchitis
Status: Terminated, Estimated PCD: 2021-04-27
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Completed, Estimated PCD: 2022-02-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Anti-viral Efficacy of Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Phase 2 Open Label Study of Magnesium L-Lactate Dihydrate (MLD10) 10 mEq Extended-Release Caplets Administered BID for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus Followed by a Blinded Random Off Phase
Status: Not yet recruiting, Estimated PCD: 2028-04-30
Clinical trial
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled, Pilot Study of the Combination of Valacyclovir + Celecoxib (IMC-2) for the Treatment of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Lidocaine for Pessary Removal and Reinsertion Pain Reduction
Status: Completed, Estimated PCD: 2023-06-23
Clinical trial
Cannabidivarin (CBDV) vs. Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Melatonin for Adolescent Migraine Prevention Study (The MAP Study).
Status: Terminated, Estimated PCD: 2019-12-01
Clinical trial
Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
the Impact of Allopurinol of HRQOL in Cirrhotic Patients
Status: Completed, Estimated PCD: 2023-01-15
Clinical trial
A Phase 2a Randomized, Single-blind, Placebo-controlled Pilot Study to Evaluate the Impact of Cariprazine (1.5mg) on Cocaine Use in OUD-CocUD Patients on Buprenorphine-naloxone.
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Assessing Efficacy of Intramuscular Promethazine for the Treatment of Intrathecal Morphine Induced Pruritus
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Insulin Resistance in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Alpelisib Pilot & Feasibility Study
Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases, a Double-blind Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)
Status: Completed, Estimated PCD: 2016-09-01
Clinical trial
Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer
Status: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
Four-site, Randomized, Parallel Design, Double-blind, Placebo-controlled, 10-week Trial of Donepezil 10 mg Daily for Verbal Memory Problems Among Adults With TBI in the Subacute or Chronic Recovery Period
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Novel Regenerative Therapeutic in Chronic Complex TBI
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Clinical trial
Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized, Double-Blind, Exploratory Trial
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment With Seltorexant
Status: Completed, Estimated PCD: 2023-04-25
Clinical trial
Brain Systems and Behaviors Underlying Response to Obesity Treatment in Children
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
the Effect of a Nitrate Patch on the Healing Process of AVN of the Knee
Status: Terminated, Estimated PCD: 2019-01-01
Clinical trial
The Impact of Inhaled Nitric Oxide (iNO) on the Neurophysiological Mechanisms of Dyspnea in Chronic Thromboembolic Disease and Post-Pulmonary Embolism (Post-PE) Related Dyspnea
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
Bone in CKD Alkali Response Pilot Trial (BICARb)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial
Status: Terminated, Estimated PCD: 2012-12-01
Clinical trial
Placebo-controlled Randomized Trial of Tecovirimat in Non-hospitalized Patients With Monkeypox: Canadian Feasibility Study (PLATINUM-CAN)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Status: Completed, Estimated PCD: 2022-11-11
Clinical trial
Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Double Blind Prospective, Non Comparative Proof of Concept Phase II Study
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Modafinil and Cognitive Function in Postural Tachycardia Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)
Status: Terminated, Estimated PCD: 2023-01-03
Clinical trial
S-Adenosyl-L-Methionine (SAMe) vs Placebo for Discomfort and Functional Limitations Associated With Osteoarthritis of the Hands: a Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Colchicine Versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and the Risk of Clinical Outcomes: The ARGO Trial
Status: Not yet recruiting, Estimated PCD: 2024-12-22
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
Status: Terminated, Estimated PCD: 2020-10-14
Clinical trial
General and Anxiety-Linked Influence of Acute Serotonin Reuptake Inhibition on Neural Responses Associated With Attended Visceral Sensation
Status: Completed, Estimated PCD: 2018-11-13
Clinical trial
INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy (INSPIRE) Study
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Prospective, Randomized, Double-blind, Multicenter Study on the Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Status: Recruiting, Estimated PCD: 2024-05-05
Clinical trial
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation in Patients With Severe Alcohol Use Disorder: A Phase II Trial
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multicenter, Open Label, Randomized, Two-period Crossover Study on the Insertion of MK-8342A (NuvaRing®) Placebo With and Without the Use of NuvaRing Applicator in Healthy Female Subjects
Status: Completed, Estimated PCD: 2015-04-10
Clinical trial
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement
Status: Completed, Estimated PCD: 2022-06-04
Clinical trial
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head And Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Status: Recruiting, Estimated PCD: 2025-01-25
Clinical trial
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
Status: Terminated, Estimated PCD: 2024-03-28
Clinical trial
Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)
Status: Withdrawn, Estimated PCD: 2024-01-01
Clinical trial
Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial
Status: Active (not recruiting), Estimated PCD: 2024-04-08
Clinical trial
GLP-1 Agonists as Neoadjuvant Therapy for Surgical Treatment of Type 2 Diabetes: A Randomized Controlled Trial
Status: Terminated, Estimated PCD: 2022-07-18
Clinical trial
A Multi-center Randomized in Double-blinded Phase III Study Comparing Standard Care Therapy Alone Versus Corticosteroids and Low-dose Methotrexate (MTX) for the First-line Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
Effect of Remimazolam on Incidence of Postoperative Nausea and Vomiting Following General Anesthesia in High-risk Patients: a Multicenter, Double-blinded, Placebo-controlled Randomized Trial
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
Influence of Endurance Training and Histamine Receptor Antagonists on the Transcriptome Response in Human Muscle
Status: Completed, Estimated PCD: 2021-12-06
Clinical trial
Pectoralis and Serratus Muscle Blocks for Analgesia After Minimally Invasive Cardiac Procedures
Status: Completed, Estimated PCD: 2022-02-28
Clinical trial
Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Phase 1b Clinical Trial of UB-312 in Patients With Synucleinopathies
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China
Status: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
Status: Not yet recruiting, Estimated PCD: 2024-09-20
Clinical trial
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
Effects of Pharmacological Dopamine Modulation on Motivation and Motor Function in Major Depression Characterized by Low-grade Inflammation.
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2020-09-07
Clinical trial
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover Phase 1/2a Study Testing Safety/Efficacy of Advair HFA (Salmeterol, Fluticasone) in Resting & Exercising Healthy & High Altitude Pulmonary Edema (HAPE) Predisposed Subjects
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis
Status: Completed, Estimated PCD: 2022-09-01
Clinical trial
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Pilot fMRI Studies of THC Effects on Memory and Reward Learning
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Cross-over Randomized Control Trial to Evaluate the Retinaldehyde Dehydrogenase Inhibitor, Disulfiram, in Improving Retinal Sensitivity in Eyes Affected by Inherited Retinal Degeneration
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Potential Role of Intravenous Lidocaine Versus Intravenous Ketamine for Pain Management in Fibromyalgia Patients
Status: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
Misophonia-Related Memory Modification Using Reconsolidation Mechanisms: Pharmacological and Behavioral Manipulation
Status: , Estimated PCD: 2024-09-01
Clinical trial
A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2008-07-01
Clinical trial
A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Randomized Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers
Status: Completed, Estimated PCD: 2023-02-17
Clinical trial
The Effects of Losartan on Attention Control: An Eye-tracking Study
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
The Effect of Acetazolamide on the Severity of REM Obstructive Sleep Apnea
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine (TACTIC): a Randomised, Double-blinded, Placebo-controlled, Multicentric Trial
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Modulation of the Brain Excitatory/Inhibitory (E/I) Balance Through Neuronal Systems in Autism Spectrum Disorder (ASD)
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Double-blind Randomized Placebo-controlled Four-arm Trial to Assess the Efficacy of Oral Bicarbonate and Intravenous Butylscopolamine Bromide to Facilitate Spontaneous (Non-operative) Delivery in Pregnant Female Participants With Induction of Labor
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Evaluation of the Prophylactic Effects of the Flavonoid Diosmin on Delayed-onset Muscle Soreness in Humans: a Randomized, Double-blinded and Placebo-controlled Single-center Clinical Trial
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Dual Anti-platelet Therapy in Chronic Obstructive Pulmonary Disease Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Insulin Regulation of Lipolysis and Lipolysis Proteins
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
Beta-blockade in Unruptured Intracranial Aneurysm
Status: Not yet recruiting, Estimated PCD: 2029-01-01
Clinical trial
Single-center, Randomized, Controlled Study to Evaluate the Effects of a Six-month Treatment With Renal Glucose Transport Inhibitor (SGLT2i) Drugs on Markers of Senescence, Inflammation and Tubulointerstitial Damage in the Kidney of Patients With Chronic Kidney Disease With or Without Type 2 Diabetes
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized Controlled Pilot Trial of Baclofen for Children With Rumination Syndrome
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP): a Pilot Trial
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Influence of Edible Marijuana on Endurance Exercise Performance
Status: Completed, Estimated PCD: 2022-07-19
Clinical trial
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Comparative Study Between Vaginal Progesterone Alone or Combined With Aspirin in Prevention of Recurrent Preterm Birth
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
Sodium-glucose Co-transporter-2 Inhibitor (SGLT2i) to Prevent of Liver Complications in Patients With Chronic Hepatitis B and Diabetes Mellitus: a Double-blind, Randomised, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2030-10-31
Clinical trial
The Efficacy and Safety of Colchicine in Improving the Stability of Coronary Plaque in Patients With Acute Coronary Syndrome
Status: Completed, Estimated PCD: 2023-08-20
Clinical trial
A Randomized Controlled Trial to Determine the Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores in Patients Having Hip and Knee Arthroplasties With Spinal Anesthesia
Status: Completed, Estimated PCD: 2018-11-30
Clinical trial
Contraceptive Hormone and Reward Measurement (CHARM Study)
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Double-Blinded Randomized Controlled Trial Examining Multimodal Opioid-Free Orthopaedic Procedures
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Evaluating the Effect of Dapagliflozin, an SGLT-2 Inhibitor, on the Counterregulatory Response to Hypoglycemia in Individuals With Type 1 Diabetes
Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
Pragmatic Research on Diuretic Management in Early Bronchopulmonary Dysplasia (PRIMED) Pilot Study
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
The Impact of Magnesium Oxide Monohydrate Compared to Placebo on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Human Cerebral Blood Flow Regulation: Sex, Mechanism, and Stress Differences
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)
Status: Completed, Estimated PCD: 2018-04-01
Clinical trial
Re-EValuating the Inhibition of Stress Erosions: Prophylaxis Against Gastrointestinal Bleeding in the Critically Ill (The REVISE) Trial
Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multiple-Dose, Active and Placebo-Controlled Efficacy Study of Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars
Status: Completed, Estimated PCD: 2020-02-20
Clinical trial
Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Dopamine and Reward Learning Across Hormonal Transition Phases
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
Status: Not yet recruiting, Estimated PCD: 2025-03-30
Clinical trial
Opiate Suicide Study in Patients With Major Depression
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
STAT (STatins and Aspirin in Trauma) Trial: A Phase II, Pragmatic, Prospective, Randomized, Double-blind, Adaptive Clinical Trial Examining the Efficacy of Statins and Aspirin in the Reduction of Acute Lung Injury and Venous Thromboembolism in Patients With Fibrinolysis Shutdown
Status: Terminated, Estimated PCD: 2021-05-24
Clinical trial
DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant
Status: Not yet recruiting, Estimated PCD: 2029-12-01
Clinical trial
Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter.
Status: Completed, Estimated PCD: 2022-12-19
Clinical trial
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Status: Completed, Estimated PCD: 2021-12-17
Clinical trial
Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomised, Double-blind, Allocation Concealed, Placebo-controlled Trial.
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)
Status: Completed, Estimated PCD: 2020-02-06
Clinical trial
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Status: Completed, Estimated PCD: 2022-04-15
Clinical trial
The Assessment for Effect of Red Ginseng Extract on Changes in Indicators of Immune Function in Vietnamese Healthy Volunteers: The Double-blind, Randomized, Placebo-controlled Trial
Status: Completed, Estimated PCD: 2022-12-03
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase II, Double-blind, Randomized, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma (Phase 2; Protocol No. P04223AM3)
Status: Completed, Estimated PCD: 2015-01-29
Clinical trial
Phase I Safety Interaction Trial of Ibudilast With Methamphetamine
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA
Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
Effect of Single Dose & Intrapocket Prophylactic Antibiotic to Cardiac Implantable Electronic Device-related Infection & Biomarkers
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Phase 2 Clinical Trial to Evaluate Efficacy and Safety of EC-18 in Moderate to Severe Atopic Dermatitis
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
Status: Active (not recruiting), Estimated PCD: 2021-05-19
Clinical trial
Multicenter Comparative Randomized Study to Assess Safety and Efficacy and Select the Optimal Dosage Regimen of REMAXA®, Enteric-coated Tablets, in Comparison With REMAXOL®, Solution for Infusions, in Patients With Intrahepatic Cholestasis Caused by Chronic Diffuse Liver Diseases
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Upadacitinib (ABT-494) for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
Status: Completed, Estimated PCD: 2016-11-25
Clinical trial
TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension
Status: Completed, Estimated PCD: 2007-10-01
Clinical trial
A Randomized, Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Status: Active (not recruiting), Estimated PCD: 2024-05-21
Clinical trial
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Status: Active (not recruiting), Estimated PCD: 2025-01-17
Clinical trial
A Phase I Study to Investigate the Pharmacokinetics and ECG Effects of Two Single Ascending Doses of Linaprazan Glurate Given as Oral Tablets to Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status: Not yet recruiting, Estimated PCD: 2026-03-19
Clinical trial
A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
Status: Completed, Estimated PCD: 2017-04-28
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Proof of Biology Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
Status: , Estimated PCD: 2026-06-01
Clinical trial
A 24-week Phase 2, Double-blind, Randomized, Placebo- Controlled, Single-center Safety and Efficacy Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO), and With a 24-week Open-label Extension, in Total 48 Weeks
Status: Completed, Estimated PCD: 2020-10-16
Clinical trial
A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Investigate Efficacy, Safety, and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension
Status: Active (not recruiting), Estimated PCD: 2024-04-11
Clinical trial
Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Status: Active (not recruiting), Estimated PCD: 2024-05-07
Clinical trial
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2023-04-14
Clinical trial
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Status: Active (not recruiting), Estimated PCD: 2023-08-23
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes
Status: Active (not recruiting), Estimated PCD: 2024-10-04
Clinical trial
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 in Japanese Participants With Obesity or Overweight
Status: Recruiting, Estimated PCD: 2025-10-12
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2024-06-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants
Status: Recruiting, Estimated PCD: 2025-07-11
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Japanese Subjects
Status: Active (not recruiting), Estimated PCD: 2024-01-18
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy.
Status: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)
Status: Active (not recruiting), Estimated PCD: 2023-10-23
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Young and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)
Status: Completed, Estimated PCD: 2012-08-01
Clinical trial
A Double-blind, Multi-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of CBP-201 in Chinese Subjects With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)
Status: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
Status: Terminated, Estimated PCD: 2023-11-28
Clinical trial
A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics
Status: Recruiting, Estimated PCD: 2026-09-09
Clinical trial
PhIb, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and PK of an i.v. mAb After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis.
Status: Active (not recruiting), Estimated PCD: 2024-06-25
Clinical trial
A Two-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Subcutaneous Doses of TCMCB07 on Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
Status: Recruiting, Estimated PCD: 2026-07-13
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Shenqi Sherong Pill in Cervical Spondylotic Myelopathy (Qi Deficiency, Blood Stasis and Kidney Deficiency Type)
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD
Status: Recruiting, Estimated PCD: 2026-03-12
Clinical trial
A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications
Status: Recruiting, Estimated PCD: 2025-02-11
Clinical trial
COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
Status: Completed, Estimated PCD: 2022-06-10
Clinical trial
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
Status: Completed, Estimated PCD: 2022-04-14
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-Severe Symptom State (HZNP-DAZ-303)
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
Status: Terminated, Estimated PCD: 2023-04-13
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting, Estimated PCD: 2025-03-13
Clinical trial
Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Status: Recruiting, Estimated PCD: 2026-02-03
Clinical trial
A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Status: Completed, Estimated PCD: 2023-05-15
Clinical trial
A Phase 1b, Double-blind, Placebo-controlled, Repeat-dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of DCR-AUD in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-08-22
Clinical trial
A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
Status: Active (not recruiting), Estimated PCD: 2024-02-15
Clinical trial
A Phase 1, 2-Part, Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB002 in Healthy Volunteers (HVs) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety and PK of ZB002 in Participants With Rheumatoid Arthritis (RA)
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia
Status: Active (not recruiting), Estimated PCD: 2017-08-18
Clinical trial
A Phase 3, 16-Week, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg Dose in the Target Knee Joint of Subjects With Moderate to Severe Osteoarthritis Pain of the Knee
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2017-02-14
Clinical trial
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide in Pediatric Participants, Ages 6 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) and of Linaclotide Versus Placebo in Pediatric Participants With Functional Constipation (FC)
Status: Active (not recruiting), Estimated PCD: 2024-05-20
Clinical trial
Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab
Status: Active (not recruiting), Estimated PCD: 2024-08-22
Clinical trial
A Phase 2a Randomized, Double-blind, Placebo-controlled, Multiple-dose, Crossover Study of the Effect of ZT-01 on Frequency of Nocturnal Hypoglycemia in Type 1 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind, Parallel-group Program to Evaluate Efficacy and Safety of Filgotinib in Adult Subjects With Active Axial Spondyloarthritis
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection
Status: Completed, Estimated PCD: 2019-03-31
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1b, Adaptive, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Design Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2026-06-26
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Status: Active (not recruiting), Estimated PCD: 2023-08-11
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Investigate the Efficacy, Safety and Tolerability of Oral Administered AK0901 Capsules in Children Aged 6-12 Years Old With Attention Deficit Hyperactivity Disorder
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB107 in Healthy Adult Participants
Status: Completed, Estimated PCD: 2024-03-05
Clinical trial
Randomized, Double-Blind, Placebo And Active Controlled, Study To Evaluate Two Strengths Of Concomitantly Dosed Naproxen Sodium With Acetaminophen, Compared With Naproxen Sodium and Hydrocodone/Acetaminophen In Postoperative Dental Pain
Status: Completed, Estimated PCD: 2019-11-07
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study)
Status: Completed, Estimated PCD: 2014-05-14
Clinical trial
A Randomized Double-blinded Placebo Controlled Single Center Phase I Study of Escalating Single Intravenous Doses of NI-0501 in Healthy Volunteers
Status: Completed, Estimated PCD: 2013-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Parallel Design Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects
Status: Recruiting, Estimated PCD: 2023-09-15
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase Ⅲ Study to Evaluate the Efficacy and Safety of NABOTA® in Subjects With Benign Masseteric Hypertrophy
Status: Completed, Estimated PCD: 2021-01-07
Clinical trial
Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2012-05-01
Clinical trial
An Early Phase 2 Clinical Study of KSP-0243 in Patients With Mild to Moderate Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Multi-center, Randomized, Single-blind, Placebo-controlled to Evaluate Safety and Efficacy of ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus
Status: Completed, Estimated PCD: 2023-11-14
Clinical trial
A Full-Factorial, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Efficacy and Safety Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen, and Naproxen Sodium in Postoperative Dental Pain
Status: Recruiting, Estimated PCD: 2024-05-17
Clinical trial
A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)
Status: Terminated, Estimated PCD: 2021-10-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants
Status: Completed, Estimated PCD: 2023-05-04
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients With Spasticity Due to Multiple Sclerosis
Status: Terminated, Estimated PCD: 2023-02-10
Clinical trial
Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity
Status: Active (not recruiting), Estimated PCD: 2024-09-20
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Thrombopoietin Mimetic Peptide-Fc Fusion Protein for Injection (QL0911) in the Prevention of Chemotherapy- Induced Thrombocytopenia
Status: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
Multicenter, Double-blind, Placebo-controlled, Maximum 10 Days Administration Study to Evaluate the Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
Status: Completed, Estimated PCD: 2022-02-24
Clinical trial
A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam™ (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post Infusion
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Status: Terminated, Estimated PCD: 2021-04-14
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Status: Recruiting, Estimated PCD: 2025-06-27
Clinical trial
A Phase IIa ,Randomized, Double-blind, Placebo-controlled, Dose-exploration Study of JMKX000189 in Treatment of Moderate to Severe Active Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.)
Status: Completed, Estimated PCD: 2021-08-20
Clinical trial
A Multicentre Double-blind Placebo-controlled Randomized Study of Efficacy and Safety of Cytoflavin®, Intravenous Administration and Enteric-coated Tablets, Used in Elderly Patients for Prevention of Cognitive Decline After Major Surgery
Status: Completed, Estimated PCD: 2019-04-11
Clinical trial
A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Chronic Low Back Pain
Status: Completed, Estimated PCD: 2023-06-09
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Status: Terminated, Estimated PCD: 2022-07-11
Clinical trial
A Phase 2, Randomized, Controlled Evaluation of the Efficacy and Safety of HTX-011 or HTX-002 for Post-Operative Analgesia Following Abdominoplasty Surgery
Status: Completed, Estimated PCD: 2017-03-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older
Status: Completed, Estimated PCD: 2023-02-21
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Above.
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Status: Completed, Estimated PCD: 2017-08-01
Clinical trial
Single-blind, Randomized, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JTT-662 Administered for 28 Days in Subjects With Type 2 Diabetes Mellitus on Metformin Monotherapy
Status: Completed, Estimated PCD: 2021-02-17
Clinical trial
Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial
Status: Completed, Estimated PCD: 2020-04-30
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Volunteers
Status: Terminated, Estimated PCD: 2022-06-15
Clinical trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Status: Terminated, Estimated PCD: 2022-11-01
Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain
Status: Completed, Estimated PCD: 2022-01-17
Clinical trial
A Phase I/II,Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Safety,Efficacy and Immunogenicity of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2023-02-13
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19
Status: Terminated, Estimated PCD: 2021-12-13
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
Status: Completed, Estimated PCD: 2022-07-07
Clinical trial
A Randomised, Single-blind, Placebo-controlled Trial in Parallel Group Design to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356225 Administered as Oral Solution and Tablets to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Bioavailability Comparison of BI 1356225 as Tablet With and Without Food
Status: Completed, Estimated PCD: 2019-12-23
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
Status: Completed, Estimated PCD: 2022-06-07
Clinical trial
A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
Status: Completed, Estimated PCD: 2021-07-26
Clinical trial
Efficacy and Safety of Intravenous Infusion of SHR-1906 in Patients With Idiopathic Pulmonary Fibrosis: a Multicenter, Randomized, Double-blind, Parallel Placebo-controlled Phase II Trial
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study
Status: Terminated, Estimated PCD: 2022-11-28
Clinical trial
Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia.
Status: Completed, Estimated PCD: 2022-09-22
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
Status: Completed
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
Status: Recruiting, Estimated PCD: 2026-01-19
Clinical trial
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Clinical trial
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Completed, Estimated PCD: 2024-03-12
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis
Status: Active (not recruiting), Estimated PCD: 2024-10-07
Clinical trial
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age
Status: Completed, Estimated PCD: 2022-12-29
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
Status: Completed, Estimated PCD: 2023-06-13
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
Status: Recruiting, Estimated PCD: 2029-06-29
Clinical trial
A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Completed, Estimated PCD: 2020-11-12
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-08-18
Clinical trial
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of Subcutaneously Administered Secukinumab in Patients With New-onset of Giant Cell Arteritis (GCA) Who Are in Clinical Remission and Eligible for Treatment With Glucocorticoid-monotherapy
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Status: Recruiting, Estimated PCD: 2027-12-10
Clinical trial
Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying mRNA Influenza Vaccine in Healthy Adults
Status: Active (not recruiting), Estimated PCD: 2024-09-24
Clinical trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor
Status: Recruiting, Estimated PCD: 2026-09-11
Clinical trial
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study to Assess the Safety and Tolerability of Monthly Subcutaneous Administrations of a Low and High Dose Cohort of Osocimab to ESRD Patients on Regular Hemodialysis
Status: Completed, Estimated PCD: 2021-12-28
Clinical trial
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia
Status: Completed, Estimated PCD: 2023-02-10
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Status: Recruiting, Estimated PCD: 2025-09-18
Clinical trial
A Placebo-controlled, Randomized, Double-blind, Single and Multiple Dose-escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of C16TR for Inhalation to Determine Its Safety, Tolerability, and Pharmacokinetics With an Open-label Tyvaso® Cohort in Healthy Volunteers
Status: Completed, Estimated PCD: 2015-12-18
Clinical trial
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
Status: Terminated, Estimated PCD: 2021-02-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2b Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2026-06-16
Clinical trial
A Phase 2 Double-blind, Multicentre, Placebo Controlled, Parallel Group Design to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
Status: Completed, Estimated PCD: 2024-04-01
Clinical trial
A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury.
Status: Completed, Estimated PCD: 2002-09-01
Clinical trial
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
Status: Recruiting, Estimated PCD: 2025-12-19
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Status: Recruiting, Estimated PCD: 2026-05-08
Clinical trial
Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease
Status: Completed, Estimated PCD: 2023-08-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2
Status: Completed, Estimated PCD: 2021-10-04
Clinical trial
Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL
Status: Active (not recruiting), Estimated PCD: 2023-07-05
Clinical trial
A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2024-03-07
Clinical trial
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Status: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo
Status: Completed, Estimated PCD: 2004-06-01
Clinical trial
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
Status: Completed, Estimated PCD: 2023-08-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Danicamtiv in Healthy Japanese and Caucasian Participants
Status: Recruiting, Estimated PCD: 2023-08-29
Clinical trial
A Single, Dose Escalation, Optimal Dose Finding Phase I/IIa Clinical Trial to Evaluate Safety and Explore Efficacy of the Single Treatment of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis
Status: Not yet recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Healthy Subjects
Status: Completed, Estimated PCD: 2016-09-01
Clinical trial
A Multicentric, Randomized, Double-Blind, Placebo- and Positive-Controlled 4-way Crossover Study to Evaluate the Effects of Single and Repeated Administration of Oral Seltorexant as an add-on Medication to an Antidepressant on On-Road Driving Performance in Participants With Major Depressive Disorder
Status: Completed, Estimated PCD: 2023-03-16
Clinical trial
A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients
Status: Completed, Estimated PCD: 2022-11-17
Clinical trial
A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment
Status: Completed, Estimated PCD: 2016-05-01
Clinical trial
AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118) Combined With Tislelizumab (VDT482) Plus Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Chemotherapy as First-line Therapy for Participants With Advanced Triple Negative Breast Cancer (TNBC)
Status: Withdrawn, Estimated PCD: 2029-07-17
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Status: Active (not recruiting), Estimated PCD: 2018-06-25
Clinical trial
A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies
Status: Completed, Estimated PCD: 2019-05-31
Clinical trial
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria
Status: Withdrawn, Estimated PCD: 2024-07-31
Clinical trial
Phase II Long-term Extension Study to Assess the Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Status: Terminated, Estimated PCD: 2021-06-22
Clinical trial
A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
Status: Terminated, Estimated PCD: 2022-03-16
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
Status: Completed, Estimated PCD: 2020-02-25
Clinical trial
Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of NNC0480-0389 in Combination With Semaglutide s.c.
Status: Completed, Estimated PCD: 2022-03-16
Clinical trial
A Phase II Multi-center, Randomized,Blind, Placebo-controlled Study to Evaluate Safety,Tolerance and Efficacy of ASC22 Combined With ART in Subjects With Human Immunodeficiency Virus
Status: Recruiting, Estimated PCD: 2023-12-06
Clinical trial
A Phase I Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-10-07
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Status: Completed, Estimated PCD: 2022-04-19
Clinical trial
A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy of Intranasal STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
Status: Withdrawn, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis
Status: Terminated, Estimated PCD: 2022-07-21
Clinical trial
A Multicentric, Randomized, Double-Blind, Comparative, Prospective, Placebo-controlled, Phase-II/III Clinical Trial (ACCROS-I)
Status: Completed, Estimated PCD: 2022-03-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second-Generation Ligand-Conjugated Antisense Inhibitor of Prekallikrein, in Patients With Hereditary Angioedema
Status: Completed, Estimated PCD: 2021-01-04
Clinical trial
A Randomized, Double-Blind, Placebo- and Active- Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Study of a Test Acetaminophen 500 mg Tablet in Postoperative Dental Pain
Status: Completed, Estimated PCD: 2016-10-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Status: Terminated, Estimated PCD: 2023-09-29
Clinical trial
Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
A Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Treatment With Solriamfetol in Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea Syndrome (OSA) With a 12-week Treatment Period
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
Status: Terminated, Estimated PCD: 2022-07-30
Clinical trial
A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia
Status: Completed, Estimated PCD: 2021-07-20
Clinical trial
A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-019 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)
Status: Completed, Estimated PCD: 2022-03-28
Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
Status: Terminated, Estimated PCD: 2023-04-15
Clinical trial
A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients
Status: Completed, Estimated PCD: 2013-12-01
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-06-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)
Status: Completed, Estimated PCD: 2022-02-04
Clinical trial
A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty
Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Randomized, Investigator and Participant Blinded, Placebo Controlled, Multiple Ascending Dose, Two Part Design Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of MHS552 in Adults With Type 1 Diabetes Mellitus (T1DM)
Status: Withdrawn, Estimated PCD: 2025-04-14
Clinical trial
A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
iCP-NI - A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Intravenous Infusion, Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
Status: , Estimated PCD: 2023-08-17
Clinical trial
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Status: Completed, Estimated PCD: 2021-07-31
Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects With Androgenetic Alopecia (AGA)
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Pilot Phase II Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral AND017 to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
Status: Completed, Estimated PCD: 2023-07-05
Clinical trial
A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
Status: Terminated, Estimated PCD: 2022-04-11
Clinical trial
A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-02-22
Clinical trial
A Randomised, Double-Blind Phase II Trial of Topical HDIT101 Versus Placebo in Patients With Chronic Recurrent HSV-1 Infection and Orolabial Lesion
Status: Terminated, Estimated PCD: 2023-05-31
Clinical trial
A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).
Status: Completed, Estimated PCD: 2021-10-01
Clinical trial
A Multicenter, Double-blind, Randomized and Placebo-controlled Pivotal Phase 3 Study to Evaluate the Safety and Efficacy of T89 in the Prevention and Treatment of Acute Mountain Sickness (AMS) After Rapid Ascent
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older
Status: Active (not recruiting), Estimated PCD: 2024-02-02
Clinical trial
A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection
Status: Completed, Estimated PCD: 2010-12-01
Clinical trial
A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection
Status: Completed, Estimated PCD: 2022-09-07
Clinical trial
A Study to Evaluate the Effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2021-09-28
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
Status: Withdrawn, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis
Status: Completed, Estimated PCD: 2020-01-02
Clinical trial
A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV Doses of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Status: Terminated, Estimated PCD: 2022-03-09
Clinical trial
Efficacy of Xian-Lian-Jie-Du Optimization Decoction as an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB/IIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Status: Completed, Estimated PCD: 2015-01-08
Clinical trial
A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Status: Completed, Estimated PCD: 2015-11-26
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2021-09-24
Clinical trial
Treatment Safety and Efficacy Using Pro-ocular™ 1% for Chronic Ocular Graft-versus-host Disease (GvHD) Following Allogeneic Hematopoietic Stem Cell Transplantation.
Status: Completed, Estimated PCD: 2021-10-31
Clinical trial
A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and Cold
Status: Not yet recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants
Status: Completed, Estimated PCD: 2022-09-01
Clinical trial
A Single-Dose, Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Determine the Abuse Potential of Single Oral Dose of Seltorexant Compared To Suvorexant and Zolpidem
Status: Completed, Estimated PCD: 2023-05-12
Clinical trial
A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma
Status: Terminated, Estimated PCD: 2022-01-17
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
Status: Completed, Estimated PCD: 2021-07-29
Clinical trial
Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
Status: Completed, Estimated PCD: 2022-01-24
Clinical trial
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2022-01-10
Clinical trial
SYR-472/CCT-002
Status: Completed, Estimated PCD: 2013-07-01
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 O1 Serotype Inaba Strain CVD 103-HgR
Status: Completed, Estimated PCD: 2015-02-01
Clinical trial
A Randomized, Double-Masked, Vehicle-Controlled, Parallel Evaluation of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution
Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Single-center Randomized Double-blind Placebo-controlled Study to Investigate the Safety Tolerability and PK of SAD and MAD of AP303 Following Oral Administration and the Effect of Food on the PK of AP303 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-06-16
Clinical trial
Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients
Status: Terminated, Estimated PCD: 2022-06-06
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Proof-of-concept Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Overactive Bladder (OAB) Over a 12-week Treatment Period
Status: Completed, Estimated PCD: 2021-12-22
Clinical trial
RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Status: Completed, Estimated PCD: 2023-08-11
Clinical trial
A Single Center, Double-Blinded, Phase 1a Randomized Study to Evaluate Safety and Pharmacokinetics of a New Manganese Based Magnetic Resonance Imaging (MRI) Contrast Agent, RVP-001, in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2022-07-22
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
A Study Of The Tolerability, Safety, And Efficacy Of DMT310 For The Treatment Of Acne Rosacea
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects With Autism Spectrum Disorder
Status: Completed, Estimated PCD: 2022-10-17
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension
Status: Completed, Estimated PCD: 2014-03-01
Clinical trial
Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
Status: Completed, Estimated PCD: 2021-07-08
Clinical trial
mRNA-1345-P901 Study: RSV Outcomes Study Extension (ROSE)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status: Completed, Estimated PCD: 2019-02-25
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy
Status: Completed, Estimated PCD: 2014-08-01
Clinical trial
Interventional, Randomized, Double-Blind, Sequential-Group, Placebo-Controlled, Single-Ascending Oral Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AG06474 and Open-Label, Cross-Over Study to Investigate Intra-Subject Variability and the Effect of Food in Healthy Young Men
Status: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Single Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2018-01-25
Clinical trial
An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2019-12-22
Clinical trial
A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide
Status: Completed, Estimated PCD: 2018-07-01
Clinical trial
A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to Less Than 18 Years With Chronic Hepatitis C Infection
Status: Completed, Estimated PCD: 2019-10-28
Clinical trial
XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor
Status: Active (not recruiting), Estimated PCD: 2022-08-15
Clinical trial
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects
Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder
Status: Completed, Estimated PCD: 2023-07-05
Clinical trial
A Phase 1 Placebo-controlled Study of the Safety and Tolerability of Rectally Administered Single Ascending Doses of IW-3300 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-03-09
Clinical trial
A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Status: Completed, Estimated PCD: 2020-09-14
Clinical trial
A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects With Familial Adenomatous Polyposis
Status: Completed, Estimated PCD: 2021-09-13
Clinical trial
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Status: Completed, Estimated PCD: 2022-07-08
Clinical trial
A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
Status: Completed, Estimated PCD: 2022-12-24
Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Status: Completed, Estimated PCD: 2019-11-25
Clinical trial
Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac®) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis/Rhinoconjuntivitis
Status: , Estimated PCD: 2024-02-01
Clinical trial
TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis
Status: Completed, Estimated PCD: 2022-04-01
Clinical trial
Randomized, Double-blind (Patient, Investigator), Placebo-controlled, Parallel Group, Single Dosing Study on Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of BI 1569912 as Adjunctive Therapy in Patients With Major Depressive Disorder
Status: Completed, Estimated PCD: 2023-11-16
Clinical trial
A Phase Ⅲ, Double-blind, Randomized, Placebo-Controlled Multi-centre Study to Assess the Efficacy and Safety of Ensartinib Versus Placebo as Adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Stage Ⅱ- ⅢB Non-small Cell Lung Cancer, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled Dose Escalation and Dose Finding Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines
Status: Terminated, Estimated PCD: 2022-10-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Status: Completed, Estimated PCD: 2021-05-31
Clinical trial
A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.
Status: Completed, Estimated PCD: 2004-03-01
Clinical trial
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KN019 in Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
Status: Completed, Estimated PCD: 2022-07-28
Clinical trial
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-05-20
Clinical trial
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older
Status: Completed, Estimated PCD: 2021-11-19
Clinical trial
A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status: Completed, Estimated PCD: 2020-02-28
Clinical trial
A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis
Status: Completed, Estimated PCD: 2017-11-27
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part (SAD and MAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of ARN-75039 When Administered By The Orally Route in Healthy Adult Subjects
Status: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Doses of NNC0365-3769 (Mim8) in Healthy Subjects and in Subjects With Haemophilia A With or Without Factor VIII Inhibitors
Status: Completed, Estimated PCD: 2023-10-06
Clinical trial
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Completed, Estimated PCD: 2022-03-27
Clinical trial
China Multi-regional Clinical Trial: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
Status: Completed, Estimated PCD: 2021-09-23
Clinical trial
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-29
Clinical trial
A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate GB004 in Adult Subjects With Mild-to-moderate Active Ulcerative Colitis
Status: Terminated, Estimated PCD: 2022-06-01
Clinical trial
A First-in-human, Randomized, Subject-blinded, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-08-03
Clinical trial
A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19
Status: Terminated, Estimated PCD: 2023-02-27
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Single Dose, 2-Way, 2-Period Crossover Safety and Exploratory Efficacy Study of INP105 (POD-OLZ) for the Acute Treatment of Agitation in Adolescents and Young Adults With Autism Spectrum Disorder
Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma
Status: Completed, Estimated PCD: 2020-12-03
Clinical trial
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in the Treatment of Subjects With Peripheral Neuropathic Pain, Associated With Allodynia
Status: Completed, Estimated PCD: 2006-10-01
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia
Status: Completed, Estimated PCD: 2022-11-28
Clinical trial
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects
Status: Completed, Estimated PCD: 2017-03-20
Clinical trial
A Phase I Bridging Study to Evaluate the PK, Safety and Tolerability of SR750 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-09-06
Clinical trial
A Randomized, Double-Masked, Single-Center, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of SJP-0132 in Subjects With Dry Eye Disease
Status: Completed, Estimated PCD: 2020-03-03
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer
Status: Completed, Estimated PCD: 2017-10-23
Clinical trial
A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Prospective, Randomized, Double-blind Phase 2b Clinical Trial to Investigate the Efficacy and Safety of SP-8203 in Patients With Acute Ischemic Stroke Requiring Recombinant Tissue Plasminogen Activator (rtPA) Standard of Care
Status: Completed, Estimated PCD: 2020-10-19
Clinical trial
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2023-09-26
Clinical trial
A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression
Status: Completed, Estimated PCD: 2022-03-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single- Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics Properties of iN1011-N17 After Oral Administration in Healthy Volunteers
Status: Completed, Estimated PCD: 2023-10-08
Clinical trial
A Phase 4 Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Single-Dose Six-Way Crossover Study Evaluating the Abuse Potential of Lyrica® Taken Orally With Oxycodone HCL in Healthy Non-Drug Dependent Recreational Opioid Users
Status: Completed, Estimated PCD: 2022-04-01
Clinical trial
A Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Investigate the Efficacy and Safety of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis
Status: Terminated, Estimated PCD: 2022-11-10
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
Status: Completed, Estimated PCD: 2022-01-04
Clinical trial
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3471851 in Japanese and Caucasian Healthy Subjects
Status: Completed, Estimated PCD: 2020-03-06
Clinical trial
Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections.
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye
Status: Completed, Estimated PCD: 2022-05-06
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
Status: Completed, Estimated PCD: 2021-05-11
Clinical trial
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1839100 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-993 in Healthy Adults
Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With Dyslipidemia
Status: Completed, Estimated PCD: 2022-09-10
Clinical trial
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
Status: Completed, Estimated PCD: 2019-12-10
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Phase I Study To Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Subcutaneous Doses of CM-101 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2019-05-05
Clinical trial
Randomised, Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity Against Influenza Infection, Safety, Tolerability, and Pharmacokinetics of CC-42344 Via a Human Viral Challenge Model in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.
Status: Completed, Estimated PCD: 2004-03-01
Clinical trial
Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial)
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
Status: Completed, Estimated PCD: 2019-01-21
Clinical trial
A Phase I, Randomized, Blinding, Single-dose, Placebo Control Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effect of GR2002 in Chinese Health Volunteers
Status: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis
Status: Terminated, Estimated PCD: 2023-10-18
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases
Status: Completed, Estimated PCD: 2020-01-22
Clinical trial
A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis
Status: Completed, Estimated PCD: 2023-07-13
Clinical trial
A Randomized, 3-Treatment, 3-Period, 6-Sequence, Crossover, Placebo- and Active-Controlled, Double-Blind for ALXN1840 (Open-Label for Moxifloxacin) Thorough QT/QTc Study to Evaluate ALXN1840 on Cardiac Repolarization in Healthy Adults
Status: Completed, Estimated PCD: 2021-03-24
Clinical trial
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
Status: , Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Status: Completed, Estimated PCD: 2017-09-28
Clinical trial
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
Efficacy and Safety of the SQ Tree Sublingual Immunotherapy Tablet in Children and Adolescents With Moderate to Severe Allergic Rhinitis and/or Conjunctivitis Induced by Pollen From Birch and Trees Belonging to the Birch Homologous Group
Status: Completed, Estimated PCD: 2023-07-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Subcutaneous Doses of Efavaleukin Alfa in Subjects With Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2021-10-12
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Status: Terminated, Estimated PCD: 2021-03-24
Clinical trial
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection
Status: Completed, Estimated PCD: 2020-04-02
Clinical trial
A Phase IIb, Randomized, Multi-Center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Status: Active (not recruiting), Estimated PCD: 2023-11-02
Clinical trial
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects.
Status: Completed, Estimated PCD: 2021-10-22
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Completed, Estimated PCD: 2022-05-03
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Clinical Study of Chiauranib Capsule in Patients With Progressed or Relapsed Small-cell Lung Cancer After 2 Lines Chemotherapy (CHIS)
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Extended-release Capsules as Monotherapy or as Adjunct to SSRI in Adult Subjects With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
A Phase 2a, Multi-centre, Placebo Controlled, Randomized, Assessor Blind Study of Bolus 5-fluorouracil and Infused Leucovorin Plus Either Infused TK-90 for Parenteral Use or Infused TK-90 Placebo Administered Weekly for 6 Consecutive Weeks to Patients With Colorectal Cancer.
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-07-21
Clinical trial
A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation
Status: Completed, Estimated PCD: 2023-11-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
Status: Completed, Estimated PCD: 2008-04-01
Clinical trial
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obese Subjects
Status: Completed, Estimated PCD: 2021-06-16
Clinical trial
A Phase Ⅲ, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance
Status: Completed, Estimated PCD: 2024-02-22
Clinical trial
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
Status: Recruiting, Estimated PCD: 2028-09-30
Clinical trial
Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery: A Randomized, Double-blind, Placebo-controlled Trial
Status: Terminated, Estimated PCD: 2022-11-19
Clinical trial
Adenosine Receptors From Genes to Behavior: Neurobehavioral Correlates of Caffeine on Anxiety, Avoidance, Decision-Making and Interoception in Healthy Individuals and Panic Disorder.
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial)
Status: Active (not recruiting), Estimated PCD: 2019-04-25
Clinical trial
Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)
Status: Recruiting, Estimated PCD: 2025-09-18
Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Active (not recruiting), Estimated PCD: 2021-03-18
Clinical trial
A Randomized, Double-blind, Placebo Controlled, Dose Escalation Pilot Study Evaluating the Efficacy of Two Doses of Duloxetine and Amitriptyline in Interstitial Lung Disease-related Cough
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease
Status: , Estimated PCD: 2027-01-01
Clinical trial
Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial
Status: Completed, Estimated PCD: 2024-03-22
Clinical trial
Reishi Mushroom Extract for Fatigue and/or Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Status: Terminated, Estimated PCD: 2022-01-24
Clinical trial
The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
Status: Terminated, Estimated PCD: 2023-01-11
Clinical trial
CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Status: Completed, Estimated PCD: 2021-02-01
Clinical trial
Multicenter Double Blind Randomized Phase II Trial of Olaparib vs Placebo as Maintenance Therapy in Platinum-sensitive Advanced Endometrial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
Aggression and Social-Emotional Information Processing: Neural Correlates During Alcohol Intoxication.
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Effect of Nicotine on Acquisition and Extinction of a Conditioned Place Preference in a Virtual Reality Environment
Status: Withdrawn, Estimated PCD: 2018-06-22
Clinical trial
Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Status: Completed, Estimated PCD: 2022-03-04
Clinical trial
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (DISH)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With Acute Ischemic Stroke
Status: Not yet recruiting, Estimated PCD: 2025-03-28
Clinical trial
Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Investigation of the Effect of MMP-9 Inhibition With Minocycline on the Reconsolidation of Intrusive Trauma- or Cocaine-related Memories
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness: A Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial
Status: Terminated, Estimated PCD: 2011-12-01
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
Status: Completed, Estimated PCD: 2022-09-01
Clinical trial
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy: A Key to Improving Sleep and Gait Performance
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Efficacy of Phosphodiesterase Type 5 Inhibitors in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase II Multi-site Study of Autologous Cord Blood Cells for Hypoxic (HIE)
Status: Completed, Estimated PCD: 2019-08-05
Clinical trial
AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-01-11
Clinical trial
Ketorolac in Palatoplasty: A Randomized Blinded Controlled Trial.
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Phase 2 Placebo-controlled Randomized Trial of LACTIN-V (Lactobacillus Crispatus CTV-05) Among Women at High Risk of HIV Acquisition in Durban, South Africa
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
Fecal Microbiota Transplantation (FMT CAPSULE DE, FMPCapDE, MTP-CP101) in Kidney Stone Patients (FMT IND STUDY)
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-06-01
Clinical trial
Assessing the Efficacy of Ginger Powder Capsules as an Analgesic for Intraoperative and Post- Endodontic Pain Management in Mandibular Molars With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized, 52-week Treatment Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Estradiol Effects on Behavioral and Reward Sensitivity to Alcohol Across the Menstrual Cycle
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
*Full Title of the Submission: Psychostimulant Augmentation of Repetitive TMS (rTMS) for the Treatment of Major Depressive Disorder: A Randomized, Placebo-controlled Clinical Trial
Status: , Estimated PCD: 2025-09-19
Clinical trial
Treating Bacterial Overgrowth in Parkinson's Disease
Status: Completed, Estimated PCD: 2017-08-01
Clinical trial
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Ability of Oral Steroid (Oxandrolone) to Halt Fatty Infiltration and Aid Rotator Cuff Healing: A Double-Blind, Randomized Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Status: Not yet recruiting, Estimated PCD: 2028-12-31
Clinical trial
Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task
Status: Active (not recruiting), Estimated PCD: 2025-12-15
Clinical trial
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial "DEFENCE" (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Status: Active (not recruiting), Estimated PCD: 2023-09-14
Clinical trial
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones
Status: Recruiting, Estimated PCD: 2028-05-31
Clinical trial
Varenicline for Comorbid Tobacco and Cannabis Use in Veterans
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Effect of Intravenous Immunoglobulins on Painful Sensory Neuropathy Evaluated by Aggregated N-of-one Trials
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Participants With Systemic Sclerosis
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
The Role of Estrogen in the Neurobiology of Eating Disorders: A Study of Cognitive Flexibility and Reward in Eating Disorders
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
The Vascular Effects of Endothelin Receptor Antagonism in Systemic Vasculitis
Status: Completed, Estimated PCD: 2020-01-01
Clinical trial
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol: A Randomized Controlled Study (THC PTSD-trial)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang (XCHT) Against Irinotecan-Induced Gut Toxicities(Clinical Study Part:Randomized Controlled Trial)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Acute Effects of Vaping Nicotine on Reward Processing and Inhibitory Control in Young Adults
Status: Completed, Estimated PCD: 2022-08-17
Clinical trial
Efficacy of Fecal Microbiota Transplantation (FMT) in Irritable Bowel Syndrome (IBS): A Randomized, Placebo-controlled, Double-blind Study
Status: Recruiting, Estimated PCD: 2024-08-19
Clinical trial
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Status: Completed, Estimated PCD: 2022-09-16
Clinical trial
Suppression of Daytime and Nighttime LH Frequency by Progesterone in Early Pubertal Girls With and Without Hyperandrogenemia (JCM024)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2 Single Center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
Randomised, Double Blind, Placebo-controlled Trial of L-serine in Hereditary Sensory Neuropathy Type 1.
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Effect of Eszopiclone on Adherence to Continuous Positive Airway Pressure (CPAP) and Severity of Insomnia in Patients With Comorbidity Between Insomnia and Obstructive Sleep Apnea (COMISA)
Status: Recruiting, Estimated PCD: 2025-03-20
Clinical trial
Analgesic and Subjective Effects of Terpenes Administered Alone and in Combination With THC
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
Phase 2 Randomised Controlled Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction (CLAD)
Status: Completed, Estimated PCD: 2023-09-13
Clinical trial
Cyclosporine In Takotsubo Syndrome (CIT) Trial
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
The Effects of Different Doses of Colchicine on High-sensitivity C-reactive Protein in Patients After Percutaneous Coronary Intervention
Status: Completed, Estimated PCD: 2023-12-25
Clinical trial
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase 2 Randomized Controlled Trial of Sildenafil Citrate for Treatment of Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Single-Dose Versus 3-Day Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate: A Pragmatic, Multicentre Randomised Placebo Controlled Non-Inferiority Trial
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation (ARO-DECAMP): a Multi-centre, Randomized, Placebo-controlled Feasibility Pilot Trial
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Efficacy of Intralesional Vitamin D Injection for Treatment of Common Warts: A Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
Efficacy and Safety of Washed Microbiota Transplantation for Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Study
Status: Not yet recruiting, Estimated PCD: 2029-06-01
Clinical trial
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 3 - Interferon Beta-1A and Peginterferon Beta-1A
Status: Completed, Estimated PCD: 2021-01-26
Clinical trial
Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial
Status: Completed, Estimated PCD: 2010-09-01
Clinical trial
Randomized Placebo-controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Systemic Allergic Reactions to SARS-CoV-2 Vaccination
Status: Completed, Estimated PCD: 2022-04-20
Clinical trial
A Clinical Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-03-04
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Subjects With Refractory Chronic Cough
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index ≥27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease.
Status: Recruiting, Estimated PCD: 2029-02-01
Clinical trial
A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
Status: Withdrawn, Estimated PCD: 2024-02-01
Clinical trial
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
Status: Recruiting, Estimated PCD: 2026-05-13
Clinical trial
A Randomized Controlled Double-Blind Trial of Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
Influence of Domperidon on the Experience of Emotions, Brain and Bodily Activity
Status: Recruiting, Estimated PCD: 2024-03-30
Clinical trial
Road to Discovery for Combination Probiotic BB-12 With LGG (Different Doses) in Treating Autism Spectrum Disorder Disorders
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Effects of Single Doses of NaV1.8 Inhibitors on C-Nociceptor Action Potentials in Healthy Adults
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Interplay Between Gut Microbiota and Adaptive Immunity in Amyotrophic Lateral Sclerosis: a Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Post Operative Atril Fibrillation : The Impact of Oral Vitamin C in Reducing the Risk in Egyptian CABG Patients
Status: Active (not recruiting), Estimated PCD: 2023-10-15
Clinical trial
The Association Between Postpartum Aspirin Use and NT-proBNP Levels as a Marker for Maternal Health Outcomes.
Status: Completed, Estimated PCD: 2024-05-21
Clinical trial
Orexin's Role in The Neurobiology of Substance Use Disorder
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
The Role of Histamine in Muscle Protein Synthesis Following Chronic Resistance Training
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2017-05-19
Clinical trial
Propranolol for Sleep Apnea Therapy
Status: Completed, Estimated PCD: 2024-05-01
Clinical trial
A Phase 1, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Participants
Status: Not yet recruiting, Estimated PCD: 2025-08-14
Clinical trial
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patients - A Confirmatory Phase III MNCCTN Trial
Status: Withdrawn, Estimated PCD: 2023-12-29
Clinical trial
Studying the Role of Brain Molecules for Decision Making
Status: Completed, Estimated PCD: 2021-12-13
Clinical trial
Pregabalin for the Treatment of Abdominal Pain From Adhesions: Placebo Controlled Trial
Status: Terminated, Estimated PCD: 2008-08-01
Clinical trial
A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
Status: Recruiting, Estimated PCD: 2025-05-06
Clinical trial
Abaloparatide Versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients With Late-onset OTC Deficiency
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of Chinese Herbal Therapy and Multiple Food Allergen Oral Immunotherapy
Status: Completed, Estimated PCD: 2020-07-02
Clinical trial
Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients
Status: Completed, Estimated PCD: 2011-04-01
Clinical trial
Effects of Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study
Status: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Preoperative Tamsulosin to Prevent Postoperative Urinary Retention in Females After Surgery For Pelvic Floor Disorders
Status: Active (not recruiting), Estimated PCD: 2024-02-11
Clinical trial
The Role of Pharmacological Agents in Restoring Neuronal Excitability After Chronic Spinal Cord Injury (SCI)
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
The Joint Effects of Dog-rose, Cranberry Leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac for Controlling Blood Glucose of Patients With Type II Diabetes Mellitus: A Phase 1-2 Randomized Placebo-Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2024-02-28
Clinical trial
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
The Efficacy of Long-Acting Nalbuphine Sebacate (Naldebain) for Pain Management After Knee Arthroplasty
Status: Completed, Estimated PCD: 2022-11-28
Clinical trial
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Behavioral Mechanisms of Lorcaserin Treatment for Smoking Cessation
Status: Terminated, Estimated PCD: 2020-02-26
Clinical trial
Daily Vitamin D for Sickle-cell Respiratory Complications
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Adjuvant Treatment With Pramipexole to Reduce the Dose of Opioids Necessary for Analgesia in Acute Renal Colic
Status: Completed, Estimated PCD: 2023-01-24
Clinical trial
Efficacy of Sildenafil Citrate to Reduce the Rate of Cesarean Section for Intrapartum Fetal Distress During Induction of Labor
Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
Enhancing the Natriuretic Peptide System in HFpEF: A Randomized Double-Blind Placebo-Controlled Triple Crossover Study
Status: , Estimated PCD: 2027-04-01
Clinical trial
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: A Pilot, Placebo-controlled, Randomized Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase III, Multicentre, Randomized, Double-blind, Single-Dose, 2-Arm, 2-Period, Crossover Study to Investigate the Efficacy of PT027 Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (BREATH)
Status: Recruiting, Estimated PCD: 2024-07-23
Clinical trial
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 3-ARM, STUDY TO INVESTIGATE PAIN RESPONSE WITH INTRANASAL ZAVEGEPANT COMPARED WITH PLACEBO IN THE ACUTE TREATMENT OF MULTIPLE MIGRAINE ATTACKS IN ADULT PARTICIPANTS
Status: Not yet recruiting, Estimated PCD: 2027-02-15
Clinical trial
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
An Open Label, Parallel Single Center Trial of Wharton's Jelly Derived Allogeneic Mesenchymal Stromal Cells Repeatedly Treated to Preserve Endogenous Insulin Production in Adult Patients Diagnosed With Type 1 Diabetes
Status: Active (not recruiting), Estimated PCD: 2020-12-10
Clinical trial
A Phase II/III, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection
Status: Withdrawn, Estimated PCD: 2022-02-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain
Status: Terminated, Estimated PCD: 2021-09-23
Clinical trial
A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients With Diabetic Macular Edema
Status: Completed, Estimated PCD: 2014-10-30
Clinical trial
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Status: Terminated, Estimated PCD: 2023-03-24
Clinical trial
Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug
Status: Withdrawn, Estimated PCD: 2017-06-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Status: Completed, Estimated PCD: 2018-03-15
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2022-07-04
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of NLS-2 (Mazindol Extended-Release) Tablets in the Treatment of Narcolepsy Type 1
Status: Not yet recruiting, Estimated PCD: 2025-01-15
Clinical trial
THE EFFECTS OF SITAXSENTAN ONCE DAILY DOSING ON PROTEINURIA, 24-HOUR BLOOD PRESSURE, AND ARTERIAL STIFFNESS IN SUBJECTS WITH CHRONIC KIDNEY DISEASE
Status: Completed, Estimated PCD: 2009-03-06
Clinical trial
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 When Administered to Healthy Japanese Adults (18-40 Years of Age) in the United States
Status: Completed, Estimated PCD: 2023-08-10
Clinical trial
A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients With Chronic Widespread Musculoskeletal Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome (Disorder)
Status: Terminated, Estimated PCD: 2023-05-24
Clinical trial
A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Status: Completed, Estimated PCD: 2023-01-06
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Randomized, Placebo-controlled, Single-Ascending Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-12-29
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Compound LB54640 in Healthy Overweight and Obese Subjects
Status: Completed, Estimated PCD: 2022-03-30
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-12-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.
Status: Completed, Estimated PCD: 2016-05-19
Clinical trial
A Phase I, Double Blind, Placebo Controlled, Single Ascending Dose Study of Intravenously Administered Ir-CPI to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2020-07-18
Clinical trial
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Status: Completed, Estimated PCD: 2022-05-20
Clinical trial
A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Status: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2018-10-08
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single and Multiple Ascending Doses of FRTX-02 in Healthy Subjects and Subjects With Atopic Dermatitis
Status: Terminated, Estimated PCD: 2023-02-08
Clinical trial
A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life
Status: Completed, Estimated PCD: 2021-02-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
Status: Terminated, Estimated PCD: 2020-07-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis
Status: Completed, Estimated PCD: 2021-08-17
Clinical trial
COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults
Status: Completed, Estimated PCD: 2021-12-21
Clinical trial
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Study Investigating the Safety, Tolerability and Pharmacokinetic Properties of Lu AG09222 in Healthy Caucasian, Chinese and Japanese Subjects
Status: Completed, Estimated PCD: 2022-10-30
Clinical trial
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Completed, Estimated PCD: 2016-09-12
Clinical trial
A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase 1 Randomized, Double Blinded, Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of 611 in Adult Healthy Male and Female Volunteers
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
A 24-week Multi-center, Double-blind, Placebo Controlled Dose-range Finding Study to Investigate the Efficacy and Safety of Oral QBW251 in COPD Patients on Triple Inhaled Therapy (LABA / LAMA / ICS)
Status: Completed, Estimated PCD: 2021-10-08
Clinical trial
A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)
Status: Completed, Estimated PCD: 2023-08-23
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-controlled Phase II Study of The Efficacy And Safety of HSK16149 In The Treatment of Patients With Orthopedic Perioperative Analgesia
Status: Completed, Estimated PCD: 2023-06-12
Clinical trial
A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
Status: Completed, Estimated PCD: 2023-04-27
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)
Status: Active (not recruiting), Estimated PCD: 2023-08-28
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 764122 (Single-blind, Partially Randomised, Placebo-controlled, Parallel (Sequential) Group Design) and the Effect of Food on BI 764122 (Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Design) in Healthy Male Subjects
Status: Completed, Estimated PCD: 2019-08-12
Clinical trial
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status: Completed, Estimated PCD: 2018-04-05
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Active (not recruiting), Estimated PCD: 2022-07-25
Clinical trial
Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Status: Terminated, Estimated PCD: 2020-04-01
Clinical trial
A Phase 1, Randomized, Partial Double-Blind, Placebo- and Positive-Controlled, Three-way Crossover Study to Evaluate the Effect of MT-7117 on the QT/QTc Interval in Healthy Subjects
Status: Completed, Estimated PCD: 2022-02-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Status: Completed, Estimated PCD: 2022-01-26
Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2
Status: Active (not recruiting), Estimated PCD: 2019-07-23
Clinical trial
A Randomized, Placebo Controlled, Double Blind, Single and Repeat Dose Escalation Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and Open Label Assessment of Coadministration of GSK3915393 With Grapefruit Juice and Itraconazole on the Pharmacokinetics of GSK3915393
Status: Completed, Estimated PCD: 2021-06-29
Clinical trial
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Status: Completed, Estimated PCD: 2022-06-17
Clinical trial
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Status: Completed, Estimated PCD: 2023-06-05
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Laparoscopic Colectomy
Status: Completed, Estimated PCD: 2022-11-03
Clinical trial
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Status: Completed, Estimated PCD: 2019-12-10
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD.
Status: Completed, Estimated PCD: 2017-11-08
Clinical trial
A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women
Status: Completed, Estimated PCD: 2018-10-19
Clinical trial
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Terminated, Estimated PCD: 2022-04-01
Clinical trial
A Single-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3462817 in Healthy Japanese and Non-Japanese Participants
Status: Completed, Estimated PCD: 2023-03-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Status: Completed, Estimated PCD: 2023-06-29
Clinical trial
A Phase 2a Double-blind, Placebo-controlled, Parallel Study of PH94B Nasal Spray in the Treatment of Adjustment Disorder With Anxiety
Status: Completed, Estimated PCD: 2022-12-14
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy
Status: Terminated, Estimated PCD: 2022-03-17
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures
Status: Completed, Estimated PCD: 2019-01-22
Clinical trial
Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid
Status: Terminated, Estimated PCD: 2021-03-29
Clinical trial
A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis
Status: Completed, Estimated PCD: 2009-09-01
Clinical trial
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2010-10-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
Status: Not yet recruiting, Estimated PCD: 2023-06-30
Clinical trial
An Exploratory, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Orally Administered GLPG2737 for 52 Weeks, Followed by an Open-label Extension Period of 52 Weeks in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status: Terminated, Estimated PCD: 2022-12-14
Clinical trial
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Status: Terminated, Estimated PCD: 2022-02-02
Clinical trial
A Ph1a/1b, First in Human, Participant and Investigator-blind Sponsor-unblinded Randomized Placebo-controlled Multiple Dose Study of EDP1867 in Healthy Volunteers & Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
Status: Completed, Estimated PCD: 2022-02-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Primary Sjögren's Syndrome
Status: Terminated, Estimated PCD: 2021-10-28
Clinical trial
Double-Blind, Randomized, Placebo-controlled, Safety and Efficacy Trial of BHV-3500 (Zavegepant) Intranasal for the Acute Treatment of Migraine
Status: Completed, Estimated PCD: 2021-10-10
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Randomised, Double Blinded, Placebo-controlled Single and Multiple Ascending Dose Study of Orally Administered RV299 to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect in Healthy Adult Participants
Status: Completed, Estimated PCD: 2022-07-27
Clinical trial
Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Status: Completed, Estimated PCD: 2022-08-08
Clinical trial
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
Status: Completed, Estimated PCD: 2021-11-09
Clinical trial
A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the ATXN2 Gene
Status: Active (not recruiting), Estimated PCD: 2026-07-15
Clinical trial
A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In- Human Study of Orally Administered EDP-323 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses, Multiple Ascending Doses, and the Effect of Food on EDP-323 Pharmacokinetics in Healthy Participants
Status: Completed, Estimated PCD: 2023-03-29
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
Effects of MIB-626 (β-Nicotinamide Mononucleotide) With and Without A High-Intensity Multi-Dimensional Exercise Training Program on Physical Performance, Muscle Bioenergetics, and Neuropsychological Performance in Highly Fit Young Adults
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura
Status: Completed, Estimated PCD: 2014-03-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia
Status: Terminated, Estimated PCD: 2022-01-19
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-02-16
Clinical trial
A Multicenter Trial of the Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Tislelizumab Combined With Chemotherapy Versus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active (not recruiting), Estimated PCD: 2021-03-26
Clinical trial
A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study
Status: Active (not recruiting), Estimated PCD: 2023-03-01
Clinical trial
Combined Randomized, Double-blind, Dose-confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-week Treatment With 1% GPB Cream vs Placebo and Open-label Phase 3b Study to Assess Long-term Efficacy and Safety in Patients With Primary Axillary Hyperhidrosis Treated With 1% GPB Cream
Status: Completed, Estimated PCD: 2021-11-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Clinical Response After 4-week Oral Treatment With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
Status: Completed, Estimated PCD: 2023-02-09
Clinical trial
Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)
Status: Terminated, Estimated PCD: 2022-07-20
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of XNW3009 in Healthy Adult Subject
Status: Completed, Estimated PCD: 2021-01-20
Clinical trial
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Terminated, Estimated PCD: 2023-09-04
Clinical trial
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee
Status: Completed, Estimated PCD: 2022-07-18
Clinical trial
A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing
Status: Completed, Estimated PCD: 2021-01-15
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Status: Completed, Estimated PCD: 2021-10-27
Clinical trial
A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19
Status: Completed, Estimated PCD: 2021-06-07
Clinical trial
A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Status: Completed, Estimated PCD: 2021-03-12
Clinical trial
A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial
Status: Completed, Estimated PCD: 2021-10-01
Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure
Status: Completed, Estimated PCD: 2019-11-13
Clinical trial
A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia
Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451(Pomotrelvir) Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19
Status: Active (not recruiting), Estimated PCD: 2023-06-12
Clinical trial
Randomized Double-Blind Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B Virologically Suppressed for at Least Twelve Months on Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide or Entecavir
Status: Completed, Estimated PCD: 2021-03-10
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled 3-Period Single-Dose Crossover Study to Evaluate the Safety and Efficacy of Two Doses of AD-109 in Mild to Moderate Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2021-05-31
Clinical trial
A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex® in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-withdrawal Phase (Part B) for a Subset of Patients
Status: Completed, Estimated PCD: 2007-07-01
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of TRC041266 Compared to Placebo in Patients With Chronic Stable Heart Failure, an LVEF ≥40%, Moderate to Severe Diastolic Dysfunction and Type 2 Diabetes Mellitus
Status: Withdrawn, Estimated PCD: 2024-06-01
Clinical trial
A Phase Ia Clinical Study of HIV Entry Inhibitor CPT31: Single Ascending Dose Study of Safety, Tolerability, Immunogenicity, and Pharmacokinetics in Healthy Adults
Status: Completed, Estimated PCD: 2021-04-26
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Status: Completed, Estimated PCD: 2020-04-14
Clinical trial
A Single-centre, Randomized, Double-blind, Dose-ascending, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TID Doses (One Day) of GSK2982772 in Japanese Healthy Male Subjects
Status: Completed, Estimated PCD: 2018-09-21
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata
Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Multicenter Double-blind Placebo-Controlled Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children
Status: Completed, Estimated PCD: 2019-02-18
Clinical trial
A Phase 2a, Multi-Center, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification With ABI-H0731 in Subjects With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
Status: Terminated, Estimated PCD: 2021-04-08
Clinical trial
A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis
Status: Completed, Estimated PCD: 2013-05-01
Clinical trial
A Randomized, Blinded, Placebo-Controlled, Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
Status: Completed, Estimated PCD: 2022-09-15
Clinical trial
A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)
Status: Terminated, Estimated PCD: 2021-06-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 When Administered Orally to Healthy and Obese Adult Subjects
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Status: Completed, Estimated PCD: 2023-07-19
Clinical trial
A Phase 2a Trial to Evaluate the Safety, Tolerability, and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection
Status: Completed, Estimated PCD: 2013-11-01
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7999, a TMPRSS6 Antagonist, in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-08-24
Clinical trial
A Multicentre, Multinational, Randomised, Double-Blind, Parallel-Group Study Comparing ACR16 45 mg Once-Daily or Twice-Daily Versus Placebo for the Symptomatic Treatment of Huntington's Disease
Status: Completed, Estimated PCD: 2010-06-14
Clinical trial
A 54-Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition Lead-in)
Status: Terminated, Estimated PCD: 2023-10-23
Clinical trial
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2020-06-24
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study, Evaluating the Efficacy and Safety of Recombinant Fully Human Anti-RANKL Monoclonal Antibody in Postmenopausal Osteoporosis Subjects With Increased Bone Fracture Risk
Status: Completed, Estimated PCD: 2021-09-27
Clinical trial
Safety and Efficacy of HB-1 for Panic Disorder: A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Status: Completed, Estimated PCD: 2020-08-28
Clinical trial
A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase I Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
Status: Active (not recruiting), Estimated PCD: 2023-11-21
Clinical trial
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (SRL)
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Status: Recruiting, Estimated PCD: 2028-06-30
Clinical trial
A Phase I, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of VX-840 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-11-07
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2020-03-13
Clinical trial
A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Status: Completed, Estimated PCD: 2022-08-25
Clinical trial
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING SINGLE SUBCUTANEOUS DOSE OF PF-06480605 IN JAPANESE HEALTHY PARTICIPANTS
Status: Completed, Estimated PCD: 2020-11-11
Clinical trial
A Phase IIa, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller
Status: Completed, Estimated PCD: 2022-05-19
Clinical trial
A Phase 2, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA X for Forehead Lines
Status: Completed, Estimated PCD: 2022-09-06
Clinical trial
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Status: Completed, Estimated PCD: 2022-12-19
Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis
Status: Completed, Estimated PCD: 2022-05-04
Clinical trial
A Phase 2 Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19
Status: Withdrawn, Estimated PCD: 2023-02-07
Clinical trial
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Status: Terminated, Estimated PCD: 2022-06-13
Clinical trial
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis' Roflumilast Cream 0.3% to Arcutis's Zoryve™ (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis
Status: Completed, Estimated PCD: 2023-08-08
Clinical trial
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
A Multi-center, Randomized, Two-stage, Phase II Clinical Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Diagnostic or Therapeutic Colonoscopy
Status: Completed, Estimated PCD: 2020-12-28
Clinical trial
Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib
Status: Completed, Estimated PCD: 2016-12-05
Clinical trial
A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses
Status: Terminated, Estimated PCD: 2023-03-14
Clinical trial
An Adaptive Design, Phase I/IIa, Open Label, Multicentre, Single Dose Escalation and Multiple Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous and Subcutaneous Doses of SerpinPC in Healthy Male Volunteers and Male Participants With Severe Haemophilia A or B With or Without Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase Ib, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 Tablets in Mild or Moderate COVID-19 Patients
Status: Not yet recruiting, Estimated PCD: 2023-03-08
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.
Status: Completed, Estimated PCD: 2023-01-30
Clinical trial
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Completed, Estimated PCD: 2012-06-27
Clinical trial
A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
Status: Completed, Estimated PCD: 2020-07-27
Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Lucid-21-302 in Healthy Volunteers Under Fed and Fasted Conditions
Status: Completed, Estimated PCD: 2023-07-29
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-03-11
Clinical trial
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence
Status: Completed, Estimated PCD: 2021-11-18
Clinical trial
Pilot/Phase IIa Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
Status: Completed, Estimated PCD: 2016-09-21
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19
Status: Completed, Estimated PCD: 2021-04-07
Clinical trial
Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2019-05-20
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI112 in Patients With Moderate to Severe Active Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-03-28
Clinical trial
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
Status: Completed, Estimated PCD: 2022-07-26
Clinical trial
A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Male and Female Subjects
Status: Completed, Estimated PCD: 2010-09-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Completed, Estimated PCD: 2015-08-30
Clinical trial
Rosiglitazone Adjunctive Therapy for Severe Malaria in Children
Status: Completed, Estimated PCD: 2020-03-01
Clinical trial
Cannabidiol Effects on Fear Extinction in Social Phobia
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
The Effect of the Combination of Mecobalamin and Ceftriaxone Sodium on Liver Injury in Sepsis and Clinical Prognosis Observation
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion (AUVELITY) as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Short Course Radiotherapy Based Total Neoadjuvant Therapy With Or Without Chlorophyllin (SCOTCH Study)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Albuminuric Non-Diabetic Chronic Kidney Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Efficacy of Intracavernosal (Xeomin®) 100U as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors
Status: Active (not recruiting), Estimated PCD: 2025-03-28
Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase II, Placebo-controlled Study of BacoMind® Bacopa Monnieri Standardized Extract in Gulf War Illness
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
The Role of Exercise Training Combined With Tocilizumab on Visceral and Epicardial Adipose Tissue and Gastric Emptying in a High Risk Population: an Exploratory Double-blind, Placebo-controlled Randomised Trial
Status: Completed, Estimated PCD: 2018-04-01
Clinical trial
Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects
Status: Completed, Estimated PCD: 2024-02-09
Clinical trial
Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.
Status: Completed, Estimated PCD: 2005-12-01
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Completed, Estimated PCD: 2016-03-01
Clinical trial
A Double-Blind Randomized Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Associations of Estradiol and Stress Reactivity in Pre- and Postmenopausal Women
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Autologous Volar Fibroblast Injection Into the Stump Site of Amputees
Status: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
Randomized Controlled Trial of Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Role of Intravenous Tranexamic Acid Use in Patients Undergoing Breast Free Flap Reconstruction: Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-05-13
Clinical trial
The Effect of Continuous Intravenous Infusion of Lidocaine on Postoperative Pulmonary Complications and Prognosis in Emergency Surgical Patients With Intra-abdominal Infection
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Impact of Statin Therapy on Adaptations to Aerobic Exercise
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
The NIPA Study: A Randomized Double-blind Control Clinical Trial Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients
Status: Recruiting, Estimated PCD: 2026-03-22
Clinical trial
Randomized, Double-blind, Placebo-controlled Phase 1 Trial of the RSV/Flu-01E Vaccine for the Prevention of Respiratory Syncytial Virus Infection in Volunteers Aged 18 to 59 Years and Over 60 Years
Status: Completed, Estimated PCD: 2023-06-19
Clinical trial
A Phase I/II, Randomized, Double-blind, Placebo-controlled, Parallel, 2-arms Clinical Trial to Assess the Safety and Efficacy of Intrathecal Administration of WJ-MSC in Chronic Traumatic Cervical Incomplete Spinal Cord Injury
Status: Completed, Estimated PCD: 2024-01-20
Clinical trial
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Does a Repeat Course of Antenatal Corticosteroids in Pregnant Women With Preterm Premature Rupture of Membranes Decrease Neonatal Morbidity?
Status: Terminated, Estimated PCD: 2023-12-20
Clinical trial
Effectiveness of Melissa Officinalis in Various Concentrations for the Treatment of Probable Sleep Bruxism in Children and Adolescents: Controlled and Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming With Env-C Plasmid DNA Vaccine Alone, With Different Adjuvants, or With an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting With the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine With or Without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya
Status: Completed, Estimated PCD: 2024-01-24
Clinical trial
NSAIDs in Sciatica (NIS), an Investigator Initiated Randomised Placebo Controlled Trial of Naproxen
Status: Completed, Estimated PCD: 2023-06-22
Clinical trial
Platelet Rich Plasma for Patients With Recurrent Implantation Failure: A Prospective Randomized Pilot Study
Status: Completed, Estimated PCD: 2023-12-20
Clinical trial
A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction: A Double-Blind, Placebo Control Randomized Trial (BINOS)
Status: Recruiting, Estimated PCD: 2025-12-20
Clinical trial
PARASTOP - Paracetamol With Strong Opioids. A Randomized, Double-blind, Parallel-group Non-inferiority Phase III Withdrawal Trial of Paracetamol Versus Placebo in Conjunction With Opioids for Moderate to Severe Cancer-related Pain
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Effect of Low-dose Dexmedetomidine on Postoperative Delirium in Patients After Cardiac Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2021-07-03
Clinical trial
Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease
Status: , Estimated PCD: 2025-12-01
Clinical trial
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)
Status: Completed, Estimated PCD: 2008-11-01
Clinical trial
Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Clinical trial
Oral Bedtime Melatonin in Critically Ill Patients
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Clinical Trial (RCT) to Evaluate the Ability of Mirtazapine (MZP) to Increase Methamphetamine (MA) Abstinence Among Treatment-seeking Medication for Opioid Use Disorder (MOUD) Adults
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase I/II, Double-Blind, Placebo-Controlled Study: Assessing Safety and Efficacy of Preoperative Renal Allograft Infusions of C1 Inhibitor (Berinert®) (Human) (C1INH) vs. Placebo Administration in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI)
Status: Active (not recruiting), Estimated PCD: 2022-07-31
Clinical trial
PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
Multi-Nutrient Supplement for Radio-Protection
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Impact of Intraoperative Goal-directed Blood Pressure Management and Dexmedetomidine on Outcomes of High-risk Patients After Major Abdominal Surgeries: a 2×2 Factorial Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2020-10-29
Clinical trial
EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized Controlled Trial Versus Placebo
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages, PREMI Trial
Status: Recruiting, Estimated PCD: 2026-07-29
Clinical trial
Clinical Study Evaluating the Efficacy and Safety of Adjunctive Use of Montelukast in Rheumatoid Arthritis Patients
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
Safety and Efficacy of Suvorexant for Opioid/Stimulant Co-use Among Individuals in Treatment for Opioid Use Disorder (OUD)
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT), Substudies: MRI, Cognitive
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?
Status: Completed, Estimated PCD: 2019-01-01
Clinical trial
Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression - 2
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Status: Completed, Estimated PCD: 2022-07-29
Clinical trial
Midodrine for the Early Liberation of Vasopressor Support in the ICU - The LIBERATE Pilot Study
Status: Completed, Estimated PCD: 2022-07-31
Clinical trial
A Phase III, Double-blind, Placebo-controlled, Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Ghrelin (OXE--103) for Acute Concussion Management
Status: Completed, Estimated PCD: 2022-10-30
Clinical trial
A Phase III, Randomized, Double-Blind Placebo-Controlled, Non-Inferiority, Multi-Center Study of the Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Rose Geranium in Sesame Oil Nasal Spray as an Agent to Improve Symptoms of Nasal Vestibulitis: A Phase III Double Blinded Randomized Controlled Trial
Status: Completed, Estimated PCD: 2022-12-15
Clinical trial
A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids
Status: Completed, Estimated PCD: 2008-09-01
Clinical trial
Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
Status: Not yet recruiting, Estimated PCD: 2028-08-31
Clinical trial
A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.
Status: Completed, Estimated PCD: 2014-02-28
Clinical trial
A Multi-centre, Double-blind Randomised Controlled Trial to Compare Mirtazapine Versus Placebo Over 12 Weeks in Patients With Multimorbid Major Depression and Inflammatory Bowel Disease (MD-IBD): a Feasibility Study
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.
Status: Recruiting, Estimated PCD: 2026-02-20
Clinical trial
Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises
Status: Not yet recruiting, Estimated PCD: 2029-03-23
Clinical trial
Metformin as RenoProtector in Non-Diabetic Patients With Progressive Chronic Kidney Disease (CKD Stages 2, 3A and 3B): a Multi-centre, Practice-oriented, Repurposing, Double-blind, Placebo-controlled, Randomized Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone (LH) Pulse Frequency in Pubertal Girls With Hyperandrogenism? (CBS010)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Role of Hyperinsulinemia in Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis: Diazoxide Pilot & Feasibility Study
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Respiratory Mechanics Following Brain Injury: The Role of Inhaled Nitric Oxide
Status: Completed, Estimated PCD: 2023-12-28
Clinical trial
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
Status: Active (not recruiting), Estimated PCD: 2024-06-12
Clinical trial
Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Efficacy of add-on PEramPanel in Focal Motor Status Epilepticus
Status: Terminated, Estimated PCD: 2022-11-02
Clinical trial
ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Status: Not yet recruiting, Estimated PCD: 2026-08-23
Clinical trial
Oral Cannabidiol for Tobacco Cessation
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Efficacy of Chinese Herbal Medicine Xiaojidaozhi Decoction in the Treatment of Childhood Functional Constipation: a Double Blind, Randomized and Placebo-controlled Trial
Status: Completed, Estimated PCD: 2018-05-01
Clinical trial
TELEHEART: Telotristat Ethyl in a Heart Biomarker Study
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Restoration of Hypoglycemia Awareness With Metoclopramide
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Metoprolol to Reduce Perioperative Myocardial Injury
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
The Psychobiology of Resilience in Mother-child Pairs: Inhaled Oxytocin and HPA Axis Reactivity
Status: Completed, Estimated PCD: 2023-07-25
Clinical trial
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Placebo-controlled, Double Blind Pilot Crossover Trial of Levocarnitine for the Treatment of Keratoconjunctivitis Sicca in Sjogren's Syndrome
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled Trial
Status: Completed, Estimated PCD: 2011-05-01
Clinical trial
Comparative Efficacy of Xiaopi Granules and Decoction in Improving Pathological Complete Response of Neoadjuvant Chemotherapy of Triple-negative Breast Cancer: a Randomized, Double-blind, Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-12-30
Clinical trial
Longterm Transfer of FRozen Encapsulated Multidonor Stool Filtrate or Encapsulated Multidonor Microbiome for Chronic Active Ulcerative COlitis
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen
Status: Terminated, Estimated PCD: 2023-01-18
Clinical trial
The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Radiotherapy Plus Xevinapant or Placebo in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: a Randomized Phase II Study RAVINA
Status: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
Dupilumab in the Treatment of Pediatric Alopecia Areata
Status: Not yet recruiting, Estimated PCD: 2028-04-30
Clinical trial
Impact of Chronic Nabilone Self-administration on Body Weight, Metabolic Markers, Gut Microbiota, and Neural Circuitry in Human Obesity
Status: Terminated, Estimated PCD: 2023-08-14
Clinical trial
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-04-29
Clinical trial
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health
Status: Not yet recruiting, Estimated PCD: 2030-12-31
Clinical trial
A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension
Status: Active (not recruiting), Estimated PCD: 2019-11-27
Clinical trial
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Status: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)
Status: Completed, Estimated PCD: 2014-09-18
Clinical trial
Amantadine Hydrochloride for Treatment of Symptoms of the Post-traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Completed, Estimated PCD: 2007-11-01
Clinical trial
The Effect of Foot Reflexology and Knee Massage Applied With Black Cumin Extract Oil on Pain and Fatigue Symptoms in Elderly People With Knee Osteoarthritis
Status: Completed, Estimated PCD: 2020-02-19
Clinical trial
The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals
Status: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People With Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x4 Factorial Randomized Placebo-Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
PDE4 Inhibition in the Treatment of Seborrheic Dermatitis and Papulopustular Rosacea With PF-07038124
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P06107)
Status: Completed, Estimated PCD: 2013-08-28
Clinical trial
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II
Status: Terminated, Estimated PCD: 2023-06-27
Clinical trial
Clinical Study of Ligustrazine in Treating Alcohol Addiction
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir
Status: Terminated, Estimated PCD: 2018-10-22
Clinical trial
The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Assesment of ODF ( Oral Dissolvable Film) With Long-term CBD Release in the Treatment of Temporomandibular Disorders
Status: Recruiting, Estimated PCD: 2023-07-30
Clinical trial
Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults
Status: Completed, Estimated PCD: 2022-05-08
Clinical trial
Continuous Erector Spinae Plane Blocks for Analgesia and Improving Incentive Spirometry Following Traumatic Rib Fractures
Status: Terminated, Estimated PCD: 2022-03-26
Clinical trial
A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia.
Status: Completed, Estimated PCD: 2017-01-18
Clinical trial
Evaluation of the Safety, Tolerability and Immunological Response to Lactobacillus Johnsonii N6.2 in Children and Adolescents With T1D
Status: Recruiting, Estimated PCD: 2025-05-18
Clinical trial
Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Status: Completed, Estimated PCD: 2019-01-24
Clinical trial
Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Pilot Study of Omega-3 Polyunsaturated Fatty Acid Treatment in Mild Acute TBI (OPTIMA-TBI Pilot)
Status: Terminated, Estimated PCD: 2021-07-27
Clinical trial
A Randomised Crossover Pilot Study of the Effects of Tezacaftor/Ivacaftor and Ivacaftor on Gastrointestinal Function Using Magnetic Resonance Imaging Parameters in People With Cystic Fibrosis
Status: Completed, Estimated PCD: 2020-10-29
Clinical trial
Product A (Test Product), Product B (Control Product) Evaluation of Human Efficacy for Skin Moisturization and Wrinkle Improvement
Status: Completed, Estimated PCD: 2021-11-05
Clinical trial
Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)
Status: Active (not recruiting), Estimated PCD: 2023-12-15
Clinical trial
A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
Status: Completed, Estimated PCD: 2011-03-01
Clinical trial
Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
NMDA Modulation in Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Trial Investigating the Effect of Semaglutide on Atherosclerosis in Patients With Cardiovascular Disease and Type 2 Diabetes
Status: Completed, Estimated PCD: 2022-12-16
Clinical trial
Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder
Status: Completed, Estimated PCD: 2023-04-19
Clinical trial
Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
Status: Not yet recruiting, Estimated PCD: 2030-08-01